

Curriculum Vitae and Bibliography

Shaji Kunnathu Kumar, MD

Personal Information

Place of Birth: Vaikom, India
Citizenship: United States of America
Work Address: Mayo Clinic Rochester
200 First St SW
Rochester, MN 55905-0001
507-284-2017
Email Address: Kumar.Shaji@mayo.edu

Present Academic Rank and Position

Consultant - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 01/01/2008 - Present
Professor of Medicine - Mayo Clinic College of Medicine and Science 09/01/2012 - Present
Chair - Myeloma Amyloidosis Dysproteinemia Group, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 12/03/2016 - Present
Master's Faculty Privileges in Clinical & Translational Science - Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine and Science 05/15/2017 - Present
Vice Chair - Research - Division of Medicine & Medical Specialties, Mayo Clinic, Rochester, Minnesota 08/08/2018 - Present
Research Chair - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 06/02/2022 - Present
Chair - Hematology Research, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 2022 - Present

Education

Union Christian College - Pre-Medical 1985 - 1987
All-India Institute of Medical Sciences - MB BS 1987 - 1991
All-India Institute of Medical Sciences - Internship, Rotatory Internship 1992
All-India Institute of Medical Sciences - Clinical Residency, Internal Medicine 1993 - 1996
Institute Rotary Cancer Hospital, All-India Institute of Medical Sciences - Senior Resident, Medical Oncology 1996 - 1997
Mayo Graduate School of Medicine, Mayo Clinic College of Medicine - Clinical Residency, Internal Medicine 1997 - 1999
Internal Medicine, Programs in Rochester, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine, Rochester, Minnesota - Resident 03/29/1997 - 06/25/1999
Mayo Graduate School of Medicine, Mayo Clinic College of Medicine - Fellow, Hematology/ Oncology 1999 - 2003
Hematology/Oncology, Programs in Rochester, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine, Rochester, Minnesota - Resident 06/26/1999 - 06/27/2003
DFCI/Harvard Cancer Center - Research Associate, Mayo Foundation Scholar (Multiple Myeloma) 2003 - 2004

Additional Education

Completed Six weeks Training in Molecular Biology Techniques
Department of Biochemistry and Molecular Biology, Mayo Clinic 01/2001 - 02/2001
Workshop in "Molecular Biology in Clinical Oncology"
American Association for Cancer Research 06/2001
Workshop in "Methods in Clinical Cancer Research" 07/2002

American Association for Cancer Research, Vail, Colorado

Clinical Epidemiology Workshop

08/2002

Cancer Education Consortium, Brewster, Massachusetts

Certificate in Clinical and Translational Research

08/2009

Mayo Clinic CTSA and Mayo Graduate School

Certification

Board Certifications

American Board of Internal Medicine (ABIM)

Internal Medicine

1999 - Present

Hematology

2004 - Present

Medical Oncology

2004 - Present

Educational Commission for Foreign Medical Graduates (ECFMG)

ECFMG

1996 - Present

Medical Council of India

Internal Medicine

1993 - Present

Licensure

India 11051 (Medical)

Minnesota 41493 (Medical)

Honors and Awards

Kirpal Kaur Award for Best Resident - Department of Medicine, All India Institute of Medical Sciences, New Delhi 01/1993

American Association of Cancer Research Award - Molecular Biology Workshop, Aspen, CO 07/2001

Travel Award for Presentation at Special Topic Conference on Hepatic Venocclusive Disease, Atlanta, GA - American Association for the Study of Liver Diseases 03/2002

Methods in Clinical Cancer Research Award - American Association for Cancer Research and American Society of Clinical Oncology Workshop 07/2002

Cancer Education Consortium Award - Epidemiology and Trial Design, Brewster, MA 08/2002

Merit Award - American Society of Clinical Oncology 01/2003

William Summerskill Award - Department of Internal Medicine, Mayo Clinic 01/2003

Young Investigator Award - Eastern Cooperative Oncology Group (ECOG) 2014 - Present

Teacher of the Year, Hematology and Oncology - Mayo Fellows' Association 2014 - Present

Mark and Judy Mullins Professor of Hematologic Malignancies - Named Professorship Committee - Mayo Clinic, Mayo Clinic Committees, Rochester, Minnesota 01/01/2020 - Present

Brian Durie Outstanding Achievement Award - International Myeloma Working Group, Rochester, Minnesota 06/23/2021 - Present

Previous Professional Positions and Major Appointments

Assistant Professor of Medicine - Mayo Clinic College of Medicine and Science 04/01/2002 - 10/31/2006

Assistant Professor of Oncology - Mayo Clinic College of Medicine and Science 04/01/2002 - 11/01/2007

Mayo Foundation Scholar - Dana-Farber Harvard Cancer Institute, Boston, Massachusetts 2003 - 2004

Senior Associate Consultant - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota	2005 - 12/31/2007
Associate Professor of Medicine - Mayo Clinic College of Medicine and Science	11/01/2006 - 08/31/2012
Medical Director, Cancer Clinical Research Office - Mayo Clinic Cancer Center	12/01/2014 - 05/31/2021

Professional Memberships and Societies

Professional Memberships and Services

American Association for Cancer Research Member	01/2000 - Present
American Medical Association Member	01/1998 - Present
American Society for Blood and Marrow Transplantation Member	01/1999 - Present
American Society of Clinical Oncology Member	01/1999 - Present
American Society of Hematology Member	01/1999 - Present
European Hematology Association Member	07/2008 - Present
International Myeloma Society Treasurer	03/01/2017 - Present
International Society of Amyloidosis Vice President	10/01/2022 - Present
Society for Clinical Trials Active Member	04/2011

Journal Responsibilities

Journal Editorial Responsibilities

Advances in Hematology Board Member	- 12/31/2022
American Journal of Hematology Editorial Advisory Board Associate Editor	01/2009 - 12/2011 12/2011 - 12/31/2022
Blood Advances Editorial Board Member	09/2016 - Present
Blood Cancer Journal Editorial Advisory Board	01/01/2017 - Present
Community Oncology Editorial Advisory Board	11/2012 - 12/31/2022
European Journal of Clinical and Medical Oncology Board Member	07/2011 - 12/31/2022
Indian Society of Hematology and Transfusion Medicine International Editorial Board member	03/2014 - Present
LANCET Hematology Editorial Advisory Board	07/16/2014 - 12/31/2017
Leukemia Board Member	09/2010 - Present
Leukemia Research Reports Section Editor	02/2016 - 01/01/2019

Oncology and Hematology Review Editor-in-Chief	03/01/2017 - 12/31/2022
Oncology and Therapy Editor-in-Chief	05/31/2017 - 12/31/2022
The Hematologist Editor in Chief	01/01/2023 - Present

Journal Other Responsibilities

Advances in Therapy Advisory Board Member	06/2009 - Present
Clinical Oncology News Advisory Board Member	04/2011 - Present

Education Interests and Accomplishments

Curriculum and Course Development

BMT Core Curriculum For Heme Onc Trainees Graduate School of Medicine Advanced Myeloma Fellowship One year fellowship after Hematology Oncology fellowship Graduate School of Medicine	01/01/2017 - Present
---	----------------------

Teaching

Teaching Medical Students rotating through Internal Medicine and sub-specialties in-patient services Mayo Medical School Rochester, Minnesota	
Teaching Medical Students rotating through Hematology and Oncology in-patient teaching and consults services Mayo Medical School Rochester, Minnesota	
Hepatic Veno-occlusive Disease Post Hematopoietic Stem Cell Transplantation Transplant Center Grand Rounds, Mayo Clinic Rochester, Minnesota	02/2002
Hepatic Veno-occlusive Disease (Sinusoidal Obstruction Syndrome) Post-hematopoietic Stem Cell Transplantation Hematology Core Curriculum Presentation Mayo Graduate School of Medicine	11/2002
Effect of bcl2 Overexpression on Measles Virus Mediated Cytotoxicity in Lymphoma Cell Lines Molecular Medicine Program Presentation, Mayo Clinic Rochester, Minnesota	12/19/2002
Multiple Myeloma - A Review Tuesday morning lecture series. Austin Medical Center Austin, Minnesota	06/10/2003
Cord Blood Transplantation-Current Status BMT Core Curriculum Transplant Center, Mayo Clinic	01/2006
Current Approaches to Managing Multiple Myeloma Current Issues in Cancer Care Nursing	07/29/2009
Myeloma: Clinical Manifestations, Prognostic Factors, and Treatment Mayo Graduate School of Medicine	03/2011
Multiple Myeloma: mSMART approach Professional Development Seminar for Nursing Staff	03/21/2011

Nursing

Multiple Myeloma: Current Approaches to Risk Adapted Therapy
Professional Development Seminar for Nursing Staff
Nursing

09/2011

Mentorship

Simpson MD, Lijo (Hematology/Oncology Fellow)

06/2005 - 06/2009

Description:**Current Status:** Private Practice**Outcome:**

Zirkzadeh MD, Ali (Clinical Fellow)

09/2005 - 06/2009

Description:**Current Status:** Consultant, General Internal Medicine**Outcome:**

Tan MD, Tow (Hematology/Oncology Fellow)

06/2007 - 06/2009

Description:**Current Status:** Private Practice**Outcome:**

Naina, Harris (Hematology/Oncology Fellow)

07/2007 - 06/2010

Description:**Current Status:** Faculty Member, Department of Hematology/Oncology, UT Southwestern, TX**Outcome:** Publications, presentations related to transplantation.

Kapoor MD, Prashant (Research Fellow)

01/2008 - Present

Description:**Current Status:** Consultant in Hematology, Mayo Clinic, Rochester**Outcome:** Several high impact papers in top journals on various aspects of myeloma, future staff position at Mayo.

Sinha, Shirshendu (Clinical Research Trainee)

01/2009 - 06/2011

Description:**Current Status:** Fellow in psychiatry, May Clinic**Outcome:** Several publications related to myeloma. Long term goal of pursuing psychiatric aspects of oncology

Ramakrishnan, Vijay (Basic Scientist Postdoctoral Fellow)

06/2009 - Present

Description:**Current Status:** Post Doctoral Fellow**Outcome:**

Madan, Sumit (Clinical Fellow)

07/2009 - 06/2011

Description:**Current Status:** Faculty, UT San Antonio**Outcome:** Published several manuscripts related to myeloma, likely to pursue an academic career in hematological malignancies.

Srivastava, Geetika (Hematology/Oncology Fellow)

07/2010 - 06/2013

Description:**Current Status:** Heme Onc Fellow at Mayo**Outcome:**

Gonsalves, Wison (Hematology/Oncology Fellow)

07/2011 - Present

Description:**Current Status:** Consultant , Hematology, Mayo Clinic, Rochester**Outcome:**

Rana, Vishal (Hematology/Oncology Fellow)

07/2011 - 06/2014

Description:**Current Status:** Private Practice**Outcome:**

Pandey, Shivilal (Research Trainee)

08/2012 - Present

Description:**Current Status:** Fellow**Outcome:**

Painuly, Utkarsh Description: Current Status: Residency in Internal Medicine, Galway Ireland Outcome:	07/2013 - 12/2014
Sidana, Surbhi (Hematology/Oncology Fellow) Description: Current Status: Fellow in Hematology Oncology, Mayo Clinic Outcome:	07/2015 - Present
Moritz, Binder (Hematology/Oncology Fellow) Description: Current Status: Fellow Heme Onc Outcome:	01/2016 - Present
Tandon, Nidhi (Research Fellow) Description: Current Status: Consultant Hematology, Narayan Hridulaya, Bangalore, India Outcome:	07/2016 - 02/2018
Lakshman, Arjun (Research Fellow) Description: Current Status: Research Fellow Outcome:	07/2017 - Present
Mellors, Patrick (Resident) Description: Current Status: Outcome:	09/2017 - Present

Academic Career Development

Faculty Enhancement and Educational Development Program Mayo	12/2010
---	---------

Institutional/Departmental Administrative Responsibilities, Committee Memberships and Other Activities

Mayo Clinic

Mayo Clinic Cancer Center Mayo Clinic Cancer Center Work Groups Mayo Clinic Cancer Center, Disease/Discipline Oriented Groups (DOG) Myeloma, Amyloid, and Dysproteinemia DOG Chair	12/01/2016 - Present
Mayo Clinic Committees Institutional Review Board	01/2009 - 12/31/2012

Mayo Clinic in Rochester

Department of Internal Medicine Division of Hematology Amyloid Interest Group Member Bone Marrow Transplant Program Member Dysproteinemia Clinic Member	
Mayo Clinic Rochester Committees Clinical Practice Committee - Rochester Transfusion Subcommittee Member	08/2008 - 12/31/2019

Mayo Medical Center	
Cancer Center Clinical Research	
Medical Director	11/2013 - 06/30/2021
Transplant Center Research Committee	
Vice Chair	09/2013 - 06/30/2021
Activities at Other Institutions	
ABMTR/IBMTR	
CIBMTR Plasma Cell Disorders Working Committee	
Co-Chair	02/23/2017 - Present
American Society of Hematology	
Chair, Plasma cell disorders Scientific Committee	12/07/2019 - Present
Multiple Myeloma Research Consortium	
Vice Chair	09/2016 - 12/01/2019
National Cancer Institute Myeloma Steering Committee	
Co-Chair	02/2016 - Present
National Comprehensive Cancer Network (NCCN) Myeloma Committee	
Chair	06/2016 - Present

Presentations Extramural

National or International

Invited

Monoclonal Antibodies in Multiple Myeloma Multiple Myeloma Summit Seoul, SOUTH KOREA, South Korea	- 06/18/2016
Novel Therapies for Multiple Myeloma American Society of Hematology Annual Meeting Atlanta, Georgia	12/2005
Can novel agents replace autologous stem cell transplantation (HDT) in myeloma? Cascais, Portugal	03/2008
Prognostic Factors and Staging system in Multiple Myeloma San Juan	10/2008
Therapeutic Interventions to Prevent Progression of MGUS to Multiple Myeloma AACR Cancer Prevention MEeting 2008 Washington, District of Columbia	11/2008
Improving Outcomes in Multiple Myeloma: Optimizing Induction Therapy in the Transplant Setting Massachusetts General Hospital Boston, Massachusetts	02/2009
Anti-angiogenic therapies for Multiple Myeloma International Myeloma Workshop 2009 Washington, District of Columbia	03/2009
Multiple Myeloma: A 'Decade of Progress' Medical Grand Rounds at RUSH Chicago, Illinois	04/2009
Stem cell transplantation in the era of novel agents: keeping options open EBMT Annual Meeting Education Program Gothenburg, Sweden	04/2009
Current Approaches to Managing Multiple Myeloma Oncology Nursing Society Tampa, Florida	10/2009
Multiple Myeloma: A 'Decade of Progress'	11/2009

Medical Grand Rounds at University of Pittsburgh
Pittsburgh, Pennsylvania

Clinical Debates in Multiple Myeloma: The Evolving Role of Transplant City of Hope Duarte, California	01/2010
Best of ASCO 2010: Treatment Approaches to Multiple Myeloma San Francisco, California	07/2010
ASH 2010 Highlights: Multiple Myeloma ASH New York, New York	02/2011
Stem Cell Transplantation for Myeloma: 2011 and Beyond Hematologic Malignancies: New Therapies and the Evolving Role of Transplant Chicago, Illinois	10/2011
Treatment of Newly Diagnosed Myeloma: Mayo Clinic Approach Invited Lecture: University Hospital Department of Hematology Krakow, Poland	10/2011
How I treat relapsed and / or refractory Multiple Myeloma? Indian Society of Hematology Chandigarh, India	11/2011
Management of Multiple Myeloma: Impact of Novel Molecules Targeted Therapy in Malignancy: Where the Future Is New Delhi	11/2011
When and why do I use maintenance therapy in myeloma? Indian Society of Hematology Chandigarh, India	11/2011
Emerging Treatment Options for Patients With Multiple Myeloma Fifth Annual Review of the ASH Annual Meeting: Updates in the Treatment and Management of Hematologic Malignancies Nashville, Tennessee	01/24/2012
Does risk matter when choosing therapy? ASCO symposium ASCO Annual Meeting Chicago, Illinois	05/31/2012
High risk myeloma - how to identify and manage Princess Margaret Hospital Myeloma Days Toronto, Ontario, Canada	06/12/2012
Disease Monitoring in Myeloma: The new and the old ASH Annual meeting Symposium Atlanta, Georgia	12/05/2012
Serum Free Light Chain estimation in plasma cell disorders: What have we learned? Tata Memorial Hospital Hematology Meeting Mumbai, India	03/01/2013
Multiple Myeloma: How do I treat? International Lymphoma Workshop Lugano, Switzerland	06/19/2013
MGUS and smoldering myeloma: Time to intervene? South African Society of Medical Oncology Annual Meeting	08/29/2013
Clonal evolution in monoclonal gammopathies New Trends in Hematology Istanbul, Turkey	10/08/2013
Monoclonal gammopathy of 'undetermined' significance: still 'undetermined'? European School of Hematology Dublin, Ireland	10/16/2013

Role of Stem Cell Transplant Annual Society of Hematology Friday Symposium New Orleans, Louisiana	12/06/2013
Risk Stratification in Myeloma and its Relevance in Clinical Practice Christian Medical College Annual Hematology Conference Vellore, Tamil Nadu, India	02/11/2014
Progress in Targeting the Proteasome in Relapsed/Refractory Multiple Myeloma European Hematology Association Annual Meeting Milano, Italy	06/11/2014
Impact of Prognostic Factors and Staging on Therapy Selection Annual Myeloma Meeting San Juan, Puerto Rico	06/14/2014
Multiple Myeloma: Matching therapy to patient ECOG Annual Meeting Fort Lauderdale, Florida	11/14/2014
Screening and Diagnosis of Monoclonal Gammopathies Hematocon 2014 Hyderabad, India	11/16/2014
Should MRD be Used to Guide Treatment Decisions ASH Annual Meeting Washington DC	12/05/2014
What should we do after high dose therapy? ASBMT Annual Meeting Satellite Symposium Grapevine, Texas	02/26/2015
Pim kinase inhibitors Myeloma 2015 Boston, Massachusetts	04/10/2015
New targets in Multiple Myeloma SOHO Annual Meeting Houston, Texas	04/30/2015
MGUS and SMM: Diagnosis, Prognosis, and Treatment 2015 Myeloma Summit and Flow Cytometry Workshop Beijing, China	05/14/2015
Global Advances in Myeloma: Providing Best Options for Treatment in 2015 ASH Annual Meeting Symposium Orlando, Florida	12/04/2015
Risk Adapted Therapy-Yes, of course! European Multiple Myeloma Academy Vienna, Austria	01/30/2016
Translating Biology to Therapy: The Success Story of Myeloma International Cancer Congress 2016 New Delhi, India	02/06/2016
Evolving Paradigms in Frontline Therapy for Multiple Myeloma 20th Annual Congress on Hematologic Malignancies Miami, Florida	03/18/2016
Management of Relapsed / Refractory Myeloma 8th Annual Hematologic Malignancies Demystified New York	03/19/2016
Current Management of Standard Risk Myeloma 12th International Conference of the Asian Clinical Oncology Society New Delhi, India	04/09/2016
Evolving Treatment Options and Clinical Benefits Update in MM	04/19/2016

AMCP Managed Care & Specialty Pharmacy Annual Meeting
South San Francisco, California

Is personalized therapy ready for primetime ? 05/11/2016
New Drugs in Hematology
Bologna, Italy

Making the Most of Initial Therapy of Multiple Myeloma: What's New? 06/09/2016
European Hematology Association Annual Meeting
Copenhagen, Denmark

Myeloma updates 06/19/2016
Best of ASCO 2016
Miami, Florida

Impact of Cytogenetics and Mutations on Therapy in Multiple Myeloma 06/22/2016
Innovations in Hematology 2016
Tel Aviv, Israel

New IMWG Response Criteria 06/24/2016
Advances in MRD resting in Myeloma
New York

Management of Myeloma 07/21/2016
International Myeloma Foundation Master Class
Sao Paulo, Brazil

Updates to diagnosis and staging in Multiple Myeloma 09/02/2016
International Workshop in Hematology and 8th Annual Meet of Odisha Hematology
Cuttack, India

MRD in myeloma: Why, When, and How? 09/09/2016
SOHO Annual Meeting
Houston, Texas

Stem Cell transplantation for myeloma: where do we stand today? 10/06/2016
Saudi Lymphoma/ Myeloma Meeting 2016
Riyadh, Saudi Arabia

Managing Elderly Patients With Multiple Myeloma 11/04/2016
PER Hematological Malignancies Meeting
Paris, France

How Do I Treat Relapsed/Refractory Multiple Myeloma? 11/12/2016
Haematocon 2016
Jaipur, India

Risk assessment in myeloma 12/02/2016
ASH Annual Meeting Symposium
San Diego, California

Sequencing therapies in relapsed myeloma 02/23/2017
ASBMT Annual Meeting satellite symposia
Orlando

New Options in the Management of Multiple Myeloma 03/25/2017
NCCN Annual Meeting
Orlando

Management of High Risk Myeloma 03/26/2017
Canadian Conference on Lymphoproliferative Disorders (CCOLD)
Whistler, British Columbia, Canada

Newly diagnosed Multiple Myeloma: the role of looking different; from skeletal X-ray 05/18/2017
to CT, from Bence Jones to free light chains in plasma
European School of Haematology
Paris, France

Sequencing therapies in relapsed myeloma 06/02/2017
ASCO Annual Meeting Symposia

North Chicago, Illinois

Minimal residual disease (MRD) in myeloma
MANAGING MULTIPLE MYELOMA (M3)
Melbourne, Australia 08/17/2017

Diagnostic approach to plasma cell disorders
SOHO Annual meeting
Houston, Texas 09/14/2017

Risk Adapted Treatment Strategy in Myeloma
3rd Union International Summit on Lymphoma and Myeloma
Tianjing, China 09/22/2017

MGUS & Smoldering Myeloma. How to predict outcome & "To treat or not to treat"
INTERNATIONAL MYELOMA SOCIETY Educational Symposia Series
Prague, Czech Republic 09/29/2017

Current Strategies for Management of Newly Diagnosed Multiple Myeloma
NCCN Hematologic Malignancies
San Francisco, California 10/06/2017

Novel Therapeutic Strategies for Multiple Myeloma
Japanese Society of Hematology
Tokyo, Japan 10/22/2017

Predictors of disease progression in MGUS and SMM
Haematocon 2017
Guwahati, India 11/04/2017

Updates on the Treatment of High-Risk Multiple Myeloma
Chemotherapy Foundation Symposium
New York 11/08/2017

Emerging Options in Multiple Myeloma: Targeted, Immune, and Epigenetic
Therapies
ASH Education Session
Atlanta, Georgia 12/06/2017

Oral

A Clinical Profile of Chronic Lymphocytic Leukemia
Annual Conference of the Association of Physicians of India 06/1993

Cyclosporine Therapy in Aplastic Anemia
Annual Conference of Association of Physicians of India 06/1994

Thrombocytopenia During Epoprostenol Infusion for Primary Pulmonary
Hypertension: Is there a Relation to Dose?
American Society of Hematology Meeting 12/1998

Natural History of Acute Portal Vein and Acute Mesenteric Venous Thrombosis
Poster
Digestive Diseases Week
San Diego, California 05/2000

Acquired von Willebrand's Disease: A Single Institution Experience
International Hemophilia Congress
Montreal, Quebec, Canada 06/2000

Splenectomy in Chronic Immune Thrombocytopenia and Salvage Therapies for
Post-splenectomy Relapses
International Society of Hematology Annual Meeting
Toronto, Ontario, Canada 08/2000

Primary Cardiac Sarcomas-A Single Institution Experience
American Society of Clinical Oncology Meeting
San Francisco, California 05/2001

Expression of VEGF and its Receptors by Myeloma Cells 04/2002

Plenary Session II, American Federation of Medical Research Annual Meeting
Baltimore, Maryland

Acquired von Willebrand Syndrome (AVWS) in Chronic Myeloproliferative Disorders (MPD): Clinical and Laboratory Features, and Response to Therapy 12/2002
American Society of Hematology Meeting

Peripheral Blood Stem Cell Transplantation for Primary Systemic Amyloidosis with Cardiac Involvement 12/2002
American Society of Hematology Annual Meeting
Philadelphia, Pennsylvania

Autologous Peripheral Blood Stem Cell Transplantation for Primary Refractory Multiple Myeloma 05/2003
IXth International Multiple Myeloma Workshop
Salamanca, Spain

Single Agent Dexamethasone for Induction in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplants 05/2003
IXth International Multiple Myeloma Workshop
Salamanca, Spain

ENMD-0995 (S 3-APG), a Novel Thalidomide Analogue, Has Promising Clinical Activity for Patients with Relapsed Refractory Multiple Myeloma. Preliminary Results of a Phase I Clinical Trial 12/2003
American Society of Hematology Annual Meeting
San Diego, California

Prognostic Value of Bone Marrow Angiogenesis in Patients with Multiple Myeloma Undergoing High Dose Therapy 12/2003
American Society of Hematology Annual Meeting
San Diego, California

Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance 12/2003
American Society of Hematology Annual Meeting
San Diego, California

Analysis of Outcome after Autologous Stem Transplantation in Patients with Newly Diagnosed Myeloma: Comparison of Different Induction Regimens. 12/2006
American Society of Hematology Annual Meeting

Comparable Outcomes in Secretory (SM) Versus Non-Secretory (NSM) Multiple Myeloma (MM) with Autologous Hematopoietic Stem Cell Transplantation (AuHCT) 12/2007
American Society of Hematology Annual Meeting

Improving Survival in Multiple Myeloma: Impact of Novel Therapies 12/2007
American Society of Hematology Annual Meeting

Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma 12/2007
American Society of Hematology Annual Meeting

Prognostic Value of Serum Lactate Dehydrogenase (LDH) in Patients with Primary Systemic Amyloidosis Undergoing Stem Cell Transplantation 12/2007
American Society of Hematology Annual Meeting

Serum Uric Acid Is a Novel Prognostic Factor in Patients with Primary Systemic Amyloidosis 12/2007
American Society of Hematology Annual Meeting

Phase II Trial of Lenalidomide (RevlimidTM) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma 12/2008
American Society of Hematology Annual Meeting

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study 12/2008

American Society of Hematology Annual Meeting

Allogeneic Stem Cell Transplantation (SCT) for Multiple Myeloma (MM) - What Has Changed? : A CIBMTR Analysis From 1989 - 2005 12/2009
American Society of Hematology Annual Meeting

Changes in Serum Free Light Chain Rather Than Intact Monoclonal Immunoglobulin Levels Predict Outcome with Therapy in Patients with Light Chain Amyloidosis 12/2009
American Society of Hematology Annual Meeting

Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation 12/2009
American Society of Hematology Annual Meeting

Novel Three- and Four-Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study 12/2009
American Society of Hematology Annual Meeting

Myeloma - Biology and Pathophysiology Session 12/2010
American Society of Hematology Annual Meeting

Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study 12/2010
American Society of Hematology Annual Meeting

Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma 12/2010
American Society of Hematology Annual Meeting

Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma (MM): results from a phase 1 dose-escalation study 12/2011
American Society of Hematology Annual Meeting

Poster

Prophylaxis of GVHD with Cyclosporine-Prednisone is Associated with an Increased Risk of Chronic GVHD 02/1999
Poster
American Society of Bone Marrow Transplantation Annual Conference
Keystone, Colorado

A 25 Year Single Institutional Experience with Autoimmune Factor VIII Inhibitors (Acquired Hemophilia) 12/2000
Poster
American Society of Hematology Annual Meeting
San Francisco, California

Bone Marrow Angiogenesis in Multiple Myeloma : Effect of Therapy and Prognostic Value 12/2000
Poster
American Society of Hematology Annual Meeting
San Francisco, California

Early Prediction of Relapse after Allogenic Transplantation for AML 12/2000
American Society of Hematology Annual Meeting
San Francisco, California

High Incidence of Gastrointestinal Bleeding after Autologous Transplantation for Primary Systemic Amyloidosis 12/2000
Poster
American Society of Hematology Annual Meeting
San Francisco, California

Omission of Day +11 Methotrexate for Graft-versus-host Disease Prophylaxis after Allogeneic BMT Increases the Risk of Severe Acute Graft-versus-host Disease Poster American Society of Hematology Annual Meeting San Francisco, California	12/2000
Charcoal Hemofiltration For Hepatic Venous Occlusive Disease After Hematopoietic Stem Cell Transplantation Poster American Society of Hematology Annual Meeting Orlando, Florida	12/2001
Lymphocyte Recovery After Allogeneic Bone Marrow Transplantation Predicts Risk Of Relapse In Acute Lymphoblastic Leukemia Poster American Society of Bone Marrow Transplantation Annual Conference Orlando, Florida	02/2002
Hepatic Venous Outflow Obstruction Among Patients With Chronic Myeloproliferative Disorders Poster AASLD Single Topic Conference :Hepatic Vascular Diseases: Hepatic Venooclusive Disease and Hepatic Vascular Thrombosis Atlanta, Georgia	03/2002
Autologous Peripheral Blood Stem Cell Transplantation for Primary Refractory Multiple Myeloma Poster American Society of Hematology Annual Meeting Philadelphia, Pennsylvania	12/2002
Bcl-2 Over-Expression Results in Decreased Measles Virus Mediated Cytotoxicity in Lymphoma Cell Lines Poster American Society of Hematology Annual Meeting Philadelphia, Pennsylvania	12/2002
Expression of Angiogenic Cytokines by Plasma Cells: A Comparison of MGUS, Smoldering Myeloma and Newly Diagnosed Symptomatic Myeloma Poster American Society of Hematology Annual Meeting Philadelphia, Pennsylvania	12/2002
Natural History of Relapsed Multiple Myeloma Poster American Society of Hematology Annual Meeting Philadelphia, Pennsylvania	12/2002
Plasma Cell Labeling Index: Comparison of Peripheral Blood vs Bone Marrow Myeloma Plasma Cells Poster American Society of Hematology Annual Meeting Philadelphia, Pennsylvania	12/2002
Prognostic Value of Angiogenesis in Solitary Plasmacytoma Poster American Society of Hematology Annual Meeting Philadelphia, Pennsylvania	12/2002
Serum Syndecan (CD138) Levels Are Increased in Patients with Symptomatic Multiple Myeloma Compared to Normal Controls, MGUS, and Smoldering Myeloma Poster American Society of Hematology Annual Meeting Philadelphia, Pennsylvania	12/2002
Single Agent Dexamethasone for Induction in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplants	12/2002

Poster

American Society of Hematology Annual Meeting
Philadelphia, Pennsylvania

Effect of Allogeneic Stem Cell Transplantation on Bone Marrow (BM) Angiogenesis in Chronic Myelogenous Leukemia 02/2003

Poster

American Society of Bone Marrow Transplantation Annual Conference
Keystone, Colorado

Lymphocyte Recovery after Allogeneic Stem Cell Transplantation: Comparison of Bone Marrow and Peripheral Blood Stem Cell Transplantation 02/2003

Poster

American Society of Bone Marrow Transplantation Annual Conference
Keystone, Colorado

Comparison of Three Different Induction Regimens in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation 05/2003

Poster Discussion

American Society of Clinical Oncology Annual Meeting
Chicago, Illinois

Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Reduced Renal Function: A Matched Set Comparison. 12/2006

American Society of Hematology Annual Meeting

Autologous Stem Cell Transplantation Provides Additional Cyto-reduction Following Induction Therapy in Multiple Myeloma. 12/2006

American Society of Hematology Annual Meeting

Comparison of Serum Free Light Chain Levels and 24 Hour Urinary Monoclonal Protein Secretion in Patients with Myeloma: Concordant Changes with Response to Therapy. 12/2006

American Society of Hematology Annual Meeting

Epigallocatechin-3-Gallate (EGCG), a Polyphenol Extracted from Green Tea, Has Significant In Vitro Activity Against Myeloma Cells. 12/2006

American Society of Hematology Annual Meeting

High Incidence of IgH Translocations in Monoclonal Gammopathies with Abnormal Free Light Chain Levels. 12/2006

American Society of Hematology Annual Meeting

Mi-63, a Small Molecule Inhibitor of MDM2-p53 Interaction, Has Significant In Vitro Activity in Multiple Myeloma. 12/2006

American Society of Hematology Annual Meeting

Delayed Platelet Engraftment and Outcome of Stem Cell Transplant for Multiple Myeloma: Possible Microenvironment Effect? 12/2007

American Society of Hematology Annual Meeting

Effect of Thrombotic Events on Overall Survival in Patients with Newly Diagnosed Myeloma: Analysis from a Randomized Phase III Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma (E1A00) 12/2007

American Society of Hematology Annual Meeting

Outcome after Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Preceding Plasma Cell Disorders 12/2007

American Society of Hematology Annual Meeting

Pegylated Liposomal Doxorubicin (PLD) in Combination with Bortezomib (B) May Provide Therapeutic Advantage for High-Risk Multiple Myeloma Patients Relapsing within 12 Months of Stem Cell Transplant 12/2007

American Society of Hematology Annual Meeting

Association of High Levels of Free Light Chain and the Presence of IgH Translocations in Multiple Myeloma and Prognostic Implications 12/2008

American Society of Hematology Annual Meeting

Normalization of the Serum Free Light Chain (FLC) Ratio Is Associated with Superior Overall Survival among Myeloma Patients Achieving Immunofixation Negative State: Results Support Incorporation of Serum FLC Ratio in Stringent CR Definition American Society of Hematology Annual Meeting	12/2008
Response Duration with Initial Therapy Is a Major Predictor of Overall Survival in Multiple Myeloma: Analysis from Multiple Phase III ECOG Clinical Trials American Society of Hematology Annual Meeting	12/2008
Serum Immunoglobulin Free Light Chain in Primary Amyloidosis: Prognostic Value and Correlations with Clinical Features American Society of Hematology Annual Meeting	12/2008
Stem Cell Mobilization Following Initial Therapy with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma American Society of Hematology Annual Meeting	12/2008
A Novel Prognostic Staging System for Light Chain Amyloidosis (AL) Incorporating Markers of Plasma Cell Burden and Organ Involvement American Society of Hematology Annual Meeting	12/2009
A Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone (RCD) in Patients with Light Chain Amyloidosis American Society of Hematology Annual Meeting	12/2009
Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study American Society of Hematology Annual Meeting	12/2009
Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study American Society of Clinical Oncology Annual Meeting	06/2010
Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function American Society of Hematology Annual Meeting	12/2010
Recent Improvements In Survival In Light Chain Amyloidosis and the Importance of An Early Mortality Risk Score American Society of Hematology Annual Meeting	12/2010
Differences in patterns of treatment and outcome among patients with relapsed refractory multiple myeloma from United States, Europe and Asia American Society of Hematology Annual Meeting	12/2011
Phase I trial of a novel combination of an HDAC inhibitor (LBH589) and an mTOR inhibitor (RAD001) in lymphoid and plasma cell malignancies American Society of Hematology Annual Meeting	12/2011
Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-based Initial Therapy American Society of Hematology Annual Meeting	12/2011

Regional

Invited

Stem Cell Transplantation for Myeloma Invited lecture for fellows Buffalo, New York	03/2007
An Update on the Treatment of Multiple Myeloma and Amyloidosis 20th Annual Mayo Clinic Hematology/Oncology Reviews Amelia Island, Florida	06/2009
ASH 2009 Updates: Myeloma and Amyloidosis	01/2010

7th Annual Mayo Clinic Hematology Review Minneapolis, Minnesota	
Tumor Microenvironment in Myeloma: Role of Angiogenesis 4th Mayo Clinic Angiogenesis Symposium Mackinaw, Michigan	08/2010
Angiogenesis in Myeloma: Role of Microenvironment in Cancer University of Georgia Athens, Georgia	11/2010
Optimal Strategies for Nontransplantation Candidates VA Medical Center Hackensack, New Jersey	01/2011
Advances in the management of multiple myeloma Hackensack University Medical Center Hackensack, New Jersey	03/2011
Emerging Targets and Therapies in Myeloma 9th Annual LLS Multiple Myeloma Conference Milwaukee	10/2011
Cure for multiple myeloma: Are we any closer? Grand Rounds Buffalo, New York	09/12/2012
Current Approaches to Managing Multiple Myeloma Grand Rounds Pgimer Chandigarh, India	09/29/2012
Cure for myeloma: Are we there yet? Grand Rounds, Henry Ford Detroit, Michigan	11/21/2013
Salvage Options in Myeloma Hematology meet, Apollo Hospitals Delhi, India	02/04/2014
Clinical Trials in 17p deleted myeloma PMH Myeloma Days Toronto, Ontario, Canada	04/18/2014
Multiple Myeloma: State of the art 2015 Amrita Institute of Medical Science Grand Rounds Kochi, India	12/24/2014
Multiple Myeloma: State of the Art 2015 PGIMER, Grand Rounds Hematology Chandigarh, India	01/05/2015
Multiple Myeloma: New Tools, New Paradigms UAB Hematology Update Keynote Birmingham, Alabama	02/28/2015
Impact of Prognostic Factors and Staging on Therapy Selection Moffit Cancer Center Annual update Fort Lauderdale, Florida	03/06/2015
Multiple Myeloma and Hematopoietic Cell Transplantation (HCT) National Marrow Donor Program	05/06/2016
The Evolving Role of Proteasome Inhibitors EPIC Mul(ple Myeloma in 2016 and Beyond: An Expert Panel Discussion Scottsdale, Arizona	08/26/2016
Epidemiology of MGUS and SMM Grand Rounds, PGIMER Chandigarh, India	09/30/2016

Transplant and CAR-T Cell Therapy for Myeloma Annual Mayo Hematology Update Scottsdale, Arizona	01/28/2017
ASH Highlights Kidwai Memorial Institute of Oncology Bangalore, India	02/11/2017
The Evolving Role of Stem Cell Transplantation in Multiple Myeloma Hematologic Malignancies: New Therapies and the Evolving Role of Transplant Chicago, Illinois	03/17/2017
Recent Advances in Myeloma 5th International Conference on Advances in Hematology & Oncology	08/12/2017
Approaches To Newly Diagnosed MM In Transplant Ineligible Patients INTERNATIONAL MYELOMA SOCIETY Educational Symposia Series Washington DC, Maryland	10/28/2017

Visiting Professorship

Visiting Professorships

Multiple Myeloma: Treatment and Management Strategies 2009 2009 Visiting Professors for Hematology/ Oncology fellows: Multiple Myeloma Buffalo, New York	07/2009
Angiogenesis in Myeloma: Role of Microenvironment in Cancer University of Georgia at Athens Athens, Georgia	11/16/2010

Clinical Practice Interests and Accomplishments

Epidemiology of Monoclonal gammopathies Risk stratification in multiple myeloma and high risk myeloma
Prognosis and treatment of Light chain amyloidosis Stem cell transplantation

Research Interests and Accomplishments

Study of Multiple Myeloma biology with focus on angiogenesis and bone marrow microenvironment, Development of novel targeted therapeutic agents for multiple myeloma, Phase 1 and 2 clinical trials in myeloma, Biology of High risk myeloma, Clinical Bone marrow Transplantation Research,

Quality Initiatives

Quality Improvement Projects

Cancer Center Clinical Trial Budget Process Improvement (Silver Project) Desirae D. Sagdalen (Project Editor, Team Lead), Shaji Kumar, M.D. (Team Lead), Patrick (Pat) J. Finneman Killinger, M.A. (Team Lead), Nicole K. Knutson, M.H.A., Jamie L. Crawley, Aimee L. Tillman, M.B.A., PMP.	10/22/2015
--	------------

Research Grants Awarded

Active Grants

Federal

Principal Investigator	Specialized Program of Research Excellence in Medicine - Career Development Award. Funded by National Cancer Institute. (P50 CA 100707 (CDA))	07/2004 - 06/2007
Program Director / Principal Investigator	Impact of Genetic susceptibility along the continuum from MGUS to MM. Funded by National Cancer Institute. (U01 CA 271014)	05/2022 - 04/2027
Program Director / Principal Investigator	Identifying predictive markers of progression from smoldering multiple myeloma to multiple myeloma - Year 2 Pilot. Funded by National Cancer Institute. (U01 CA271410)	10/2022 - 05/2027
Co-Program Director / Principal	Onset and biomarkers for progression of monoclonal gammopathies - Restructured - Years 7-8; Restructured - Years 8 -11. Funded by National Cancer Institute. (R01 CA 168762)	07/2019 - 06/2025

Investigator		
Co-Investigator	Differences in Tumor Biology of Multiple Myeloma in Association with African Ancestry. Funded by National Cancer Institute. (R37 CA272883)	09/2023 - 08/2028
Co-Investigator	Next-Generation Whole-Body MRI for Detection and Assessment of Therapy Response in Bone Lesions. Funded by National Cancer Institute. (R01 CA283663)	07/2024 - 06/2028

Federal sub award

Program Director / Principal Investigator	Mayo Clinic Multiple Myeloma SPORE Project 2; "Multi-Omics of high-risk MM". Funded by National Cancer Institute. (CA 186781)	09/2021 - 08/2026
Program Director / Principal Investigator	GSK Triple Refractory. Funded by GlaxoSmithKline	10/2022 - 09/2023
Program Director / Principal Investigator	International Myeloma Foundation IMWG Study of the Natural History for Triple-Class Refractory Multiple Myeloma Patients. Funded by Regeneron Pharmaceuticals	10/2022 - 09/2023

Foundation

Program Director / Principal Investigator	MMRC Site Grant Agreement. Funded by Multiple Myeloma Research Consortium. (SIG Horizon Platform Trial program)	01/2023 - 12/2025
Program Director / Principal Investigator	ASH Research Collaborative Data Hub Multiple Myeloma Study Participation Grant. Funded by ASH Research Collaborative	10/2023 - 10/2026
Co-Investigator	MMRF Immune Atlas - Statement of Work #5. Funded by Multiple Myeloma Research Foundation	03/2023 - 02/2025

Industry

Program Director / Principal Investigator	MCR MC1181 Phase 2 Trial of MLN9708 in Patients With Relapsed Multiple Myeloma Who Are Not Refractory to Bortezomib. Funded by Millennium Pharmaceuticals, Inc.. (Protocol X16001 / MC1181 / Millennium Agmt No. 223625)	06/2011 - 06/2013
Program Director / Principal Investigator	Replacement Arm 1 (Sponsor Amend 3): MC1382: Phase 1/2 trial of MLN9708 in combination with cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Funded by Millennium Pharmaceuticals, Inc.. (MC1382 / Millennium Protocol: X16009)	06/2013 - 05/2019
Program Director / Principal Investigator	MC1487 MCR Budget Dr Kumar. Funded by Millennium: The Takeda Oncology Company. (X16025)	08/2015 - 08/2018
Program Director / Principal Investigator	Janssen. Funded by Janssen Research and Development, LLC. (54767414MMY2010)	12/2016 - 12/2019
Program Director / Principal Investigator	Budget Replace#1(PA# 3) -BS001 (ASCENT). Funded by International Myeloma Foundation. (BS001)	05/2018 - 11/2019
Program Director / Principal Investigator	Takeda. Funded by Millennium Pharmaceuticals, Inc.. (X16079)	06/2018 - 05/2021
Program Director / Principal Investigator	NEW ARM Investigational Drug Name: Belantamab / MyDRUG Sub Protocol Y2. Funded by Multiple Myeloma Research Consortium. (MMRC-085)	04/2019 - 04/2022
Program Director / Principal Investigator	New ARM Investigational Drug Name: Selinexor / MyDRUG Sub Protocol Y3. Funded by Multiple Myeloma Research Consortium. (MMRC-085)	04/2019 - 04/2022

Program Director / Principal Investigator	NO CHANGES THIS ARM Investigational Drug Name: Enasidenib MyDRUG Sub Protocol B1 - IDH2 Activating Mutation. Funded by Multiple Myeloma Research Consortium. (MMRC-085)	04/2019 - 04/2022
Program Director / Principal Investigator	NO CHANGES TO THIS ARM Investigational Drug Name: Abemaciclib / MyDRUG Sub Protocol A1. Funded by Multiple Myeloma Research Consortium. (MMRC-085)	04/2019 - 04/2022
Program Director / Principal Investigator	NO CHANGES TO THIS ARM Investigational Drug Name: Cobimetinib MyDRUG Sub Protocol C1 - RAF/RAS Mutation. Funded by Multiple Myeloma Research Consortium. (MMRC-085)	04/2019 - 04/2022
Program Director / Principal Investigator	NO CHANGES TO THIS ARM Investigational Drug Name: Daratumumab / MyDRUG Sub Protocol Y1. Funded by Multiple Myeloma Research Consortium. (MMRC-085)	04/2019 - 04/2022
Program Director / Principal Investigator	NO CHANGES TO THIS ARM Investigational Drug Name: Venetoclax MyDRUG Sub Protocol E1. Funded by Multiple Myeloma Research Consortium. (MMRC-085)	04/2019 - 04/2022
Program Director / Principal Investigator	NO CHANGES TO THIS ARM MyDRUG Sub Protocol D1 - Erdafitinib. Funded by Multiple Myeloma Research Consortium. (MMRC-085)	04/2019 - 04/2022
Program Director / Principal Investigator	ECOG-ACRIN EAA173. Funded by Janssen Scientific Affairs, LLC. (EAA173J)	04/2019 - 12/2022
Program Director / Principal Investigator	AMEND #7: ARM A TNB383B.0001. Funded by TeneoOne, Inc. (TNB383B.0001 TNB-383B)	08/2019 - 08/2021
Program Director / Principal Investigator	AMEND #7: ARM B TNB383B.0001. Funded by TeneoOne, Inc. (TNB383B.0001 TNB-383B)	08/2019 - 08/2021
Program Director / Principal Investigator	AMEND #7: ARM E TNB383B.0001. Funded by TeneoOne, Inc. (TNB383B.0001 TNB-383B)	08/2019 - 08/2021
Program Director / Principal Investigator	AMEND #7: ARM F TNB383B.0001. Funded by TeneoOne, Inc. (TNB383B.0001 TNB-383B)	08/2019 - 08/2021
Program Director / Principal Investigator	Collaborative Research Agreement: Telo Genomics - Lab Services. Funded by Telo Genomics	11/2019 - 11/2020
Program Director / Principal Investigator	Amend #4: CT053-MM-02. Funded by CARsgen Therapeutics Corporation . (CT053-MM-02)	12/2019 - 12/2024
Program Director / Principal Investigator	Cohort C. Funded by Allogene Therapeutics. (ALLO-715-101)	05/2020 - 04/2022
Program Director / Principal Investigator	Cohorts A & B. Funded by Allogene Therapeutics. (ALLO-715-101)	05/2020 - 04/2022
Program Director / Principal Investigator	Budget Replacement_PA3_CC-98633-MM-001. Funded by Juno Therapeutics . (CC-98633-MM-001)	09/2020 - 09/2022
Program Director / Principal Investigator	Replacement #1 Prospective Observational Study of Patient-Reported and Clinical Outcomes among Patients with Triple-Class Refractory Multiple Myeloma (TCR MM) (A MagnetisMM-Real World [RW] Study). Funded by Pfizer Pharmaceuticals	09/2021 - 09/2023
Program Director / Principal Investigator	CC-98633-MM-001 - Secondment. Funded by ThreeWire, Inc.	10/2021 - 04/2022

Program Director / Principal Investigator	R5458-ONC-2012-Cohort 5. Funded by Regeneron Pharmaceuticals, Incorporated. (R5458-ONC-2012 Kumar)	06/2022 - 06/2024
Program Director / Principal Investigator	R5458-ONC-2012-Cohort 6. Funded by Regeneron Pharmaceuticals, Incorporated. (R5458-ONC-2012 Kumar)	06/2022 - 06/2024
Program Director / Principal Investigator	320mg Monotherapy ESC. Funded by AbbVie Inc.. (M21-406)	11/2022 - 11/2024
Program Director / Principal Investigator	80mg Monotherapy ESC. Funded by AbbVie Inc.. (M21-406)	11/2022 - 11/2024
Program Director / Principal Investigator	Am#2 - M24-108_ARM A. Funded by AbbVie Inc.. (M24-108)	05/2023 - 05/2024
Program Director / Principal Investigator	Am#2 - M24-108_ARM B. Funded by AbbVie Inc.. (M24-108)	05/2023 - 05/2024
Program Director / Principal Investigator	Am#2 - M24-108_ARM C. Funded by AbbVie Inc.. (M24-108)	05/2023 - 05/2024
Program Director / Principal Investigator	Am #2 CO43476 Cohorts A1, B1, A2, and B2 and TCZ Treatment. Funded by Genentech Inc. (CO43476)	05/2023 - 05/2025
Program Director / Principal Investigator	MC210808 Dr. Kumar's IIT with venetoclax. Funded by Genentech Inc. (MC210808)	09/2023 - 09/2026
Program Director / Principal Investigator	Amend #1: A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma. Funded by Janssen Research and Development, LLC. (64007957MMY1003)	11/2023 - 10/2025
Program Director / Principal Investigator	Amend #1: GC012F-CD19/BCMA-001. Funded by Astra Zeneca Pharmaceuticals. (GC012F-CD19/BCMA-001)	02/2024 - 01/2027
Program Director / Principal Investigator	IQVIA RRMM Retrospective Chart Review. Funded by Kite Pharmaceuticals	08/2024 - 02/2025
Program Director / Principal Investigator	OriCAR-017-US-P1. Funded by Oricell Therapeutics Inc. (OriCAR-017-US-P1)	01/2025 - 01/2027
Program Director / Principal Investigator	Arm 1: Etentamig (ABBV-383). Funded by AbbVie Inc.. (M22-574)	04/2025 - 04/2026
Program Director / Principal Investigator	Arm 2: SAT. Funded by AbbVie Inc.. (M22-574)	04/2025 - 04/2026
Co-Investigator	MC078E, "Phase I/II Study Of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine And Prednisone (R2chop) Chemoimmunotherapy In Patients With Newly Diagnosed Diffuse Large Cell And Follicular Grade IIIA/B B Cell Lymphoma". Funded by Celgene. (MC078E/RV-NHL-PI-325)	02/2008 - 01/2012

Mayo Clinic

Program Director / Principal Investigator	EAA181 Arm A Induction. Funded by Hybrid Intramural Proposal for Cancer Center	03/2021 - 02/2026
Program Director / Principal Investigator	EAA181 Arm B & C Consolidation and Maintenance. Funded by Hybrid Intramural Proposal for Cancer Center	03/2021 - 02/2026
Program Director / Principal Investigator	Identifying Mechanisms of Immunotherapeutic Resistance in Extramedullary Multiple Myeloma through a Spatial Characterization of the Immune Tumor Microenvironment . Funded by SGP - Small Grants Program <\$10K	01/2024 - 01/2026

Completed Grants**Federal**

Principal Investigator	Chromosomal Abnormalities in Myeloma as Detected by FISH. Funded by National Cancer Institute. (R01 CA083724)	03/2006 - 02/2008
Program Director / Principal Investigator	Onset and biomarkers for progression of monoclonal gammopathies. Funded by National Cancer Institute. (R01 CA 168762)	07/2012 - 04/2019
Program Director / Principal Investigator	Prevalence and Progression of Monoclonal Gammopathies. Funded by National Cancer Institute. (R01 CA 107476)	04/2014 - 08/2021
Co-Investigator	Signal transduction inhibitor therapy for Lymphoma. Funded by National Cancer Institute. (R01 CA 127433)	09/2007 - 07/2014
Co-Investigator	Phase I Clinical Trials of Anticancer Agents. Funded by National Cancer Institute. (U01 CA 69912)	07/2008 - 02/2014
Co-Investigator	Prevalence and Progression of Monoclonal Gammopathies. Funded by National Cancer Institute. (R01 CA 107476)	03/2009 - 04/2014

Federal sub award

Program Director / Principal Investigator	MMRC-020-021. Funded by Cephalon, Incorporated. (MMRC-020 -021)	09/2009 - 08/2011
Program Director / Principal Investigator	Translation of Novel Therapeutic Targets in Multiple Myeloma. Funded by National Cancer Institute. (CA 167511)	01/2013 - 12/2017
Program Director / Principal Investigator	The Role of Cereblon Pathways in Myeloma. Funded by National Cancer Institute. (CA 183968)	04/2014 - 06/2019
Program Director / Principal Investigator	MN Partnership for Biotechnology - Predicting Response and Resistance to Proteasome Inhibitors in Multiple Myeloma. Funded by Minnesota Partnership for Biotechnology and Medical Genomics. (P004925901)	02/2015 - 01/2018
Program Director / Principal Investigator	Arm A: MCR: 54767414MMY3008. Funded by Janssen Research and Development, LLC. (54767414MMY3008 219155 100806)	06/2015 - 05/2020
Program Director / Principal Investigator	Arm B: MCR:54767314MMY3008 (Includes Mayo Fees). Funded by Janssen Research and Development, LLC. (54767414MMY3008 219155 100806)	06/2015 - 05/2020
Program Director / Principal Investigator	Mayo Clinic Multiple Myeloma SPORE Project 4; "Clonal Evolution in Multiple Myeloma". Funded by National Cancer Institute. (CA 186781)	09/2015 - 08/2021
Program Director / Principal Investigator	MC1582 MCR Dr S Kumar MDM2 MMRC-061. Funded by Multiple Myeloma Research Consortium. (MMRC-061)	12/2015 - 12/2018

Program Director / Principal Investigator	Project 1 High Throughput Drug Screening and Correlations with Mutational Status in Myeloma Cell Lines and Patient Samples - added 7/2020. Funded by National Cancer Institute. (CA 224018)	09/2017 - 08/2023
Program Director / Principal Investigator	Project 3 - Modeling Proteasome Inhibitor Response and Resistance in Cell Lines and Patient Samples with Single Cell Analysis of Subpopulations. Funded by National Cancer Institute. (CA 224018)	09/2017 - 08/2023
Program Director / Principal Investigator	EAA172 Lab Support- Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone with or without Venetoclax in Relapsed/Refractory Multiple Myeloma. Funded by Genentech Inc. (EAA172)	01/2019 - 12/2019
Program Director / Principal Investigator	EAA172 Lab Support- Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone with or without Venetoclax in Relapsed/Refractory Multiple Myeloma. Funded by Genentech Inc. (EAA172)	01/2019 - 12/2019
Program Director / Principal Investigator	Early Onset Myeloma Initiative. Funded by National Cancer Institute. (CA 189823)	08/2021 - 07/2023
Co-Investigator	Signal transduction inhibitor therapy for Lymphoma. Funded by National Cancer Institute. (CA 97274)	07/2007 - 06/2012
Co-Investigator	MC0882: A Phase 2 Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide and Dexamethasone (R2-CD) for symptomatic untreated low grade non-Hodgkin lymphoma. Funded by Celgene. (RV-NHL-PI-0336/MC0882)	05/2008 - 04/2013
Co-Investigator	MC0885, Rev/Dex in MM patients with impaired renal function. Funded by Celgene. (RV-MM-PI-0394/MC0885)	08/2008 - 07/2012
Co-Program Director / Principal Investigator	MC088A. Funded by Millennium Pharmaceuticals, Inc.. (MC088A/X14003)	01/2009 - 01/2012
Co-Investigator	Celgene/MC0981. Funded by Celgene. (MC0981 / RV-NHL-PI-0466)	09/2009 - 08/2014
Co-Investigator	Novartis/MC0981. Funded by Novartis. (MC0981 / CRAD001NUS113T)	09/2009 - 08/2014
Co-Investigator	A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies. Funded by Genzyme Corporation. (CIBMTR PROTOCOL 09-PLEX / Genzyme Protocol #MAMO0109-2)	04/2013 - 03/2016
Co-Investigator	Influence of germ line genetic variation on myeloma progression and survival. Funded by National Cancer Institute. (CA 191896)	12/2014 - 11/2017
Co-Program Director / Principal Investigator	TED10893 Phase II. Funded by Sanofi Aventis. (Work Order No. 11 / Protocol No. TED10893)	01/2015 - 01/2017
Co-Investigator	Developing a resource for genomic and racial characterization to address racial disparities in the biology and prevalence of multiple myeloma. Funded by National Cancer Institute. (CA 186781)	09/2018 - 08/2019

Foundation

Program Director / Principal Investigator	National Foundation for Cancer Research: Institute for Clinical Research Excellence. Funded by National Foundation for Cancer Research	01/2007 - 12/2009
Program Director / Principal Investigator	Targeting Vascular Endothelial Growth Factor for Treatment of Myeloma. Funded by Multiple Myeloma Research Foundation	09/2007 - 06/2011

Program Director / Principal Investigator	Natural History of Relapsed Myeloma. Funded by International Myeloma Foundation. (IMF-01)	04/2009 - 03/2011
Program Director / Principal Investigator	Multiple Myeloma Research Consortium Project Coordinator. Funded by Multiple Myeloma Research Consortium. (MMRC)	10/2009 - 12/2009
Program Director / Principal Investigator	MMRC Site Investment Grant. Funded by Multiple Myeloma Research Consortium. (MMRC-2011)	01/2011 - 12/2015
Program Director / Principal Investigator	MMRF-11-001, A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles (the "Study"). Funded by Multiple Myeloma Research Foundation. (MMRF-11-001)	06/2012 - 06/2020
Program Director / Principal Investigator	Observational Study of the Regional Variation of Clinical Outcomes and Treatment of Patients with Relapsed Multiple Myeloma. Funded by International Myeloma Foundation. (IMF-03)	07/2012 - 06/2013
Program Director / Principal Investigator	International Myeloma Foundation Study of the Natural History of Relapsed and Refractory Multiple Myeloma in the Era of Novel Agents: Medical Chart Review. Funded by International Myeloma Foundation	01/2015 - 12/2016
Program Director / Principal Investigator	The international Myeloma Foundation for Shaji Kumar. Funded by International Myeloma Foundation	01/2015 - 12/2016
Program Director / Principal Investigator	INTERNATIONAL MYELOMA FOUNDATION ASSESSING OUTCOMES AFTER INITIAL RELAPSE AND IMPACT ON HEALTH CARE UTILIZATION IN THE CURRENT ERA: MEDICAL CHART REVIEW. Funded by International Myeloma Foundation	12/2015 - 11/2017
Program Director / Principal Investigator	MMRC Site Grant Agreement. Funded by Multiple Myeloma Research Consortium	01/2016 - 12/2022
Program Director / Principal Investigator	Dr. Kumar 2015 MMRF Innovator Award. Funded by Multiple Myeloma Research Foundation	04/2016 - 03/2017
Program Director / Principal Investigator	MCR MMRF-002: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies. Funded by Multiple Myeloma Research Foundation	10/2016 - 09/2022
Program Director / Principal Investigator	Redefining natural history of smoldering multiple myeloma and developing a new risk stratification system. Funded by International Myeloma Foundation	09/2017 - 08/2020
Program Director / Principal Investigator	Dr. Kumar 2018 MMRC Innovator Award. Funded by Multiple Myeloma Research Consortium	12/2018 - 12/2019
Program Director / Principal Investigator	Immune Profiling of the Bone Marrow Microenvironment in Multiple Myeloma. Funded by Multiple Myeloma Research Foundation	05/2019 - 12/2019
Program Director / Principal Investigator	MMRF Immune Atlas. Funded by Multiple Myeloma Research Foundation	10/2020 - 09/2021

Industry

Principal Investigator	Pre-clinical Evaluation of Polyclonal Rabbit Anti-Thymocyte Globulin in Multiple Myeloma. Funded by Genzyme Corporation. (GENZYME #14; 1A5554)	03/2005 - 02/2006
------------------------	--	-------------------

Program Director / Principal Investigator	Celene - #37 - Amdt #1 - CC-5013 - MM-016 - A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects with Multiple Myeloma. Funded by Celgene. (CC-5013-MM-016)	04/2006 - 03/2009
Principal Investigator	Preclinical/Laboratory work to investigate the biology of BLyS and APRIL in Multiple Myeloma using TACI-Ig and other drugs. Funded by ZymoGenetics, Inc.. (ZYMOGENETICS #4, 1A5988)	05/2006 - 04/2008
Program Director / Principal Investigator	MC058E - A Phase II Trial of Revlimid, Cyclophosphamide and Dexamethasone in Patients with Newly Diagnosed Active Multiple Myeloma. Funded by Celgene. (RV-MM-PI-0116/MC058E)	06/2006 - 05/2009
Program Director / Principal Investigator	MC0685 - A Phase II Trial of Revlimid, Cyclophosphamide and Dexamethasone in Patients with Primary Systemic Amyloidosis. Funded by Celgene. (MC0685/RV-AMY-PI-0145)	01/2007 - 12/2009
Program Director / Principal Investigator	Laboratory Services Agreement for Protocol C05008 "Phase 1/2 Study of VELCADE (Bortezomib), Dexamethasone, and Revlimid (Lenalidomide) (VDR) versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid (VDCR) in Subjects with Prev...". Funded by Millennium Pharmaceuticals, Inc.. (Millennium Agreement No. 215153)	06/2007 - 05/2009
Program Director / Principal Investigator	C05008: "Phase 1/2 Study of VELCADE (Bortezomib), Dexamethasone, and Revlimid (Lenalidomide) (VDR) versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid (VDCR) in Subjects with Previously Untreated Multiple Myeloma". Funded by Millennium Pharmaceuticals, Inc.. (Protocol C05008 / Agreement No. 215348)	11/2007 - 10/2010
Program Director / Principal Investigator	MC078A, "A Phase I/II Study of the Sorafenib in Combination with Lenalidomide in Patients with Relapsed Multiple Myeloma". Funded by Bayer HealthCare AG. (MC078A / SR06-933)	01/2008 - 12/2010
Program Director / Principal Investigator	REPLACEMENT BUDGET - Amendment #1 - MC0687 - A Phase II Trial of Thymoglobulin and Melphalan in Patients with Relapsed Multiple Myeloma. Funded by Genzyme Corporation. (MC0687)	04/2008 - 03/2010
Program Director / Principal Investigator	MC0884 - Correlative work. Funded by Celgene. (RV-MM-PI-0367/MC0884)	09/2008 - 09/2010
Program Director / Principal Investigator	MC0884, "A Phase II Trial of Revlimid® and "On demand" dexamethasone dosing in Patients with Newly Diagnosed Symptomatic Multiple Myeloma". Funded by Celgene. (RV-MM-PI-0367/MC0884)	09/2008 - 09/2010
Program Director / Principal Investigator	A Phase I/II Trial of LBH589 and RAD001 in Patients with Relapsed Multiple Myeloma or Non-Hodgkin's Lymphoma. Funded by Novartis. (CLBH589BUS17T/MC0886)	10/2008 - 09/2010
Program Director / Principal Investigator	In vitro effects of pomalidomide in primary Myeloma cells obtained from patients with relapsed Myeloma who are refractory to lenalidomide. Funded by Celgene	01/2009 - 12/2009
Program Director / Principal Investigator	MC0889. Funded by Genzyme Corporation. (MC0889)	01/2009 - 01/2010
Program Director / Principal Investigator	TAK-901_101: Phase 1 study of TAK-901 in Subjects with Advanced Hematologic Malignancies. Funded by Millennium Pharmaceuticals, Inc.. (Protocol TAK 901-101)	09/2009 - 08/2010
Program Director / Principal Investigator	C16004. Funded by Millennium Pharmaceuticals, Inc.. (Protocol C16004 / Appendix Agmt #219618)	10/2009 - 09/2011
Program Director / Principal Investigator	MC0985: Phase II study of bortezomib, cyclophosphamide and dexamethasone in patients with primary systemic (light chain amyloidosis). Funded by Millennium Pharmaceuticals, Inc..	12/2009 - 12/2012

(MC0985 / Protocol X05306 / Agreement No. 220519)

Program Director / Principal Investigator	C16005. Funded by Millennium Pharmaceuticals, Inc.. (Protocol C16005 / Millennium Agreement Number 220299)	10/2010 - 09/2013
Program Director / Principal Investigator	MC1187: Phase 2 trial of retreatment with lenalidomide and dexamethasone for patients with relapsed myeloma. Funded by Celgene. (Celgene Reference # RV-MM-PI-0474)	01/2012 - 01/2015
Program Director / Principal Investigator	Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined and significance and smoldering myeloma. Funded by Janssen Research and Development, LLC	04/2012 - 03/2014
Program Director / Principal Investigator	NO COST END DATE EXT: Replacement #3 CLGH447X2101 Escalation. Funded by Novartis. (Protocol LGH447X2101)	06/2012 - 09/2017
Program Director / Principal Investigator	NO COST END DATE EXT: Replacement #3 CLGH447X2101 Expansion. Funded by Novartis. (Protocol LGH447X2101)	06/2012 - 09/2017
Program Director / Principal Investigator	C16010: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma. Funded by Millennium Pharmaceuticals, Inc.. (Protocol C16010)	09/2012 - 09/2015
Program Director / Principal Investigator	Bdget Amnd 2 (Protcl Amend 4) - Safety Expansion-M12-901: A Phase 1b Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects who are Receiving Bortezomib and Dexamethasone as their Standard Therapy. Funded by AbbVie Inc.. (Protocol M12-901)	12/2012 - 12/2015
Program Director / Principal Investigator	Bdget Amnd 2 (Protcl Amend 4) -Dose Escalation M12-901: A Phase 1b Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects who are Receiving Bortezomib and Dexamethasone as their Standard Therapy. Funded by AbbVie Inc.. (Protocol M12-901)	12/2012 - 12/2015
Program Director / Principal Investigator	Pilot study to assess the clinical outcomes of patients with newly diagnosed multiple myeloma receiving frontline bortezomib-containing three-drug regimens. Funded by Millennium	03/2013 - 02/2014
Program Director / Principal Investigator	MC1287: A Phase 2 Trial of Carfilzomib Consolidation Following Autologous Stem Cell Transplantation for Multiple Myeloma (CAMEL 2). Funded by Onyx Pharmaceuticals Corporation. (MC1287 / Protocol 117659 / Onyx Reference Number: IST-CAR-551)	03/2013 - 02/2019
Program Director / Principal Investigator	MCR MC1286: Bortezomib, melphalan and low dose TBI conditioning for patients undergoing autologous stem cell transplantation for multiple myeloma. Funded by Millennium: The Takeda Oncology Company. (MC1286 / Millennium Protocol X05399)	04/2013 - 03/2018
Program Director / Principal Investigator	Prognostic significance of Alpha 1-acid glycoprotein (AAG) in multiple myeloma. Funded by Array BioPharma, Inc.	08/2013 - 07/2014
Program Director / Principal Investigator	C16014: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma. Funded by Millennium Pharmaceuticals, Inc.. (Protocol C16014)	08/2013 - 07/2016
Program Director / Principal Investigator	Amend 1 Repl C16020 Arm C. Funded by Millennium Pharmaceuticals, Inc.. (Millennium Protocol C16020 / Appendix 21)	04/2014 - 03/2017

Program Director / Principal Investigator	Amend 1 Repl C16020 Arms A & B. Funded by Millennium Pharmaceuticals, Inc.. (Millennium Protocol C16020 / Appendix 21)	04/2014 - 03/2017
Program Director / Principal Investigator	Replacement Budget #3 - Rd Arm. Funded by Janssen Research and Development, LLC. (5476741MMY3003)	04/2015 - 09/2017
Program Director / Principal Investigator	Repl Am 3 (INTERNAL ONLY): MK-3475-155 CLL. Funded by Merck & Co., Inc.. (MK-3475-155)	08/2016 - 08/2019
Program Director / Principal Investigator	Repl Am 3 (INTERNAL ONLY): MK-3475-155 DLBCL. Funded by Merck & Co., Inc.. (MK-3475-155)	08/2016 - 08/2019
Program Director / Principal Investigator	Repl Am 3 (INTERNAL ONLY): MK-3475-155 MM. Funded by Merck & Co., Inc.. (MK-3475-155)	08/2016 - 08/2019
Program Director / Principal Investigator	A non-interventional study exploring quality of life in multiple myeloma according to treatment following autologous stem cell transplant. Funded by Celgene. (MRS-MM-REV-USA-071020151)	09/2016 - 09/2017
Program Director / Principal Investigator	MC168C Vene-Ixa AbbVie budget. Funded by Multiple Myeloma Research Consortium. (ABT-199)	02/2017 - 01/2021
Program Director / Principal Investigator	C16029: Arm A. Funded by Takeda Pharmaceuticals International Co. . (C16029)	01/2018 - 12/2019
Program Director / Principal Investigator	C16029: Arm B. Funded by Takeda Pharmaceuticals International Co. . (C16029)	01/2018 - 12/2019
Program Director / Principal Investigator	INCREASE PATIENTS TO 29 Amend 2 (Replc) Phase 1 ARM (ProtocolAmend6). Funded by AbbVie Inc.. (M13-367)	01/2018 - 01/2021
Program Director / Principal Investigator	NO CHANGES for Amend 2 (Replc) Dose Escalation and Safety Expansion Arms (Prot Amend 6). Funded by AbbVie Inc.. (M13-367)	01/2018 - 01/2021
Program Director / Principal Investigator	Phase 2 ARM (Prot Amend6). Funded by AbbVie Inc.. (M13-367)	01/2018 - 01/2021
Program Director / Principal Investigator	A Phase 1 Multicenter Study of KITE-585, an Autologous anti-BCMA CAR T Cell Therapy, in Subjects with Relapsed/refractory Multiple Myeloma. Funded by Kite Pharmaceuticals. (KITE 585-501)	03/2018 - 03/2023
Program Director / Principal Investigator	Natural history of t(11;14) myeloma. Funded by AbbVie Inc.	06/2018 - 05/2020
Program Director / Principal Investigator	Amendment 1 - Service Agreement- My Drug (MMRC-085) with Dr. Kumar. Funded by Multiple Myeloma Research Consortium. (MY DRUG MMRC-085)	07/2018 - 07/2022
Program Director / Principal Investigator	ECTx (MCR-lead) D7900C00001; A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects with Relapsed/Refractory Multiple Myeloma. Funded by MedImmune, Inc.. (D7900C00001 05970099)	08/2018 - 08/2020
Program Director / Principal Investigator	ECTx TAK-169-1001 Kumar Every-Other-Week Dosing. Funded by Molecular Templates, Inc.. (TAK-169-1001)	10/2019 - 10/2021
Program Director	ECTx TAK-169-1001 Amd3 Kumar Weekly Dosing. Funded by	10/2019 - 10/2021

/ Principal Investigator	Molecular Templates, Inc.. (TAK-169-1001)	
Program Director / Principal Investigator	Characterization of outcomes, quality of life, and management of conversion to subcutaneous Daratumumab in multiple myeloma patients receiving Daratumumab intravenous therapy. Funded by Nference, Inc.	07/2020 - 03/2021
Program Director / Principal Investigator	A study of Patient and Provider Experience with Subcutaneous Daratumumab Compared with Intravenous Daratumumab. Funded by Nference, Inc.	11/2020 - 03/2021
Program Director / Principal Investigator	MC1989. Funded by GlaxoSmithKline. (MC1989)	03/2021 - 03/2025
Program Director / Principal Investigator	PCL 19135 - Chart Review. Funded by Amgen	04/2021 - 03/2022
Program Director / Principal Investigator	CDAP: Characterization of conversion from daratumumab IV to subcutaneous daratumumab in multiple myeloma patients - Extension Study. Funded by Nference, Inc.	06/2021 - 07/2021
Program Director / Principal Investigator	MCP: Daratumumab and DRd regimen (daratumumab, lenalidomide, and dexamethasone) treatment in Multiple Myeloma Patients. Funded by Nference, Inc.	11/2021 - 02/2022
Program Director / Principal Investigator	Am #1 ALLO-605-201. Funded by Allogene Therapeutics. (ALLO-605-201)	12/2021 - 12/2024
Program Director / Principal Investigator	Light Chain Amyloidosis Real World Evidence (RWE) Consortium (LARC): Multi-Center Chart Review. Funded by Genentech Inc	07/2022 - 07/2023
Program Director / Principal Investigator	Am 1- MCP: Patient characteristics, workflow, healthcare resource utilization, and transition of care related to initiating teclistamab within the Mayo Clinic. Funded by Nference, Inc.	10/2022 - 05/2023
Program Director / Principal Investigator	ACCRU-MY-1901. Funded by ACCRU (Industry). (ACCRU-MY-1901)	03/2023 - 03/2025
Co-Investigator	TRM-1-MM01 - A Phase I , Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of TRM-1 (Fully-human Monoclonal Antibody to the Trail-R1) in Subjects with Multiple Myeloma. Funded by Human Genome Sciences, Inc.. (HGS #4; 1A4824)	04/2003 - 03/2006
Co-Investigator	CC-5013-MM-020. Funded by Celgene. (CC-5013-MM-020)	07/2007 - 07/2012
Co-Investigator	MOZ00607. Funded by Genzyme Corporation. (MOZ00607)	07/2007 - 07/2009
Co-Investigator	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion in Combination with Corticosteroids for the Treatment of diagnosed Acute GVHD. Funded by Osiris Therapeutics, Inc.. (Protocol 265)	12/2007 - 11/2008
Co-Investigator	101MY201, "A Phase 1/2, Two Arm, Dose Finding Study of Natalizumab for the Treatment of Subjects with Relapsed or Refractory Multiple Myeloma". Funded by Biogen Idec . (101MY201)	04/2008 - 03/2011
Co-Investigator	CC-5013-NHL-005. Funded by Celgene. (CC-5013-NHL-005)	05/2008 - 04/2010
Co-Investigator	LS0382 - CTI. Funded by Spectrum Pharmaceuticals, Inc.. (LS0382)	05/2008 - 04/2013
Co-Investigator	LS0382 - Pfizer. Funded by Pfizer Inc.. (Pfizer Tracking # GA8501YD/LS0382)	05/2008 - 04/2013

Co-Investigator	CRAD001N2201, "An Open-Label, Single-Arm Phase II Study Of RAD001 In Patients With Refractory Mantle Cell Lymphoma". Funded by Novartis. (CRAD001N2201)	08/2008 - 07/2010
Co-Investigator	CLBH589E2214, Panobinostat in Hodgkin's Lymphoma. Funded by Novartis. (LBH589E2214)	10/2008 - 09/2010
Co-Investigator	C-935788-017. Funded by Rigel Pharmaceuticals, Inc.. (C-935788-017)	01/2009 - 12/2010
Co-Investigator	SG035-0003. Funded by SeaGen. (SG035-0003)	01/2009 - 12/2010
Co-Investigator	SG035-0004. Funded by SeaGen. (SG035-0004)	01/2009 - 12/2010
Co-Investigator	CC-5013-MCL-001. Funded by Celgene. (Protocol: CC-5013-MCL-001 / The)	01/2009 - 01/2012
Co-Investigator	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) with Everolimus (RAD001) and Alemtuzumab: A Phase I/II Study. Funded by Novartis. (MC088C/CRAD001NUS100T)	03/2009 - 02/2013
Co-Investigator	CC-4047-MM-002. Funded by Celgene. (CC-4047-MM-002)	03/2009 - 02/2014
Co-Investigator	Amend #5 Repl Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) with Everolimus (RAD001) and Alemtuzumab: A Phase I/II Study. Funded by Novartis. (MC088C/CRAD001NUS100T)	03/2009 - 12/2017
Co-Investigator	A Phase I/IIa randomized, observer-blind, placebo controlled, multicenter study to evaluate the safety and immunogenicity of the GSK Biologicals? herpes zoster vaccine. Funded by GlaxoSmithKline. (110258/ETR (Zoster-001 PRI))	05/2009 - 04/2011
Co-Investigator	Amendment 2 Replacement OMB110921- A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Funded by GlaxoSmithKline. (OMB110921)	05/2009 - 04/2011
Co-Investigator	MC0983 - PCO for CLL. Funded by Novartis. (MC0983 / Protocol #OFT113301)	09/2009 - 08/2012
Co-Investigator	CRAD001N2301. Funded by Novartis. (CRAD001N2301)	09/2009 - 08/2014
Co-Investigator	Amendment #1, Replacement: Fx1B-201, " The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with V122I or Wild-Type TTR Amyloid Cardiomyopathy". Funded by FoldRx. (Fx1B-201)	11/2009 - 10/2010
Co-Investigator	SGN75-001 Schedule A. Funded by SeaGen. (Protocol SGN75-001)	11/2009 - 11/2011
Co-Investigator	SGN75-001 Schedule B. Funded by SeaGen. (Protocol SGN75-001)	11/2009 - 11/2011
Co-Investigator	CNT0328MCD2001. Funded by Janssen Research and Development, LLC. (CNT0328MCD2001)	12/2009 - 12/2012
Co-Program Director / Principal Investigator	Combined MCA/MCR/MMRC: Phase I/II Study of combination of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma. Funded by Millennium Pharmaceuticals, Inc.. (MC088A)	12/2009 - 12/2012
Co-Investigator	HGS1029-C1080. Funded by Human Genome Sciences, Inc.. (HGS1029-C1080)	01/2010 - 12/2011
Co-Investigator	SGN35-009. Funded by SeaGen. (SGN35-009)	01/2010 - 12/2011
Co-Investigator	Replacement Amendment #1 CRAD001NUS65: An Open-label, Single-arm Phase II Study of RAD001 in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. Funded by Novartis. (CRAD001NUS65)	01/2010 - 12/2012
Co-Investigator	P276-00-23-08. Funded by Piramal Life Sciences Limited. (P276-00/23/08)	03/2010 - 02/2012

Co-Investigator	M06-814, "A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Lymphoid Malignancies". Funded by Abbott Laboratories. (Protocol M06-814)	04/2010 - 03/2012
Co-Investigator	CTKI258A2204. Funded by Novartis. (CTKI258A2204)	06/2010 - 05/2012
Co-Investigator	CLBH589E2301. Funded by Novartis. (CLBH589E2301)	06/2010 - 05/2015
Co-Investigator	PX-171-009. Funded by Onyx Pharmaceuticals Corporation. (Protocol PX-171-009)	08/2010 - 07/2013
Co-Investigator	LS1084, "Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab, Rituximab, and PGG Beta Glucan". Funded by Biothera, Inc.. (LS1084)	09/2010 - 08/2013
Co-Investigator	MC0986. Funded by Novartis. (MC0986/CLBH589BUS59T)	11/2010 - 10/2016
Co-Investigator	IM-T-hA20/90Y-hLL2-01 Veltuzumab/90Y-Epratuzumab Tetraxetan in NHL. Funded by Immunomedics. (Protocol IM-T-hA20/90Y-hLL2-01)	02/2011 - 02/2013
Co-Program Director / Principal Investigator	Internal Budget Revision: Phase 2 Trial Of Pembrolizumab, Lenalidomide And Dexamethasone For Initial Therapy Of Newly Diagnosed Multiple Myeloma Eligible For Stem Cell Transplantation. Funded by Merck & Co., Inc.. (MC1588)	11/2016 - 10/2019
Co-Program Director / Principal Investigator	Internal Budget Revisions: Venetoclax/Placebo Arm. Funded by AbbVie Inc.. (M14-031)	05/2017 - 05/2021
Co-Program Director / Principal Investigator	Venetoclax/Placebo Arm. Funded by AbbVie Inc.. (M14-031)	05/2017 - 05/2021
Co-Program Director / Principal Investigator	ACCRU-MY-1601; Randomized Phase II Trial of Daratumumab Retreatment in Patients with Relapsed Multiple Myeloma. Funded by Janssen Scientific Affairs, LLC. (5476741MMY2049)	12/2018 - 12/2023
Co-Program Director / Principal Investigator	Replacement #1 No PA ECTx-MCR-Phase 1b-TAK-981 + Daratumumab & Hyaluronidase-fihj. Funded by Takeda Development Center Americas, Inc. . (TAK-981-1503)	06/2021 - 05/2023
Co-Program Director / Principal Investigator	Replacement #1 No PA ECTx-MCR-Phase 1b-TAK-981 + Mezagitamab. Funded by Takeda Development Center Americas, Inc. . (TAK-981-1503)	06/2021 - 05/2023
Consultant	Replacment Budget #3 -DRd Arm. Funded by Janssen Research and Development, LLC. (5476741MMY3003)	04/2015 - 09/2017

Mayo Clinic

Principal Investigator	Evaluation of bcl2 small molecule in myeloma, funded by Heme Malignancy Program. Funded by Other Mayo	05/2005 - 04/2006
Principal Investigator	Vascular Endothelial Growth Factor (VEGF) As A Therapeutic Target In Multiple Myeloma. Funded by Mayo CR20 Funding	10/2005 - 12/2008
Program Director / Principal Investigator	Induction of bone marrow angiogenesis is a mechanism of disease progression and resistance in multiple myeloma. Funded by Development - Gifts from benefactors	02/2011 - 01/2014
Program Director / Principal Investigator	Clinical outcomes and predictive factors in 17p deleted multiple myeloma.. Funded by SGP - Small Grants Program <\$10K	11/2013 - 11/2015
Program Director / Principal Investigator	Dyspro Development Plan - #2 Flow Technologist. Funded by Development - Gifts from benefactors	10/2017 - 09/2022

Investigator

Program Director / Principal Investigator	Dyspro Development Plan - #3 Bioinformatics. Funded by Development - Gifts from benefactors	10/2017 - 09/2022
Program Director / Principal Investigator	Dyspro Development Plan - #4 Young Investigators. Funded by Development - Gifts from benefactors	10/2017 - 09/2022
Program Director / Principal Investigator	Dyspro Development Plan - #5 Amyloid Clinical Trials. Funded by Development - Gifts from benefactors	10/2017 - 09/2022
Program Director / Principal Investigator	Dyspro Development Plan #1 Kurtz and PCD Fellows. Funded by Development - Gifts from benefactors	10/2017 - 09/2022
Co-Investigator	Altered metabolic pathways as a mechanism of therapeutic resistance to immunomodulators in Multiple Myeloma. Funded by Eagle Funds for Cancer Research	06/2015 - 05/2016
Co-Program Director / Principal Investigator	ECTx TARGETING THE WARBURG EFFECT AND MITOCHONDRIAL DYSFUNCTION IN RELAPSED MULTIPLE MYELOMA. Funded by Development - Gifts from benefactors	07/2019 - 12/2021
Co-Investigator	EARLY DIAGNOSIS AND INTERVENTION IN MONOCLONAL GAMMOPATHIES. Funded by Development - Gifts from benefactors	09/2020 - 08/2024
Co-Investigator	Development of t(11;14) Multiple Myeloma. Funded by Center for Biomedical Discovery	01/2021 - 12/2022
Co-Investigator	Bergsagel: Project 4: 'Direct to Drug' Screening for t(4;14) Multiple Myeloma. Funded by Development - Gifts from benefactors	02/2021 - 01/2023

Inventions, Commercialization and Offering

A. Patent	Patent Number	Country	Date Filed	Date Issued
Assessing and Treating Precursor Plasma Cell Disorders Wilson I. Gonsalves M.D., Shaji Kumar M.D., K. Sreekumaran Nair M.D., Vijay Ramakrishnan Ph.D.	10996224	USA	03/2018	05/2021

Bibliography

Peer-reviewed Articles

1. Guleria R, **Kumar S**, Agarwal S, Prasad L. Renal failure with skeletal abnormalities. *Postgrad Med J*. 1996; 72:569-570. PMID: 8949600 PMCID: PMC2398559
2. **Kumar S**, Mow BM, Kaufmann SH. Hypercalcemia complicating leukemic transformation of agnogenic myeloid metaplasia-myelofibrosis. *Mayo Clin Proc*. 1999 Dec; 74(12):1233-7. PMID: 10593353 DOI: 10.4065/74.12.1233
3. Jatoi A, **Kumar S**, Sloan JA, Nguyen PL. On appetite and its loss. *J Clin Oncol*. 2000 Aug; 18: (15)2930-2. PMID: 10920143 DOI: 10.1200/JCO.2000.18.15.2930
4. **Kumar S**, Lacy MQ. 59-year-old man with pelvic pain and hypergammaglobulinemia. *Mayo Clin Proc*. 2001 Mar; 76(3):311-4. PMID: 11243278 DOI: 10.4065/76.3.311
5. **Kumar SK**, Goldberg RM. Adjuvant chemotherapy for colon cancer. *Curr Oncol Rep*. 2001 Mar; 3 (2):94-101 PMID: 11177740 DOI: 10.1007/s11912-001-0007-6
6. Capizzi SA, **Kumar S**, Huneke NE, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Gastineau DA, Prakash UB, Tefferi A. Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2001 Jun; 27 (12):1299-303 PMID: 11548849 DOI: 10.1038/sj.bmt.1703075
7. **Kumar S**, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Harmsen WS, Litzow MR. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease. *Bone Marrow Transplant*. 2001 Jun; 27(11):1133-40. PMID: 11551023 DOI: 10.1038/sj.bmt.1703053
8. Kumar S, **Kumar S**, Tefferi A. Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation--case report and review of literature. *Ann Hematol*. 2001 Jul; 80 (7):430-5 PMID: 11529471 DOI: 10.1007/s002770100301
9. **Kumar S**, Dispenzieri A, Lacy MQ, Litzow MR, Gertz MA. High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. *Bone Marrow Transplant*. 2001 Aug; 28(4):381-5. PMID: 11571511 DOI: 10.1038/sj.bmt.1703155
10. Tefferi A, **Kumar S**, Wolf RC, Lacy MQ, Inwards DJ, Gloor JM, Albright RC, Kamath PS, Litzow MR. Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2001 Nov; 28(10):997-9. PMID: 11753559 DOI: 10.1038/sj.bmt.1703267
11. **Kumar S**, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. *Bone Marrow Transplant*. 2001 Nov; 28 (10):951-6 PMID: 11753550 DOI: 10.1038/sj.bmt.1703262
12. **Kumar S**, Sarr MG, Kamath PS. Mesenteric venous thrombosis. *N Engl J Med*. 2001 Dec 6; 345 (23):1683-8 PMID: 11759648 DOI: 10.1056/NEJMra010076
13. **Kumar S**, Pruthi RK, Nichols WL. Acquired von Willebrand disease. *Mayo Clin Proc*. 2002 Feb; 77 (2):181-7 PMID: 11838652 DOI: 10.4065/77.2.181
14. **Kumar S**, Menke DM, Dewald GW, Colon-Otero G. Agnogenic myeloid metaplasia associated with Klinefelter syndrome: a case report. *Ann Hematol*. 2002 Apr; 81(4):215-8. Epub 2002 Mar 07. PMID: 11976824 DOI: 10.1007/s00277-002-0430-2
15. Kumar S, **Kumar S**, Witzig TE, Rajkumar SV. Thalidomide as an anti-cancer agent. *J Cell Mol Med*. 2002 Apr-Jun; 6 (2):160-74 PMID: 12169202 PMCID: PMC6740081 DOI: 10.1111/j.1582-4934.2002.tb00184.x
16. **Kumar S**, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. *Ann Hematol*. 2002 Jun; 81(6):312-9. PMID: 12107560
17. Porrata LF, Litzow MR, Tefferi A, Letendre L, **Kumar S**, Geyer SM, Markovic SN. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. *Leukemia*. 2002 Jul; 16 (7):1311-8 PMID: 12094255 DOI: 10.1038/sj.leu.2402503
18. **Kumar S**, Wolf RC, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease. *Bone Marrow Transplant*. 2002 Aug; 30(3):161-5. PMID: 12189534 DOI: 10.1038/sj.bmt.1703616
19. **Kumar S**, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Bone marrow angiogenesis in multiple myeloma: effect of therapy. *Br J Haematol*. 2002 Dec; 119 (3):665-71 PMID: 12437642 DOI: 10.1046/j.1365-2141.2002.03871.x

20. Bucheit AD, **Kumar S**, Grote DM, Lin Y, von Messling V, Cattaneo RB, Fielding AK. An oncolytic measles virus engineered to enter cells through the CD20 antigen. *Mol Ther*. 2003 Jan; 7 (1):62-72 PMID: 12573619 DOI: 10.1016/s1525-0016(02)00033-3
21. **Kumar S**, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, Fonseca R, Hayman SR, Lust JA, Kyle RA, Greipp PR, Witzig TE, Rajkumar SV. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. *Mayo Clin Proc*. 2003 Jan; 78(1):34-9. PMID: 12528875 DOI: 10.4065/78.1.34
22. **Kumar S**, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Wellik L, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Prognostic value of angiogenesis in solitary bone plasmacytoma. *Blood*. 2003 Mar 1; 101 (5):1715-7 Epub 2002 Oct 17 PMID: 12393501 DOI: 10.1182/blood-2002-08-2441
23. **Kumar S**, Pruthi RK, Nichols WL. Acquired von Willebrand's syndrome: a single institution experience. *Am J Hematol*. 2003 Apr; 72(4):243-7. PMID: 12666134 DOI: 10.1002/ajh.10298
24. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, Iturria N, **Kumar S**, Lust JA, Kyle RA, Greipp PR, Witzig TE. Thalidomide as initial therapy for early-stage myeloma. *Leukemia*. 2003 Apr; 17 (4):775-9. PMID: 12682636 DOI: 10.1038/sj.leu.2402866
25. **Kumar S**, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. *Mayo Clin Proc*. 2003 May; 78(5):589-98. PMID: 12744547 DOI: 10.4065/78.5.589
26. Jatoi A, **Kumar S**, Sloan JA, Nguyen PL. On appetite and its loss. *J Clin Oncol*. 2003 May 1; 21(9 Suppl):79s-81s. PMID: 12743203 DOI: 10.1200/JCO.2003.01.180
27. **Kumar S**, Kamath PS. Acute superior mesenteric venous thrombosis: One disease or two? *Am J Gastroenterol*. 2003 Jun; 98(6):1299-304. PMID: 12818273
28. **Kumar S**, Witzig TE, Greipp PR, Rajkumar SV. Bone marrow angiogenesis and circulating plasma cells in multiple myeloma. *Br J Haematol*. 2003 Jul; 122 (2):272-4 PMID: 12846897 DOI: 10.1046/j.1365-2141.2003.04428.x
29. **Kumar S**, Kimlinger TK, Lust JA, Donovan K, Witzig TE. Expression of CD52 on plasma cells in plasma cell proliferative disorders. *Blood*. 2003 Aug 1; 102 (3):1075-7 Epub 2003 Apr 24 PMID: 12714489 DOI: 10.1182/blood-2002-12-3784
30. **Kumar S**, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR. Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. *Leukemia*. 2003 Sep; 17(9):1865-70. PMID: 12970788 DOI: 10.1038/sj.leu.2403055
31. **Kumar S**, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR, Rajkumar SV. Expression of VEGF and its receptors by myeloma cells. *Leukemia*. 2003 Oct; 17(10):2025-31. PMID: 14513053 DOI: 10.1038/sj.leu.2403084
32. Thompson MA, Witzig TE, **Kumar S**, Timm MM, Haug J, Fonseca R, Greipp PR, Lust JA, Rajkumar SV. Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. *Br J Haematol*. 2003 Oct; 123 (2):305-8 PMID: 14531913 DOI: 10.1046/j.1365-2141.2003.04605.x
33. **Kumar S**, Litzow MR, Rajkumar SV. Effect of allogeneic stem cell transplantation on bone marrow angiogenesis in chronic myelogenous leukemia. *Bone Marrow Transplant*. 2003 Dec; 32(11):1065-9. PMID: 14625577
34. Huber MR, **Kumar S**, Tefferi A. Treatment advances in adult immune thrombocytopenic purpura. *Ann Hematol*. 2003 Dec; 82(12):723-37. PMID: 13680177
35. Raje N, **Kumar S**, Hideshima T, et al. Combination of the mTOR inhibitor Rapamycin and RevlimidTM(CC-5013) has synergistic activity in multiple myeloma. *Blood*. 2004. PMID: 0
36. **Kumar S**, Witzig TE, Dispenzieri A, Lacy MQ, Wellik LE, Fonseca R, Lust JA, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. *Leukemia*. 2004 Mar; 18(3):624-7. PMID: 14749707 DOI: 10.1038/sj.leu.2403285
37. **Kumar S**, Witzig TE, Rajkumar SV. Thalidomid: current role in the treatment of non-plasma cell malignancies. *J Clin Oncol*. 2004 Jun 15; 22(12):2477-88. PMID: 15197211 DOI: 10.1200/JCO.2004.10.127
38. **Kumar SK**, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR, Kyle RA, Greipp PR. Clinical course of patients with relapsed multiple myeloma. *Mayo Clin Proc*. 2004 Jul; 79 (7):867-74 PMID: 15244382 DOI: 10.4065/79.7.867
39. **Kumar S**, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. *Bone Marrow Transplant*. 2004 Jul; 34(2):161-7. PMID: 15133489

40. **Kumar S**, Gertz MA, Dispenzieri A, Lacy MQ, Wellik LA, Fonseca R, Lust JA, Witzig TE, Kyle RA, Greipp PR, Rajkumar SV. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. *Bone Marrow Transplant*. 2004 Aug; 34(3):235-9. PMID: 15170170 DOI: 10.1038/sj.bmt.1704555
41. **Kumar S**, Witzig TE, Timm M, Haug J, Wellik L, Kimlinger TK, Greipp PR, Rajkumar SV. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. *Blood*. 2004 Aug 15; 104 (4):1159-65 Epub 2004 May 06 PMID: 15130943 DOI: 10.1182/blood-2003-11-3811
42. **Kumar S**, Rajkumar SV, Greipp PR, Witzig TE. Cell proliferation of myeloma plasma cells: Comparison of the blood and marrow compartments. *Am J Hematol*. 2004 Sep; 77(1):7-11. PMID: 15307099
43. **Kumar S**, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. *Bone Marrow Transplant*. 2004 Sep; 34(6):485-90. PMID: 15286691 DOI: 10.1038/sj.bmt.1704633
44. **Kumar S**, Anderson KC. Drug insight: thalidomide as a treatment for multiple myeloma. *Nat Clin Pract Oncol*. 2005 May; 2(5):262-70. PMID: 16264962 PMCID: PMC0 DOI: 10.1038/ncponc0174
45. **Kumar S**, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. *Leukemia*. 2005 Aug; 19 (8):1466-70 PMID: 15959533 DOI: 10.1038/sj.leu.2403823
46. Raje N, **Kumar S**, Hideshima T, Roccato A, Ishitsuka K, Yasui H, Shiraishi N, Chauhan D, Munshi NC, Green SR, Anderson KC. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. *Blood*. 2005 Aug 1; 106(3):1042-7. PMID: 15827128 PMCID: PMC1895150 DOI: 10.1182/blood-2005-01-0320
47. **Kumar S**, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, Lust JA, Gertz MA, Greipp PR, Witzig TE. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. *Journal of Clinical Oncology*. 2005 Aug 20; 23(24):5668-74. PMID: 16110026
48. Lacy MQ, Hogan WJ, Gertz MA, Dispenzieri A, Rajkumar SV, Hayman S, **Kumar S**, Litzow MR, Schroeter AL. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. *Arch Dermatol*. 2005 Oct; 141(10):1277-82. PMID: 16230566 DOI: 10.1001/archderm.141.10.1277
49. **Kumar S**, Rajkumar SV. Thalidomide and dexamethasone: therapy for multiple myeloma. *Expert Rev Anticancer Ther*. 2005 Oct; 5(5):759-66. PMID: 16221046 DOI: 10.1586/14737140.5.5.759
50. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, **Kumar S**, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. *Blood*. 2005 Dec 15; 106 (13):4050-3 Epub 2005 Aug 23 PMID: 16118317 PMCID: PMC1895238 DOI: 10.1182/blood-2005-07-2817
51. Roccato AM, Hideshima T, Raje N, **Kumar S**, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. *Cancer Res*. 2006 Jan 1; 66(1):184-91. PMID: 16397231 DOI: 10.1158/0008-5472.CAN-05-1195
52. **Kumar S**, Raje N, Hideshima T, Ishitsuka K, Podar K, Le Gouille S, Chauhan D, Richardson P, Munshi NC, Anderson K. FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. *Br J Haematol*. 2006 Mar; 132(6):698-704. PMID: 16487170 DOI: 10.1111/j.1365-2141.2005.05946.x
53. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. *Expert Rev Anticancer Ther*. 2006 Mar; 6(3):343-60. PMID: 16503852 DOI: 10.1586/14737140.6.3.343
54. Dispenzieri A, Lacy MQ, Katzmman JA, Rajkumar SV, Abraham RS, Hayman SR, **Kumar SK**, Clark R, Kyle RA, Litzow MR, Inwards DJ, Ansell SM, Micallef IM, Porrata LF, Elliott MA, Johnston PB, Greipp PR, Witzig TE, Zeldenrust SR, Russell SJ, Gastineau D, Gertz MA. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. *Blood*. 2006 Apr 15; 107 (8):3378-83 Epub 2006 Jan 05 PMID: 16397135 PMCID: PMC1895763 DOI: 10.1182/blood-2005-07-2922
55. Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz MA, Lacy MQ, Dispenzieri A, **Kumar S**, Rajkumar SV, Lust JA, Kyle RA, Zeldenrust SR, Hayman SR, Fonseca R. Clinical implication of centrosome amplification in plasma cell neoplasm. *Blood*. 2006 May 1; 107 (9):3669-75 Epub 2005 Dec 22 PMID: 16373658 PMCID: PMC1895774 DOI: 10.1182/blood-2005-09-3810
56. **Kumar S**, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. *Eur J Cancer*.

2006 Jul; 42 (11):1612-22 Epub 2006 June 05 PMID: 16750621 DOI: 10.1016/j.ejca.2006.04.004

57. Kimlinger T, Kline M, **Kumar S**, Lust J, Witzig T, Rajkumar SV. Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. *Haematologica*. 2006 Aug; 91(8):1033-40. Epub 2006 Jul 25. PMID: 16870555
58. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, **Kumar S**, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. *Mayo Clin Proc*. 2006 Aug; 81 (8):1047-53 PMID: 16901028 DOI: 10.4065/81.8.1047
59. Bryce AH, Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Inwards DJ, Yasenchak CA, **Kumar SK**, Gertz MA. Response to rituximab in patients with type II cryoglobulinemia. *Clin Lymphoma Myeloma*. 2006 Sep; 7 (2):140-4. PMID: 17026826 DOI: 10.3816/CLM.2006.n.052
60. Raje N, **Kumar S**, Hideshima T, Ishitsuka K, Yasui H, Chhetri S, Vallet S, Vonescu E, Shiraishi N, Kiziltepe T, Elford HL, Munshi NC, Anderson KC. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells. *Br J Haematol*. 2006 Oct; 135(1):52-61. Epub 2006 Aug 22. PMID: 16925573 DOI: 10.1111/j.1365-2141.2006.06261.x
61. Timm MM, Kimlinger TK, Haug JL, Kline MP, Greipp PR, Rajkumar SV, **Kumar SK**. Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma. *Leukemia*. 2006 Oct; 20: (10)1863-9. PMID: 16932343 DOI: 10.1038/sj.leu.2404359
62. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, **Kumar S**, Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. *Proc Natl Acad Sci U S A*. 2006 Dec 19; 103(51):19478-83. Epub 2006 Dec 12. PMID: 17164332 PMCID: PMC1748251 DOI: 10.1073/pnas.0609329103
63. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, **Kumar SK**, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. *Blood*. 2007 Jan 15; 109 (2):465-70 Epub 2006 Sept 28 PMID: 17008538 DOI: 10.1182/blood-2006-07-032987
64. Bhattacharya R, Patra CR, Verma R, **Kumar S**, Greipp PR, Mukherjee P. Gold Nanoparticles Inhibit the Proliferation of Multiple Myeloma Cells. *Advanced Materials*. 2007 Feb; 19(5):711-6.
65. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, **Kumar S**, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. *Leukemia*. 2007 Mar; 21(3):529-34. Epub 2007 Jan 18. PMID: 17230230 DOI: 10.1038/sj.leu.2404516
66. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar S**. Transplantation for amyloidosis. *Curr Opin Oncol*. 2007 Mar; 19(2):136-41. PMID: 17272986
67. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, **Kumar S**, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. *Mayo Clin Proc*. 2007 Mar; 82: (3)323-41. PMID: 17352369 DOI: 10.4065/82.3.323
68. Chng WJ, **Kumar S**, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, Carpten J, Gertz M, Rajkumar SV, Lacy M, Dispenzieri A, Kyle R, Greipp P, Bergsagel PL, Fonseca R. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. *Cancer Res*. 2007 Apr 1; 67(7):2982-9. PMID: 17409404 DOI: 10.1158/0008-5472.CAN-06-4046
69. Kline M, Donovan K, Wellik L, Lust C, Jin W, Moon-Tasson L, Xiong Y, Witzig TE, **Kumar S**, Rajkumar SV, Lust JA. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. *Leuk Res*. 2007 May; 31(5):591-8. PMID: 16879867
70. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar S**, Leung N, Gastineau DA. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. *Bone Marrow Transplant*. 2007 May; 39(10):605-11. Epub 2007 Mar 19. PMID: 17369867 DOI: 10.1038/sj.bmt.1705627
71. Dingli D, Pacheco JM, Dispenzieri A, Hayman SR, **Kumar SK**, Lacy MQ, Gastineau DA, Gertz MA. In vivo and in silico studies on single versus multiple transplants for multiple myeloma. *Cancer Sci*. 2007 May; 98 (5):734-9 Epub 2007 Mar 14 PMID: 17359286 PMCID: PMC11159774 DOI: 10.1111/j.1349-7006.2007.00450.x
72. **Kumar S**. Role of autologous stem cell transplantation in multiple myeloma. *Curr Hematol Malig Rep*. 2007 May; 2 (2):121-7 PMID: 20425360 DOI: 10.1007/s11899-007-0017-z

73. Leung N, Dispenzieri A, Lacy MQ, **Kumar SK**, Hayman SR, Fervenza FC, Cha SS, Gertz MA. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. *Clin J Am Soc Nephrol*. 2007 May; 2(3):440-4. Epub 2007 Apr 04. PMID: 17699449 DOI: 10.2215/CJN.02450706
74. Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA, Greipp PR, **Kumar S**. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. *Leukemia*. 2007 Jul; 21(7):1549-60. Epub 2007 Apr 26. PMID: 17460700 DOI: 10.1038/sj.leu.2404719
75. Dingli D, Pacheco JM, Dispenzieri A, Hayman SR, **Kumar SK**, Lacy MQ, Gastineau DA, Gertz MA. Serum M-spike and transplant outcome in patients with multiple myeloma. *Cancer Sci*. 2007 Jul; 98 (7):1035-40 Epub 2007 May 04 PMID: 17488336 PMCID: PMC11159012 DOI: 10.1111/j.1349-7006.2007.00499.x
76. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, **Kumar S**, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. *Cancer Cell*. 2007 Aug; 12 (2):131-44 PMID: 17692805 PMCID: PMC2083698 DOI: 10.1016/j.ccr.2007.07.003
77. **Kumar S**, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, Litzow MR, Fonseca R, Roy V, Rajkumar SV, Gertz MA. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. *Leukemia*. 2007 Sep; 21 (9):2035-42 Epub 2007 June 21 PMID: 17581613 DOI: 10.1038/sj.leu.2404801
78. Morice WG, Hanson CA, **Kumar S**, Frederick LA, Lesnick CE, Greipp PR. Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. *Leukemia*. 2007 Sep; 21(9):2043-6. Epub 2007 Apr 26. PMID: 17460704 DOI: 10.1038/sj.leu.2404712
79. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**, Leung N, Gastineau DA. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. *Haematologica*. 2007 Oct; 92 (10):1415-8 PMID: 17768110 DOI: 10.3324/haematol.11413
80. Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B, Zeldenrust SR, **Kumar S**, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Bergsagel PL, Stewart AK, Rajkumar SV. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. *Mayo Clin Proc*. 2007 Oct; 82 (10):1179-84 PMID: 17908524 DOI: 10.4065/82.10.1179
81. Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K, Schneider P, Dai NT, **Kumar SK**, Smith BD, Karp JE, Adjei AA, Kaufmann SH. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. *J Biol Chem*. 2007 Oct 12; 282 (41):29831-46 Epub 2007 Aug 13 PMID: 17698840 DOI: 10.1074/jbc.M706110200
82. **Kumar S**. Lenalidomide with or without dexamethasone for relapsed or refractory multiple myeloma. *Am J Hematol Oncol*. 2007 Nov; 6(11):644-5, 650. PMID: 0
83. Dingli D, Pacheco JM, Nowakowski GS, **Kumar SK**, Dispenzieri A, Hayman SR, Lacy MQ, Gastineau DA, Gertz MA. Relationship between depth of response and outcome in multiple myeloma. *J Clin Oncol*. 2007 Nov 1; 25(31):4933-7. PMID: 17971591 DOI: 10.1200/JCO.2007.11.7879
84. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**, Leung N, Gastineau DA. Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). *Bone Marrow Transplant*. 2007 Nov; 40(10):989-93. Epub 2007 Sep 10. PMID: 17846598 DOI: 10.1038/sj.bmt.1705848
85. **Kumar SK**, Hayman SR, Kyle RA. Autologous stem cell transplantation in the elderly including pre- and post-treatment options. *Bone Marrow Transplant*. 2007 Dec; 40(12):1115-21. Epub 2007 Aug 06. PMID: 17680019 DOI: 10.1038/sj.bmt.1705800
86. Gertz M, Lacy M, Dispenzieri A, Hayman S, **Kumar S**, Buadi F, Leung N, Litzow M. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. *Leuk Lymphoma*. 2008 Jan; 49 (1):36-41 PMID: 18203009 DOI: 10.1080/10428190701684518
87. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, Clark RJ, Melton LJ 3rd, Gertz MA, **Kumar SK**, Fonseca R, Jelinek DF, Rajkumar SV. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. *Blood*. 2008 Jan 15; 111 (2):785-9 Epub 2007 Oct 17 PMID: 17942755 PMCID: PMC2200851 DOI: 10.1182/blood-2007-08-108357
88. **Kumar SK**, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. *Blood*. 2008 Mar 1; 111 (5):2516-20 Epub 2007 Nov 01 PMID: 17975015 PMCID: PMC2254544 DOI: 10.1182/blood-2007-10-116129
89. **Kumar S**, Dispenzieri A, Lacy MQ, Hayman SR, Leung N, Zeldenrust SR, Buadi FK, Kyle RA, Rajkumar SV,

- Gertz MA. Serum uric acid: novel prognostic factor in primary systemic amyloidosis. *Mayo Clin Proc.* 2008 Mar; 83(3):297-303. PMID: 18315995 DOI: 10.4065/83.3.297
90. **Kumar SK**, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. *Br J Haematol.* 2008 Apr; 141(2):205-11. Epub 2008 Mar 03. PMID: 18318761 DOI: 10.1111/j.1365-2141.2008.07069.x
 91. **Kumar S**. Role of allogeneic stem cell transplantation in multiple myeloma. *Curr Hematol Malig Rep.* 2008 Apr; 3 (2):99-106 PMID: 20425453 DOI: 10.1007/s11899-008-0015-9
 92. Dispenzieri A, Lacy MQ, Hayman SR, **Kumar SK**, Buadi F, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Elliott MA, Micallef IN, Ansell SM, Hogan WJ, Porrata LF, Johnston PA, Afessa B, Bryce A, Kyle RA, Gertz MA. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. *Eur J Haematol.* 2008 May; 80 (5):397-406 Epub 2008 Jan 23 PMID: 18221391 PMCID: PMC2327207 DOI: 10.1111/j.1600-0609.2008.01037.x
 93. Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA, Greipp PR, **Kumar S**. R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. *Exp Hematol.* 2008 May; 36 (5):568-76 Epub 2008 Mar 17 PMID: 18346839 PMCID: PMC3904353 DOI: 10.1016/j.exphem.2008.01.003
 94. **Kumar SK**, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. *Bone Marrow Transplant.* 2008 Jun; 41 (12):1013-9 Epub 2008 Mar 10 PMID: 18332915 DOI: 10.1038/bmt.2008.24
 95. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, **Kumar S**, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russell SJ, Kyle RA, Winters JL. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. *Kidney Int.* 2008 Jun; 73 (11):1282-8 Epub 2008 Apr 02 PMID: 18385667 DOI: 10.1038/ki.2008.108
 96. Simpson L, **Kumar SK**, Okuno SH, Schaff HV, Porrata LF, Buckner JC, Moynihan TJ. Malignant primary cardiac tumors: review of a single institution experience. *Cancer.* 2008 Jun; 112 (11):2440-6 PMID: 18428209 DOI: 10.1002/cncr.23459
 97. Ege H, Gertz MA, Markovic SN, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**, Porrata LF. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. *Br J Haematol.* 2008 Jun; 141 (6):792-8 Epub 2008 Apr 10 PMID: 18410454 DOI: 10.1111/j.1365-2141.2008.07123.x
 98. Wang L, **Kumar S**, Fridley BL, Kalari KR, Moon I, Pelleymounter LL, Hildebrandt MA, Batzler A, Eckloff BW, Wieben ED, Greipp PR. Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics. *Clin Cancer Res.* 2008 Jun 1; 14 (11):3503-13 PMID: 18519783 PMCID: PMC2778274 DOI: 10.1158/1078-0432.CCR-07-5150
 99. Shaikh A, Habermann TM, Fidler ME, **Kumar S**, Leung N. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenstrom's macroglobulinemia. *Clin Exp Nephrol.* 2008 Aug; 12 (4):292-295 Epub 2008 Feb 22 PMID: 18288560 DOI: 10.1007/s10157-008-0042-9
 100. Lacy MQ, Dispenzieri A, Hayman SR, **Kumar S**, Kyle RA, Rajkumar SV, Edwards BS, Rodeheffer RJ, Frantz RP, Kushwaha SS, Clavell AL, Dearani JA, Sundt TM, Daly RC, McGregor CG, Gastineau DA, Litzow MR, Gertz MA. Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy. *J Heart Lung Transplant.* 2008 Aug; 27 (8):823-9 Epub 2008 July 03 PMID: 18656793 DOI: 10.1016/j.healun.2008.05.016
 101. **Kumar SK**, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. *Am J Hematol.* 2008 Aug; 83(8):614-7. PMID: 18429054 DOI: 10.1002/ajh.21191
 102. **Kumar S**, Dingli D, Dispenzieri A, Lacy M, Hayman SR, Buadi F, Rajkumar S, Litzow M, Gertz M. Impact of additional cytorreduction following autologous SCT in multiple myeloma. *Bone Marrow Transplant.* 2008 Aug; 42 (4):259-64 Epub 2008 June 16 PMID: 18560409 PMCID: PMC3904360 DOI: 10.1038/bmt.2008.166
 103. **Kumar S**, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Litzow MR, Gertz MA. Impact of early relapse after auto-SCT for multiple myeloma. *Bone Marrow Transplant.* 2008 Sep; 42(6):413-20. Epub 2008 Jun 30. PMID: 18587435 DOI: 10.1038/bmt.2008.180
 104. Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, Elliott MA, Gastineau DA, Hayman SR, Hogan WJ, Inwards DJ, Johnston PB, **Kumar S**, Lacy MQ, Leung N, Micallef IN, Porrata LF, Schafer BA, Wolf RC, Litzow MR. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. *Mayo Clin Proc.* 2008 Oct; 83(10):1131-8. PMID: 18828972 DOI: 10.4065/83.10.1131
 105. **Kumar S**, Perez WS, Zhang MJ, Ballen K, Bashey A, To LB, Bredeson CN, Cairo MS, Elfenbein GJ, Freytes

- CO, Gale RP, Gibson J, Kyle RA, Lacy MQ, Lazarus HM, McCarthy PL, Milone GA, Moreb JS, Pavlovsky S, Reece DE, Vesole DH, Wiernik PH, Hari P. Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. *Biol Blood Marrow Transplant*. 2008 Oct; 14 (10):1134-1140 PMID: 18804043 PMCID: PMC2634851 DOI: 10.1016/j.bbmt.2008.07.011
106. Snozek CL, Katzmman JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM, Melton LJ 3rd, **Kumar S**, Greipp PR, Clark RJ, Rajkumar SV. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. *Leukemia*. 2008 Oct; 22 (10):1933-7 Epub 2008 July 03 PMID: 18596742 PMCID: PMC2614406 DOI: 10.1038/leu.2008.171
 107. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, **Kumar S**, Kyle RA, Fonseca R, Greipp PR, Lust JA, Rajkumar VS, Hayman SR, Buadi F, Russell SJ, Zeldenrust SR, Dispenzieri A. A novel report of cig-FISH and cytogenetics in POEMS syndrome. *Am J Hematol*. 2008 Nov; 83 (11):840-1 PMID: 18839437 PMCID: PMC3956589 DOI: 10.1002/ajh.21285
 108. Patra CR, Verma R, **Kumar S**, Greipp PR, Mukhopadhyay D, Mukherjee P. Fabrication of gold nanoparticle for potential application in multiple myeloma. *J Biomed Nanotechnol*. 2008 Dec; 4(4):499-507. PMID: 0 DOI: 10.1166/jbn.2008.015
 109. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, **Kumar S**, Hayman SR, Russell SJ, Buadi FK, Geyer SM, Campbell ME, Kyle RA, Rajkumar SV, Greipp PR, Kline MP, Xiong Y, Moon-Tasson LL, Donovan KA. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1beta-induced interleukin 6 production and the myeloma proliferative component. *Mayo Clin Proc*. 2009 Feb; 84 (2):114-22 PMID: 19181644 PMCID: PMC2664581 DOI: 10.4065/84.2.114
 110. **Kumar S**. Stem cell transplantation for multiple myeloma. *Curr Opin Oncol*. 2009 Mar; 21 (2):162-70 PMID: 19532019 PMCID: PMC2908007 DOI: 10.1097/CCO.0b013e328324bc04
 111. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, **Kumar S**, Hayman S, Buadi F, Kyle RA, Greipp PR, Lust JA, Russell S, Rajkumar SV, Fonseca R, Dispenzieri A. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. *Haematologica*. 2009 Mar; 94 (3):380-6 Epub 2009 Feb 11 PMID: 19211640 PMCID: PMC2649355 DOI: 10.3324/haematol.13369
 112. Gertz MA, **Kumar SK**, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Gastineau DA, Winters JL, Litzow MR. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. *Bone Marrow Transplant*. 2009 Apr; 43 (8):619-25 Epub 2008 Nov 10 PMID: 18997825 PMCID: PMC2914501 DOI: 10.1038/bmt.2008.369
 113. Costa LJ, **Kumar S**, Dispenzieri A, Hayman SE, Buadi FK, Dingli D, Litzow MR, Gertz MA, Lacy MQ. Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. *Leuk Lymphoma*. 2009 May; 50(5):781-7. PMID: 19330657 DOI: 10.1080/10428190902803644
 114. Landgren O, Kyle RA, Pfeiffer RM, Katzmman JA, Caporaso NE, Hayes RB, Dispenzieri A, **Kumar S**, Clark RJ, Baris D, Hoover R, Rajkumar SV. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. *Blood*. 2009 May 28; 113(22):5412-7. Epub 2009 Jan 29. PMID: 19179464 PMCID: PMC2689042 DOI: 10.1182/blood-2008-12-194241
 115. Sadek I, Dispenzieri A, Gertz MA, **Kumar S**. Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma. *Leuk Lymphoma* 2009 Jun; 50 (6):1033-5 PMID: 19455462 DOI: 10.1080/10428190902919218
 116. Chen C, Reece DE, Siegel D, Niesvizky R, Boccia RV, Stadtmauer EA, Abonour R, Richardson P, Matous J, **Kumar S**, Bahlis NJ, Alsina M, Vescio R, Coutre SE, Pietronigro D, Knight RD, Zeldis JB, Rajkumar V. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. *Br J Haematol*. 2009 Jul; 146(2):164-70. Epub 2009 May 26. PMID: 19545290 PMCID: PMC2728892 DOI: 10.1111/j.1365-2141.2009.07728.x
 117. Ng AC, **Kumar SK**, Rajkumar SV, Drake MT. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. *Am J Hematol*. 2009 Jul; 84 (7):397-400 PMID: 19415724 PMCID: PMC2895403 DOI: 10.1002/ajh.21412
 118. Peng KW, Dogan A, Vrana J, Liu C, Ong HT, **Kumar S**, Dispenzieri A, Dietz AB, Russell SJ. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. *Am J Hematol*. 2009 Jul; 84 (7):401-7 PMID: 19507209 PMCID: PMC2805200 DOI: 10.1002/ajh.21444
 119. Kapoor P, **Kumar S**, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. *Blood*. 2009 Jul 16; 114 (3):518-21 Epub 2009 Mar 26 PMID: 19324902 PMCID: PMC2713462 DOI: 10.1182/blood-2009-01-202010

120. Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL, Phelps TK, Dispenzieri A, **Kumar SK**, Katzmman JA, Rajkumar SV. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. *Blood*. 2009 Jul 23; 114 (4):785-90 Epub 2009 Jan 29 PMID: 19179466 PMCID: PMC2716020 DOI: 10.1182/blood-2008-12-192575
121. **Kumar S**, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG, Rajkumar SV, International Myeloma Working Group. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. *Blood*. 2009 Aug 27; 114 (9):1729-35 Epub 2009 June 26 PMID: 19561323 DOI: 10.1182/blood-2009-04-205013
122. Chee CE, **Kumar S**, Larson DR, Kyle RA, Dispenzieri A, Gertz MA, Colby CL, Rajkumar SV. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. *Blood*. 2009 Sep 24; 114 (13):2617-8 Epub 2009 July 29 PMID: 19641191 PMCID: PMC2756122 DOI: 10.1182/blood-2009-01-198788
123. Gertz MA, Leung N, Lacy MQ, Dispenzieri A, Zeldenrust SR, Hayman SR, Buadi FK, Dingli D, Greipp PR, **Kumar SK**, Lust JA, Rajkumar SV, Russell SJ, Witzig TE. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. *Nephrol Dial Transplant*. 2009 Oct; 24(10):3132-7. Epub 2009 Apr 29. PMID: 19403931 DOI: 10.1093/ndt/gfp201
124. Gupta M, Ansell SM, Novak AJ, **Kumar S**, Kaufmann SH, Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. *Blood*. 2009 Oct 1; 114 (14):2926-35 Epub 2009 July 29 PMID: 19641186 PMCID: PMC2756203 DOI: 10.1182/blood-2009-05-220889
125. Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, Bianchi G, Podar K, Tai YT, Mitsiades C, Raje N, Jaye DL, **Kumar SK**, Richardson P, Munshi N, Anderson KC. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. *Cancer Cell*. 2009 Oct 6; 16 (4):309-23. PMID: 19800576 PMCID: PMC2762396 DOI: 10.1016/j.ccr.2009.08.019
126. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, **Kumar S**, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. *J Clin Oncol*. 2009 Oct 20; 27 (30):5008-14 Epub 2009 Aug 31 PMID: 19720894 DOI: 10.1200/JCO.2009.23.6802
127. Dispenzieri A, Gertz MA, Hayman SR, Buadi F, **Kumar S**, Reeder CB, Zeldenrust SR, Rajkumar SV, Detweiler-Short K, Lust JA, Witzig TE, Greipp PR, Russell SJ, Dingli D, Allred J, Laumann K, Thompson MA, Fonseca R, Stewart AK, Bergsagel PL, Mikhael JR, Roy V, Kyle R, Lacy MQ. A pilot study of pomalidomide and dexamethasone in previously treated light chain amyloidosis patients. *Blood*. 2009 Nov 20; 114(22):1482-3.
128. Sinha Shirshendu, **Kumar SK**, Gastineau DA, Hogan WJ, Buadi F, Dingli D, Dispenzieri A, Gertz MA, Greiner Carl, Hayman SR, Inwards DJ, Johnston PB, Lacy MQ, Litzow MR, Porrata LF, Winters JL, Micallef IN. Predicting Poor Peripheral Blood Stem Cell Mobilization Using Initial Peripheral CD34 Counts in Patients with Lymphoma *Blood*. November 2009; 114(22):4228.
129. Gay F, Hayman S, Lacy MQ, Buadi F, Gertz MA, **Kumar S**, Dispenzieri A, Mikhael JR, Bergsagel L, Dingli D, Reeder CB, Lust JA, Russell S, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle R, Greipp PR, Stewart AK, Rajkumar SV. Superiority of lenalidomide-dexamethasone versus thalidomide-dexamethasone as initial therapy for newly diagnosed multiple myeloma. *Blood*. 2009 Nov 20; 114(22):1494-5.
130. Lacy MQ, Mandrekar S, Dispenzieri A, Hayman S, **Kumar S**, Buadi F, Dingli D, Litzow M, Wettstein P, Padley D, Kabat B, Gastineau D, Rajkumar SV, Gertz MA. Idiotypic-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. *Am J Hematol*. 2009 Dec; 84 (12):799-802 PMID: 19899131 PMCID: PMC2908015 DOI: 10.1002/ajh.21560
131. **Kumar SK**, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. *Mayo Clin Proc* 2009 Dec; 84 (12):1095-110 PMID: 19955246 PMCID: PMC2787395 DOI: 10.4065/mcp.2009.0603
132. Schaefer EW, **Kumar S**, Dispenzieri A, Allred JB, Gertz MA, Lacy MQ, Rajkumar SV, Mandrekar SJ. Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myeloma. *Cancer*. 2010 Feb 1; 116 (3):640-6 PMID: 19924791 PMCID: PMC2905541 DOI: 10.1002/cncr.24767
133. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, **Kumar S**, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR,

- Stewart AK, Rajkumar SV. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. *Blood*. 2010 Feb 18; 115 (7):1343-50 Epub 2009 Dec 11 PMID: 20008302 PMCID: PMC2826759 DOI: 10.1182/blood-2009-08-239046
134. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, **Kumar S**. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. *Oncogene*. 2010 Feb 25; 29 (8):1190-202 Epub 2009 Nov 23 PMID: 19935717 PMCID: PMC2908017 DOI: 10.1038/onc.2009.403
 135. Madan S, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Zeldenrust SR, Rajkumar SV, Gertz MA, **Kumar SK**. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. *Mayo Clin Proc*. 2010 Mar; 85 (3):232-8 PMID: 20194151 PMCID: PMC2843113 DOI: 10.4065/mcp.2009.0547
 136. Sinha S, Rajkumar SV, Lacy MQ, Hayman SR, Buadi FK, Dispenzieri A, Dingli D, Kyle RA, Gertz MA, **Kumar S**. Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. *Br J Haematol*. 2010 Mar; 148 (6):853-8 Epub 2009 Dec 03 PMID: 19958361 PMCID: PMC2864312 DOI: 10.1111/j.1365-2141.2009.08023.x
 137. Dingli D, Tan TS, **Kumar SK**, Buadi FK, Dispenzieri A, Hayman SR, Lacy MQ, Gastineau DA, Hogan WJ, Gertz MA. Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. *Neurology*. 2010 Mar 16; 74(11):913-8. PMID: 20231668 DOI: 10.1212/WNL.0b013e3181d55f4d
 138. Gertz MA, **Kumar S**, Lacy MQ, Dispenzieri A, Dingli D, Hayman SR, Buadi FK, Hogan WJ. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. *Blood*. 2010 Mar 25; 115 (12):2348-53; quiz 2560 Epub 2010 Jan 20 PMID: 20089967 DOI: 10.1182/blood-2009-07-235531
 139. Lorenz EC, Sethi S, Poshusta TL, Ramirez-Alvarado M, **Kumar S**, Lager DJ, Fervenza FC, Leung N. Renal failure due to combined cast nephropathy, amyloidosis and light-chain deposition disease. *Nephrol Dial Transplant*. 2010 Apr; 25(4):1340-3. Epub 2010 Jan 08. PMID: 20061318 DOI: 10.1093/ndt/gfp735
 140. **Kumar S**. Multiple myeloma - current issues and controversies. *Cancer Treat Rev*. 2010 May; 36 Suppl 2:S3-11 PMID: 20472186 DOI: 10.1016/S0305-7372(10)70006-2
 141. Dispenzieri A, Katzmman JA, Kyle RA, Larson DR, Melton LJ 3rd, Colby CL, Therneau TM, Clark R, **Kumar SK**, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. *Lancet*. 2010 May 15; 375 (9727):1721-8 PMID: 20472173 PMCID: PMC2904571 DOI: 10.1016/S0140-6736(10)60482-5
 142. Dispenzieri A, Wiseman GA, Lacy MQ, Hayman SR, **Kumar SK**, Buadi F, Dingli D, Laumann KM, Allred J, Geyer SM, Litzow MR, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Johnston PB, Hogan WJ, Gertz MA. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. *Am J Hematol*. 2010 Jun; 85 (6):409-13 PMID: 20513117 PMCID: PMC3900492 DOI: 10.1002/ajh.21696
 143. Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, Bergsagel PL, Lacy MQ, Dingli DD, Ketterling RP, Buadi F, Kyle RA, Witzig TE, Greipp PR, Dispenzieri A, **Kumar S**. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapies. *Mayo Clin Proc*. 2010 Jun; 85 (6):532-7 PMID: 20511484 PMCID: PMC2878257 DOI: 10.4065/mcp.2009.0677
 144. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kroger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M, **International Myeloma Working Group**. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. *Leukemia*. 2010 Jun; 24 (6):1121-7 Epub 2010 Apr 22 PMID: 20410922 PMCID: PMC7020664 DOI: 10.1038/leu.2010.60
 145. Stankowski-Drengler T, Gertz MA, Katzmman JA, Lacy MQ, **Kumar S**, Leung N, Hayman SR, Buadi F, Kyle RA, Rajkumar SV, Dispenzieri A. Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. *Am J Hematol*. 2010 Jun; 85 (6):431-4 PMID: 20513121 PMCID: PMC2902776 DOI: 10.1002/ajh.21707
 146. **Kumar S**. Treatment of newly diagnosed multiple myeloma: advances in current therapy. *Med Oncol*. 2010 Jun; 27 Suppl 1:S14-24 Epub 2009 Dec 25 PMID: 20035387 DOI: 10.1007/s12032-009-9370-1
 147. **Kumar SK**, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. *Leukemia*. 2010 Jul; 24 (7):1350-6 Epub 2010 May

27 PMID: 20508619 PMCID: PMC2957585 DOI: 10.1038/leu.2010.116

148. Pavletic SZ, **Kumar S**, Mohty M, de Lima, Foran JM, Pasquini M, Zhang MJ, Giralt S, Bishop MR, Weisdorf D. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. *Biol Blood Marrow Transplant*. 2010 Jul; 16(7):871-90. Epub 2010 Apr 24. PMID: 20399876 PMCID: PMC2916039 DOI: 10.1016/j.bbmt.2010.04.004
149. Gay F, Rajkumar SV, Coleman M, **Kumar S**, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. *Am J Hematol*. 2010 Sep; 85 (9):664-9 PMID: 20645430 PMCID: PMC3956597 DOI: 10.1002/ajh.21777
150. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, **Kumar SK**, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. *Mayo Clin Proc*. 2010 Sep; 85 (9):824-33 Epub 2010 Aug 11 PMID: 20702770 PMCID: PMC2931618 DOI: 10.4065/mcp.2010.0304
151. **Kumar S**, Kimlinger T, Morice W. Immunophenotyping in multiple myeloma and related plasma cell disorders. *Best Pract Res Clin Haematol*. 2010 Sep; 23 (3):433-51 PMID: 21112041 PMCID: PMC3005703 DOI: 10.1016/j.beha.2010.09.002
152. Gay F, Vincent Rajkumar S, Falco P, **Kumar S**, Dispenzieri A, Petrucci MT, Gertz MA, Boccadoro M, Keith Stewart A, Keith Stewart, Palumbo A. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. *Eur J Haematol*. 2010 Sep; 85 (3):200-8 Epub 2010 May 08 PMID: 20477865 DOI: 10.1111/j.1600-0609.2010.01469.x
153. Ramakrishnan V, Kimlinger T, Haug J, Timm M, Wellik L, Halling T, Pardanani A, Tefferi A, Rajkumar SV, **Kumar S**. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. *Am J Hematol*. 2010 Sep; 85 (9):675-86 PMID: 20652971 PMCID: PMC2940994 DOI: 10.1002/ajh.21785
154. Bianchi G, Kyle RA, Colby CL, Larson DR, **Kumar S**, Katzmann JA, Dispenzieri A, Therneau TM, Cerhan JR, Melton LJ 3rd, Rajkumar SV. Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. *Blood*. 2010 Sep 23; 116 (12):2019-25; quiz 2197 Epub 2010 May 21 PMID: 20495076 PMCID: PMC2951852 DOI: 10.1182/blood-2010-04-277566
155. Dispenzieri A, Dingli D, **Kumar SK**, Rajkumar SV, Lacy MQ, Hayman S, Buadi F, Zeldenrust S, Leung N, Detweiler-Short K, Lust JA, Russell SJ, Kyle RA, Gertz MA. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. *Am J Hematol*. 2010 Oct; 85 (10):757-9 PMID: 20872958 PMCID: PMC3691013 DOI: 10.1002/ajh.21822
156. Kapoor P, Greipp PT, Schaefer EW, Mandrekar SJ, Kamal AH, Gonzalez-Paz NC, **Kumar S**, Greipp PR. Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience. *Mayo Clin Proc*. 2010 Oct; 85 (10):905-12 Epub 2010 July 15 PMID: 20634497 PMCID: PMC2947962 DOI: 10.4065/mcp.2010.0159
157. Detweiler-Short K, Hayman S, Gertz MA, Lacy MQ, Dispenzieri A, **Kumar S**, Zeldenrust SR, Russell SJ, Lust JA, Kyle RA, Greipp PR, Witzig TE, Vincent Rajkumar S. Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. *Am J Hematol*. 2010 Oct; 85 (10):737-40 PMID: 20730790 PMCID: PMC3022372 DOI: 10.1002/ajh.21821
158. Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, **Kumar S**, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). *Leukemia*. 2010 Nov; 24 (11):1934-9 Epub 2010 Sept 09 PMID: 20827286 PMCID: PMC2978257 DOI: 10.1038/leu.2010.190
159. Dispenzieri A, Abraham M, Hayman SR, Buadi F, **Kumar S**, Reeder CB, Mikhael JR, Zeldenrust S, Rajkumar SV, Short KD, Greipp PR, Russell SJ, Dingli D, Allred J, Laumann K, Fonseca R, Bergsagel PL, Roy V, Stewart K, Lacy M. A phase-2 study of pomalidomide and dexamethasone in previously treated light chain (AL) amyloidosis. *Blood*. 2010 Nov 19; 116(21):434-5.
160. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**, Dingli D, Ansell SM, Gastineau DA, Inwards DJ, Johnston PB, Litzow MR, Micallef IN, Porrata LF, Leung N, Hogan WJ, Buadi FK. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. *Leuk Lymphoma*. 2010 Dec; 51 (12):2181-7 Epub 2010 Oct 20 PMID: 20958232 DOI: 10.3109/10428194.2010.524329

161. Reece DE, Vesole DH, Shrestha S, Zhang MJ, Perez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, **Kumar S**, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN. Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. *Clin Lymphoma Myeloma Leuk*. 2010 Dec; 10(6):458-63. PMID: 21156462 PMCID: PMC3370942 DOI: 10.3816/CLML.2010.n.078
162. **Kumar S**, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, Hayman SR, Buadi FK, Leung N, Zeldenrust SR, Ramirez-Alvarado M, Clark RJ, Kyle RA, Rajkumar SV, Gertz MA. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. *Blood*. 2010 Dec 9; 116 (24):5126-9 Epub 2010 Aug 26 PMID: 20798235 PMCID: PMC3012533 DOI: 10.1182/blood-2010-06-290668
163. Siragusa S, Morice W, Gertz MA, Kyle RA, Greipp PR, Lust JA, Witzig TE, Lacy MQ, Zeldenrust SR, Rajkumar SV, Russell SJ, Hayman SR, Buadi F, **Kumar SK**, Dingli D, Dispenzieri A. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. *Ann Hematol*. 2011 Jan; 90(1):101-6. Epub 2010 Jul 20. PMID: 20645101 DOI: 10.1007/s00277-010-1028-8
164. Madan S, **Kumar S**. Current treatment options for elderly patients with multiple myeloma: Clinical impact of novel agents. *Therapy*. 2011; 8(4):415-29.
165. **Kumar SK**, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Short-Detweiler K, Zeldenrust SR, Leung N, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Dispenzieri A. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. *Mayo Clin Proc*. 2011 Jan; 86 (1):12-8 PMID: 21193650 PMCID: PMC3012628 DOI: 10.4065/mcp.2010.0480
166. Kyle RA, Dispenzieri A, **Kumar S**, Larson D, Therneau T, Rajkumar SV. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenstrom's macroglobulinemia (SWM). *Clin Lymphoma Myeloma Leuk*. 2011 Feb; 11(1):74-6. PMID: 21454195 DOI: 10.3816/CLML.2011.n.011
167. Naina HV, Pruthi RK, Inwards DJ, Dingli D, Litzow MR, Ansell SM, William HJ, Dispenzieri A, Buadi FK, Elliott MA, Gastineau DA, Gertz MA, Hayman SR, Johnston PB, Lacy MQ, Micallef IN, Porrata LF, **Kumar S**. Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization. *Bone Marrow Transplant*. 2011 Feb; 46(2):291-3. Epub 2010 May 03. PMID: 20436522 DOI: 10.1038/bmt.2010.106
168. **Kumar SK**, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Tan T, Sinha S, Leung N, Kyle RA, Rajkumar SV, Gertz MA. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. *Am J Hematol*. 2011 Mar; 86 (3):251-5 Epub 2011 Feb 15 PMID: 21328431 PMCID: PMC3773466 DOI: 10.1002/ajh.21948
169. Dimopoulos M, Kyle R, Femand JP, Rajkumar SV, San Miguel, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksac M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, **Kumar S**, Giral S, Munshi NC, Jagannath S, International Myeloma. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. *Blood*. 2011 May 5; 117(18):4701-5. Epub 2011 Feb 03. PMID: 21292778 DOI: 10.1182/blood-2010-10-299529
170. Patel B, Dey A, Ghorani E, **Kumar S**, Malam Y, Rai L, Steele AJ, Thomson J, Wickremasinghe RG, Zhang Y, Castleton AZ, Fielding AK. Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights. *Mol Ther*. 2011 Jun; 19(6):1034-40. Epub 2011 Mar 22. PMID: 21427708 PMCID: PMC3129803 DOI: 10.1038/mt.2011.44
171. Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, **Kumar S**, Rajkumar SV, Kyle RA, Leung N. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. *J Am Soc Nephrol*. 2011 Jun; 22(6):1129-36. Epub 2011 Apr 21. PMID: 21511832 PMCID: PMC3103732 DOI: 10.1681/ASN.2010080857
172. Herrmann SM, Gertz MA, Stegall MD, Dispenzieri A, Cosio FC, **Kumar S**, Lacy MQ, Dean PG, Prieto M, Zeldenrust SR, Buadi FK, Russell SJ, Nyberg SL, Hayman SR, Dingli D, Fervenza FC, Leung N. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. *Nephrol Dial Transplant*. 2011 Jun; 26(6):2032-6. Epub 2011 May 4 PMID: 21543655 DOI: 10.1093/ndt/gfr067
173. **Kumar S**. Treatment of newly diagnosed multiple myeloma in transplant-eligible patients. *Curr Hematol Malig Rep*. 2011 Jun; 6 (2):104-12 PMID: 21394431 DOI: 10.1007/s11899-011-0083-0
174. Sinha S, Gastineau D, Micallef I, Hogan W, Ansell S, Buadi F, Dingli D, Dispenzieri A, Gertz M, Greiner C, Hayman S, Inwards D, Johnston P, Lacy M, Litzow M, Porrata L, Winters JL, **Kumar S**. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. *Bone Marrow Transplant*. 2011 Jul; 46 (7):943-9 Epub 2010 Oct 11 PMID: 20935680 PMCID: PMC3021104 DOI: 10.1038/bmt.2010.236

175. Gertz MA, Gastineau DA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**, Dingli D, Leung N, Wolf RC, Hogan WJ, Buadi FK. SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. *Bone Marrow Transplant*. 2011 Jul; 46(7):956-61. Epub 2010 Oct 25. PMID: 20972466 DOI: 10.1038/bmt.2010.233
176. Gertz MA, Lacy MQ, Dispenzieri A, **Kumar SK**, Buadi FK, Dingli D, Leung N, Hogan WJ, Hayman SR. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. *Bone Marrow Transplant*. 2011 Jul; 46 (7):970-5 Epub 2010 Oct 11 PMID: 20935685 DOI: 10.1038/bmt.2010.234
177. **Kumar SK**, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J, Laumann K, Greipp PR, Lust JA, Gertz MA, Zeldenrust SR, Bergsagel PL, Reeder CB, Witzig TE, Fonseca R, Russell SJ, Mikhael JR, Dingli D, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. *Am J Hematol*. 2011 Aug; 86 (8):640-5 Epub 2011 May 31 PMID: 21630308 PMCID: PMC3901994 DOI: 10.1002/ajh.22053
178. Madan S, Lacy MQ, Dispenzieri A, Gertz MA, Buadi F, Hayman SR, Detweiler-Short K, Dingli D, Zeldenrust S, Lust J, Greipp PR, Rajkumar SV, **Kumar S**. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. *Blood*. 2011 Aug 18; 118 (7):1763-5 Epub 2011 June 14 PMID: 21673347 PMCID: PMC3158710 DOI: 10.1182/blood-2011-04-350009
179. **Kumar S**, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale RP, Hari PN. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. *Blood*. 2011 Aug 18; 118 (7):1979-88 Epub 2011 June 20 PMID: 21690560 PMCID: PMC3158724 DOI: 10.1182/blood-2011-02-337329
180. **Kumar SK**. Myeloma ASH 2010 highlights. *Am J Hematol*. 2011 Sep; 86 (9):820-3 Epub 2011 July 28 PMID: 21800357 DOI: 10.1002/ajh.22090
181. Wadhera RK, Kyle RA, Larson DR, Dispenzieri A, **Kumar S**, Lazarus HM, Rajkumar SV. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. *Blood*. 2011 Sep 15; 118 (11):2985-7 Epub 2011 July 15 PMID: 21765020 PMCID: PMC3175778 DOI: 10.1182/blood-2011-04-349175
182. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, **Kumar S**, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. *Blood*. 2011 Sep 15; 118 (11):2970-5 Epub 2011 June 20 PMID: 21690557 PMCID: PMC3291492 DOI: 10.1182/blood-2011-04-348896
183. **Kumar SK**, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Haug JL, Siegel DS, Greipp PR, Fonseca R, Rajkumar SV. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. *Blood*. 2011 Oct 20; 118 (16):4359-62 Epub 2011 Aug 22 PMID: 21860025 PMCID: PMC3204907 DOI: 10.1182/blood-2011-03-342089
184. D'Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, Kyle RA, **Kumar S**, Greipp PR, Lust JA, Russell SJ, Zeldenrust S, Dingli D, Witzig TE, Rajkumar SV, Dispenzieri A. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. *Blood*. 2011 Oct 27; 118 (17):4663-5 Epub 2011 Aug 31 PMID: 21881050 DOI: 10.1182/blood-2011-06-362392
185. Kapoor P, Thenappan T, Singh E, **Kumar S**, Greipp PR. Cardiac amyloidosis: a practical approach to diagnosis and management. *Am J Med*. 2011 Nov; 124(11):1006-15. PMID: 22017778 DOI: 10.1016/j.amjmed.2011.04.013
186. Jacobus SJ, **Kumar S**, Uno H, Van Wier, Ahmann GJ, Henderson KJ, Callander NS, Williams ME, Siegel DS, Greipp PR, Rajkumar SV, Fonseca R. Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. *Br J Haematol*. 2011 Nov; 155(3):340-8. Epub 2011 Sep 09. PMID: 21902684 PMCID: PMC3192237 DOI: 10.1111/j.1365-2141.2011.08849.x
187. Ng AC, Khosla S, Charatcharoenwittaya N, **Kumar SK**, Achenbach SJ, Holets MF, McCready LK, Melton LJ 3rd, Kyle RA, Rajkumar SV, Drake MT. Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1alpha levels in patients with MGUS. *Blood*. 2011 Dec 15; 118 (25):6529-34 Epub 2011 Oct 31 PMID: 22042700 PMCID: PMC3242716 DOI: 10.1182/blood-2011-04-351437
188. Irazabal MV, Eirin A, Gertz MA, Dispenzieri A, **Kumar S**, Buadi FK, Lacy MQ, Hayman SR, Dingli D, Hogan WJ, Gastineau DA, Glavey SV, Amer H, Leung N. Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis. *Am J Hematol*. 2012 Jan; 87 (1):51-4. Epub 2011 Nov 11. PMID: 22076913 DOI: 10.1002/ajh.22202
189. Ramakrishnan V, Kimlinger T, Haug J, Painuly U, Wellik L, Halling T, Rajkumar SV, **Kumar S**. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. *PLoS One*. 2012;

7 (11):e50005 Epub 2012 Nov 21 PMID: 23185517 PMCID: PMC3503708 DOI: 10.1371/journal.pone.0050005

190. Painuly U, **Kumar S**. Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. *Clinical Medicine Insights: Oncology*. 2012; 7:53-73.
191. Ozsan GH, Micallef IN, Dispenzieri A, **Kumar S**, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Wolf RC, Gastineau DA, Hogan WJ, Gertz MA. Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma. *Am J Hematol*. 2012 Jan; 87(1):1-4. Epub 2011 Sep 29. PMID: 21959988 DOI: 10.1002/ajh.22179
192. **Kumar SK**, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Blade J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. *Leukemia*. 2012 Jan; 26 (1):149-57 Epub 2011 July 29 PMID: 21799510 PMCID: PMC4109061 DOI: 10.1038/leu.2011.196
193. Gertz MA, Buadi FK, Hayman SR, Dingli D, Dispenzieri A, Greipp PR, **Kumar SK**, Lacy MQ, Lust JA, Leung N, Rajkumar SV, Russell SJ, Zeldenrust SR, Mikhael JR, Roy V, Kyle RA. Immunoglobulin D amyloidosis: a distinct entity. *Blood*. 2012 Jan 5; 119 (1):44-8 Epub 2011 Nov 07 PMID: 22065594 DOI: 10.1182/blood-2011-06-358895
194. Khan ML, Reeder CB, **Kumar SK**, Lacy MQ, Reece DE, Dispenzieri A, Gertz MA, Greipp P, Hayman S, Zeldenhurst S, Dingli D, Lust J, Russell S, Laumann KM, Mikhael JR, Leif Bergsagel P, Fonseca R, Vincent Rajkumar S, Keith Stewart A. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. *Br J Haematol*. 2012 Feb; 156 (3):326-33 Epub 2011 Nov 23 PMID: 22107129 DOI: 10.1111/j.1365-2141.2011.08949.x
195. Ramakrishnan V, Ansell S, Haug J, Grote D, Kimlinger T, Stenson M, Timm M, Wellik L, Halling T, Rajkumar SV, **Kumar S**. MRK003, a gamma-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. *Leukemia*. 2012 Feb; 26 (2):340-8 Epub 2011 Aug 09 PMID: 21826062 PMCID: PMC4384189 DOI: 10.1038/leu.2011.192
196. Madan S, **Kumar SK**, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Hogan WJ, Leung N, Grogan M, Gertz MA. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. *Blood*. 2012 Feb 2; 119 (5):1117-22 Epub 2011 Dec 06 PMID: 22147893 PMCID: PMC3277349 DOI: 10.1182/blood-2011-07-370031
197. Bianchi G, **Kumar S**, Ghobrial IM, Roccaro AM. Cell Trafficking in Multiple Myeloma. *Open J Hematol*. 2012 Feb 21; 3 (Suppl 1) PMID: 23762527 PMCID: PMC3677225 DOI: 10.13055/ojhmt.3_s1_04.120221
198. Eirin A, Irazabal MV, Gertz MA, Dispenzieri A, Lacy MQ, **Kumar S**, Sethi S, Nasr SH, Cornell LD, Fidler ME, Fervenza FC, Leung N. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. *Nephrol Dial Transplant*. 2012 Mar; 27(3):1097-101. Epub 2011 Nov 07. PMID: 22067518 DOI: 10.1093/ndt/gfr381
199. **Kumar S**. Risk of early death in multiple myeloma. *Clin Adv Hematol Oncol*. 2012 Mar; 10(3):172-4. PMID: 22402425
200. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Halling T, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, **Kumar S**. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. *Am J Hematol*. 2012 Mar; 87 (3):277-83 Epub 2011 Dec 21 PMID: 22190165 PMCID: PMC3465673 DOI: 10.1002/ajh.22263
201. **Kumar S**, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Hayman SR, Buadi FK, Dingli D, Knudson RA, Greenberg A, Russell SJ, Zeldenrust SR, Lust JA, Kyle RA, Bergsagel L, Rajkumar SV. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. *Blood*. 2012 Mar 1; 119 (9):2100-5 Epub 2012 Jan 10 PMID: 22234687 PMCID: PMC3311247 DOI: 10.1182/blood-2011-11-390658
202. **Kumar SK**, Lacy MQ, Dispenzieri A, Buadi FK, Hayman SR, Dingli D, Gay F, Sinha S, Leung N, Hogan W, Rajkumar SV, Gertz MA. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. *Cancer*. 2012 Mar 15; 118 (6):1585-92 Epub 2011 Aug 25 PMID: 22009602 PMCID: PMC3262884 DOI: 10.1002/cncr.26422
203. **Kumar S**, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. *J Clin Oncol*. 2012 Mar 20; 30 (9):989-95 Epub 2012 Feb 13 PMID: 22331953 PMCID: PMC3675680 DOI: 10.1200/JCO.2011.38.5724
204. Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, Berenson JR, Bird JM, Dispenzieri A,

- Gajewski JL, Gale RP, Holmberg L, **Kumar S**, Kyle RA, Lazarus HM, Lonial S, Mikhael J, Milone GA, Munker R, Nath R, Saccaro S, To LB, Vogl DT, Wirk B, Hari P. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. *Leukemia*. 2012 May; 26(5):1091-7. Epub 2011 Nov 01. PMID: 22042147 PMCID: PMC3274611 DOI: 10.1038/leu.2011.312
205. Greenberg AJ, Rajkumar SV, Larson DR, Dispenzieri A, Therneau TM, Colby CL, Phelps TK, **Kumar SK**, Katzmman JA, Kyle RA, Slager SL, Vachon CM. Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma. *Br J Haematol*. 2012 May; 157 (4):472-5 PMID: 22629552 PMCID: PMC3375594 DOI: 10.1111/j.1365-2141.2012.09075.x
 206. Kyle RA, Benson JT, Larson DR, Therneau TM, Dispenzieri A, **Kumar S**, Melton LJ 3rd, Rajkumar SV. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. *Blood*. 2012 May 10; 119 (19):4462-6 Epub 2012 Mar 26 PMID: 22451426 PMCID: PMC3362362 DOI: 10.1182/blood-2011-10-384768
 207. **Kumar S**, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. *Blood*. 2012 May 10; 119 (19):4375-82 Epub 2012 Mar 15 PMID: 22422823 DOI: 10.1182/blood-2011-11-395749
 208. **Kumar SK**, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. *Blood*. 2012 May 24; 119 (21):4860-7 Epub 2012 Apr 13 PMID: 22504925 PMCID: PMC3418771 DOI: 10.1182/blood-2012-01-407791
 209. Dispenzieri A, Katzmman JA, Kyle RA, Larson DR, Therneau TM, Colby CL, Clark RJ, Mead GP, **Kumar S**, Melton LJ 3rd, Rajkumar SV. Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. *Mayo Clin Proc*. 2012 Jun; 87 (6):517-23 PMID: 22677072 PMCID: PMC3538473 DOI: 10.1016/j.mayocp.2012.03.009
 210. Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, **Kumar SK**, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, Roy V, Witzig TE, Lust JA, Russell SJ, Gertz MA, Lacy MQ. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. *Blood*. 2012 Jun 7; 119 (23):5397-404 Epub 2012 Apr 04 PMID: 22493299 PMCID: PMC3369677 DOI: 10.1182/blood-2012-02-413161
 211. Warsame R, Gertz MA, Lacy MQ, Kyle RA, Buadi F, Dingli D, Greipp PR, Hayman SR, **Kumar SK**, Lust JA, Russell SJ, Witzig TE, Mikhael J, Leung N, Zeldenrust SR, Rajkumar SV, Dispenzieri A. Trends and outcomes of modern staging of solitary plasmacytoma of bone. *Am J Hematol*. 2012 Jul; 87 (7):647-51 Epub 2012 May 02 PMID: 22549792 PMCID: PMC4440242 DOI: 10.1002/ajh.23201
 212. D'Souza A, Lacy M, Gertz M, **Kumar S**, Buadi F, Hayman S, Dingli D, Zeldenrust S, Kyle R, Ansell S, Inwards D, Johnston P, Micallef I, Porrata L, Litzow M, Gastineau D, Hogan W, Dispenzieri A. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. *Blood*. 2012 Jul 5; 120 (1):56-62 Epub 2012 May 18 PMID: 22611150 DOI: 10.1182/blood-2012-04-423178
 213. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, **Kumar S**, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL. Clonal competition with alternating dominance in multiple myeloma. *Blood*. 2012 Aug 2; 120 (5):1067-76 Epub 2012 Apr 12 PMID: 22498740 PMCID: PMC3412330 DOI: 10.1182/blood-2012-01-405985
 214. Bleeker JS, Gertz MA, Pellikka PA, Larson DR, Buadi F, Dingli D, Dispenzieri A, Hayman SR, Hogan W, **Kumar S**, Rajkumar SV, Lacy MQ. Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation. *Eur J Haematol*. 2012 Sep; 89(3):228-35. Epub 2012 Jul 13. PMID: 22672722 DOI: 10.1111/j.1600-0609.2012.01815.x
 215. Therneau TM, Kyle RA, Melton LJ 3rd, Larson DR, Benson JT, Colby CL, Dispenzieri A, **Kumar S**, Katzmman JA, Cerhan JR, Rajkumar SV. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. *Mayo Clin Proc*. 2012 Nov; 87 (11):1071-9 Epub 2012 Aug 07 PMID: 22883742 PMCID: PMC3541934 DOI: 10.1016/j.mayocp.2012.06.014
 216. Leung N, Gertz M, Kyle RA, Fervenza FC, Irazabal MV, Eirin A, **Kumar S**, Cha SS, Rajkumar SV, Lacy MQ, Zeldenrust SR, Buadi FK, Hayman SR, Nasr SH, Sethi S, Ramirez-Alvarado M, Witzig TE, Herrmann SM, Dispenzieri A. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. *Clin J Am Soc Nephrol*. 2012 Dec; 7 (12):1964-8 Epub 2012 Sept 27 PMID: 23024162 PMCID: PMC3513751 DOI: 10.2215/CJN.11161111
 217. Cordes S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, **Kumar SK**, Hogan WJ, Gertz MA. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. *Cancer*.

2012 Dec 15; 118(24):6105-9. Epub 2012 Jun 15. PMID: 22707405 DOI: 10.1002/cncl.27660

218. Palladini G, Dispenzieri A, Gertz MA, **Kumar S**, Wechalekar A, Hawkins PN, Schonland S, Hegenbart U, Comenzo R, Kastiris E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. *J Clin Oncol*. 2012 Dec 20; 30(36):4541-9. Epub 2012 Oct 22. PMID: 23091105 DOI: 10.1200/JCO.2011.37.7614
219. Witzig TE, Laumann KM, Lacy MQ, Hayman SR, Dispenzieri A, **Kumar S**, Reeder CB, Roy V, Lust JA, Gertz MA, Greipp PR, Hassoun H, Mandrekar SJ, Rajkumar SV. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. *Leukemia*. 2013 Jan; 27 (1):220-5 Epub 2012 Aug 20 PMID: 22902362 PMCID: PMC3912579 DOI: 10.1038/leu.2012.236
220. Bianchi G, Sacco A, **Kumar S**, Rossi G, Ghobrial I, Roccaro A. Candidate genes of Waldenström's macroglobulinemia: Current evidence and research. *Application of Clinical Genetics*. 2013; 6:32-42.
221. Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, Hayman SR, Hogan WJ, Johnston PB, Lacy MQ, Ansell SM, Buadi F, Dingli D, Dispenzieri A, Litzow MR, Porrata LF, Winters JL, **Kumar S**. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. *Biol Blood Marrow Transplant*. 2013 Jan; 19 (1):87-93 Epub 2012 Aug 23 PMID: 22922211 DOI: 10.1016/j.bbmt.2012.08.010
222. Painuly U, **Kumar S**. Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. *Clin Med Insights Oncol*. 2013; 7:53-73 Epub 2013 Feb 28 PMID: 23492937 PMCID: PMC3588852 DOI: 10.4137/CMO.S7764
223. Greenberg AJ, Lee AM, Serie DJ, McDonnell SK, Cerhan JR, Liebow M, Larson DR, Colby CL, Norman AD, Kyle RA, **Kumar S**, Rajkumar SV, Diasio RB, Slager SL, Vachon CM. Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma. *Leukemia*. 2013 Feb; 27: (2):515-6. PMID: 22945773 PMCID: PMC3707297 DOI: 10.1038/leu.2012.232
224. **Kumar SK**. Digging deeper with allogeneic transplantation in multiple myeloma. *Biol Blood Marrow Transplant*. 2013 Mar; 19(3):335-6. Epub 2013 Jan 02. PMID: 23291232 DOI: 10.1016/j.bbmt.2012.12.020
225. Kyle RA, Therneau TM, Dispenzieri A, **Kumar S**, Benson JT, Larson DR, Melton LJ 3rd, Rajkumar SV. Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia. *Clin Lymphoma Myeloma Leuk*. 2013 Apr; 13 (2):184-6 Epub 2013 Mar 13 PMID: 23490989 PMCID: PMC3654087 DOI: 10.1016/j.clml.2013.02.005
226. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, **Kumar S**, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. *Mayo Clin Proc*. 2013 Apr; 88 (4):360-76 PMID: 23541011 DOI: 10.1016/j.mayocp.2013.01.019
227. Fernandez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, **Kumar SK**, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Blade J, Orlowski RZ, Shah JJ, International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. *Leukemia*. 2013 Apr; 27(4):780-91. Epub 2012 Nov 21 PMID: 23288300 PMCID: PMC4112539 DOI: 10.1038/leu.2012.336
228. Gertz MA, Lacy MQ, Dispenzieri A, **Kumar SK**, Dingli D, Leung N, Hogan WJ, Buadi FK, Hayman SR. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. *Bone Marrow Transplant*. 2013 Apr; 48(4):557-61. Epub 2012 Sep 10. PMID: 22964596 DOI: 10.1038/bmt.2012.170
229. Gonsalves WI, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Hogan WJ, **Kumar SK**. Second auto-SCT for treatment of relapsed multiple myeloma. *Bone Marrow Transplant*. 2013 Apr; 48(4):568-73. Epub 2012 Sep 24. PMID: 23000647 DOI: 10.1038/bmt.2012.183
230. Larsen JT, **Kumar SK**, Dispenzieri A, Kyle RA, Katzmman JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. *Leukemia*. 2013 Apr; 27 (4):941-6 Epub 2012 Oct 16 PMID: 23183428 PMCID: PMC3629951 DOI: 10.1038/leu.2012.296
231. Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, **Kumar S**, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H,

- Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research. Salvage second hematopoietic cell transplantation in myeloma. *Biol Blood Marrow Transplant*. 2013 May; 19(5):760-6. PMID: 23298856 PMCID: PMC3816739 DOI: 10.1016/j.bbmt.2013.01.004
232. Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, Zeldenrust S, Buadi F, Witzig T, Hayman S, Lust J, Russell S, Lin Y, Rajkumar VS, **Kumar S**, Leung N, Dingli D, Dispenzieri A. Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. *Am J Hematol*. 2013 May; 88(5):375-8. Epub 2013 Mar 19. PMID: 23508840 DOI: 10.1002/ajh.23413
 233. Leung N, Glavey SV, **Kumar S**, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Gertz MA. A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? *Haematologica*. 2013 Jun; 98(6):988-92 PMID: 23729727 PMCID: PMC3669457 DOI: 10.3324/haematol.2012.079210
 234. Humeniuk MS, Gertz MA, Lacy MQ, Kyle RA, Witzig TE, **Kumar SK**, Kapoor P, Lust JA, Hayman SR, Buadi FK, Rajkumar SV, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Leung N, Dispenzieri A. Outcomes of patients with POEMS syndrome treated initially with radiation. *Blood*. 2013 Jul 4; 122(1):68-73 Epub 2013 May 22 PMID: 23699599 PMCID: PMC4067496 DOI: 10.1182/blood-2013-03-487025
 235. Hegerova LT, Swiecicki PL, **Kumar SK**. 35-year-old man with Fever and abdominal pain. *Mayo Clin Proc*. 2013 Aug; 88(8):866-70. PMID: 23910413 DOI: 10.1016/j.mayocp.2012.10.007
 236. Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, Ketterling RP, Lust JA, Kyle RA, **Kumar SK**. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. *Leukemia*. 2013 Aug; 27(8):1738-44 Epub 2013 Mar 21 PMID: 23515097 PMCID: PMC3773463 DOI: 10.1038/leu.2013.86
 237. Singla A, Hogan WJ, Ansell SM, Buadi FK, Dingli D, Dispenzieri A, Gastineau DA, Gertz MA, Hayman SR, Inwards DJ, Johnston PB, Lacy MQ, Litzow MR, Micallef IN, Porrata LF, **Kumar SK**. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant*. 2013 Aug; 19(8):1233-7. Epub 2013 Jun 06. PMID: 23747600 PMCID: PMC3752294 DOI: 10.1016/j.bbmt.2013.05.019
 238. Greenberg AJ, Cousin M, **Kumar S**, Ketterling RP, Knudson RA, Larson D, Colby C, Scott C, Vachon CM, Vincent Rajkumar S. Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma. *Eur J Haematol*. 2013 Sep; 91(3):193-195 Epub 2013 July 22 PMID: 23647020 PMCID: PMC3762589 DOI: 10.1111/ejh.12133
 239. Keyzner A, D'Souza A, Lacy M, Gertz M, Hayman S, Buadi F, **Kumar S**, Dingli D, Engebretson A, Tong C, Dispenzieri A. Low levels of interleukin-1 receptor antagonist (IL-1RA) predict engraftment syndrome after autologous stem cell transplantation in POEMS syndrome and other plasma cell neoplasms. *Biol Blood Marrow Transplant*. 2013 Sep; 19(9):1395-8. Epub 2013 Jun 20. PMID: 23792270 DOI: 10.1016/j.bbmt.2013.06.012
 240. Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, **Kumar SK**, Kimlinger TK, Northfelt DW, Flynn PJ, Jaeckle KA, Kaufmann TJ, Buckner JC. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. *Clin Cancer Res*. 2013 Sep 1; 19(17):4816-23 Epub 2013 July 05 PMID: 23833308 PMCID: PMC3869574 DOI: 10.1158/1078-0432.CCR-13-0708
 241. Gonsalves WI, Gertz MA, Dispenzieri A, Lacy MQ, Lin Y, Singh PP, Gupta V, Hayman SR, Buadi FK, Dingli D, Kapoor P, McCurdy AR, **Kumar SK**. Implications of continued response after autologous stem cell transplantation for multiple myeloma. *Blood*. 2013 Sep 5; 122(10):1746-9 Epub 2013 July 17 PMID: 23863899 PMCID: PMC3765057 DOI: 10.1182/blood-2013-03-492678
 242. Chanan-Khan AA, Swaika A, Paulus A, **Kumar SK**, Mikhael JR, Rajkumar SV, Dispenzieri A, Lacy MQ. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. *Blood Cancer J*. 2013 Sep 6; 3:e143 Epub 2013 Sept 06 PMID: 24013664 PMCID: PMC3789204 DOI: 10.1038/bcj.2013.38
 243. Srivastava G, Rana V, Lacy MQ, Buadi FK, Hayman SR, Dispenzieri A, Gertz MA, Dingli D, Zeldenrust S, Russell S, McCurdy A, Kapoor P, Kyle R, Rajkumar SV, **Kumar S**. Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. *Leukemia*. 2013 Oct; 27(10):2062-6 Epub 2013 May 07 PMID: 23648667 PMCID: PMC3795989 DOI: 10.1038/leu.2013.143
 244. Dispenzieri A, Seenithamby K, Lacy MQ, **Kumar SK**, Buadi FK, Hayman SR, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Johnston PB, Porrata LF, Patnaik MM, Hogan WJ, Gertz MA. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. *Bone Marrow Transplant*. 2013 Oct; 48(10):1302-7. Epub 2013 Apr 22. PMID: 23604010 DOI: 10.1038/bmt.2013.53
 245. **Kumar SK**, Jett J, Marks R, Richardson R, Quevedo F, Moynihan T, Croghan G, Markovic SN, Bible KC, Qin R, Tan A, Molina J, Kaufmann SH, Erlichman C, Adjei AA. Phase 1 study of sorafenib in combination with

- bortezomib in patients with advanced malignancies. *Invest New Drugs*. 2013 Oct; 31 (5):1201-6 Epub 2013 July 26 PMID: 23887852 PMCID: PMC3779429 DOI: 10.1007/s10637-013-0004-2
246. Thyagarajan B, Arora M, Guan W, Barcelo H, Jackson S, **Kumar S**, Gertz M. Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patients. *Leuk Res*. 2013 Nov; 37(11):1527-31. Epub 2013 Oct 12. PMID: 24129343 DOI: 10.1016/j.leukres.2013.07.012
 247. Glavey SV, Gertz MA, Dispenzieri A, **Kumar S**, Buadi F, Lacy M, Hayman SR, Dingli D, McCurdy A, Hogan WJ, Gastineau DA, Leung N. Long-term outcome of patients with multiple myeloma-related advanced renal failure following auto-SCT. *Bone Marrow Transplant*. 2013 Nov; 48(12):1543-7. Epub 2013 Aug 05. PMID: 23912663 DOI: 10.1038/bmt.2013.109
 248. Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A, Freytes C, Vesole D, Gale RP, Anderson K, Wirk B, Savani BN, Waller EK, Schouten H, Lazarus H, Meehan K, Sharma M, Kamble R, Vij R, **Kumar S**, Nishihori T, Kindwall-Keller T, Saber W, Hari PN. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. *Biol Blood Marrow Transplant*. 2013 Nov; 19(11):1615-24. Epub 2013 Aug 11. PMID: 23939198 PMCID: PMC3952066 DOI: 10.1016/j.bbmt.2013.08.002
 249. Kourelis TV, **Kumar SK**, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust S, Leung N, Kyle RA, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Rajkumar SV, McCurdy A, Dispenzieri A. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. *J Clin Oncol*. 2013 Dec 1; 31 (34):4319-24 Epub 2013 Oct 21 PMID: 24145344 PMCID: PMC4881366 DOI: 10.1200/JCO.2013.50.8499
 250. Greenberg AJ#, Walters DK#, **Kumar SK**, Rajkumar SV, Jelinek DF. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels. *Eur J Haematol*. 2013 Dec; 91 (6):504-13 Epub 2013 Sept 17 PMID: 23992230 PMCID: PMC3834223 DOI: 10.1111/ejh.12192
 251. Burnette BL, Dispenzieri A, **Kumar S**, Harris AM, Sloan JA, Tilburt JC, Kyle RA, Rajkumar SV. Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies. *Cancer*. 2013 Dec 15; 119 (24):4308-15 Epub 2013 Sept 19 PMID: 24105720 PMCID: PMC3855162 DOI: 10.1002/cncr.28340
 252. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, **Kumar SK**. Smoldering multiple myeloma requiring treatment: time for a new definition? *Blood*. 2013 Dec 19; 122 (26):4172-81 Epub 2013 Oct 21 PMID: 24144641 PMCID: PMC3952477 DOI: 10.1182/blood-2013-08-520890
 253. Kapoor P, **Kumar SK**, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, Russell SJ, Hayman SR, Witzig TE, Lust JA, Leung N, Lin Y, Zeldenrust SR, McCurdy A, Greipp PR, Kyle RA, Rajkumar SV, Gertz MA. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. *J Clin Oncol*. 2013 Dec 20; 31 (36):4529-35 Epub 2013 Nov 18 PMID: 24248686 PMCID: PMC3871514 DOI: 10.1200/JCO.2013.49.0086
 254. Glavey SV, Gertz MA, Dispenzieri A, **Kumar S**, Buadi F, Lacy M, Hayman SR, Kapoor P, Dingli D, McCurdy A, Hogan WJ, Gastineau DA, Leung N. Erratum: Long-term outcome of patients with multiple myeloma-related advanced renal failure following auto-SCT (*Bone Marrow Transplantation* (2014) 49 (996) DOI:10.1038/bmt.2014.24). *Bone Marrow Transplant*. 2014; 49(7):996.
 255. Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Ahmann G, **Kumar S**, Rajkumar SV, Mikhael J, Laplant B, Champion MD, Laumann K, Barlogie B, Fonseca R, Bergsagel PL, Lacy M, Stewart AK. The clinical significance of cereblon expression in multiple myeloma. *Leuk Res*. 2014 Jan; 38 (1):23-8 Epub 2013 Sept 05 PMID: 24129344 PMCID: PMC3905958 DOI: 10.1016/j.leukres.2013.08.015
 256. Farr JN, Zhang W, **Kumar SK**, Jacques RM, Ng AC, McCreedy LK, Rajkumar SV, Drake MT. Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. *Blood*. 2014 Jan 30; 123 (5):647-9 Epub 2013 Nov 13 PMID: 24227822 PMCID: PMC3907752 DOI: 10.1182/blood-2013-05-505776
 257. Paulus A#, Chitta K#, Akhtar S, Personett D, Miller KC, Thompson KJ, Carr J, **Kumar S**, Roy V, Ansell SM, Mikhael JR, Dispenzieri A, Reeder CB, Rivera CE, Foran J, Chanan-Khan A. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia. *Br J Haematol*. 2014 Feb; 164 (3):352-365 Epub 2013 Nov 17 PMID: 24236538 PMCID: PMC4406280 DOI: 10.1111/bjh.12633
 258. Rosinol L, **Kumar S**, Moreau P, Cavo M. Initial treatment of transplant-eligible patients in multiple myeloma. *Expert Rev Hematol*. 2014 Feb; 7(1):43-53. Epub 2014 Jan 07. PMID: 24392968 DOI: 10.1586/17474086.2014.871200
 259. **Kumar S**. Maintenance therapy in multiple myeloma. *Clin Adv Hematol Oncol*. 2014 Feb; 12(2):133-4. PMID: 24892259

260. **Kumar SK**, Mikhael J, Laplant B, Lacy MQ, Buadi FK, Dingli D, Gertz MA, Laumann K, Miceli T, Mahlman M, Bergsagel LP, Hayman SR, Reeder C, Stewart AK, Dispenzieri A, Gastineau DA, Winters JL. Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. *Bone Marrow Transplant*. 2014 Feb; 49 (2):201-5 Epub 2013 Nov 04 PMID: 24185588 PMCID: PMC3946357 DOI: 10.1038/bmt.2013.175
261. Costa LJ, Nista EJ, Buadi FK, Lacy MQ, Dispenzieri A, Kramer CP, Edwards KH, Kang Y, Gertz MA, Stuart RK, **Kumar S**. Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification. *Biol Blood Marrow Transplant*. 2014 Feb; 20(2):222-8. Epub 2013 Nov 6 PMID: 24211319 DOI: 10.1016/j.bbmt.2013.11.003
262. Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, **Kumar SK**. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. *Leukemia*. 2014 Feb; 28 (2):398-403 Epub 2013 Sept 05 PMID: 24005246 PMCID: PMC3924716 DOI: 10.1038/leu.2013.258
263. Dispenzieri A, Gertz MA, **Kumar SK**, Lacy MQ, Kyle RA, Saenger AK, Grogan M, Zeldenrust SR, Hayman SR, Buadi F, Greipp PR, Leung N, Russell SR, Dingli D, Lust JA, Rajkumar SV, Jaffe AS. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. *Heart*. 2014 Mar; 100 (5):383-8 Epub 2014 Jan 08 PMID: 24402772 DOI: 10.1136/heartjnl-2013-304957
264. Kourelis TV, **Kumar SK**, Srivastava G, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust SR, Leung N, Kyle RA, Russell SJ, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, Rajkumar SV, Dispenzieri A. Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. *Am J Hematol*. 2014 Mar; 89 (3):302-5 Epub 2014 Feb 18 PMID: 24265187 DOI: 10.1002/ajh.23634
265. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, **Kumar S**, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, Miguel JF. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). *Leukemia*. 2014 Mar; 28 (3):525-42 Epub 2013 Nov 20 PMID: 24253022 PMCID: PMC4143389 DOI: 10.1038/leu.2013.350
266. Palumbo A, Bringhen S, **Kumar SK**, Lupporelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. *Lancet Oncol*. 2014 Mar; 15 (3):333-42 Epub 2014 Feb 11 PMID: 24525202 DOI: 10.1016/S1470-2045(13)70609-0
267. Parikh SA, Kapoor P, Letendre L, **Kumar S**, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. *Mayo Clin Proc*. 2014 Apr; 89 (4):484-92 Epub 2014 Feb 26 PMID: 24581757 DOI: 10.1016/j.mayocp.2013.12.012
268. **Kumar SK**, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. *Leukemia*. 2014 May; 28 (5):1122-8 Epub 2013 Oct 25 PMID: 24157580 PMCID: PMC4000285 DOI: 10.1038/leu.2013.313
269. Warsame R, Bang SM, **Kumar SK**, Gertz MA, Lacy MQ, Buadi F, Dingli D, Hayman SR, Kapoor P, Kyle RA, Leung N, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Rajkumar SV, Dispenzieri A. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. *Eur J Haematol*. 2014 Jun; 92(6):485-90. Epub 2014 Mar 2 PMID: 24502602 DOI: 10.1111/ejh.12282
270. Ramakrishnan V, Painuly U, Kimlinger T, Haug J, Rajkumar SV, **Kumar S**. Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. *Leukemia*. 2014 Jul; 28 (7):1519-28 Epub 2014 Jan 09 PMID: 24402161 PMCID: PMC4090267 DOI: 10.1038/leu.2014.2
271. Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R, **Kumar SK**, Dispenzieri A, Greenberg AJ, Therneau TM, Melton LJ 3rd, Caporaso N, Korde N, Roschewski M, Costello R, McQuillan GM, Rajkumar SV. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. *Leukemia*. 2014 Jul; 28 (7):1537-42 Epub 2014 Jan 20 PMID: 24441287 PMCID: PMC4090286 DOI: 10.1038/leu.2014.34
272. Gonsalves WI, Rajkumar SV, Go RS, Dispenzieri A, Gupta V, Singh PP, Buadi FK, Lacy MQ, Kapoor P, Dingli D, Lust JA, Zeldenrust SR, Hayman SR, Kyle RA, Gertz MA, **Kumar SK**. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. *Blood*. 2014 Aug 7; 124 (6):907-12 Epub 2014 June 23 PMID: 24957143 PMCID: PMC4126330 DOI: 10.1182/blood-2014-03-565051
273. **Kumar SK**, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui AM, Gupta N, Di Bacco A,

- Yu J, Shou Y, Niesvizky R. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. *Blood*. 2014 Aug 14; 124 (7):1047-55 Epub 2014 June 05 PMID: 24904120 PMCID: PMC4468583 DOI: 10.1182/blood-2014-01-548941
274. Mughal TI, Girnius S, Rosen ST, **Kumar S**, Wiestner A, Abdel-Wahab O, Kiladjian JJ, Wilson WH, Van Etten RA. Emerging therapeutic paradigms to target the dysregulated janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. *Leuk Lymphoma*. 2014 Sep; 55(9):1968-79. PMID: 24206094 PMCID: PMC4344832
 275. Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Melton LJ 3rd, Benson JT, **Kumar S**, Rajkumar SV. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. *Lancet Haematol*. 2014 Oct 1; 1 (1):e28-e36 PMID: 25530988 PMCID: PMC4266993 DOI: 10.1016/S2352-3026(14)70001-8
 276. Pandya C, Hashmi S, Khera N, Gertz MA, Dispenzieri A, Hogan W, Siddiqui M, Noyes K, **Kumar SK**. Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. *Clin Transplant*. 2014 Oct; 28(10):1084-91. PMID: 25040732
 277. Raje N, Faiman B, Harvey RD, Kurtin SE, Lonial S, **Kumar SK**, Cohen AD, Conde MA, Giralt SA, Recine MS, Tombler ER, Stadtmauer E, Jagannath S, Anderson KC, Managing Myeloma Continuing Education Initiative Advisory Group. Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. *Clin Lymphoma Myeloma Leuk*. 2014 Oct; 14: (5)356-69. PMID: 25066040 DOI: 10.1016/j.clml.2014.04.011
 278. Gonsalves WI, Rajkumar SV, Gupta V, Morice WG, Timm MM, Singh PP, Dispenzieri A, Buadi FK, Lacy MQ, Kapoor P, Gertz MA, **Kumar SK**. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. *Leukemia*. 2014 Oct; 28(10):2060-5. Epub 2014 Mar 12. PMID: 24618735 PMCID: PMC4162866 DOI: 10.1038/leu.2014.98
 279. Kourelis TV, **Kumar SK**, Go RS, Kapoor P, Kyle RA, Buadi FK, Gertz MA, Lacy MQ, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Zeldenrust SR, Rajkumar SV, Dispenzieri A. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. *Am J Hematol*. 2014 Nov; 89(11):1051-4. Epub 2014 Sep 02. PMID: 25111004 DOI: 10.1002/ajh.23827
 280. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, **Kumar S**, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol*. 2014 Nov; 15 (12):e538-48 Epub 2014 Oct 26 PMID: 25439696 DOI: 10.1016/S1470-2045(14)70442-5
 281. Ramakrishnan V, Kimlinger T, Timm M, Haug J, Rajkumar SV, **Kumar S**. Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001. *Leuk Res*. 2014 Nov; 38 (11):1358-66 Epub 2014 Sept 28 PMID: 25282334 PMCID: PMC5645028 DOI: 10.1016/j.leukres.2014.09.004
 282. Gonsalves WI, Morice WG, Rajkumar V, Gupta V, Timm MM, Dispenzieri A, Buadi FK, Lacy MQ, Singh PP, Kapoor P, Gertz MA, **Kumar SK**. Quantification of clonal circulating plasma cells in relapsed multiple myeloma. *Br J Haematol*. 2014 Nov; 167 (4):500-5 Epub 2014 Aug 12 PMID: 25113422 PMCID: PMC4211997 DOI: 10.1111/bjh.13067
 283. **Kumar S**. Post-transplant therapy in multiple myeloma: a hung jury? *Lancet Haematol*. 2014 Dec; 1: (3)e90-1. PMID: 27029233 DOI: 10.1016/S2352-3026(14)00024-6
 284. **Kumar SK**, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG, Rajkumar V. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. *Lancet Oncol*. 2014 Dec; 15 (13):1503-1512 Epub 2014 Nov 14 PMID: 25456369 DOI: 10.1016/S1470-2045(14)71125-8
 285. Zand L, Nasr SH, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, **Kumar S**, Kyle RA, Fervenza FC, Sethi S, Dingli D, Rajkumar SV, Kapoor P, McCurdy A, Leung N. Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. *Leuk Lymphoma*. 2015; 56 (12):3357-64 Epub 2015 May 12 PMID: 25860232 DOI: 10.3109/10428194.2015.1040011
 286. Larsen JT, **Kumar S**. Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies. *Rare Cancers Ther*. 2015; 3:47-68 Epub 2015 Aug 28 PMID: 27182478 PMCID: PMC4837942 DOI: 10.1007/s40487-015-0009-4
 287. Costa LJ, **Kumar S**, Stowell SA, Dermer SJ. Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma. *Cancer Control*. 2015 Jan; 22

(1):87-94. PMID: 25504282

288. Greenberg AJ, Philip S, Paner A, Velinova S, Badros A, Catchatourian R, Ketterling R, Kyle RA, **Kumar S**, Vachon CM, Rajkumar SV. Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. *Blood Cancer J*. 2015 Jan 2; 5 (1):e271 Epub 2015 Jan 02 PMID: 25555162 PMCID: PMC5404218 DOI: 10.1038/bcj.2014.91
289. **Kumar SK**, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK, Mayo Phase 2 Consortium. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. *Blood*. 2015 Jan 15; 125 (3):443-8 Epub 2014 Nov 13 PMID: 25395429 PMCID: PMC4296007 DOI: 10.1182/blood-2014-05-573741
290. Vij R, **Kumar S**, Zhang MJ, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP, Kindwall-Keller TL, Kyle RA, Landsburg DJ, Lazarus HM, Munker R, Roy V, Sharma M, Vogl DT, Wirk B, Hari PN. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. *Biol Blood Marrow Transplant*. 2015 Feb; 21 (2):335-41 Epub 2014 Nov 01 PMID: 25445028 PMCID: PMC4297511 DOI: 10.1016/j.bbmt.2014.10.023
291. Chawla SS, **Kumar SK**, Dispenzieri A, Greenberg AJ, Larson DR, Kyle RA, Lacy MQ, Gertz MA, Rajkumar SV. Clinical Course and Prognosis of Non-Secretory Multiple Myeloma. *Eur J Haematol*. 2015 Feb 16 [Epub ahead of print] PMID: 25690913 DOI: 10.1111/ejh.12534
292. **Kumar SK**. Bisphosphonates in multiple myeloma: a fractured consensus. *Leuk Lymphoma* 2015 Mar; 56 (3):553-4 Epub 2014 Nov 05 PMID: 25224456 DOI: 10.3109/10428194.2014.964703
293. Kaufman GP, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, **Kumar SK**. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. *Am J Hematol*. 2015 Mar; 90 (3):181-6 Epub 2015 Jan 16 PMID: 25388651 PMCID: PMC5780648 DOI: 10.1002/ajh.23898
294. Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Kapoor P, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust S, Kyle RA, Gertz MA, **Kumar SK**. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. *Blood Cancer J*. 2015 Mar 20; 5:e296 PMID: 25794132 PMCID: PMC4382661 DOI: 10.1038/bcj.2015.20
295. Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, **Kumar SK**, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. *Blood*. 2015 Mar 26; 125 (13):2068-74 Epub 2015 Jan 27 PMID: 25628469 PMCID: PMC4375104 DOI: 10.1182/blood-2014-12-615187
296. Mahindra A, Raval G, Mehta P, Brazauskas R, Zhang MJ, Zhong X, Bird JM, Freytes CO, Hale GA, Herzig R, Holmberg LA, Kamble RT, **Kumar S**, Lazarus HM, Majhail NS, Marks DI, Moreb JS, Olsson R, Saber W, Savani BN, Schiller GJ, Tay J, Vogl DT, Waller EK, Wiernik PH, Wirk B, Lonial S, Krishnan AY, Dispenzieri A, Brandenburg NA, Gale RP, Hari PN. New cancers after autotransplantations for multiple myeloma. *Biol Blood Marrow Transplant*. 2015 Apr; 21 (4):738-45 Epub 2014 Dec 31 PMID: 25555448 PMCID: PMC4359647 DOI: 10.1016/j.bbmt.2014.12.028
297. Warsame R, **Kumar SK**, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Ketterling RP, Lin Y, Russell S, Hwa L, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Dispenzieri A. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. *Blood Cancer J*. 2015 May 1; 5:e310 Epub 2015 May 01 PMID: 25933374 PMCID: PMC4423220 DOI: 10.1038/bcj.2015.34
298. Bhutani G, Nasr SH, Said SM, Sethi S, Fervenza FC, Morice WG, Kurtin PJ, Buadi FK, Dingli D, Dispenzieri A, Gertz MA, Lacy MQ, Kapoor P, **Kumar S**, Kyle RA, Rajkumar SV, Leung N. Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. *Mayo Clin Proc*. 2015 May; 90 (5):587-96 PMID: 25939936 DOI: 10.1016/j.mayocp.2015.01.024
299. Dispenzieri A, Gertz MA, Saenger A, **Kumar SK**, Lacy MQ, Buadi FK, Dingli D, Leung N, Zeldenrust S, Hayman SR, Kapoor P, Grogan M, Hwa L, Russell SJ, Go RS, Rajkumar SV, Kyle RA, Jaffe A. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. *Am J Hematol*. 2015 Jun; 90: (6)524-8. PMID: 25753178 DOI: 10.1002/ajh.24001
300. Gertz MA, Terpos E, Dispenzieri A, **Kumar S**, Shah RA, Orlowski R, Kastiris E, Dimopoulos MA, Shah J. Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. *Leuk Lymphoma*. 2015 Jun; 56(6):1723-6. PMID: 25284489
301. Mir MA, Kapoor P, **Kumar S**, Pandey S, Dispenzieri A, Lacy MQ, Dingli D, Hogan W, Buadi F, Hayman S, Gandhi M, Gertz MA. Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple

myeloma at Mayo Clinic. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 (6):349-357.e2 Epub 2015 Apr 02
 PMID: 25958193 DOI: 10.1016/j.clml.2015.03.016

302. Chawla SS, **Kumar SK**, Dispenzieri A, Greenberg AJ, Larson DR, Kyle RA, Lacy MQ, Gertz MA, Rajkumar SV. Clinical course and prognosis of non-secretory multiple myeloma. Eur J Haematol. 2015 Jul; 95 (1):57-64 Epub 2015 Jan 21 PMID: 25382589 DOI: 10.1111/ejh.12478
303. Ziv E#, Dean E#, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudzinski M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczynszyn A, **Kumar S**, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Vangsted AJ, Watek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nat Commun. 2015 Jul 22; 6:7539 Epub 2015 July 22 PMID: 26198393 PMCID: PMC4656791 DOI: 10.1038/ncomms8539
304. Dispenzieri A, Buadi F, **Kumar SK**, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc. 2015 Aug; 90(8):1054-81. PMID: 26250727 DOI: 10.1016/j.mayocp.2015.06.009
305. **Kumar SK**, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015 Aug 14; 5:e338 PMID: 26275080 PMCID: PMC4558585 DOI: 10.1038/bcj.2015.60
306. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, **Kumar S**, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10; 33 (26):2863-9 Epub 2015 Aug 03 PMID: 26240224 PMCID: PMC4846284 DOI: 10.1200/JCO.2015.61.2267
307. Binder M, Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Lust JA, Kapoor P, Lin Y, Go RS, Hwa YL, Kyle RA, **Kumar SK**. Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. Am J Hematol. 2015 Oct; 90: (10)888-91. PMID: 26148022 DOI: 10.1002/ajh.24107
308. Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hwa YL, Dingli D, Kapoor P, Hayman SR, Lust JA, Kyle RA, **Kumar SK**. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Leukemia. 2015 Oct; 29 (10):2033-8 Epub 2015 May 12 PMID: 25962523 PMCID: PMC4598254 DOI: 10.1038/leu.2015.118
309. Vu T, Gonsalves W, **Kumar S**, Dispenzieri A, Lacy MQ, Buadi F, Gertz MA, Rajkumar SV. Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. Blood Cancer J. 2015 Oct 23; 5:e363 PMID: 26495860 PMCID: PMC4635199 DOI: 10.1038/bcj.2015.91
310. Siontis B, **Kumar S**, Dispenzieri A, Drake MT, Lacy MQ, Buadi F, Dingli D, Kapoor P, Gonsalves W, Gertz MA, Rajkumar SV. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer J. 2015 Oct 23; 5:e364 PMID: 26495861 PMCID: PMC4635196 DOI: 10.1038/bcj.2015.87
311. Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, **Kumar SK**, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Multiple myeloma, version 2.2016. J. Natl. Compr. Cancer Netw. 2015 Nov; 13(11):1398-435.
312. Majithia N, Vincent Rajkumar S, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, Hayman SR, Dingli D, Kapoor P, Hwa L, Lust JA, Russell SJ, Go RS, Kyle RA, **Kumar SK**. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am J Hematol. 2015 Nov; 90 (11):981-5 Epub 2015 Oct 06 PMID: 26214732 PMCID: PMC5801545 DOI: 10.1002/ajh.24131
313. D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, **Kumar S**, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015 Nov 10; 33 (32):3741-9 Epub 2015 Sept 14 PMID: 26371138 PMCID: PMC4737858 DOI:

10.1200/JCO.2015.62.4015

314. Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, **Kumar S**, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Tureson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. *Biol Blood Marrow Transplant*. 2015 Dec; 21 (12):2039-2051 Epub 2015 Sept 30 PMID: 26428082 PMCID: PMC4757494 DOI: 10.1016/j.bbmt.2015.09.016
315. **Kumar SK**, Krishnan A, LaPlant B, Laumann K, Roy V, Zimmerman T, Gertz MA, Buadi FK, Stockerl Goldstein K, Birgin A, Fiala M, Duarte L, Maharaj M, Levy J, Vij R. Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. *Am J Hematol*. 2015 Dec; 90 (12):1106-10 Epub 2015 Oct 06 PMID: 26331432 DOI: 10.1002/ajh.24181
316. Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, **Kumar SK**, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. *Bone Marrow Transplant*. 2015 Dec; 50 (12):1513-8 Epub 2015 Aug 24 PMID: 26301967 PMCID: PMC4548821 DOI: 10.1038/bmt.2015.190
317. Cordes S, Gertz MA, Buadi FK, Lin Y, Lacy MQ, Kapoor P, **Kumar SK**, McCurdy A, Dispenzieri A, Dingli D, Hayman SR, Hogan WJ, Pruthi RK. Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. *Blood Coagul Fibrinolysis*. 2016 Jan; 27: (1)101-8. PMID: 26218969 DOI: 10.1097/MBC.0000000000000367
318. Tandon N, Ramakrishnan V, **Kumar SK**. Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. *Clin Pharmacol*. 2016; 8:35-44 Epub 2016 May 06 PMID: 27226735 PMCID: PMC4866749 DOI: 10.2147/CPAA.S94021
319. Ramakrishnan VG, **Kumar SK**. Inhibitors of the Cyclin-Dependent Kinase and PIM Kinase Pathways in the Treatment of Myeloma. *Cancer J*. 2016 Jan-Feb; 22: (1)7-11. PMID: 26841010 DOI: 10.1097/PPO.0000000000000171
320. Gonsalves WI, Godby K, **Kumar SK**, Costa LJ. Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma. *Am J Hematol*. 2016 Jan; 91: (1)101-8. PMID: 26214377 DOI: 10.1002/ajh.24129
321. Laubach J, **Kumar S**. Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. *Cancer Treat Res*. 2016; 169:145-167. PMID: 27696262 DOI: 10.1007/978-3-319-40320-5_9
322. Rajkumar SV, **Kumar S**. Multiple Myeloma: Diagnosis and Treatment. *Mayo Clin Proc*. 2016 Jan; 91 (1):101-19 PMID: 26763514 PMCID: PMC5223450 DOI: 10.1016/j.mayocp.2015.11.007
323. Kaufman GP, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Lust JA, Russell S, Go RS, Hwa YL, Kyle RA, Rajkumar SV, **Kumar SK**. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. *Leukemia*. 2016 Mar; 30 (3):633-9 Epub 2015 Oct 21 PMID: 26487275 DOI: 10.1038/leu.2015.287
324. Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, **Kumar SK**. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. *Blood Cancer J*. 2016 Mar 11; 6:e401 PMID: 26967818 PMCID: PMC4817098 DOI: 10.1038/bcj.2016.15
325. Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, **Kumar SK**, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. *J Natl Compr Canc Netw*. 2016 Apr; 14 (4):389-400 PMID: 27059188 PMCID: PMC6016087 DOI: 10.6004/jnccn.2016.0046
326. **Kumar SK**, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lefeuvre MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV. Treatment outcomes, health-

care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. *Leukemia* 2016 Apr; 30 (4):995-8 Epub 2015 Aug 14 PMID: 26271606 DOI: 10.1038/leu.2015.225

327. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, **Kumar S**, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG, TOURMALINE-MM1 Study Group. Oral ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med*. 2016 Apr 28; 374 (17):1621-34 PMID: 27119237 DOI: 10.1056/NEJMoa1516282
328. Mullikin TC, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lin Y, Dingli D, Go RS, Hayman SR, Zeldenrust SR, Russell SJ, Lust JA, Leung N, Kapoor P, Kyle RA, Gertz MA, **Kumar SK**. Clinical characteristics and outcomes in biclonal gammopathies. *Am J Hematol*. 2016 May; 91 (5):473-5 Epub 2016 Apr 06 PMID: 26840395 PMCID: PMC5780647 DOI: 10.1002/ajh.24319
329. Chng WJ, Chung TH, **Kumar S**, Usmani S, Munshi N, Avet-Loiseau H, Goldschmidt H, Durie B, Sonneveld P. Gene signature combinations improve prognostic stratification of multiple myeloma patients. *Leukemia*. 2016 May; 30 (5):1071-8 Epub 2015 Dec 16 PMID: 26669975 DOI: 10.1038/leu.2015.341
330. Kourelis TV, Buadi FK, Gertz MA, Lacy MQ, **Kumar SK**, Kapoor P, Go RS, Lust JA, Hayman SR, Rajkumar V, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Leung N, Hwa YL, Gonsalves W, Kyle RA, Dispenzieri A. Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. *Leukemia*. 2016 May; 30 (5):1079-85 Epub 2015 Dec 16 PMID: 26669974 DOI: 10.1038/leu.2015.344
331. Mitra AK, Mukherjee UK, Harding T, Jang JS, Stessman H, Li Y, Abyzov A, Jen J, **Kumar S**, Rajkumar V, Van Ness B. Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. *Leukemia*. 2016 May; 30 (5):1094-102 Epub 2015 Dec 29 PMID: 26710886 DOI: 10.1038/leu.2015.361
332. Gonsalves WI, Timm MM, Rajkumar SV, Morice WG, Dispenzieri A, Buadi FK, Lacy MQ, Dingli D, Leung N, Kapoor P, Kyle RA, Gertz MA, **Kumar SK**. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. *Leuk Res*. 2016 May; 44:32-9 Epub 2016 Mar 10 PMID: 26994849 PMCID: PMC4837079 DOI: 10.1016/j.leukres.2016.03.003
333. Kourelis TV, Buadi FK, **Kumar SK**, Gertz MA, Lacy MQ, Dingli D, Go RS, Kapoor P, Lust JA, Hayman SR, Hwa Y, Rajkumar SV, Zeldenrust SR, Russell SJ, Lin Y, Leung N, Kyle RA, Gonsalves WI, Dispenzieri A. Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. *Am J Hematol*. 2016 Jun; 91 (6):585-9 Epub 2016 Apr 13 PMID: 26972803 DOI: 10.1002/ajh.24356
334. Rosenthal A, **Kumar S**, Hofmeister C, Laubach J, Vij R, Dueck A, Gano K, Stewart AK. A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma. *Br J Haematol* 2016 Jul; 174 (2):323-5 Epub 2015 Sept 25 PMID: 26403323 PMCID: PMC4820359 DOI: 10.1111/bjh.13765
335. Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, **Kumar SK**, Leung N, Lust J, Rajkumar SV, Russell SJ, Suman VJ, Le-Rademacher JG, Hogan WJ. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. *Cancer*. 2016 Jul 15; 122 (14):2197-205 Epub 2016 May 03 PMID: 27142462 PMCID: PMC4930380 DOI: 10.1002/cncr.30051
336. Ravi P, **Kumar S**, Larsen JT, Gonsalves W, Buadi F, Lacy MQ, Go R, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. *Blood Cancer J*. 2016 Jul 29; 6 (7):e454 Epub 2016 July 29 PMID: 27471870 PMCID: PMC5030386 DOI: 10.1038/bcj.2016.65
337. Rajan AM, **Kumar S**. New investigational drugs with single-agent activity in multiple myeloma. *Blood Cancer J*. 2016 Jul 29; 6 (7):e451 Epub 2016 July 29 PMID: 27471867 PMCID: PMC5030378 DOI: 10.1038/bcj.2016.53
338. Gonsalves WI, Rajkumar SV, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Go RS, Leung N, Kapoor P, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Hwa YL, Kourelis TV, Kyle RA, **Kumar SK**. Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. *Bone Marrow Transplant* 2016 Aug; 51 (8):1156-8 Epub 2016 Apr 11 PMID: 27064687 DOI: 10.1038/bmt.2016.91
339. Higgins LS, Go RS, Dingli D, **Kumar SK**, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lust JA, Kapoor P, Leung N, Lin Y, Kourelis TV, Gertz MA, Kyle RA, Gonsalves WI. Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. *Clin Lymphoma Myeloma Leuk*. 2016 Aug; 16 (8):447-52 Epub 2016 May 05 PMID: 27238425 DOI: 10.1016/j.clml.2016.04.009
340. **Kumar S**, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P,

Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol*. 2016 Aug; 17 (8):e328-e346 PMID: 27511158 DOI: 10.1016/S1470-2045(16)30206-6

341. Leung N, **Kumar SK**, Glavey SV, Dispenzieri A, Lacy MQ, Buadi FK, Hayman SR, Dingli D, Kapoor P, Zeldenrust SR, Russell SJ, Lust JA, Hogan WJ, Rajkumar SV, Gastineau DA, Kourelis TV, Lin Y, Gonsalves WI, Go RS, Gertz MA. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. *Nephrol Dial Transplant*. 2016 Aug; 31 (8):1284-9 Epub 2015 Nov 30 PMID: 26627634 DOI: 10.1093/ndt/gfv328
342. Ramakrishnan V, Gomez M, Prasad V, Kimlinger T, Painuly U, Mukhopadhyay B, Haug J, Bi L, Rajkumar SV, **Kumar S**. Smac mimetic LCL161 overcomes protective ER stress induced by obataclax, synergistically causing cell death in multiple myeloma. *Oncotarget*. 2016 Aug 30; 7 (35):56253-56265 PMID: 27494845 PMCID: PMC5302912 DOI: 10.18632/oncotarget.11028
343. Muchtart E, Dispenzieri A, **Kumar SK**, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Gertz MA. Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. *Haematologica*. 2016 Sep; 101 (9):1102-9 Epub 2016 June 16 PMID: 27479823 PMCID: PMC5060027 DOI: 10.3324/haematol.2016.147041
344. Hwa YL, **Kumar SK**, Gertz MA, Lacy MQ, Buadi FK, Kourelis TV, Gonsalves WI, Rajkumar SV, Go RS, Leung N, Kapoor P, Dingli D, Kyle RA, Russell S, Lust JA, Hayman SR, Lin Y, Zeldenrust S, Dispenzieri A. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. *Am J Hematol*. 2016 Oct; 91 (10):984-8 Epub 2016 July 14 PMID: 27341539 DOI: 10.1002/ajh.24453
345. Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjane A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, **Kumar S**, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. *Biol Blood Marrow Transplant*. 2016 Oct; 22 (10):1893-1899 Epub 2016 Aug 02 PMID: 27496215 PMCID: PMC5090978 DOI: 10.1016/j.bbmt.2016.07.007
346. Muchtart E, Derudas D, Mauermann M, Liewluck T, Dispenzieri A, **Kumar SK**, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Gonsalves W, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Gertz MA. Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. *Mayo Clin Proc*. 2016 Oct; 91: (10)1354-1361. PMID: 27712634 DOI: 10.1016/j.mayocp.2016.06.027
347. Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, Hayman SR, Dingli D, Kapoor P, Hwa L, Lust JA, Russell SJ, Go RS, Kyle RA, **Kumar SK**. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. *Leukemia*. 2016 Nov; 30 (11):2208-2213 Epub 2016 May 23 PMID: 27211270 PMCID: PMC5541860 DOI: 10.1038/leu.2016.147
348. Paludo J, Painuly U, **Kumar S**, Gonsalves WI, Rajkumar V, Buadi F, Lacy MQ, Dispenzieri A, Kyle RA, Mauermann ML, McCurdy A, Dingli D, Go RS, Hayman SR, Leung N, Lust JA, Lin Y, Gertz MA, Kapoor P. Myelomatous Involvement of the Central Nervous System. *Clin Lymphoma Myeloma Leuk*. 2016 Nov; 16 (11):644-654 Epub 2016 Aug 10 PMID: 27624224 DOI: 10.1016/j.clml.2016.08.010
349. Milani P, Vincent Rajkumar S, Merlini G, **Kumar S**, Gertz MA, Palladini G, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Hwa YL, Gonsalves WI, Zeldenrust SR, Kyle RA, Dispenzieri A. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. *Am J Hematol*. 2016 Nov; 91 (11):1129-1134 Epub 2016 Aug 29 PMID: 27508522 PMCID: PMC5129512 DOI: 10.1002/ajh.24532
350. Kourelis TV, Nasr SH, Dispenzieri A, **Kumar SK**, Gertz MA, Fervenza FC, Buadi FK, Lacy MQ, Erickson SB, Cosio FG, Kapoor P, Lust JA, Hayman SR, Rajkumar V, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Gonsalves W, Lorenz EC, Zand L, Kyle RA, Leung N. Outcomes of patients with renal monoclonal immunoglobulin deposition disease. *Am J Hematol*. 2016 Nov; 91 (11):1123-1128 Epub 2016 Aug 29 PMID: 27501122 DOI: 10.1002/ajh.24528
351. **Kumar SK**, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Gonsalves W, Witzig TE, Ailawadhi S, Dingli D, Go RS, Lin Y, Rivera CE, Rajkumar SV, Lacy MQ. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. *Blood*. 2016 Nov 17; 128 (20):2415-2422 Epub 2016 Oct 04 PMID: 27702799 PMCID: PMC5114487 DOI: 10.1182/blood-2016-05-717769
352. Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV,

Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, **Kumar SK**, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W. A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. *Cancer Epidemiol Biomarkers Prev*. 2016 Dec; 25 (12):1609-1618 Epub 2016 Sept 01 PMID: 27587788 PMCID: PMC5524541 DOI: 10.1158/1055-9965.EPI-15-1193

353. Costa LJ, Hari PN, **Kumar SK**. Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. *Leuk Lymphoma*. 2016 Dec; 57 (12):2827-2832 Epub 2016 Apr 22 PMID: 27104965 DOI: 10.3109/10428194.2016.1170828
354. Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, Calcinotto A, Riggs DL, Keane N, Ahmann GJ, Morrison KM, Fonseca R, Lacy MQ, Dingli D, **Kumar SK**, Ailawadhi S, Dispenzieri A, Buadi F, Gertz MA, Reeder CB, Lin Y, Chanan-Khan AA, Stewart AK, Fooksman D, Bergsagel PL. IAP antagonists induce anti-tumor immunity in multiple myeloma. *Nat Med*. 2016 Dec; 22 (12):1411-1420 Epub 2016 Nov 14 PMID: 27841872 PMCID: PMC5515246 DOI: 10.1038/nm.4229
355. Chakraborty R, Muchtar E, **Kumar SK**, Jevremovic D, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. *Blood Cancer J*. 2016 Dec 16; 6 (12):e512 PMID: 27983726 PMCID: PMC5223152 DOI: 10.1038/bcj.2016.117
356. Hwa YL, Shi Q, **Kumar SK**, Lacy MQ, Gertz MA, Kapoor P, Buadi FK, Leung N, Dingli D, Go RS, Hayman SR, Gonsalves WI, Russell S, Lust JA, Lin Y, Rajkumar SV, Dispenzieri A. Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. *Am J Hematol*. 2017 Jan; 92 (1):50-55 Epub 2016 Nov 18 PMID: 27733010 PMCID: PMC5217079 DOI: 10.1002/ajh.24582
357. Muchtar E, Dispenzieri A, **Kumar SK**, Buadi FK, Lacy MQ, Zeldenrust S, Hayman SR, Leung N, Kourelis TV, Gonsalves W, Chakraborty R, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, Kyle RA, Rajkumar SV, Gertz MA. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. *Leukemia*. 2017 Jan; 31 (1):92-99 Epub 2016 May 23 PMID: 27211265 DOI: 10.1038/leu.2016.140
358. Richardson PG, **Kumar S**, Laubach JP, Paba-Prada C, Gupta N, Berg D, van de Velde H, Moreau P. New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib. *J Blood Med*. 2017; 8:107-121 Epub 2017 Aug 22 PMID: 28860887 PMCID: PMC5573039 DOI: 10.2147/JBM.S102328
359. Gonsalves WI, Rajkumar SV, Dispenzieri A, Dingli D, Timm MM, Morice WG, Lacy MQ, Buadi FK, Go RS, Leung N, Kapoor P, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Hwa L, Kourelis TV, Kyle RA, Gertz MA, **Kumar SK**. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. *Leukemia*. 2017 Jan; 31(1):130-135. Epub 2016 Jul 26. PMID: 27457702 PMCID: PMC5244483 DOI: 10.1038/leu.2016.205
360. Muchtar E, Jevremovic D, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Go RS, Chakraborty R, Zeldenrust S, **Kumar SK**, Kyle RA, Rajkumar SV, Gertz MA. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. *Blood*. 2017 Jan 5; 129 (1):82-87 Epub 2016 Oct 11 PMID: 27729322 DOI: 10.1182/blood-2016-06-721878
361. Costa LJ, Brill IK, Omel J, Godby K, **Kumar SK**, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. *Blood Adv*. 2017 Jan 10; 1 (4):282-287 Epub 2017 Jan 04 PMID: 29296944 PMCID: PMC5727774 DOI: 10.1182/bloodadvances.2016002493
362. Chakraborty R, Muchtar E, **Kumar SK**, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. *Leuk Lymphoma*. 2017 Feb; 58 (2):308-315 Epub 2016 July 07 PMID: 27390076 DOI: 10.1080/10428194.2016.1201572
363. Jouni H, Aubry MC, Lacy MQ, Vincent Rajkumar S, **Kumar SK**, Frye RL, Herrmann J. Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors. *Am J Hematol*. 2017 Feb; 92 (2):220-221 PMID: 27859518 DOI: 10.1002/ajh.24608
364. Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M,

Hashmi S, Holmberg L, Hossain N, Kamble RT, Khafan-Dabaja M, Kindwall-Keller T, Kyle R, **Kumar S**, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. *Biol Blood Marrow Transplant*. 2017 Feb; 23 (2):269-277 Epub 2016 Nov 15 PMID: 27864161 PMCID: PMC5346183 DOI: 10.1016/j.bbmt.2016.11.011

365. **Kumar SK**, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2017 Feb; 15: (2)230-269. PMID: 28188192
366. Tandon N, Rajkumar SV, LaPlant B, Pettinger A, Lacy MQ, Dispenzieri A, Buadi FK, Gertz MA, Hayman SR, Leung N, Go RS, Dingli D, Kapoor P, Lin Y, Hwa YL, Fonder AL, Hobbs MA, Zeldenrust SR, Lust JA, Gonsalves WI, Russell SJ, **Kumar SK**. Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. *Blood Cancer J*. 2017 Feb 17; 7 (2):e528 PMID: 28211889 PMCID: PMC5386331 DOI: 10.1038/bcj.2017.13
367. Yanamandra U, Khattry N, **Kumar S**, Raje N, Jain A, Jagannath S, Menon H, Kumar L, Varma N, Varma S, Saikia T, Malhotra P, for IMAGE Group. Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference. *Indian J Hematol Blood Transfus*. 2017 Mar; 33 (1):15-21 Epub 2017 Jan 02 PMID: 28194051 PMCID: PMC5280871 DOI: 10.1007/s12288-016-0773-9
368. Muchtar E, Dispenzieri A, **Kumar SK**, Buadi FK, Lacy MQ, Zeldenrust S, Hayman SR, Leung N, Kourelis TV, Gonsalves W, Chakraborty R, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, Kyle RA, Rajkumar SV, Gertz MA. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. *Amyloid* 2017 Mar; 24 (sup1):40-41 PMID: 28434371 DOI: 10.1080/13506129.2016.1277696
369. Muchtar E, Dispenzieri A, **Kumar SK**, Buadi FK, Lacy MQ, Zeldenrust S, Hayman SR, Leung N, Chakraborty R, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, Kyle RA, Rajkumar VS, Gertz MA. Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. *Amyloid* 2017 Mar; 24 (sup1):44-45 PMID: 28434304 DOI: 10.1080/13506129.2017.1281117
370. Abeykoon JP, Paludo J, Dispenzieri A, Gertz MA, Dingli D, Baudi FK, Gonsalves WI, Kyle RA, Lacy MQ, Hayman SR, Leung N, Kourelis T, Rajkumar SV, **Kumar S**, Kapoor P. Outcome of very young (≤ 40 years) patients with immunoglobulin light chain (AL) amyloidosis. *Amyloid* 2017 Mar; 24 (sup1):50-51 PMID: 28434368 DOI: 10.1080/13506129.2017.1286584
371. Chakraborty R, Muchtar E, **Kumar SK**, Jevremovic D, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. *Biol Blood Marrow Transplant*. 2017 Apr; 23 (4):598-605 Epub 2017 Jan 20 PMID: 28115277 DOI: 10.1016/j.bbmt.2017.01.076
372. Hubbard JM, Mahoney MR, Loui WS, Roberts LR, Smyrk TC, Gatalica Z, Borad M, **Kumar S**, Alberts SR. Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). *Target Oncol*. 2017 Apr; 12 (2):201-209 PMID: 27943153 PMCID: PMC5586602 DOI: 10.1007/s11523-016-0467-0
373. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, **Kumar SK**, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. *Lancet Oncol*. 2017 Apr; 18 (4):e206-e217 PMID: 28368259 DOI: 10.1016/S1470-2045(17)30189-4
374. Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, **Kumar SK**, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA. Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. *Mayo Clin Proc*. 2017 Apr; 92 (4):578-598 Epub 2017 Mar 11 PMID: 28291589 PMCID: PMC5554888 DOI: 10.1016/j.mayocp.2017.01.003
375. Muchtar E, Gertz MA, **Kumar SK**, Lacy MQ, Dingli D, Buadi FK, Grogan M, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Dispenzieri A. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. *Blood*. 2017 Apr 13; 129 (15):2111-2119 Epub 2017 Jan 26 PMID: 28126928 PMCID: PMC5391625 DOI: 10.1182/blood-2016-11-751628

376. Rosenthal A, Dueck AC, Ansell S, Gano K, Conley C, Nowakowski GS, Camoriano J, Leis JF, Mikhael JR, Keith Stewart A, Stewart AK, Inwards D, Dingli D, **Kumar S**, Noel P, Gertz M, Porrata L, Russell S, Colgan J, Fonseca R, Habermann TM, Kapoor P, Buadi F, Leung N, Tiedemann R, Witzig TE, Reeder C. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy. *Am J Hematol*. 2017 May; 92 (5):467-472 Epub 2017 Mar 22 PMID: 28230270 DOI: 10.1002/ajh.24693
377. Warsame R, **Kumar SK**, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Russell S, Kapoor P, Go RS, Kourelis T, Gonsalves W, Zeldenrust SR, Kyle RA, Vincent Rajkumar S, Zemla T, Sloan J, Dispenzieri A. Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. *Am J Hematol*. 2017 May; 92: (5)435-440. PMID: 28181278 DOI: 10.1002/ajh.24676
378. **Kumar SK**. New Treatment Options for the Management of Multiple Myeloma. *J Natl Compr Canc Netw*. 2017 May; 15 (5S):709-712 PMID: 28515251 DOI: 10.6004/jnccn.2017.0080
379. **Kumar SK**, Vij R, Noga SJ, Berg D, Brent L, Dollar L, Chari A. Treating Multiple Myeloma Patients With Oral Therapies. *Clin Lymphoma Myeloma Leuk*. 2017 May; 17 (5):243-251 Epub 2017 Mar 07 PMID: 28347676 DOI: 10.1016/j.clml.2017.02.024
380. Mainou M, Madenidou AV, Liakos A, Paschos P, Karagiannis T, Bekiari E, Vlachaki E, Wang Z, Murad MH, **Kumar S**, Tsapas A. Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis. *Eur J Haematol*. 2017 Jun; 98 (6):563-568 Epub 2017 Mar 20 PMID: 28178364 DOI: 10.1111/ejh.12868
381. Tandon N, **Kumar SK**. Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016. *Indian J Hematol Blood Transfus*. 2017 Jun; 33 (2):153-158 Epub 2017 Feb 28 PMID: 28596644 PMCID: PMC5442069 DOI: 10.1007/s12288-017-0796-x
382. Kourelis TV, Kyle RA, Dingli D, Buadi FK, **Kumar SK**, Gertz MA, Lacy MQ, Kapoor P, Go RS, Gonsalves WI, Warsame R, Lust JA, Hayman SR, Rajkumar SV, Zeldenrust SR, Russell SJ, Lin Y, Leung N, Dispenzieri A. Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. *Mayo Clin Proc*. 2017 Jun; 92 (6):908-917 Epub 2017 May 05 PMID: 28483059 DOI: 10.1016/j.mayocp.2017.02.016
383. Muchtar E, Dean DS, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Warsame R, Gonsalves W, Kourelis TV, Go RS, Chakraborty R, Zeldenrust S, Kyle RA, Rajkumar SV, **Kumar SK**, Gertz MA. Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. *J Intern Med*. 2017 Jun; 281 (6):611-619 Epub 2017 Apr 24 PMID: 28439924 DOI: 10.1111/joim.12617
384. Tandon N, Sidana S, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Fonder AL, Hobbs MA, Hayman SR, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, **Kumar SK**. Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. *Am J Hematol*. 2017 Jun; 92 (6):549-554 Epub 2017 Apr 26 PMID: 28314084 DOI: 10.1002/ajh.24723
385. Ravi P, **Kumar S**, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. *Blood Cancer J*. 2017 Jun 16; 7 (6):e569 Epub 2017 June 16 PMID: 28622306 PMCID: PMC5584483 DOI: 10.1038/bcj.2017.46
386. Mitra AK, Harding T, Mukherjee UK, Jang JS, Li Y, HongZheng R, Jen J, Sonneveld P, **Kumar S**, Kuehl WM, Rajkumar V, Van Ness B. A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma. *Blood Cancer J*. 2017 Jun 30; 7 (6):e581 Epub 2017 June 30 PMID: 28665416 PMCID: PMC5520403 DOI: 10.1038/bcj.2017.56
387. Sidana S, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kapoor P, Gonsalves WI, Go RS, Hwa YL, Leung N, Fonder AL, Hobbs MA, Zeldenrust SR, Russell SJ, Lust JA, Kyle RA, **Kumar SK**. Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. *Am J Hematol*. 2017 Jul; 92 (7):668-673 Epub 2017 May 26 PMID: 28370486 PMCID: PMC5579826 DOI: 10.1002/ajh.24745
388. Muchtar E, Dispenzieri A, **Kumar SK**, Ketterling RP, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Gertz MA. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. *Leukemia*. 2017 Jul; 31 (7):1562-1569 Epub 2016 Dec 01 PMID: 27904139 DOI: 10.1038/leu.2016.369
389. **Kumar SK**, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC. Multiple myeloma. *Nat Rev Dis Primers*. 2017 Jul 20; 3:17046 Epub 2017 July 20 PMID: 28726797 DOI: 10.1038/nrdp.2017.46

390. **Kumar S**, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hajek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. *Br J Haematol*. 2017 Aug; 178 (4):571-582 Epub 2017 May 09 PMID: 28485007 PMCID: PMC5574012 DOI: 10.1111/bjh.14733
391. Tandon N, Muchtar E, Sidana S, Dispenzieri A, Lacy MQ, Dingli D, Buadi FK, Hayman SR, Chakraborty R, Hogan WJ, Gonsalves W, Warsame R, Kourelis TV, Leung N, Kapoor P, **Kumar SK**, Gertz MA. Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. *Bone Marrow Transplant*. 2017 Aug; 52 (8):1126-1132 Epub 2017 Apr 10 PMID: 28394369 DOI: 10.1038/bmt.2017.68
392. Chakraborty R, Muchtar E, **Kumar SK**, Jevremovic D, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. *Haematologica*. 2017 Aug; 102 (8):1439-1445 Epub 2017 May 04 PMID: 28473618 PMCID: PMC5541877 DOI: 10.3324/haematol.2017.166629
393. Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, **Kumar SK**, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. *Clin Cancer Res*. 2017 Aug 1; 23 (15):3980-3993 Epub 2017 Apr 20 PMID: 28428191 DOI: 10.1158/1078-0432.CCR-16-2895
394. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, **Kumar SK**, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. *JAMA Oncol*. 2017 Sep 1; 3 (9):1257-1265 PMID: 28056114 PMCID: PMC5556979 DOI: 10.1001/jamaoncol.2016.5763
395. Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, Gonsalves W, Warsame R, Kourelis TV, Chakraborty R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Dingli D, Leung N, Rajkumar SV, Kyle RA, **Kumar SK**, Gertz MA. Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. *Br J Haematol*. 2017 Sep; 178 (6):888-895 Epub 2017 July 12 PMID: 28699650 PMCID: PMC5591068 DOI: 10.1111/bjh.14830
396. **Kumar SK**, Laubach JP, Giove TJ, Quick M, Neuwirth R, Yung G, Rajkumar SV, Richardson PG. Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. *Br J Haematol*. 2017 Sep; 178 (5):756-763 Epub 2017 June 07 PMID: 28591409 DOI: 10.1111/bjh.14754
397. Tandon N, Sidana S, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Kyle RA, Buadi FK, Dingli D, Hayman SR, Fonder AL, Hobbs MA, Gonsalves WI, Kapoor P, Hwa YL, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, **Kumar SK**. Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. *Amyloid*. 2017 Sep; 24 (3):183-188 Epub 2017 July 12 PMID: 28699793 DOI: 10.1080/13506129.2017.1351354
398. Binder M, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, **Kumar SK**. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. *Blood Cancer J*. 2017 Sep 1; 7 (9):e600 Epub 2017 Sept 01 PMID: 28862698 PMCID: PMC5709752 DOI: 10.1038/bcj.2017.83
399. van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, Jagannath S, Jakubowiak A, **Kumar SK**, Levy JB, Auclair D, Lonial S, Reece D, Richardson P, Siegel DS, Stewart AK, Trudel S, Vij R, Zimmerman TM, Fonseca R. Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2017 Sep; 17 (9):555-562 Epub 2017 July 04 PMID: 28735890 DOI: 10.1016/j.clml.2017.06.020
400. Ghosh T, Gonsalves WI, Jevremovic D, Dispenzieri A, Dingli D, Timm MM, Morice WG, Kapoor P, Kourelis TV, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust SR, Warsame R, Hwa YL, Kyle RA, Gertz MA, Vincent Rajkumar S, **Kumar SK**. The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. *Am J Hematol*. 2017 Sep; 92(9):E507-E512. Epub 2017 Jul 19. PMID: 28568244 PMCID: PMC5546938 DOI: 10.1002/ajh.24807

401. **Kumar SK.** Checking in: T cells against multiple myeloma. *Blood* 2017 Sep 7; 130 (10):1175-1176 PMID: 28882832 DOI: 10.1182/blood-2017-05-783647
402. Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, **Kumar S**, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. *Blood*. 2017 Sep 7; 130 (10):1198-1204 Epub 2017 July 06 PMID: 28684537 PMCID: PMC5606008 DOI: 10.1182/blood-2017-05-782961
403. Hwa YL, Warsame R, Gertz MA, Buadi FK, Lacy MQ, **Kumar SK**, Dingli D, Zeldenrust SR, Leung N, Hayman SR, Kapoor P, Gonsalves WI, Kourelis TV, Russell S, Go RS, Hobbs MA, Fonder AL, Rajkumar SV, Dispenzieri A. Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. *Blood*. 2017 Sep 28; 130 (13):1578-1584 Epub 2017 Aug 14 PMID: 28807981 DOI: 10.1182/blood-2017-05-783415
404. Dispenzieri A, D'Souza A, Gertz MA, Laumann K, Wiseman G, Lacy MQ, LaPlant B, Buadi F, Hayman SR, **Kumar SK**, Dingli D, Hogan WJ, Ansell SM, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Johnston PB, Litzow MR, Witzig TE. A phase 1 trial of (90)Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. *Bone Marrow Transplant*. 2017 Oct; 52 (10):1372-1377 Epub 2017 Sept 04 PMID: 28869617 DOI: 10.1038/bmt.2017.164
405. Paludo J, Abeykoon JP, **Kumar S**, Shreders A, Ailawadhi S, Gertz MA, Kourelis T, King RL, Reeder CB, Leung N, Kyle RA, Buadi FK, Habermann TM, Dingli D, Witzig TE, Dispenzieri A, Lacy MQ, Go RS, Lin Y, Gonsalves WI, Warsame R, Lust JA, Rajkumar SV, Ansell SM, Kapoor P. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. *Br J Haematol*. 2017 Oct; 179 (1):98-105 Epub 2017 Aug 08 PMID: 28786474 DOI: 10.1111/bjh.14826
406. Gupta N, Yang H, Hanley MJ, Zhang S, Liu R, **Kumar S**, Richardson PG, Skacel T, Venkatakrishnan K. Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. *Target Oncol*. 2017 Oct; 12 (5):643-654 PMID: 28803351 PMCID: PMC5610674 DOI: 10.1007/s11523-017-0524-3
407. Landgren O, Graubard BI, **Kumar S**, Kyle RA, Katzmman JA, Murata K, Costello R, Dispenzieri A, Caporaso N, Mailankody S, Korde N, Hultcrantz M, Therneau TM, Larson DR, Cerhan JR, Rajkumar SV. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey. *Blood Cancer J*. 2017 Oct 20; 7 (10):e618 PMID: 29053158 PMCID: PMC5678222 DOI: 10.1038/bcj.2017.97
408. Lakshman A, Abeykoon JP, **Kumar SK**, Rajkumar SV, Dingli D, Buadi FK, Gonsalves WI, Leung N, Dispenzieri A, Kourelis TV, Go RS, Lacy MQ, Hobbs MA, Lin Y, Warsame R, Lust J, Fonder AL, Hwa YL, Hayman SR, Russell SJ, Kyle RA, Gertz MA, Kapoor P. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. *Am J Hematol*. 2017 Nov; 92 (11):1146-1155. Epub 2017 Sep 08. PMID: 28799231 DOI: 10.1002/ajh.24883
409. **Kumar SK**, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. *Leukemia*. 2017 Nov; 31 (11):2443-2448 Epub 2017 May 12 PMID: 28620163 DOI: 10.1038/leu.2017.138
410. Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, Gonsalves W, Warsame R, Kourelis TV, Chakraborty R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Rajkumar SV, Dingli D, Leung N, Kyle RA, **Kumar SK**, Gertz MA. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. *Ann Med*. 2017 Nov; 49 (7):545-551 Epub 2017 Mar 27 PMID: 28271734 DOI: 10.1080/07853890.2017.1304649
411. Wilson I, Gonsalves, Vijay Ramakrishnan, Taro Hitosugi, Toshi Ghosh, Dragan Jevremovic, Tumpa Dutta, Dhanajay Sakrikar, Xuan-Mai Persson, Linda Wellik, **Shaji K. Kumar**, K. Sreekumaran Nair. 2-Hydroxyglutarate Derived from Glutamine is Associated with Disease Progression in Plasma Cell Malignancies *JCI Insight*. In press;
412. **Kumar S**, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. *Blood*. 2017 Nov 30; 130 (22):2401-2409 Epub 2017 Oct 10 PMID: 29018077 DOI: 10.1182/blood-2017-06-788786

413. Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, **Kumar S**, Touzeau C, Punnoose EA, Cordero J, Munasinghe W, Jia J, Salem AH, Freise KJ, Leverson JD, Enschede SH, Ross JA, Maciag PC, Verdugo M, Harrison SJ. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. *Blood*. 2017 Nov 30; 130 (22):2392-2400 Epub 2017 Aug 28 PMID: 28847998 DOI: 10.1182/blood-2017-06-788323
414. Natoni A, Smith TAG, Keane N, McEllistram C, Connolly C, Jha A, Andrulis M, Ellert E, Raab MS, Glavey SV, Kirkham-McCarthy L, **Kumar SK**, Locatelli-Hoops SC, Oliva I, Fogler WE, Magnani JL, O'Dwyer ME. E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271. *Leukemia*. 2017 Dec; 31 (12):2642-2651 Epub 2017 Apr 25 PMID: 28439107 PMCID: PMC5729350 DOI: 10.1038/leu.2017.123
415. **Kumar S**. Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies. *Hematology Am Soc Hematol Educ Program*. 2017 Dec 8; 2017 (1):518-524 PMID: 29222300 PMCID: PMC6142613 DOI: 10.1182/asheducation-2017.1.518
416. Utkarsh Painuly*, Vijay Ramakrishnan*, Teresa Kimlinger, Linda Wellik, Jessica Haug, Wilson Gonsalves, Lintao Bi, Zhongxia Huang, S. Vincent Rajkumar, **Shaji Kumar**. Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma *Leukemia*. In revision;
417. Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, **Kumar S**, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. *Blood*. 2017 Dec 14; 130 (24):2610-2618 Epub 2017 Oct 20 PMID: 29054911 DOI: 10.1182/blood-2017-06-791228
418. Tandon N, Sidana S, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Buadi FK, Fonder AL, Hayman SR, Hwa YL, Hobbs MA, Kapoor P, Gonsalves WI, Leung N, Go RS, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, **Kumar SK**. Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). *Am J Hematol*. 2018 Jan; 93 (1):17-22 Epub 2017 Oct 20 PMID: 28960427 DOI: 10.1002/ajh.24919
419. Lakshman A, Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, **Kumar SK**. Natural history of t(11;14) multiple myeloma. *Leukemia*. 2018 Jan; 32(1):131-138. Epub 2017 Jun 27. PMID: 28655925 DOI: 10.1038/leu.2017.204
420. **Kumar SK**, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. *J Natl Compr Canc Netw*. 2018 Jan; 16 (1):11-20 PMID: 29295877 DOI: 10.6004/jnccn.2018.0002
421. Gertz MA, Buadi FK, Hayman SR, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, **Kumar S**, Kapoor P, Kourelis T, Hogan WJ. Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. *Mayo Clin Proc*. 2018 Jan; 93 (1):56-58 PMID: 29304921 DOI: 10.1016/j.mayocp.2017.09.012
422. Gonsalves WI, Ramakrishnan V, Hito Sugita T, Ghosh T, Jevremovic D, Dutta T, Sakrkar D, Petterson XM, Wellik L, **Kumar SK**, Nair KS. Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies. *JCI Insight*. 2018 Jan 11; 3 (1) PMID: 29321378 PMCID: PMC5821206 DOI: 10.1172/jci.insight.94543
423. Kyle RA, Larson DR, Therneau TM, Dispenzieri A, **Kumar S**, Cerhan JR, Rajkumar SV. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. *N Engl J Med*. 2018 Jan 18; 378 (3):241-249 PMID: 29342381 PMCID: PMC5852672 DOI: 10.1056/NEJMoa1709974
424. Gonsalves WI, Buadi FK, **Kumar SK**. Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). *Eur J Haematol*. 2018 Feb; 100 (2):215-217 Epub 2017 Nov 16 PMID: 29064593 DOI: 10.1111/ejh.12986
425. Muchtar E, **Kumar SK**, Magen H, Gertz MA. Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer. *Leuk Lymphoma*. 2018 Feb; 59 (2):288-299 Epub 2017 June 08 PMID: 28592156 DOI: 10.1080/10428194.2017.1334124
426. Lakshman A, Singh PP, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, **Kumar SK**. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. *Am J Hematol*. 2018 Feb; 93(2):179-186. Epub 2017 Nov 10. PMID: 29067723 DOI: 10.1002/ajh.24954
427. Chakraborty R, Muchtar E, **Kumar SK**, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in

- multiple myeloma patients undergoing delayed autologous stem cell transplantation. *Bone Marrow Transplant*. 2018 Feb; 53 (2):155-161 Epub 2017 Nov 13 PMID: 29131152 DOI: 10.1038/bmt.2017.228
428. Chim CS, **Kumar SK**, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. *Leukemia*. 2018 Feb; 32 (2):252-262 Epub 2017 Nov 16 PMID: 29257139 PMCID: PMC5808071 DOI: 10.1038/leu.2017.329
 429. Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, Halvorson AE, Gonsalves WI, Dingli D, Fang H, Rajkumar SV, Lacy MQ, He R, Kourelis T, Reeder CB, Novak AJ, McPhail ED, Viswanatha DS, Witzig TE, Go RS, Habermann TM, Buadi FK, Dispenzieri A, Leung N, Lin Y, Thompson CA, Hayman SR, Kyle RA, **Kumar SK**, Kapoor P. MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia. *Am J Hematol*. 2018 Feb; 93 (2):187-194 Epub 2017 Nov 17 PMID: 29080258 DOI: 10.1002/ajh.24955
 430. Waller RG, Darlington TM, Wei X, Madsen MJ, Thomas A, Curtin K, Coon H, Rajamanickam V, Musinsky J, Jayabalan D, Atanackovic D, Rajkumar SV, **Kumar S**, Slager S, Middha M, Galia P, Demangel D, Salama M, Joseph V, McKay J, Offit K, Klein RJ, Lipkin SM, Dumontet C, Vachon CM, Camp NJ. Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. *PLoS Genet*. 2018 Feb; 14 (2):e1007111 Epub 2018 Feb 01 PMID: 29389935 PMCID: PMC5794067 DOI: 10.1371/journal.pgen.1007111
 431. Krishnan A, Kapoor P, Palmer JM, Tsai NC, **Kumar S**, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. *Leukemia*. 2018 Feb 23 [Epub ahead of print] PMID: 29472721 DOI: 10.1038/s41375-018-0038-8
 432. Ravi P, **Kumar SK**, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, Rajkumar SV. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. *Blood Cancer J*. 2018 Feb 28; 8 (3):26 PMID: 29531285 PMCID: PMC5849889 DOI: 10.1038/s41408-018-0065-8
 433. Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, **Kumar SK**. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. *Leukemia*. 2018 Mar; 32 (3):729-735 Epub 2017 Sept 18 PMID: 28919633 DOI: 10.1038/leu.2017.286
 434. Sidana S, Tandon N, Gertz MA, Dispenzieri A, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Hogan WJ, **Kumar SK**. Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. *Bone Marrow Transplant*. 2018 Mar; 53 (3):326-333 Epub 2017 Dec 21 PMID: 29269795 DOI: 10.1038/s41409-017-0020-5
 435. Chakraborty R, Muchtar E, **Kumar SK**, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Warsame R, Kourelis T, Gonsalves W, Gertz MA. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. *Leukemia*. 2018 Mar; 32 (3):712-718 Epub 2017 Aug 14 PMID: 28848227 DOI: 10.1038/leu.2017.256
 436. Ailawadhi S, Mikhael JR, LaPlant BR, Laumann KM, **Kumar S**, Roy V, Dingli D, Bergsagel PL, Buadi FK, Rajkumar SV, Fonseca R, Gertz MA, Kapoor P, Sher T, Hayman SR, Stewart AK, Dispenzieri A, Kyle RA, Gonsalves WI, Reeder CB, Lin Y, Go RS, Leung N, Kourelis T, Lust JA, Russell SJ, Chanan-Khan AA, Lacy MQ. Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. *Leukemia*. 2018 Mar; 32 (3):719-728 Epub 2017 Sept 01 PMID: 28860655 DOI: 10.1038/leu.2017.258
 437. **Kumar SK**, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. *Leukemia*. 2018 Apr; 32 (4):986-995 Epub 2017 Nov 16 PMID: 29263438 PMCID: PMC5871538 DOI: 10.1038/leu.2017.331
 438. Lepori N, Cheungpasitporn W, Sethi S, Murray D, **Kumar S**, Leung N, Giridhar KV, Fervenza FC. High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy. *Clin Nephrol*. 2018 Apr; 89 (4):291-299 PMID: 29249234 DOI: 10.5414/CN109300
 439. Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, **Kumar SK**, Kapoor P, Kourelis TV, Hogan WJ, Gertz MA. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. *Blood Adv*. 2018 Apr 10; 2 (7):769-776 PMID: 29615413 PMCID: PMC5894263 DOI: 10.1182/bloodadvances.2018016782

440. Manier S, Park J, Capelletti M, Bustoros M, Freeman SS, Ha G, Rhoades J, Liu CJ, Huynh D, Reed SC, Gydush G, Salem KZ, Rotem D, Freymond C, Yosef A, Perilla-Glen A, Garderet L, Van Allen EM, **Kumar S**, Love JC, Getz G, Adalsteinsson VA, Ghobrial IM. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. *Nat Commun*. 2018 Apr 27; 9 (1):1691 PMID: 29703982 PMCID: PMC5923255 DOI: 10.1038/s41467-018-04001-5
441. Milani P, Dispenzieri A, Scott CG, Gertz MA, Perlini S, Mussinelli R, Lacy MQ, Buadi FK, **Kumar S**, Maurer MS, Merlini G, Hayman SR, Leung N, Dingli D, Klarich KW, Lust JA, Lin Y, Kapoor P, Go RS, Pellikka PA, Hwa YL, Zeldenrust SR, Kyle RA, Rajkumar SV, Grogan M. Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. *Circ Cardiovasc Imaging*. 2018 May; 11 (5):e006588 PMID: 29752392 PMCID: PMC5963522 DOI: 10.1161/CIRCIMAGING.117.006588
442. **Kumar SK**. Management of Multiple Myeloma. *J Natl Compr Canc Netw*. 2018 May; 16 (5S):624-627 PMID: 29784741 DOI: 10.6004/jnccn.2018.0040
443. Sidiqi MH, Aljama MA, Buadi FK, Warsame RM, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, **Kumar S**, Kapoor P, Kourelis T, Hogan WJ, Gertz MA. Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. *J Clin Oncol*. 2018 May 1; 36 (13):1323-1329 Epub 2018 Mar 20 PMID: 29558277 DOI: 10.1200/JCO.2017.76.9554
444. Mahajan S, Tandon N, **Kumar S**. The evolution of stem-cell transplantation in multiple myeloma. *Ther Adv Hematol*. 2018 May; 9 (5):123-133 Epub 2018 Mar 05 PMID: 29713445 PMCID: PMC5900826 DOI: 10.1177/2040620718761776
445. Sidana S, Tandon N, Dispenzieri A, Gertz MA, Rajkumar SV, **Kumar SK**. The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response. *Leukemia*. 2018 May; 32 (5):1243-1246 Epub 2018 Jan 30 PMID: 29568089 DOI: 10.1038/s41375-018-0022-3
446. Muchtar E, Gertz MA, **Kumar SK**, Lin G, Boilson B, Clavell A, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Dingli D, Rajkumar SV, Dispenzieri A, Grogan M. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? *Amyloid*. 2018 Jun; 25 (2):86-92 Epub 2018 Mar 12 PMID: 29529877 PMCID: PMC7433245 DOI: 10.1080/13506129.2018.1449744
447. Kyle RA, Larson DR, McPhail ED, Therneau TM, Dispenzieri A, **Kumar S**, Kapoor P, Cerhan JR, Rajkumar SV. Fifty-Year Incidence of Waldenstrom Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. *Mayo Clin Proc*. 2018 Jun; 93 (6):739-746 Epub 2018 Apr 12 PMID: 29656787 PMCID: PMC5988946 DOI: 10.1016/j.mayocp.2018.02.011
448. Sidana S, Tandon N, Dispenzieri A, Gertz MA, Dingli D, Jevremovic D, Morice WG, Kapoor P, Kourelis TV, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust SR, Warsame R, Hwa YL, Hobbs M, Fonder A, Kyle RA, Rajkumar SV, **Kumar SK**, Gonsalves WI. Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. *Leukemia*. 2018 Jun; 32 (6):1421-1426 Epub 2018 Feb 21 PMID: 29483709 PMCID: PMC5992020 DOI: 10.1038/s41375-018-0063-7
449. Goyal G, Bartley AC, Funni S, Inselman J, Shah ND, Marshall AL, Ashrani AA, Kapoor P, Durani U, Hashmi SK, Siddiqui MA, Buadi FK, Go RS, Kyle RA, **Kumar S**, Gonsalves WI. Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. *Leukemia*. 2018 Jun; 32 (6):1414-1420 Epub 2018 Mar 21 PMID: 29654264 PMCID: PMC6522261 DOI: 10.1038/s41375-018-0099-8
450. Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, **Kumar SK**. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. *Blood Cancer J*. 2018 Jun 12; 8(6):59. PMID: 29895887 PMCID: PMC5997745 DOI: 10.1038/s41408-018-0077-4
451. Chakraborty R, Muchtar E, **Kumar SK**, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Warsame R, Kourelis T, Gonsalves W, Gertz MA. Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. *Br J Haematol*. 2018 Jul; 182 (1):71-77 Epub 2018 Apr 29 PMID: 29707759 DOI: 10.1111/bjh.15244
452. **Kumar SK**. Monoclonal Antibodies for Myeloma: Make It Easy! *J Oncol Pract* 2018 Jul; 14 (7):423-424 PMID: 29996067 DOI: 10.1200/JOP.18.00350
453. Krishnan A, Kapoor P, Palmer JM, Tsai NC, **Kumar S**, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. *Leukemia*. 2018 Jul; 32 (7):1567-1574 Epub 2018 Feb 23 PMID: 32082000 PMCID: PMC6005710 DOI: 10.1038/s41375-018-0038-8
454. Sidiqi MH, Aljama MA, Jevremovic D, Morice WG, Timm M, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, **Kumar S**, Kapoor P, Kourelis T, Leung N, Hogan WJ, Gertz M. Plasma cell

proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. *Haematologica*. 2018 Jul; 103 (7):1229-1234 Epub 2018 Apr 19 PMID: 29674497 PMCID: PMC6029535 DOI: 10.3324/haematol.2018.189985

455. **Kumar SK**, Rajkumar SV. The multiple myelomas - current concepts in cytogenetic classification and therapy. *Nat Rev Clin Oncol*. 2018 Jul; 15 (7):409-421 PMID: 29686421 DOI: 10.1038/s41571-018-0018-y
456. Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Vincent Rajkumar S, **Kumar SK**. Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. *Am J Hematol*. 2018 Jul; 93 (7):889-894 PMID: 29659048 DOI: 10.1002/ajh.25113
457. **Kumar SK**, Buadi FK, LaPlant B, Halvorson A, Leung N, Kapoor P, Dingli D, Gertz MA, Go RS, Bergsagel PL, Lin Y, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Fonseca R, Hayman SR, Stewart AK, Lust JA, Mikhael J, Gonsalves W, Reeder C, Skacel T, Rajkumar SV, Lacy MQ. Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. *Blood Cancer J*. 2018 Jul 30; 8 (8):70 Epub 2018 July 30 PMID: 30061664 PMCID: PMC6066484 DOI: 10.1038/s41408-018-0106-3
458. Wu C, Yang T, Liu Y, Lu Y, Yang Y, Liu X, Liu X, Ye L, Sun Y, Wang X, Li Q, Yang P, Yu X, Gao S, **Kumar S**, Jin F, Dai Y, Li W. ARNT/HIF-1 β links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma. *Cancer Med*. 2018 Aug; 7 (8):3899-3911 Epub 2018 June 21 PMID: 29926531 PMCID: PMC6089175 DOI: 10.1002/cam4.1596
459. Paludo J, Abeykoon JP, Shreders A, Ansell SM, **Kumar S**, Ailawadhi S, King RL, Koehler AB, Reeder CB, Buadi FK, Dispenzieri A, Lacy MQ, Dingli D, Witzig TE, Go RS, Gonsalves WI, Kourelis T, Warsame R, Leung N, Habermann TM, Hayman S, Lin Y, Kyle RA, Rajkumar SV, Gertz MA, Kapoor P. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia. *Ann Hematol*. 2018 Aug; 97 (8):1417-1425 Epub 2018 Apr 03 PMID: 29610969 DOI: 10.1007/s00277-018-3311-z
460. Chakraborty R, Hamilton BK, Hashmi SK, **Kumar SK**, Majhail NS. Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma. *Biol Blood Marrow Transplant*. 2018 Aug; 24 (8):1546-1553 Epub 2018 Apr 04 PMID: 29626515 PMCID: PMC6108907 DOI: 10.1016/j.bbmt.2018.03.027
461. Yanamandra U, **Kumar SK**. Minimal residual disease analysis in myeloma - when, why and where. *Leuk Lymphoma*. 2018 Aug; 59 (8):1772-1784 Epub 2017 Oct 11 PMID: 29019452 PMCID: PMC6208356 DOI: 10.1080/10428194.2017.1386304
462. Lakshman A, Paul S, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, **Kumar SK**. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. *Leukemia*. 2018 Aug; 32 (8):1811-1815. Epub 2018 Jan 30. PMID: 29568092 DOI: 10.1038/s41375-018-0030-3
463. Kansagra A, Gonsalves WI, Gertz MA, Buadi FK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Kapoor P, Muchtar E, Kourelis TV, Warsame R, Leung N, Zeldenrust SR, Lust JA, Rajkumar SV, Kyle RA, Hogan W, **Kumar SK**. Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. *Biol Blood Marrow Transplant*. 2018 Oct; 24 (10):2127-2132 Epub 2018 Apr 12 PMID: 29656139 DOI: 10.1016/j.bbmt.2018.04.007
464. Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, **Kumar SK**, Gertz MA. Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. *Biol Blood Marrow Transplant*. 2018 Oct; 24 (10):2157-2159 Epub 2018 June 20 PMID: 29933071 PMCID: PMC6239955 DOI: 10.1016/j.bbmt.2018.06.017
465. Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, **Kumar SK**, Gertz MA. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. *Leukemia*. 2018 Oct; 32 (10):2240-2249 Epub 2018 Feb 20 PMID: 29581546 DOI: 10.1038/s41375-018-0060-x
466. Tschautscher M, Rajkumar V, Dispenzieri A, Lacy M, Gertz M, Buadi F, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman S, Zeldenrust S, Lust J, Russell S, Leung N, Kapoor P, Go R, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle R, **Kumar S**. Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. *Am J Hematol*. 2018 Oct; 93 (10):1207-1210 Epub 2018 Aug 15 PMID: 30016549 DOI: 10.1002/ajh.25215
467. Painuly U, Ramakrishnan V, Kimlinger T, Wellik L, Haug J, Gonsalves W, Bi L, Huang Z, Rajkumar SV, **Kumar S**. Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma. *Oncotarget*. 2018 Oct 2; 9 (77):34582-34594 Epub 2018 Oct 02 PMID: 30349651 PMCID:

PMC6195373 DOI: 10.18632/oncotarget.26180

468. Baughn LB, Pearce K, Larson D, Polley MY, Elhaik E, Baird M, Colby C, Benson J, Li Z, Asmann Y, Therneau T, Cerhan JR, Vachon CM, Stewart AK, Bergsagel PL, Dispenzieri A, **Kumar S**, Rajkumar SV. Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. *Blood Cancer J*. 2018 Oct 10; 8 (10):96 PMID: 30305608 PMCID: PMC6180134 DOI: 10.1038/s41408-018-0132-1
469. Ramakrishnan V, **Kumar S**. PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise. *Leuk Lymphoma*. 2018 Nov; 59 (11):2524-2534 Epub 2018 Jan 11 PMID: 29322846 DOI: 10.1080/10428194.2017.1421760
470. Abeykoon JP, Zanwar S, Ansell SM, Winters J, Gertz MA, King RL, Murray D, Habermann T, Dingli D, Muchtar E, Go RS, Leung N, Inwards DJ, Buadi FK, Dispenzieri A, Lacy MQ, Lin Y, Gonsalves WI, Kourelis T, Witzig TE, Thompson C, Vincent Rajkumar S, Kyle RA, **Kumar S**, Kapoor P. Predictors of symptomatic hyperviscosity in Waldenstrom macroglobulinemia. *Am J Hematol*. 2018 Nov; 93 (11):1384-1393 Epub 2018 Oct 02 PMID: 30121949 DOI: 10.1002/ajh.25254
471. Sidiqi MH, Aljama MA, Jevremovic D, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, **Kumar S**, Kapoor P, Kourelis T, Leung N, Hogan WJ, Gertz MA. Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. *Biol Blood Marrow Transplant*. 2018 Nov; 24 (11):2360-2364 Epub 2018 June 30 PMID: 29964192 PMCID: PMC6242714 DOI: 10.1016/j.bbmt.2018.06.027
472. Sidiqi MH, Aljama MA, Bin Riaz I, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Rajkumar SV, **Kumar SK**, Gertz MA. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. *Blood Cancer J*. 2018 Nov 8; 8 (11):106 Epub 2018 Nov 08 PMID: 30409963 PMCID: PMC6224498 DOI: 10.1038/s41408-018-0147-7
473. Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, Palumbo A, Luptakova K, Romanus D, Skacel T, **Kumar SK**, Anderson KC. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. *Blood Cancer J*. 2018 Nov 9; 8 (11):109 Epub 2018 Nov 09 PMID: 30413684 PMCID: PMC6226527 DOI: 10.1038/s41408-018-0141-0
474. **Kumar SK**. Timing of treatment of smoldering myeloma: delay until progression. *Blood Adv*. 2018 Nov 13; 2 (21):3050-3053 PMID: 30425069 PMCID: PMC6234369 DOI: 10.1182/bloodadvances.2018021238
475. Ravi P, **Kumar SK**, Roeker L, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. *Blood Cancer J*. 2018 Nov 15; 8(12):116. PMID: 30442928 PMCID: PMC6238010 DOI: 10.1038/s41408-018-0140-1
476. Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschmidt H, Hajek R, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, **Kumar S**, Lenhoff S, Morgan G, Rajkumar SV, Durie BGM, Moreau P. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. *Blood Cancer J*. 2018 Nov 23; 8 (12):123 PMID: 30470751 PMCID: PMC6251924 DOI: 10.1038/s41408-018-0155-7
477. Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame R, Kourelis TV, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, **Kumar SK**. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. *Blood Adv*. 2018 Nov 27; 2(22):3149-3154. PMID: 30463914 PMCID: PMC6258920 DOI: 10.1182/bloodadvances.2018024794
478. Richardson PG, Zweegman S, O'Donnell EK, Laubach JP, Raje N, Voorhees P, Ferrari RH, Skacel T, **Kumar SK**, Lonial S. Ixazomib for the treatment of multiple myeloma. *Expert Opin Pharmacother*. 2018 Dec; 19 (17):1949-1968 Epub 2018 Nov 13 PMID: 30422008 DOI: 10.1080/14656566.2018.1528229
479. Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, **Kumar S**, Mark T, D'Souza A. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. *Biol Blood Marrow Transplant*. 2018 Dec; 24 (12):2443-2449 Epub 2018 Aug 22 PMID: 30142419 PMCID: PMC6293469 DOI: 10.1016/j.bbmt.2018.08.013
480. Aljama MA, Sidiqi MH, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, **Kumar SK**. Utility and prognostic value of (18) F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. *Am J Hematol*. 2018 Dec; 93 (12):1518-1523 Epub 2018 Oct 02 PMID: 30194770 DOI: 10.1002/ajh.25279

481. Calcinotto A, Brevi A, Chesi M, Ferrarese R, Garcia Perez L, Grioni M, **Kumar S**, Garbitt VM, Sharik ME, Henderson KJ, Tonon G, Tomura M, Miwa Y, Esplugues E, Flavell RA, Huber S, Canducci F, Rajkumar VS, Bergsagel PL, Bellone M. Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. *Nat Commun*. 2018 Dec 3; 9 (1):4832 Epub 2018 Dec 03 PMID: 30510245 PMCID: PMC6277390 DOI: 10.1038/s41467-018-07305-8
482. Paquin AR, **Kumar SK**, Buadi FK, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. *Blood Cancer J*. 2018 Dec 11; 8 (12):125 PMID: 30538223 PMCID: PMC6289963 DOI: 10.1038/s41408-018-0163-7
483. Dimopoulos MA, Grosicki S, Jedrzejczak WW, Nahi H, Gruber A, Hansson M, Gupta N, Byrne C, Labotka R, Teng Z, Yang H, Grzasko N, **Kumar S**. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. *Eur J Cancer*. 2019 Jan; 106:89-98 Epub 2018 Nov 22 PMID: 30471652 DOI: 10.1016/j.ejca.2018.09.011
484. Abdallah N, **Kumar SK**. Daratumumab in untreated newly diagnosed multiple myeloma. *Ther Adv Hematol*. 2019; 10:2040620719894871 Epub 2019 Dec 23 PMID: 31903177 PMCID: PMC6928545 DOI: 10.1177/2040620719894871
485. **Kumar S**, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastritis E, Terpos E, Leleu X, Beksac M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A. Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. *Leuk Lymphoma*. 2019 Jan; 60 (1):163-171 Epub 2018 May 09 PMID: 29741423 DOI: 10.1080/10428194.2018.1459609
486. Soekojo CY, **Kumar SK**. Stem-cell transplantation in multiple myeloma: how far have we come? *Ther Adv Hematol*. 2019; 10:2040620719888111 Epub 2019 Nov 14 PMID: 31798820 PMCID: PMC6859676 DOI: 10.1177/2040620719888111
487. **Kumar SK**. Targeted Management Strategies in Multiple Myeloma. *Cancer J*. 2019 Jan/Feb; 25 (1):59-64 PMID: 30694861 DOI: 10.1097/PPO.0000000000000353
488. Jang JS#, Li Y#, Mitra AK, Bi L, Abyzov A, van Wijnen AJ, Baughn LB, Van Ness B, Rajkumar V, **Kumar S**, Jen J. Molecular signatures of multiple myeloma progression through single cell RNA-Seq. *Blood Cancer J*. 2019 Jan 3; 9 (1):2 Epub 2019 Jan 03 PMID: 30607001 PMCID: PMC6318319 DOI: 10.1038/s41408-018-0160-x
489. **Kumar SK**, Gertz MA, Dispenzieri A. Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin. *J Clin Oncol* 2019 Jan 10; 37 (2):171-173 Epub 2018 Nov 15 PMID: 30433848 DOI: 10.1200/JCO.18.01398
490. Abeykoon JP#, Zanzwar S#, Dispenzieri A, Gertz MA, Leung N, Kourelis T, Gonsalves W, Muchtar E, Dingli D, Lacy MQ, Hayman SR, Buadi F, Warsame R, Kyle RA, Rajkumar V, **Kumar S**, Kapoor P. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. *Leukemia*. 2019 Feb; 33 (2):531-536 Epub 2018 Sept 28 PMID: 30267007 DOI: 10.1038/s41375-018-0262-2
491. Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell SJ, Lust JA, Lin Y, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, **Kumar SK**, Gertz MA. Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. *Leukemia*. 2019 Feb; 33 (2):527-531 Epub 2018 Sept 26 PMID: 30258095 DOI: 10.1038/s41375-018-0258-y
492. **Kumar SK**, Grzasko N, Delimpasi S, Jedrzejczak WW, Grosicki S, Kyrtsonis MC, Spencer A, Gupta N, Teng Z, Byrne C, Labotka R, Dimopoulos MA. Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. *Br J Haematol*. 2019 Feb; 184 (4):536-546 Epub 2018 Nov 20 PMID: 30460684 DOI: 10.1111/bjh.15679
493. Clay-Gilmour AI, **Kumar S**, Rajkumar SV, Rishi A, Kyle RA, Katzmman JA, Murray DL, Norman AD, Greenberg AJ, Larson DR, O'Byrne MM, Slager SL, Vachon CM. Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. *Leukemia*. 2019 Feb; 33 (2):499-507 Epub 2018 Sept 10 PMID: 30201985 PMCID: PMC6371786 DOI: 10.1038/s41375-018-0246-2
494. **Kumar SK**, Buadi FK, Rajkumar SV. Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing. *Blood*. 2019 Feb 14; 133 (7):652-659 Epub 2018 Dec 26 PMID: 30587528 DOI: 10.1182/blood-2018-08-825349
495. Peterson JF, Rowsey RA, Marcou CA, Pearce KE, Williamson CM, Frederick LA, Greipp PT, Ketterling RP, **Kumar S**, Viswanatha DS, Polley MY, Fink JM, Reichard KK, Van Dyke DL, Baughn LB. Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. *Blood Cancer J* 2019 Feb 19; 9 (3):20 PMID: 30783078 PMCID: PMC6381150 DOI: 10.1038/s41408-019-0182-z

496. Muchtar E, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Buadi FK, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Rajkumar SV, **Kumar SK**, Dispenzieri A. A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. *Mayo Clin Proc.* 2019 Mar; 94 (3):472-483 Epub 2019 Feb 13 PMID: 30770096 DOI: 10.1016/j.mayocp.2018.08.006
497. Sidiqi MH, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, **Kumar SK**, Gertz MA. Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. *Biol Blood Marrow Transplant.* 2019 Mar; 25 (3):e108-e111 Epub 2018 Dec 07 PMID: 30529461 PMCID: PMC6445701 DOI: 10.1016/j.bbmt.2018.12.003
498. Muchtar E, Therneau TM, Larson DR, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Fonder A, Hobbs M, Hwa YL, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, **Kumar SK**, Dispenzieri A. Comparative analysis of staging systems in AL amyloidosis. *Leukemia* 2019 Mar; 33 (3):811-814 Epub 2019 Jan 23 PMID: 30675009 DOI: 10.1038/s41375-018-0370-z
499. Kyle RA, Larson DR, Kurtin PJ, **Kumar S**, Cerhan JR, Therneau TM, Rajkumar SV, Vachon CM, Dispenzieri A. Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. *Mayo Clin Proc.* 2019 Mar; 94 (3):465-471 Epub 2019 Jan 31 PMID: 30713046 PMCID: PMC6401262 DOI: 10.1016/j.mayocp.2018.08.041
500. Binder M, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, **Kumar SK**. Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. *Am J Hematol.* 2019 Mar; 94 (3):306-311 Epub 2018 Dec 13 PMID: 30516847 DOI: 10.1002/ajh.25365
501. Sidiqi MH, Aljama MA, Jevremovic D, Morice WG, Timm M, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, **Kumar S**, Kapoor P, Kourelis T, Leung N, Hogan WJ, Muchtar E, Lust JA, Rajkumar VS, Gertz MA. Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. *Bone Marrow Transplant.* 2019 Mar; 54 (3):442-447 Epub 2018 Aug 07 PMID: 30087461 DOI: 10.1038/s41409-018-0280-8
502. Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, Sidana S, Tandon N, Rajkumar SV, Dingli D, Go R, Lacy MQ, Kourelis T, Witzig TE, Inwards D, Buadi F, Gonsalves W, Habermann T, Johnston P, Nowakowski G, Kyle RA, **Kumar S**, Kapoor P. Primary systemic amyloidosis in patients with Waldenstrom macroglobulinemia. *Leukemia.* 2019 Mar; 33 (3):790-794 Epub 2018 Oct 12 PMID: 30315235 DOI: 10.1038/s41375-018-0286-7
503. Sidana S, Tandon N, Brady PA, Grogan M, Gertz MA, Dispenzieri A, Lin G, Dingli D, Buadi FK, Lacy MQ, Kapoor P, Gonsalves WI, Muchtar E, Warsame R, **Kumar SK**, Kourelis TV. Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. *Mayo Clin Proc.* 2019 Mar; 94 (3):455-464 Epub 2019 Feb 02 PMID: 30718070 DOI: 10.1016/j.mayocp.2018.08.039
504. Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, **Kumar SK**. Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. *Leukemia.* 2019 Mar; 33 (3):730-738 Epub 2018 Oct 15 PMID: 30323358 DOI: 10.1038/s41375-018-0271-1
505. Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, **Kumar SK**, Gertz MA, Roy V. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. *Bone Marrow Transplant.* 2019 Mar; 54 (3):353-367 Epub 2018 July 09 PMID: 29988062 PMCID: PMC6463224 DOI: 10.1038/s41409-018-0264-8
506. Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, **Kumar SK**. Natural history of multiple myeloma with de novo del(17p). *Blood Cancer J.* 2019 Mar 07; 9(3):32. PMID: 30846679 PMCID: PMC6405846 DOI: 10.1038/s41408-019-0191-y
507. Tandon N, Sidana S, Rajkumar SV, Gertz MA, Buadi FK, Lacy MQ, Kapoor P, Gonsalves WI, Dispenzieri A, Kourelis TV, Warsame R, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Hwa YL, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, **Kumar SK**. Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. *Blood Adv.* 2019 Mar 12; 3 (5):744-750 PMID: 30824418 PMCID: PMC6418495 DOI: 10.1182/bloodadvances.2018022806
508. Miller KC, Gertz MA, Buadi FK, Hayman SR, Wolf RC, Lacy MQ, Dispenzieri AA, Dingli D, Kapoor P, Gonsalves WI, Kourelis T, Hogan WJ, **Kumar SK**. Comparable outcomes using propylene glycol-free

- melphalan for autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2019 Apr; 54 (4):587-594 Epub 2018 Aug 16 PMID: 30116014 PMCID: PMC6377862 DOI: 10.1038/s41409-018-0302-6
509. Chim CS, **Kumar SK**, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC. Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2019 Apr; 33 (4):1058-1059 PMID: 30842604 PMCID: PMC7608453 DOI: 10.1038/s41375-019-0410-3
 510. Sidana S, Jevremovic D, Ketterling RP, Tandon N, Dispenzieri A, Gertz MA, Greipp PT, Baughn LB, Buadi FK, Lacy MQ, Morice W, Hanson C, Timm M, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Rajkumar SV, **Kumar SK**. Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. Am J Hematol. 2019 Apr; 94 (4):424-430 Epub 2019 Jan 08 PMID: 30592078 PMCID: PMC8083940 DOI: 10.1002/ajh.25391
 511. Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, **Kumar S**, Hari P. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biol Blood Marrow Transplant. 2019 Apr; 25 (4):683-688 Epub 2018 Dec 21 PMID: 30579965 PMCID: PMC6453717 DOI: 10.1016/j.bbmt.2018.12.141
 512. Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, **Kumar SK**. Substratification of patients with newly diagnosed standard-risk multiple myeloma. Br J Haematol. 2019 Apr; 185 (2):254-260 Epub 2019 Feb 15 PMID: 30768679 DOI: 10.1111/bjh.15800
 513. Harding T, Baughn L, **Kumar S**, Van Ness B. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. Leukemia. 2019 Apr; 33 (4):863-883 Epub 2019 Jan 25 PMID: 30683909 DOI: 10.1038/s41375-018-0362-z
 514. Aljama MA, Sidiqi MH, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, **Kumar SK**. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. Blood Adv. 2019 Apr 23; 3 (8):1226-1229 PMID: 30975646 PMCID: PMC6482356 DOI: 10.1182/bloodadvances.2019032458
 515. Sidana S, Tandon N, Gertz MA, Dispenzieri A, Ramirez-Alvarado M, Murray DL, Kourelis TV, Buadi FK, Kapoor P, Gonsalves W, Warsame R, Lacy MQ, Kyle RA, Rajkumar SV, **Kumar SK**, Leung N. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. Br J Haematol. 2019 May; 185 (4):701-707 Epub 2019 Mar 05 PMID: 30836444 DOI: 10.1111/bjh.15832
 516. Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis TV, Warsame R, Kyle RA, **Kumar SK**. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia. 2019 May; 33 (5):1273-1277 Epub 2019 Feb 20 PMID: 30787429 PMCID: PMC7372537 DOI: 10.1038/s41375-019-0419-7
 517. Sidiqi MH, Dasari S, McPhail ED, Buadi FK, Warsame R, Lacy MQ, Dingli D, Gonsalves WI, Kapoor P, Kourelis T, Leung N, Muchtar E, Grogan M, Lust JA, **Kumar S**, Kyle RA, Rajkumar VS, Gertz M, Dispenzieri A. Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. Am J Hematol 2019 May; 94 (5):E141-E143 Epub 2019 Feb 27 PMID: 30773682 DOI: 10.1002/ajh.25440
 518. Hwa YL, Gertz MA, **Kumar SK**, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust SR, Leung N, Hayman SR, Gonsalves WI, Kourelis TV, Warsame R, Go RS, Muchtar E, Hobbs MA, Fonder AL, Russell S, Kyle RA, Rajkumar SV, Dispenzieri A. Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia. 2019 May; 33 (5):1268-1272 Epub 2019 Feb 08 PMID: 30737485 DOI: 10.1038/s41375-019-0400-5
 519. Sidana S, Jevremovic D, Ketterling RP, Tandon N, Greipp PT, Baughn LB, Dispenzieri A, Gertz MA, Rajkumar SV, **Kumar SK**. Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. Am J Hematol 2019 May; 94 (5):E117-E120 Epub 2019 Feb 06 PMID: 30680770 PMCID: PMC8019381 DOI: 10.1002/ajh.25420
 520. Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, **Kumar S**, Lacy M, Lipe B, Little RF, Nikonova A, Omel J, Peswani N, Prica A, Raje N, Seth R, Vesole DH, Walker I, Whitley A, Wildes TM, Wong SW, Martin T. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. J Clin Oncol. 2019 May 10; 37 (14):1228-1263 Epub 2019 Apr 01 PMID: 30932732 DOI: 10.1200/JCO.18.02096
 521. **Kumar S**, Larson DR, Dispenzieri A, Therneau TM, Murray DL, Leif Bergsagel P, Kyle RA, Vincent Rajkumar S. Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies.

- Blood Cancer J. 2019 May 17; 9 (6):49 PMID: 31101803 PMCID: PMC6525262 DOI: 10.1038/s41408-019-0210-z
522. Facon T, **Kumar S**, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ, MAIA Trial Investigators. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. *N Engl J Med*. 2019 May 30; 380 (22):2104-2115 PMID: 31141632 PMCID: PMC10045721 DOI: 10.1056/NEJMoa1817249
 523. Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, Garcia-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, **Kumar S**, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfield D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. *Lancet Oncol*. 2019 Jun; 20 (6):e302-e312 PMID: 31162104 DOI: 10.1016/S1470-2045(19)30309-2
 524. Dimopoulos MA, Laubach JP, Echeveste Gutierrez MA, Grzasko N, Hofmeister CC, San-Miguel JF, **Kumar S**, Labotka R, Lu V, Berg D, Byrne C, Teng Z, Liu G, van de Velde H, Richardson PG. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. *Eur J Haematol*. 2019 Jun; 102 (6):494-503 Epub 2019 May 08 PMID: 30943323 DOI: 10.1111/ejh.13231
 525. **Kumar S**, Glazebrook KN, Broski SM. Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma. *PET Clin*. 2019 Jul; 14 (3):391-403 Epub 2019 Apr 12 PMID: 31084778 DOI: 10.1016/j.cpet.2019.03.006
 526. **Kumar SK**, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. *Leukemia*. 2019 Jul; 33 (7):1736-1746 Epub 2019 Jan 29 PMID: 30696949 PMCID: PMC6755968 DOI: 10.1038/s41375-019-0384-1
 527. Tschautscher MA, Jevremovic D, Rajkumar V, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, **Kumar SK**. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. *Am J Hematol*. 2019 Jul; 94 (7):751-756 Epub 2019 Apr 30 PMID: 30945330 DOI: 10.1002/ajh.25481
 528. Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Wolf RC, **Kumar SK**, Gertz MA. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. *Bone Marrow Transplant*. 2019 Jul; 54 (7):1077-1081 Epub 2018 Nov 02 PMID: 30390060 DOI: 10.1038/s41409-018-0388-x
 529. Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, **Kumar SK**. Impact of acquired del (17p) in multiple myeloma. *Blood Adv*. 2019 Jul 09; 3(13):1930-1938. PMID: 31248884 PMCID: PMC6616261 DOI: 10.1182/bloodadvances.2018028530
 530. **Kumar S**, Rajkumar SV. Surrogate endpoints in randomised controlled trials: a reality check. *Lancet*. 2019 Jul 27; 394 (10195):281-283 PMID: 31354129 DOI: 10.1016/S0140-6736(19)31711-8
 531. Dai Y, Jin F, Wu W, **Kumar SK**. Cell cycle regulation and hematologic malignancies. *Blood Sci*. 2019 Aug; 1 (1):34-43 Epub 2019 Sept 17 PMID: 35402801 PMCID: PMC8975093 DOI: 10.1097/BS9.0000000000000009
 532. Al Saleh AS, Sidiqi MH, Muchtar E, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Warsame RM, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Kapoor P, **Kumar SK**, Gertz MA. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. *Biol Blood Marrow Transplant*. 2019 Aug; 25 (8):1520-1525 Epub 2019 May 02 PMID: 31054986 PMCID: PMC6698422 DOI: 10.1016/j.bbmt.2019.04.024
 533. Kourelis TV, Villasboas JC, Jessen E, Dasari S, Dispenzieri A, Jevremovic D, **Kumar S**. Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies. *Blood Cancer J*. 2019 Aug 28; 9 (9):72 PMID: 31462637 PMCID: PMC6713712 DOI: 10.1038/s41408-019-0234-4
 534. Sidana S, Sidiqi MH, Dispenzieri A, Buadi FK, Lacy MQ, Muchtar E, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Leung N, Warsame R, Kourelis TV, Wolf RC, Hogan WJ, **Kumar SK**, Gertz MA. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. *Am J Hematol*. 2019 Sep; 94 (9):1020-1026 Epub 2019 July 11 PMID: 31254301 DOI: 10.1002/ajh.25566
 535. Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby

- KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, **Kumar SK**, Costa LJ. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. *Leukemia*. 2019 Sep; 33(9):2266-2275. Epub 2019 Mar 11. PMID: 30858549 PMCID: PMC6820050 DOI: 10.1038/s41375-019-0435-7
536. Ramakrishnan VG, Miller KC, Macon EP, Kimlinger TK, Haug J, Kumar S, Gonsalves WI, Rajkumar SV, **Kumar SK**. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma. *Haematologica*. 2019 Oct; 104 (10):2061-2074 Epub 2019 Mar 07 PMID: 30846494 PMCID: PMC6886422 DOI: 10.3324/haematol.2018.211110
 537. Al Saleh AS, Sidiqi MH, Sidana S, Muchtar E, Dispenzieri A, Dingli D, Lacy MQ, Warsame RM, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Wolf RC, Kapoor P, Buadi FK, **Kumar SK**, Gertz MA. Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. *Am J Hematol*. 2019 Oct; 94 (10):1066-1071 Epub 2019 July 23 PMID: 31273808 PMCID: PMC7377298 DOI: 10.1002/ajh.25572
 538. Kurzrock R, Gurski LA, Carlson RW, Ettinger DS, Horwitz SM, **Kumar SK**, Million L, von Mehren M, Benson AB 3rd. Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. *Ann Oncol*. 2019 Oct 1; 30 (10):1647-1652 PMID: 31373348 PMCID: PMC6857604 DOI: 10.1093/annonc/mdz232
 539. Kurzrock R, Gurski LA, Carlson RW, Ettinger DS, Horwitz SM, **Kumar SK**, Million L, von Mehren M, Benson AB 3rd. Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. *Ann Oncol*. 2019 Oct; 30 (10):1647-1652 Epub 2019 Dec 27 PMID: 31987456 DOI: 10.1093/annonc/mdz232
 540. **Kumar SK**, Callender NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R. Multiple myeloma, version 1.2020 featured updates to the nccn guidelines *Journal Of The National Comprehensive Cancer Network*. 2019 Oct; 17 (10):1155-65
 541. **Kumar SK**, Callender NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R. NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. *J Natl Compr Canc Netw*. 2019 Oct 1; 17 (10):1154-1165 PMID: 31590151 DOI: 10.6004/jnccn.2019.0049
 542. Hsieh RW, Go RS, Abeykoon JP, Kapoor P, **Kumar SK**, Gertz MA, Buadi FK, Leung N, Gonsalves WI, Kourelis TV, Warsame RM, Dispenzieri A, Lacy MQ, Kyle RA, Rajkumar SV, Paludo J. Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. *Cancer*. 2019 Oct 15; 125 (20):3574-3581 Epub 2019 June 28 PMID: 31251390 DOI: 10.1002/cncr.32357
 543. Sidiqi MH, Nadiminti K, Al Saleh AS, Meleveedu K, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, **Kumar SK**, Gertz MA. Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. *Bone Marrow Transplant*. 2019 Nov; 54 (11):1775-1779 Epub 2019 Apr 08 PMID: 30962503 DOI: 10.1038/s41409-019-0524-2
 544. Moreau P, **Kumar S**, Boccia R, Iida S, Goldschmidt H, Cocks K, Trigg A, Zahlten-Kumeli A, Yucel E, Panjabi SS, Dimopoulos M. Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m² vs. twice-weekly 27 mg/m² carfilzomib (randomized A.R.R.O.W. study). *Leukemia*. 2019 Dec; 33 (12):2934-2946 Epub 2019 May 15 PMID: 31092895 DOI: 10.1038/s41375-019-0480-2
 545. Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, **Kumar SK**. Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. *Leuk Lymphoma*. 2019 Dec; 60 (12):2960-2967 Epub 2019 May 16 PMID: 31096812 DOI: 10.1080/10428194.2019.1613536
 546. Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, Grogan M, AbouEzzeddine OF, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Zeldenrust S, Kyle RA, Rajkumar SV, **Kumar SK**, Dispenzieri A. Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. *Br J Haematol*. 2019 Dec; 187 (5):588-594 Epub 2019 July 12 PMID: 31298751 PMCID: PMC6872910 DOI: 10.1111/bjh.16096
 547. Raab MS, Thomas SK, Ocio EM, Guenther A, Goh YT, Talpaz M, Hohmann N, Zhao S, Xiang F, Simon C, Vanasse KG, **Kumar SK**. The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. *Leukemia*. 2019 Dec; 33 (12):2924-2933 Epub 2019 May 15 PMID: 31092894 DOI: 10.1038/s41375-019-0482-0
 548. Miller KC, Gertz MA, Buadi FK, Hayman SR, Lacy MQ, Dispenzieri AA, Dingli D, Kapoor P, Gonsalves WI,

- Kourelis T, Muchtar E, Hogan WJ, **Kumar SK**. The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. *Bone Marrow Transplant*. 2019 Dec; 54 (12):2039-2050 Epub 2019 June 12 PMID: 31190005 PMCID: PMC6893102 DOI: 10.1038/s41409-019-0590-5
549. Murray D, **Kumar SK**, Kyle RA, Dispenzieri A, Dasari S, Larson DR, Vachon C, Cerhan JR, Rajkumar SV. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. *Blood Cancer J*. 2019 Dec 13; 9 (12):102 PMID: 31836698 PMCID: PMC6910906 DOI: 10.1038/s41408-019-0263-z
 550. Smadbeck J, Peterson JF#, Pearce KE, Pitel BA, Figueroa AL, Timm M, Jevremovic D, Shi M, Stewart AK, Braggio E, Riggs DL, Bergsagel PL, Vasmataz G, Kearney HM, Hoppman NL, Ketterling RP, **Kumar S**, Rajkumar SV, Greipp PT, Baughn LB. Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. *Blood Cancer J*. 2019 Dec 16; 9 (12):103 PMID: 31844041 PMCID: PMC6914798 DOI: 10.1038/s41408-019-0255-z
 551. Nandakumar B, **Kumar SK**, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Siddiqui M, Zeldenrust S, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. *Clin Lymphoma Myeloma Leuk*. 2020 Jan; 20 (1):53-56 Epub 2019 Oct 09 PMID: 31685378 PMCID: PMC6960347 DOI: 10.1016/j.clml.2019.09.624
 552. Li Z, **Kumar S**, Jin DY, Calin GA, Chng WJ, Siu KL, Poon MW, Chim CS. Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination. *Cancer Cell Int*. 2020; 20:403 Epub 2020 Aug 25 PMID: 32855620 PMCID: PMC7446116 DOI: 10.1186/s12935-020-01504-4
 553. Al Saleh AS, Sidiqi MH, Dispenzieri A, Kapoor P, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kourelis TV, Gertz MA, Go RS, Kyle RA, Rajkumar SV, **Kumar SK**. Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. *Am J Hematol*. 2020 Jan; 95 (1):4-9 Epub 2019 Oct 29 PMID: 31612526 PMCID: PMC7377299 DOI: 10.1002/ajh.25657
 554. Yao Q, Bai Y, **Kumar S**, Au E, Orfao A, Chim CS. Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR. *Front Oncol*. 2020; 10:611021 Epub 2021 Jan 29 PMID: 33585233 PMCID: PMC7878533 DOI: 10.3389/fonc.2020.611021
 555. Misund K#, Keane N#, Stein CK, Asmann YW, Day G, Welsh S, Van Wier SA, Riggs DL, Ahmann G, Chesi M, Viswanatha DS, **Kumar SK**, Dispenzieri A, Gonzalez-Calle V, Kyle RA, O'Dwyer M, Rajkumar SV, Kortum KM, Keats JJ, Fonseca R, Stewart AK, Kuehl WM, Braggio E, Bergsagel PL, MMRF CoMMpass Network. MYC dysregulation in the progression of multiple myeloma. *Leukemia* 2020 Jan; 34 (1):322-326 Epub 2019 Aug 22 PMID: 31439946 PMCID: PMC6923575 DOI: 10.1038/s41375-019-0543-4
 556. Warsame R, LaPlant B, **Kumar SK**, Laumann K, Perez Burbano G, Buadi FK, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves WI, Kourelis T, Lust J, Russell SJ, Zeldenrust S, Lin Y, Muchtar E, Go RS, Vincent Rajkumar S, Dispenzieri A. Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. *Blood Cancer J*. 2020 Jan 8; 10 (1):4 Epub 2020 Jan 08 PMID: 31913261 PMCID: PMC6949262 DOI: 10.1038/s41408-019-0266-9
 557. Abdallah N, Kapoor P, Murray DL, Buadi FK, Dingli D, Dispenzieri A, Gertz MA, Go RS, Gonsalves WI, Hayman SR, Kourelis TV, Lacy MQ, Leung N, Lust JA, Muchtar E, Warsame R, Kyle RA, Rajkumar SV, **Kumar SK**. Utility of serum free light chain ratio in response definition in patients with multiple myeloma. *Blood Adv*. 2020 Jan 28; 4 (2):322-326 PMID: 31978213 PMCID: PMC6988402 DOI: 10.1182/bloodadvances.2019001099
 558. Abeykoon JP, Zanwar S, Ansell SM, Gertz MA, **Kumar S**, Manske M, Novak AJ, King R, Greipp P, Go R, Inwards D, Muchtar E, Habermann T, Witzig TE, Thompson CA, Dingli D, Lacy MQ, Leung N, Dispenzieri A, Gonsalves W, Warsame R, Kyle RA, Rajkumar V, Parikh SA, Kapoor P. Ibrutinib monotherapy outside of clinical trial setting in Waldenstrom macroglobulinaemia: practice patterns, toxicities and outcomes. *Br J Haematol*. 2020 Feb; 188 (3):394-403 Epub 2019 Aug 29 PMID: 31468508 DOI: 10.1111/bjh.16168
 559. Dispenzieri A, Arendt B, Dasari S, Kohlhagen M, Kourelis T, **Kumar SK**, Leung N, Muchtar E, Buadi FK, Warsame R, Kyle RA, Lacy MQ, Dingli D, Kapoor P, Gonsalves WI, Go RS, Hayman SR, Hwa YL, Fonder A, Hobbs M, Jevremovic D, Lust JA, Zeldenrust S, Russell SJ, Rajkumar SV, Gertz MA, Murray D. Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. *Blood Cancer J*. 2020 Feb 25; 10 (2):20 PMID: 32098948 PMCID: PMC7042300 DOI: 10.1038/s41408-020-0291-8
 560. Gonsalves WI, Jevremovic D, Nandakumar B, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Siddiqui MA, Kyle RA, Gertz MA, Rajkumar SV, **Kumar SK**. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. *Am J Hematol*. 2020 Mar; 95 (3):310-315 Epub 2020 Jan 08 PMID: 31867775 PMCID: PMC7724649 DOI: 10.1002/ajh.25709
 561. Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, **Kumar S**, Gertz MA, Quinquenel A, Delmer A,

- Gonsalves W, Cornillet-Lefebvre P, He R, Warsame R, Buadi FK, Novak AJ, Greipp PT, Inwards D, Habermann TM, Micallef I, Go R, Muchtar E, Kourelis T, Dispenzieri A, Lacy MQ, Dingli D, Nowakowski G, Thompson CA, Johnston P, Thanarajasingam G, Bennani NN, Witzig TE, Villasboas J, Leung N, Lin Y, Kyle RA, Rajkumar SV, Ansell SM, Le-Rademacher JG, Kapoor P. Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia. *Am J Hematol*. 2020 Mar; 95(3):274-281. Epub 2019 Dec 31. PMID: 31814157 DOI: 10.1002/ajh.25697
562. Tschautscher M, Jevremovic D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman S, Lust J, Russell S, Leung N, Go R, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Rajkumar V, **Kumar S**. Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. *Am J Hematol* 2020 Mar; 95 (3):E60-E62 Epub 2019 Dec 30 PMID: 31840857 DOI: 10.1002/ajh.25702
 563. D'Amico TA, Bandini LAM, Balch A, Benson AB, Edge SB, Fitzgerald CL, Green RJ, Koh WJ, Kolodziej M, **Kumar S**, Meropol NJ, Mohler JL, Pfister D, Walters RS, Carlson RW. Quality Measurement in Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts. *J Natl Compr Canc Netw*. 2020 Mar; 18 (3):250-259 PMID: 32135508 DOI: 10.6004/jnccn.2020.7536
 564. Muchtar E, Dispenzieri A, Jevremovic D, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Warsame R, Kourelis TV, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, **Kumar SK**, Gertz MA. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. *Amyloid*. 2020 Mar; 27 (1):13-16 Epub 2019 Sept 23 PMID: 31544536 PMCID: PMC7372715 DOI: 10.1080/13506129.2019.1666709
 565. Baughn LB, Li Z, Pearce K, Vachon CM, Polley MY, Keats J, Elhaik E, Baird M, Therneau T, Cerhan JR, Bergsagel PL, Dispenzieri A, Rajkumar SV, Asmann YW, **Kumar S**. The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias. *Blood Cancer J* 2020 Mar 16; 10 (3):39 PMID: 32179748 PMCID: PMC7075993 DOI: 10.1038/s41408-020-0294-5
 566. Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Lisa Hwa Y, Gonsalves W, Warsame R, Russell S, Lust JA, Lin Y, Zeldenrust S, Rajkumar SV, Kyle RA, **Kumar SK**, Dispenzieri A. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. *Leukemia*. 2020 Apr; 34 (4):1135-1143 Epub 2019 Nov 22 PMID: 31758090 DOI: 10.1038/s41375-019-0655-x
 567. Lonial S, Jacobus S, Fonseca R, Weiss M, **Kumar S**, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. *J Clin Oncol*. 2020 Apr 10; 38 (11):1126-1137 Epub 2019 Oct 25 PMID: 31652094 PMCID: PMC7145586 DOI: 10.1200/JCO.19.01740
 568. Sidana S#, Milani P#, Binder M, Basset M, Tandon N, Foli A, Dispenzieri A, Gertz MA, Hayman SR, Buadi FK, Lacy MQ, Kapoor P, Leung N, Rajkumar SV, Merlini G, Palladini G#, **Kumar SK**. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. *Blood Cancer J*. 2020 Apr 14; 10 (4):41 PMID: 32286270 PMCID: PMC7156647 DOI: 10.1038/s41408-020-0306-5
 569. Chakraborty R, Bin Riaz I, Malik SU, Marneni N, Mejia Garcia A, Anwer F, Khorana AA, Rajkumar SV, **Kumar S**, Murad MH, Wang Z, Khan SU, Majhail NS. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. *Cancer*. 2020 Apr 15; 126 (8):1640-1650 Epub 2020 Jan 08 PMID: 31913498 PMCID: PMC7453956 DOI: 10.1002/cncr.32682
 570. Sidana S, Larson DP, Greipp PT, He R, McPhail ED, Dispenzieri A, Murray DL, Dasari S, Ansell SM, Muchtar E, Gonsalves W, Kourelis TV, Ramirez-Alvarado M, Kapoor P, Rajkumar SV, Lacy MQ, Buadi FK, Leung N, Kyle RA, **Kumar SK**, King RL#, Gertz MA#. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. *Leukemia*. 2020 May; 34 (5):1373-1382 Epub 2019 Nov 28 PMID: 31780812 PMCID: PMC8019395 DOI: 10.1038/s41375-019-0667-6
 571. Sidana S, Muchtar E, Sidiqi MH, Jevremovic D, Dispenzieri A, Gonsalves W, Buadi F, Lacy MQ, Hayman SR, Kourelis T, Kapoor P, Go RS, Warsame R, Leung N, Rajkumar SV, Kyle RA, Gertz MA, **Kumar SK**. Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. *Am J Hematol*. 2020 May; 95 (5):497-502 Epub 2020 Feb 14 PMID: 32010993 PMCID: PMC8019396 DOI: 10.1002/ajh.25746
 572. Ravindran A, Lackore KA, Glasgow AE, Drake MT, Hobbs MA, Kourelis T, **Kumar S**, Kyle RA, Leung N, Muchtar E, Go RS. Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. *Mayo Clin Proc*. 2020 May; 95 (5):944-954 PMID: 32370855 DOI: 10.1016/j.mayocp.2019.12.033
 573. Yao Q, Bai Y, Orfao A, **Kumar S**, Chim CS. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. *J Mol Diagn*. 2020 May; 22 (5):679-684 Epub 2020 Mar 06 PMID: 32151713 DOI: 10.1016/j.jmoldx.2020.02.005

574. Sidiqi MH, Aljama M, **Kumar SK**, Jevremovic D, Buadi FK, Warsame R, Lacy MQ, Dingli D, Gonsalves WI, Fonder AL, Hobbs MA, Hwa YL, Kapoor P, Kourelis T, Leung N, Muchtar E, Lust JA, Kyle RA, Go RS, Rajkumar VS, Gertz MA, Dispenzieri A. The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied? *Blood Cancer J*. 2020 May 6; 10 (5):52 Epub 2020 May 06 PMID: 32376870 PMCID: PMC7203099 DOI: 10.1038/s41408-020-0319-0
575. Bonolo de Campos C#, Meurice N#, Petit JL, Polito AN, Zhu YX, Wang P, Bruins LA, Wang X, Lopez Armenta ID, Darvish SA, Ahmann GJ, Henderson KJ, Tian S, Kruse JJ, Stewart WM, Larsen JT, Reeder CB, Dingli D, Kapoor P, **Kumar SK**, Fonseca R, Bergsagel PL, Braggio E, Stewart AK. "Direct to Drug" screening as a precision medicine tool in multiple myeloma. *Blood Cancer J*. 2020 May 11; 10 (5):54 PMID: 32393731 PMCID: PMC7214452 DOI: 10.1038/s41408-020-0320-7
576. Sidiqi MH, Al Saleh AS, Leung N, Jevremovic D, Aljama MA, Gonsalves WI, Buadi FK, Kourelis TV, Warsame R, Muchtar E, Hobbs MA, Lacy MQ, Dingli D, Go RS, Hayman SR, Rajkumar SV, Dispenzieri A, Gertz MA, **Kumar SK**, Fonseca R, Kapoor P. Venetoclax for the treatment of translocation (11;14) AL amyloidosis. *Blood Cancer J* 2020 May 11; 10 (5):55 PMID: 32393733 PMCID: PMC7214448 DOI: 10.1038/s41408-020-0321-6
577. Mellors PW, Binder M, Ketterling RP, Greipp PT, Baughn LB, Peterson JF, Jevremovic D, Pearce KE, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, **Kumar SK**. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. *Blood Adv*. 2020 May 26; 4 (10):2236-2244 PMID: 32442300 PMCID: PMC7252538 DOI: 10.1182/bloodadvances.2019001275
578. **Kumar SK**, Majer I, Panjabi S, Medhekar R, Campioni M, Dimopoulos MA. Cost-effectiveness of once weekly carfilzomib 70 mg/m² plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States. *Expert Rev Hematol*. 2020 Jun; 13 (6):687-696 Epub 2020 Apr 06 PMID: 32249621 DOI: 10.1080/17474086.2020.1746639
579. Evans LA, Jevremovic D, Nandakumar B, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Go R, Russell S, Lust JA, Lin Y, Siddiqui M, Kyle RA, Gertz MA, Rajkumar SV, **Kumar SK**, Gonsalves WI. Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. *Am J Hematol*. 2020 Jun; 95 (6):637-642 Epub 2020 Mar 26 PMID: 32129510 PMCID: PMC7217733 DOI: 10.1002/ajh.25773
580. **Kumar S**, Rajkumar SV. BiTEing the Tumor. *J Clin Oncol*. 2020 Jun 20; 38 (18):2077-2079 Epub 2020 May 06 PMID: 32374643 DOI: 10.1200/JCO.20.00223
581. Clay-Gilmour AI, Hildebrandt MAT, Brown EE, Hofmann JN, Spinelli JJ, Giles GG, Cozen W, Bhatti P, Wu X, Waller RG, Belachew AA, Robinson DP, Norman AD, Sinnwell JP, Berndt SI, Rajkumar SV, **Kumar SK**, Chanock SJ, Machiela MJ, Milne RL, Slager SL, Camp NJ, Ziv E, Vachon CM. Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance. *Blood Adv*. 2020 Jun 23; 4 (12):2789-2797 PMID: 32569378 PMCID: PMC7322948 DOI: 10.1182/bloodadvances.2020001435
582. Gonsalves WI, Broniowska K, Jessen E, Petterson XM, Bush AG, Gransee J, Lacy MQ, Hitosugi T, **Kumar SK**. Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma. *Sci Rep*. 2020 Jun 24; 10 (1):10250 Epub 2020 June 24 PMID: 32581232 PMCID: PMC7314797 DOI: 10.1038/s41598-020-67105-3
583. Razonable RR, Marshall WF, Stevens RW, **Kumar S**, Murad MH, Wilson WR. Mayo Clinic strategies for COVID-19 rapid appraisal system for COVID-19 medical information Mayo Clinic Proceeding. 2020. PMCID: 7306744 DOI: 10.1016/j.mayocp.2020.05.042
584. Di Bacco A, Bahlis NJ, Munshi NC, Avet-Loiseau H, Masszi T, Viterbo L, Pour L, Ganly P, Cavo M, Langer C, **Kumar SK**, Rajkumar SV, Keats JJ, Berg D, Lin J, Li B, Badola S, Shen L, Zhang J, Esseltine DL, Luptakova K, van de Velde H, Richardson PG, Moreau P. c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. *Eur J Haematol*. 2020 Jul; 105 (1):35-46 Epub 2020 Apr 15 PMID: 32145111 PMCID: PMC7317705 DOI: 10.1111/ejh.13405
585. Wang LQ, **Kumar S**, Calin GA, Li Z, Chim CS. Frequent methylation of the tumour suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification. *Br J Haematol*. 2020 Jul; 190 (2):249-261 Epub 2020 Feb 20 PMID: 32079038 DOI: 10.1111/bjh.16517
586. Kourelis TV, Jevremovic D, Jessen E, Dasari S, Villasboas JC, Dispenzieri A, **Kumar S**. Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndrome. *Br J Haematol*. 2020 Jul; 190 (1):79-83 Epub 2020 Feb 20 PMID: 32080834 PMCID: PMC7329569 DOI: 10.1111/bjh.16522
587. Chesi M, Stein CK, Garbitt VM, Sharik ME, Asmann YW, Bergsagel M, Riggs DL, Welsh SJ, Meermeier EW, **Kumar SK**, Braggio E, Bergsagel PL. Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression. *Blood Cancer Discov*. 2020 Jul; 1 (1):68-81 PMID: 32954360 PMCID:

PMC7494232 DOI: 10.1158/0008-5472.BCD-19-0068

588. Abdallah N, Sidana S, Dispenzieri A, Lacy M, Buadi F, Hayman S, Kapoor P, Leung N, Dingli D, Hwa YL, Lust J, Russell S, Gonsalves W, Go R, Hogan W, Kyle R, Rajkumar SV, Gertz M, **Kumar S**. Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. *Bone Marrow Transplant*. 2020 Jul; 55 (7):1297-1304 Epub 2020 June 09 PMID: 32518290 PMCID: PMC8083941 DOI: 10.1038/s41409-020-0964-8
589. Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhitomirsky B, Dunford AJ, Salem K, Tai YT, Anand S, Mouhieddine TH, Chavda SJ, Boehner C, Elagina L, Neuse CJ, Cha J, Rahmat M, Taylor-Weiner A, Van Allen E, **Kumar S**, Kastiris E, Leshchiner I, Morgan EA, Laubach J, Casneuf T, Richardson P, Munshi NC, Anderson KC, Trippa L, Aguet F, Stewart C, Dimopoulos MA, Yong K, Bergsagel PL, Manier S, Getz G, Ghobrial IM. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. *J Clin Oncol*. 2020 Jul 20; 38 (21):2380-2389 Epub 2020 May 22 PMID: 32442065 PMCID: PMC7367550 DOI: 10.1200/JCO.20.00437
590. Mitra AK, Kumar H, Ramakrishnan V, Chen L, Baughn L, **Kumar S**, Rajkumar SV, Van Ness BG. In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma. *Blood Cancer J*. 2020 Jul 28; 10 (7):78 Epub 2020 July 28 PMID: 32724061 PMCID: PMC7387444 DOI: 10.1038/s41408-020-00344-9
591. Kastiris E, Wechalekar A, Schonland S, Sanchorawala V, Merlini G, Palladini G, Minnema M, Roussel M, Jaccard A, Hegenbart U, **Kumar S**, Cibeira MT, Blade J, Dimopoulos MA. Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. *Br J Haematol*. 2020 Aug; 190 (3):346-357 Epub 2020 July 04 PMID: 32480420 PMCID: PMC7300844 DOI: 10.1111/bjh.16898
592. Al Saleh AS, Sidiqi MH, Muchtar E, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Kapoor P, **Kumar SK**, Gertz MA. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2020 Aug; 26 (8):1402-1405 Epub 2020 May 15 PMID: 32422250 PMCID: PMC7371505 DOI: 10.1016/j.bbmt.2020.04.024
593. Baffour FI, Glazebrook KN, **Kumar SK**, Broski SM. Role of imaging in multiple myeloma. *Am J Hematol*. 2020 Aug; 95 (8):966-977 Epub 2020 May 18 PMID: 32350883 DOI: 10.1002/ajh.25846
594. Sethi S, Nast CC, D'Agati VD, Fervenza FC, Glassock RJ, Stokes MB, De Vriese AS, Appel GB, Chang A, Cosio F, Herrera Hernandez L, Markowitz GS, **Kumar SK**, Alexander MP, Amer H, Murray D, Nasr SH, Leung N, Pani A, Picken MM, Ravindran A, Roccatello D, Ronco P, Royal V, Smith KD, Wechalekar AD, Wetzels J, Zand L, Zhang P, Haas M. Standardized reporting of monoclonal immunoglobulin-associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group. *Kidney Int*. 2020 Aug; 98 (2):310-313 Epub 2020 Apr 23 PMID: 32709293 DOI: 10.1016/j.kint.2020.03.025
595. Abdallah N, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Rajkumar SV, **Kumar SK**. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. *Blood Adv*. 2020 Aug 11; 4 (15):3509-3519 PMID: 32750129 PMCID: PMC7422105 DOI: 10.1182/bloodadvances.2020002218
596. Abdallah N, Rajkumar SV, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, **Kumar SK**. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. *Blood Cancer J*. 2020 Aug 11; 10 (8):82 PMID: 32782240 PMCID: PMC7419564 DOI: 10.1038/s41408-020-00348-5
597. Zanwar S, Nandakumar B, **Kumar S**. Immune-based therapies in the management of multiple myeloma. *Blood Cancer J*. 2020 Aug 22; 10 (8):84 PMID: 32829378 PMCID: PMC7443188 DOI: 10.1038/s41408-020-00350-x
598. Paquin A, Visram A, **Kumar SK**, Gertz MA, Cantwell H, Buadi FK, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV. Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. *Blood Cancer J*. 2020 Aug 28; 10 (8):87 PMID: 32859899 PMCID: PMC7455690 DOI: 10.1038/s41408-020-00353-8
599. Sidana S, Murray DL, Dasari S, Go RS, Muchtar E, Willrich MA, Snyder M, Kohlhagen M, Lust JA, Kourelis TV, **Kumar SK**, Dispenzieri A, Gertz MA. Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. *Am J Hematol* 2020 Sep; 95 (9):E222-E225 Epub 2020 June 12 PMID: 32356376 DOI: 10.1002/ajh.25843
600. Al Saleh AS, Parmar HV, Visram A, Muchtar E, Buadi FK, Go RS, Dispenzieri A, Kapoor P, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kourelis TV, Gertz MA, Kyle RA, Rajkumar SV, **Kumar SK**. Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. *Clin Lymphoma Myeloma Leuk*. 2020 Sep; 20 (9):596-601 Epub 2020 Apr 07 PMID: 32360276 PMCID:

PMC7484262 DOI: 10.1016/j.clml.2020.03.012

601. Razonable RR, Marshall WF 3rd, Stevens RW, **Kumar S**, Murad MH, Wilson WR. Rapid Appraisal System for COVID-19 Medical Information. Mayo Clin Proc. 2020 Sep; 95 (9S):S26-S28 Epub 2020 June 22 PMID: 32948256 PMCID: PMC7306744 DOI: 10.1016/j.mayocp.2020.05.042
602. Rajkumar SV, **Kumar S**. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020 Sep 28; 10 (9):94 Epub 2020 Sept 28 PMID: 32989217 PMCID: PMC7523011 DOI: 10.1038/s41408-020-00359-2
603. **Kumar SK**, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E Jr, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020 Oct; 21 (10):1317-1330 Epub 2020 Aug 28 PMID: 32866432 PMCID: PMC7591827 DOI: 10.1016/S1470-2045(20)30452-6
604. Heybeli C, Sridharan M, Alkhateeb HB, Villasboas Bisneto JC, Buadi FK, Chen D, Dingli D, Dispenzieri A, Gertz MA, Go RS, Hashmi SK, Hayman SR, Hogan WJ, Inwards DJ, Kenderian SS, **Kumar SK**, Litzow MR, Porrata LF, Lacy MQ, Micallef IN, Patnaik MM, Shah MV, Leung N. Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2020 Oct; 95 (10):1170-1179 Epub 2020 Aug 08 PMID: 32618000 DOI: 10.1002/ajh.25922
605. Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Russell S, Lust JA, Lin Y, Zeldenrust S, Rajkumar SV, Kyle RA, **Kumar SK**, Dispenzieri A. Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia. 2020 Oct; 34 (10):2819 PMID: 32728185 DOI: 10.1038/s41375-020-0993-8
606. Mohyuddin GR, Koehn K, Costa L, **Kumar SK**, McClune B. Enrolment of racial minorities across 15 years of multiple myeloma randomised trials; calling on researchers to become agents of change. Lancet Haematol. 2020 Oct; 7 (10):e704-e706 Epub 2020 Sept 01 PMID: 32888415 DOI: 10.1016/S2352-3026(20)30281-7
607. Dispenzieri A, Larson DR, Rajkumar SV, Kyle RA, **Kumar SK**, Kourelis T, Arendt B, Willrich M, Dasari S, Murray D. N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. Leukemia. 2020 Oct; 34 (10):2749-2753 Epub 2020 June 27 PMID: 32594098 PMCID: PMC7529948 DOI: 10.1038/s41375-020-0940-8
608. Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, Williams PM, Mitchell EP, Iafrate AJ, Sklar J, Harris LN, McShane LM, Rubinstein LV, Sims DJ, Routhort M, Coffey B, Fu T, Zwiebel JA, Little RF, Marinucci D, Catalano R, Magnan R, Kibbe W, Weil C, Tricoli JV, Alexander B, **Kumar S**, Schwartz GK, Meric-Bernstam F, Lih CJ, McCaskill-Stevens W, Caimi P, Takebe N, Datta V, Arteaga CL, Abrams JS, Comis R, O'Dwyer PJ, Conley BA, NCI-MATCH Team. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst. 2020 Oct 1; 112 (10):1021-1029 PMID: 31922567 PMCID: PMC7566320 DOI: 10.1093/jnci/djz245
609. Tschautscher MA, Jevremovic D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman S, Lust J, Russell SJ, Leung N, Go RS, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Vincent Rajkumar S, **Kumar S**. Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer J 2020 Oct 2; 10 (10):95 Epub 2020 Oct 02 PMID: 33009363 PMCID: PMC7532166 DOI: 10.1038/s41408-020-00363-6
610. Mateos MV, **Kumar S**, Dimopoulos MA, Gonzalez-Calle V, Kastiris E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, Gheraldes C, Gozzetti A, Kyriakou C, Garderet L, Hansson M, Zamagni E, Fantl D, Leleu X, Kim BS, Esteves G, Ludwig H, Usmani S, Min CK, Qi M, Ukropec J, Weiss BM, Rajkumar SV, Durie BGM, San-Miguel J. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020 Oct 16; 10 (10):102 PMID: 33067414 PMCID: PMC7567803 DOI: 10.1038/s41408-020-00366-3
611. Al Saleh AS#, Sidiqi MH, Lee J, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Skaer CA, Wittwer SK, Wolf RC, Hogan WJ, **Kumar SK**, Jacob E, Gertz MA. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplant. 2020 Nov; 55 (11):2132-2137 Epub 2020 May 01 PMID: 32358546 PMCID: PMC7606597 DOI: 10.1038/s41409-020-0916-3
612. David M, Murray DL, Dispenzieri A, **Kumar S**, Gill H, Vachon C, Snyder M, Willrich M. Free Light Chain Assay Drift: Potential for Misdiagnosis? J Appl Lab Med 2020 Nov 1; 5 (6):1411-1413 PMID: 32829402 DOI: 10.1093/jalm/jfaa093
613. Dhakal B, D'Souza A, Callander N, Chhabra S, Fraser R, Davila O, Anderson K, Assal A, Badawy SM,

- Berdeja J, Cerny J, Comenzo R, Chakraborty R, Peter Gale R, Kamble R, Kharfan-Dabaja MA, Krem M, Ganguly S, Janakiram M, Kansagra A, Munker R, Murthy H, Patel S, **Kumar S**, Shah N, Qazilbash M, Hari P. Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. *Br J Haematol*. 2020 Nov; 191 (3):442-452 Epub 2020 Oct 23 PMID: 33094839 PMCID: PMC7990054 DOI: 10.1111/bjh.16987
614. Muchtar E, Gertz MA, Lacy MQ, Leung N, Buadi FK, Dingli D, Hayman SR, Go RS, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Hwa YL, Fonder A, Hobbs M, Russell S, Lust JA, Siddiqui M, Rajkumar SV, Kyle RA, **Kumar SK**, Dispenzieri A. Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. *Am J Hematol*. 2020 Nov; 95 (11):1280-1287 Epub 2020 Aug 24 PMID: 32681737 DOI: 10.1002/ajh.25940
 615. Abeykoon J, Wu X, Nowakowski KE, Dasari S, Paludo J, Weroha SJ, Hu C, Hou X, Sarkaria JN, Mladek AC, Phillips JL, Feldman A, Ravindran A, King RL, Boysen JC, Stenson M, Carr RM, Manske MK, Molina JR, Kapoor P, Parikh SA, **Kumar SK**, Robinson SI, Yu J, Boughey JC, Wang L, Goetz MP, Couch FJ, Patnaik MM, Witzig TE. CRM1 inhibitor anti-tumor activity is enhanced with salicylates by S-phase arrest and impaired DNA-damage repair. *Blood*. 2020 Nov 2 Epub 2020 Nov 02 PMID: 33140103 DOI: 10.1182/blood.2020009013
 616. Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong KL, Hungria VTM, Engelhardt M, Gay F, Garcia-Feria A, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum CA, **Kumar SK**, Stadtmauer E, Einsele H, Beksac M, Weisel KC, Anderson KC, Mateos MV, Moreau P, San Miguel J, Munshi NC, Avet-Loiseau H. Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset. *Blood*. 2020 Nov 6 Epub 2020 Nov 06 PMID: 33156904 DOI: 10.1182/blood.2020008150
 617. Facon T, Niesvizky R, Mateos MV, Siegel D, Rosenbaum C, Bringhen S, Weisel K, Ho PJ, Ludwig H, **Kumar S**, Wang K, Obreja M, Yang Z, Klippel Z, Mezzi K, Goldrick A, Tekle C, Dimopoulos MA. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. *Blood Adv*. 2020 Nov 10; 4 (21):5449-5459 PMID: 33166401 PMCID: PMC7656926 DOI: 10.1182/bloodadvances.2020001965
 618. Mikhael J, Richter J, Vij R, Cole C, Zonder J, Kaufman JL, Bensinger W, Dimopoulos M, Lendvai N, Hari P, Ocio EM, Gasparetto C, **Kumar S**, Oprea C, Chiron M, Brillac C, Charpentier E, San-Miguel J, Martin T. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. *Leukemia*. 2020 Dec; 34 (12):3298-3309 Epub 2020 May 14 PMID: 32409691 PMCID: PMC7685976 DOI: 10.1038/s41375-020-0857-2
 619. Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, Solh M, Tay J, **Kumar S**, Qazilbash MH, Shah N, Hari PN, D'Souza A. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. *Cancer*. 2020 Dec 1; 126 (23):5077-5087 Epub 2020 Sept 23 PMID: 32965680 PMCID: PMC8063213 DOI: 10.1002/cncr.33171
 620. Vaxman I, Al Saleh AS, **Kumar S**, Nitin M, Mishra N, Dispenzieri A, Buadi F, Dingli D, Lacy M, Muchtar E, Hobbs M, Fonder A, Hwa L, Visram A, Kapoor P, Siddiqui M, Lust J, Kyle R, Rajkumar V, Hayman S, Leung N, Gonsalves W, Kourelis T, Warsame R, Gertz MA. Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment. *Cancer Med*. 2020 Dec; 9 (23):8895-8901 Epub 2020 Oct 06 PMID: 33022868 PMCID: PMC7724303 DOI: 10.1002/cam4.3507
 621. Durie BGM, **Kumar SK**, Usmani SZ, Nonyane BAS, Ammann EM, Lam A, Kobos R, Maiese EM, Facon T. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma. *Am J Hematol*. 2020 Dec; 95 (12):1486-1494 Epub 2020 Sept 05 PMID: 32804408 PMCID: PMC7754114 DOI: 10.1002/ajh.25963
 622. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, **Kumar S**, Shah N, Qazilbash M, Hari P, D'Souza A. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. *Leukemia*. 2020 Dec; 34 (12):3338-3347 Epub 2020 Apr 20 PMID: 32313109 PMCID: PMC7572530 DOI: 10.1038/s41375-020-0830-0
 623. Suska A, Vesole DH, Castillo JJ, **Kumar SK**, Parameswaran H, Mateos MV, Facon T, Gozzetti A, Mikala G, Szostek M, Mikhael J, Hajek R, Terpos E, Jurczyszyn A. Plasma Cell Leukemia - Facts and Controversies: More Questions than Answers? *Clin Hematol Int*. 2020 Dec; 2 (4):133-142 Epub 2020 July 19 PMID: 34595454 PMCID: PMC8432408 DOI: 10.2991/chi.k.200706.002
 624. Bianchi G, **Kumar S**. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases. *Hematol Oncol Clin North Am*. 2020 Dec; 34 (6):1009-1026 Epub 2020 Sept 28 PMID: 33099420 DOI: 10.1016/j.hoc.2020.08.001

625. **Kumar SK**, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I, Punnoose EA, Hong WJ, Freise KJ, Yang X, Sood A, Jalaluddin M, Ross JA, Ward JE, Maciag PC, Moreau P. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncol*. 2020 Dec; 21 (12):1630-1642 Epub 2020 Oct 29 PMID: 33129376 DOI: 10.1016/S1470-2045(20)30525-8
626. **Kumar SK**, Callander NS, Adekola K, Anderson L, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Kang Y, Hultcrantz M, Larson S, Liedtke M, Martin T, Omel J, Shain K, Sborov D, Stockerl-Goldstein K, Weber D, Keller J, Kumar R. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2020 Dec 2; 18 (12):1685-1717 Epub 2020 Dec 02 PMID: 33285522 DOI: 10.6004/jnccn.2020.0057
627. Visram A, Al Saleh AS, Parmar H, McDonald JS, Lieske JC, Vaxman I, Muchtar E, Hobbs M, Fonder A, Hwa YL, Buadi FK, Dingli D, Lacy MQ, Dispenzieri A, Kapoor P, Hayman SR, Warsame R, Kourelis TV, Siddiqui M, Gonsalves WI, Lust JA, Kyle RA, Vincent Rajkumar S, Gertz MA, **Kumar SK**, Leung N. Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. *Blood Cancer J*. 2020 Dec 11; 10 (12):124 PMID: 33311451 PMCID: PMC7733489 DOI: 10.1038/s41408-020-00391-2
628. Gonsalves WI, Jang JS, Jessen E, Hitosugi T, Evans LA, Jevremovic D, Pettersson XM, Bush AG, Gransee J, Anderson EI, **Kumar SK**, Nair KS. In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells. *Cancer Metab*. 2020 Dec 11; 8 (1):29 PMID: 33308307 PMCID: PMC7731537 DOI: 10.1186/s40170-020-00235-4
629. Abdallah N, Baughn LB, Rajkumar SV, Kapoor P, Gertz MA, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Ketterling R, Bergsagel L, Greipp P, **Kumar SK**. Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. *Clin Cancer Res*. 2020 Dec 15; 26 (24):6581-6588 Epub 2020 Oct 02 PMID: 33008815 PMCID: PMC8129639 DOI: 10.1158/1078-0432.CCR-20-2283
630. Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, Hungria V, Engelhardt M, Gay F, Garcia Fera A, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum C, **Kumar S**, Stadtmauer EA, Einsele H, Beksac M, Weisel K, Anderson KC, Mateos MV, Moreau P, San-Miguel J, Munshi NC, Avet-Loiseau H. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. *Blood*. 2020 Dec 24; 136 (26):3033-3040 PMID: 33367546 PMCID: PMC7759145 DOI: 10.1182/blood.202008150
631. Cornell RF, Bishop MR, **Kumar S**, Giralto SA, Nooka AK, Larson SM, Locke FL, Raje NS, Lei L, Dong J, Le Gall JB, Rossi JM, Orlowski RZ. A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. *Am J Cancer Res*. 2021; 11 (6):3285-3293 Epub 2021 June 15 PMID: 34249462 PMCID: PMC8263642
632. Badar T, Hari P, Davila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, **Kumar S**, Shah N, D'Souza A. African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. *Cancer*. 2021 Jan 1; 127 (1):82-92 Epub 2020 Sept 23 PMID: 32966625 PMCID: PMC7736245 DOI: 10.1002/cnrc.33208
633. Ngai C, **Kumar S**, Chi-Lai Ho G, Chen S, Chim CS. Case series: MRD negativity assessment using (11)C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma. *Ther Adv Hematol*. 2021; 12:20406207211030369 Epub 2021 Sept 30 PMID: 34616538 PMCID: PMC8488511 DOI: 10.1177/20406207211030369
634. Bansal R, Kimlinger T, Gytoku KA, Smith M, Rajkumar V, **Kumar S**. Impact of CD138 Magnetic Bead-based Positive Selection on Bone Marrow Plasma Cell Surface Markers. *Clin Lymphoma Myeloma Leuk*. 2021 Jan; 21 (1):e48-e51 Epub 2020 Aug 05 PMID: 32873534 PMCID: PMC7854838 DOI: 10.1016/j.clml.2020.08.003
635. Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralto S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, **Kumar S**, Gay F, Paiva B. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. *Leukemia*. 2021 Jan; 35 (1):18-30 Epub 2020 Aug 11 PMID: 32778736 DOI: 10.1038/s41375-020-01012-4
636. Kaya EA, Baughn LB, Pham T, Ketterling RP, **Kumar SK**, Jevremovic D. Lymphoma-like double-hit genetic abnormalities (MYC/IGH and IGH/BCL2) in a case of non-secretory multiple myeloma. *Leuk Lymphoma* 2021 Jan; 62 (1):243-246 Epub 2020 Sept 21 PMID: 32955382 DOI: 10.1080/10428194.2020.1821012

637. Perrot A, Facon T, Plesner T, Usmani SZ, **Kumar S**, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho KF, Van Rampelbergh R, Uhlar CM, Wang J, Kobos R, Gries KS, Fastenau J, Weisel K. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. *J Clin Oncol*. 2021 Jan 20; 39 (3):227-237 Epub 2020 Dec 16 PMID: 33326255 PMCID: PMC8078427 DOI: 10.1200/JCO.20.01370
638. **Kumar S**, Fu A, Niesvizky R, Jagannath S, Boccia R, Raje N. Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. *Blood Adv*. 2021 Jan 26; 5 (2):367-376 PMID: 33496733 PMCID: PMC7839365 DOI: 10.1182/bloodadvances.2019001059
639. Abeykoon JP, Wu X, Nowakowski KE, Dasari S, Paludo J, Weroha SJ, Hu C, Hou X, Sarkaria JN, Mladek AC, Phillips JL, Feldman AL, Ravindran A, King RL, Boysen J, Stenson MJ, Carr RM, Manske MK, Molina JR, Kapoor P, Parikh SA, **Kumar S**, Robinson SI, Yu J, Boughey JC, Wang L, Goetz MP, Couch FJ, Patnaik MM, Witzig TE. Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. *Blood*. 2021 Jan 28; 137 (4):513-523 PMID: 33507295 PMCID: PMC7845010 DOI: 10.1182/blood.2020009013
640. Abdallah N, Muchtar E, Dispenzieri A, Gonsalves W, Buadi F, Lacy MQ, Hayman SR, Kourelis T, Kapoor P, Go RS, Warsame R, Leung N, Rajkumar SV, Kyle RA, Pruthi RK, Gertz MA, **Kumar SK**. Coagulation Abnormalities in Light Chain Amyloidosis. *Mayo Clin Proc*. 2021 Feb; 96 (2):377-387 PMID: 33549257 DOI: 10.1016/j.mayocp.2020.06.061
641. Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, **Kumar S**, Chng WJ, Hajek R, Paiva B, Waage A, Rajkumar SV, Durie B. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. *Blood Cancer J*. 2021 Feb 1; 11 (2):24 Epub 2021 Feb 01 PMID: 33563895 PMCID: PMC7873248 DOI: 10.1038/s41408-021-00408-4
642. Pang L, Rajkumar SV, Kapoor P, Buadi F, Dispenzieri A, Gertz M, Lacy M, Kyle R, **Kumar S**. Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). *Blood Cancer J*. 2021 Feb 1; 11 (2):26 Epub 2021 Feb 01 PMID: 33563898 PMCID: PMC7873268 DOI: 10.1038/s41408-021-00406-6
643. Vaxman I, Visram A, Pasvolsky O, **Kumar S**, Dispenzieri A, Buadi F, Dingli D, Lacy M, Hayman S, Kyle R, Kapoor P, Leung N, Gonsalves W, Kourelis T, Warsame R, Gertz M. Retroperitoneal involvement with light chain amyloidosis- case series and literature review. *Leuk Lymphoma*. 2021 Feb; 62 (2):316-322 Epub 2020 Oct 29 PMID: 33118418 DOI: 10.1080/10428194.2020.1832670
644. Mohyuddin GR, Rooney A, Balmaceda N, Aziz M, Sborov DW, McClune B, **Kumar SK**. Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. *Blood Adv*. 2021 Feb 23; 5 (4):1097-1101 PMID: 33606005 PMCID: PMC7903229 DOI: 10.1182/bloodadvances.2020004017
645. Abdallah N, Dispenzieri A, Muchtar E, Buadi FK, Kapoor P, Lacy MQ, Hwa YL, Fonder A, Hobbs MA, Hayman SR, Leung N, Dingli D, Lust JA, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Gertz MA, **Kumar SK**. Prognostic restaging after treatment initiation in patients with AL amyloidosis. *Blood Adv*. 2021 Feb 23; 5 (4):1029-1036 PMID: 33595624 PMCID: PMC7903228 DOI: 10.1182/bloodadvances.2020003782
646. Heybeli C, Bentall A, Wen J, Alexander MP, Buadi FK, Cosio FG, Dean PG, Dispenzieri A, Dingli D, El Ters M, Gertz MA, Hatem A, Kapoor P, Khamash H, Kourelis T, **Kumar S**, Lorenz EC, Mai M, Muchtar E, Murray DL, Prieto M, Schinstock CA, Stegall MD, Warsame R, Leung N. A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. *Kidney Int*. 2021 Mar; 99 (3):707-715 Epub 2020 July 23 PMID: 32712168 PMCID: PMC8411566 DOI: 10.1016/j.kint.2020.06.036
647. Cornell RF, Fraser R, Costa L, Goodman S, Estrada-Merly N, Lee C, Hildebrandt G, Gergis U, Farhadfar N, Freytes CO, Kamble RT, Krem M, Kyle RA, Lazarus HM, Marks DI, Meehan K, Patel SS, Ramanathan M, Olsson RF, Wagner JL, **Kumar S**, Qazilbash MH, Shah N, Hari P, D'Souza A. Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. *Transplant Cell Ther*. 2021 Mar; 27 (3):264.e1-264.e7 Epub 2020 Dec 16 PMID: 33781533 PMCID: PMC8010222 DOI: 10.1016/j.jct.2020.11.018
648. Muchtar E, Gertz MA, **Kumar SK**, Lacy MQ, Leung N, Buadi FK, Dingli D, Hayman SR, Go RS, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Hwa YL, Lisa Hwa Y, Fonder A, Hobbs M, Russell S, Lust JA, Siddiqui M, Vincent Rajkumar S, Kyle RA, Dispenzieri A. Characterization and prognostic implication of delayed complete response in AL amyloidosis. *Eur J Haematol*. 2021 Mar; 106 (3):354-361 Epub 2020 Dec 04 PMID: 33230879 PMCID: PMC8103541 DOI: 10.1111/ejh.13554
649. Nandakumar B, **Kumar SK**, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Siddiqui M, Go RS, Jevremovic D, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. *Mayo Clin Proc*. 2021 Mar;

96 (3):677-687 PMID: 33673918 PMCID: PMC7939118 DOI: 10.1016/j.mayocp.2020.06.060

650. Cook J, Johnson I, Higgins A, Sidana S, Warsame R, Gonsalves W, Gertz MA, Buadi F, Lacy M, Kapoor P, Dispenzieri A, Kourelis T, Dingli D, Fonder A, Hayman S, Hobbs M, Hwa YL, Kyle R, Leung N, Go R, Rajkumar VS, **Kumar S**. Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. *Am J Hematol*. 2021 Mar 1; 96 (3):330-337 Epub 2021 Jan 13 PMID: 33326116 DOI: 10.1002/ajh.26074
651. Visram A, Dasari S, Anderson E, **Kumar S**, Kourelis TV. Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. *Blood Cancer J*. 2021 Mar 1; 11 (3):45 Epub 2021 Mar 01 PMID: 33649314 PMCID: PMC7921408 DOI: 10.1038/s41408-021-00440-4
652. **Kumar SK**, Baz RC, Orlowski RZ, Anderson LD Jr, Ma H, Shrewsbury A, Croghan KA, Bilgi M, Kansagra A, Kapoor P, Li ZH, Brayer J. Results from lummicar-2: a phase 1b/2 study of fully human b-cell maturation antigen-specific car t cells (ct053) in patients with relapsed and/or refractory multiple myeloma *Clinical Advances in Hematology & Oncology*. 2021 Mar; 19 (3):18-9
653. Muchtar E, Dispenzieri A, Magen H, Grogan M, Mauermann M, McPhail ED, Kurtin PJ, Leung N, Buadi FK, Dingli D, **Kumar SK**, Gertz MA. Systemic amyloidosis from A (AA) to T (ATTR): a review. *J Intern Med*. 2021 Mar; 289 (3):268-292 Epub 2020 Sept 14 PMID: 32929754 DOI: 10.1111/joim.13169
654. Moreau P, **Kumar SK**, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, Joao C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Blade J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos SA, Richardson PG. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. *Lancet Oncol*. 2021 Mar; 22 (3):e105-e118 PMID: 33662288 DOI: 10.1016/S1470-2045(20)30756-7
655. Mellors PW, Dasari S, Kohlhagen MC, Kourelis T, Go RS, Muchtar E, Gertz MA, **Kumar SK**, Buadi FK, Willrich MAV, Lust JA, Kapoor P, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Warsame R, Leung NR, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Murray DL, Dispenzieri A. MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. *Blood Cancer J*. 2021 Mar 4; 11 (3):50 Epub 2021 Mar 04 PMID: 33664227 PMCID: PMC7933343 DOI: 10.1038/s41408-021-00444-0
656. Nadiminti K, Sidiqi MH, Meleveedu K, Alkhateeb HB, Hogan WJ, Litzow M, Patnaik M, **Kumar S**, Gertz M, Chen D, Shah MV. Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. *Blood Cancer J* 2021 Mar 19; 11 (3):63 PMID: 33741897 PMCID: PMC7979889 DOI: 10.1038/s41408-021-00454-y
657. Drosou ME, Vaughan LE, Muchtar E, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Go RS, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kapoor P, Kourelis T, **Kumar S**, Kyle RA, Lacy MQ, Lin Y, Lopez CL, Lust JA, Rajkumar SV, Russell SJ, Sidana S, Siddiqui MA, Sidiqi MH, Warsame R, Leung N. Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. *Am J Hematol*. 2021 Apr 01; 96(4):446-454. Epub 2021 Jan 28. PMID: 33428787 DOI: 10.1002/ajh.26092
658. Vaxman I, Sidiqi MH, Al Saleh AS, **Kumar S**, Muchtar E, Dispenzieri A, Buadi F, Dingli D, Lacy M, Hayman S, Leung N, Gonsalves W, Kourelis T, Warsame R, Hogan W, Gertz M. Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. *Bone Marrow Transplant*. 2021 Apr; 56 (4):928-935 Epub 2020 Nov 18 PMID: 33208916 DOI: 10.1038/s41409-020-01136-2
659. Abeykoon JP, Murray DL, Murray I, Jevremovic D, Otteson GE, Dispenzieri A, Arendt BK, Dasari S, Gertz M, Gonsalves WI, Kourelis TV, Muchtar E, Dingli D, Warsame R, Go RS, Lacy MQ, Leung N, Buadi F, Lin Y, Kyle RA, Rajkumar V, **Kumar S**, Kapoor P. Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. *Br J Haematol*. 2021 Apr; 193 (2):380-385 Epub 2020 Nov 20 PMID: 33216966 DOI: 10.1111/bjh.17195
660. Parmar H, Al Saleh AS, Visram A, Warsame R, Kourelis T, Gonsalves W, Dingli D, Muchtar E, Hayman S, Kapoor P, Buadi F, Dispenzieri A, Lacy M, Gertz M, **Kumar S**. Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. *Transplant Cell Ther*. 2021 Apr; 27 (4):309.e1-309.e5 Epub 2020 Dec 17 PMID: 33836869 DOI: 10.1016/j.jtct.2020.11.022
661. Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, Boise LH, Jiang Y, Yang X, Dunbar F, Vishwamitra D, Unger S, Macartney T, Pesko J, Yu Y, Salem AH, Ross JA, Hong WJ, Maciag PC,

- Pauff JM, **Kumar S**. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. *Am J Hematol*. 2021 Apr 1; 96 (4):418-427 Epub 2021 Jan 19 PMID: 33368455 PMCID: PMC7986778 DOI: 10.1002/ajh.26083
662. Parmar H, Gertz M, Anderson EI, **Kumar S**, Kourelis TV. Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma. *Blood Adv*. 2021 Apr 13; 5 (7):1797-1804 PMID: 33787859 PMCID: PMC8045512 DOI: 10.1182/bloodadvances.2020003857
663. Sidana S, Dasari S, Kourelis TV, Dispenzieri A, Murray DL, King RL, McPhail ED, Ramirez-Alvarado M, **Kumar SK**, Gertz MA. IGV gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis. *Blood Adv*. 2021 Apr 27; 5 (8):2101-2105 PMID: 33877297 PMCID: PMC8095150 DOI: 10.1182/bloodadvances.2020003671
664. Vaxman I, Visram A, **Kumar S**, Dispenzieri A, Buadi F, Dingli D, Lacy M, Muchtar E, Kapoor P, Hogan W, Hayman S, Leung N, Gonsalves W, Kourelis T, Warsame R, Berger T, Gertz MA. Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. *Bone Marrow Transplant*. 2021 May; 56 (5):1144-1150 Epub 2020 Dec 04 PMID: 33273658 DOI: 10.1038/s41409-020-01159-9
665. Visram A, Vaxman I, S Al Saleh A, Parmar H, Dispenzieri A, Kapoor P, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Warsame R, Kourelis T, Siddiqui M, Gonsalves W, Muchtar E, Lust JA, Leung N, Kyle RA, Murray D, Rajkumar SV, **Kumar S**. Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. *Leukemia*. 2021 May; 35 (5):1428-1437 Epub 2021 Feb 23 PMID: 33623138 PMCID: PMC8102180 DOI: 10.1038/s41375-021-01180-x
666. **Kumar SK**. Updates in the treatment of multiple myeloma *Journal of the National Comprehensive Cancer Network*. 2021 May; 19 (5.5):648-51
667. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, **Kumar S**, Shah N, Qazilbash M, Hari P, D'Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. *Leukemia*. 2021 Jun; 35 (6):1828 PMID: 33782538 PMCID: PMC8188513 DOI: 10.1038/s41375-021-01233-1
668. Karam D, **Kumar S**. Post-Transplant Maintenance Treatment Options in Multiple Myeloma. *Oncol Ther*. 2021 Jun; 9(1):69-88. Epub 2021 Feb 21. PMID: 33615426 PMCID: PMC8140028 DOI: 10.1007/s40487-021-00143-7
669. Muchtar E, Dispenzieri A, Gertz MA, **Kumar SK**, Buadi FK, Leung N, Lacy MQ, Dingli D, Ailawadhi S, Bergsagel PL, Fonseca R, Hayman SR, Kapoor P, Grogan M, Abou Ezzeddine OF, Rosenthal JL, Mauermann M, Siddiqui M, Gonsalves W, Kourelis TV, Larsen JT, Reeder CB, Warsame R, Go RS, Murray DL, McPhail ED, Dasari S, Jevremovic D, Kyle RA, Lin Y, Lust JA, Russell SJ, Hwa YL, Fonder AL, Hobbs MA, Rajkumar SV, Roy V, Sher T. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. *Mayo Clin Proc*. 2021 Jun; 96(6):1546-1577. PMID: 34088417 DOI: 10.1016/j.mayocp.2021.03.012
670. Mohyuddin GR, Koehn K, Abdallah AO, W Sborov D, Rajkumar SV, **Kumar S**, McClune B. Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review. *Am J Hematol*. 2021 Jun 1; 96 (6):690-697 Epub 2021 Apr 01 PMID: 33735453 DOI: 10.1002/ajh.26166
671. Mellors PW, Dasari S, Kohlhaagen MC, Kourelis T, Go RS, Muchtar E, Gertz MA, **Kumar SK**, Buadi FK, Willrich MAV, Lust JA, Kapoor P, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Warsame R, Leung NR, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Murray DL, Dispenzieri A. Correction: MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. *Blood Cancer J*. 2021 Jun 7; 11 (6):110 Epub 2021 June 07 PMID: 34099625 PMCID: PMC8184834 DOI: 10.1038/s41408-021-00496-2
672. Visram A, Soof C, Rajkumar SV, **Kumar SK**, Bujarski S, Spektor TM, Kyle RA, Berenson JR, Dispenzieri A. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. *Blood Cancer J*. 2021 Jun 24; 11 (6):120 Epub 2021 June 24 PMID: 34168119 PMCID: PMC8225625 DOI: 10.1038/s41408-021-00505-4
673. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, **Kumar S**, Shah N, Qazilbash M, Hari P, D'Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. *Leukemia*. 2021 Jul; 35 (7):2141 PMID: 34091601 DOI: 10.1038/s41375-021-01304-3
674. Goldman-Mazur S, **Kumar SK**. Current approaches to management of high-risk multiple myeloma. *Am J*

- Hematol. 2021 Jul 1; 96 (7):854-871 Epub 2021 Apr 13 PMID: 33725367 DOI: 10.1002/ajh.26161
675. Berbari HE, **Kumar SK**. Initial Therapeutic Approaches to Patients with Multiple Myeloma. Adv Ther. 2021 Jul; 38 (7):3694-3711 Epub 2021 June 18 PMID: 34145483 DOI: 10.1007/s12325-021-01824-5
 676. **Kumar S**. Multiple Myeloma: From Baby Steps to Giant Strides. JCO Oncol Pract 2021 Jul; 17 (7):419-420 Epub 2021 June 10 PMID: 34110922 DOI: 10.1200/OP.21.00327
 677. Facon T, Venner CP, Bahlis NJ, Offner F, White DJ, Karlin L, Benboubker L, Rigaudeau S, Rodon P, Voog E, Yoon SS, Suzuki K, Shibayama H, Zhang X, Twumasi-Ankrah P, Yung G, Rifkin RM, Moreau P, Lonial S, **Kumar SK**, Richardson PG, Rajkumar SV. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2021 Jul 1; 137 (26):3616-3628 PMID: 33763699 PMCID: PMC8462404 DOI: 10.1182/blood.2020008787
 678. Muchtar E, Dispenzieri A, **Kumar SK**, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Leung N, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Hwa YL, Fonder A, Hobbs M, Go RS, Rajkumar SV, Kyle RA, Hogan WJ, Gertz MA. Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. Transplant Cell Ther. 2021 Jul; 27 (7):589.e1-589.e6 Epub 2021 Apr 08 PMID: 33839316 DOI: 10.1016/j.jtct.2021.03.031
 679. Castillo JJ, Callander NS, Baljevic M, Sborov DW, **Kumar S**. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. Am J Hematol. 2021 Jul 1; 96 (7):846-853 Epub 2021 Mar 25 PMID: 33709474 PMCID: PMC8252623 DOI: 10.1002/ajh.26155
 680. Evans LA, Go R, Warsame R, Nandakumar B, Buadi FK, Dispenzieri A, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Kourelis TV, Russell S, Lust JA, Lin Y, Siddiqui M, Kyle RA, Gertz MA, Rajkumar SV, **Kumar S**, Gonsalves WI. The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. Clin Lymphoma Myeloma Leuk. 2021 Jul; 21 (7):451-460.e2 Epub 2021 Feb 17 PMID: 33785296 PMCID: PMC8592381 DOI: 10.1016/j.clml.2021.02.001
 681. Kaddoura M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Hwa L, Fonder A, Hobbs M, Hayman S, Lust J, Leung N, Go RS, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Broski SM, Rajkumar V, **Kumar S**. Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Adv. 2021 Jul 13; 5 (13):2753-2759 PMID: 34242392 PMCID: PMC8288674 DOI: 10.1182/bloodadvances.2020004131
 682. Abeykoon JP#, Zanwar S#, Ansell SM, Muchtar E, He R, Greipp PT, King RL, Ailawadhi S, Paludo J, Larsen JT, Habermann TM, Inwards D, Go RS, Thanarajasingam G, Buadi F, Dispenzieri A, Thompson CA, Witzig TE, Lacy M, Gonsalves W, Nowakowski GS, Dingli D, Rajkumar SV, Kyle RA, Sher T, Roy V, Rosenthal A, Chanan-Khan AA, Reeder C, Gertz MA, **Kumar S**, Kapoor P. Assessment of fixed-duration therapies for treatment-naïve Waldenstrom macroglobulinemia. Am J Hematol. 2021 Aug 1; 96 (8):945-953 Epub 2021 May 22 PMID: 33909933 DOI: 10.1002/ajh.26210
 683. Richardson PG, **Kumar SK**, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Gimsing P, Garderet L, Touzeau C, Buadi FK, Laubach JP, Cavo M, Darif M, Labotka R, Berg D, Moreau P. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2021 Aug 1; 39 (22):2430-2442 Epub 2021 June 11 PMID: 34111952 DOI: 10.1200/JCO.21.00972
 684. Ravindran A, Greipp PT, Wongchaowart N, Smadbeck JB, Peterson JF, Ketterling RP, **Kumar SK**, Baughn LB. Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding. Clin Lymphoma Myeloma Leuk. 2021 Sep; 21 (9):e710-e713 Epub 2021 May 09 PMID: 34172422 DOI: 10.1016/j.clml.2021.05.001
 685. **Kumar S**, Williamson M, Ogbu U, Surinach A, Arndorfer S, Hong WJ. Front-line treatment patterns in multiple myeloma: An analysis of U.S.-based electronic health records from 2011 to 2019. Cancer Med. 2021 Sep; 10 (17):5866-5877 Epub 2021 Aug 16 PMID: 34402201 PMCID: PMC8419764 DOI: 10.1002/cam4.4137
 686. Vaxman I, Muchtar E, Jacob E, Kapoor P, **Kumar S**, Dispenzieri A, Buadi F, Dingli D, Gonsalves W, Kourelis T, Warsame R, Lacy M, Hogan W, Gertz MA. The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. Transplant Cell Ther. 2021 Sep; 27 (9):770.e1-770.e7 Epub 2021 June 18 PMID: 34153504 PMCID: PMC8403627 DOI: 10.1016/j.jtct.2021.06.016
 687. Sidiqi MH, Al Saleh AS, **Kumar SK**, Leung N, Jevremovic D, Muchtar E, Gonsalves WI, Kourelis TV, Warsame R, Buadi FK, Lacy MQ, Kyle RA, Go R, Hobbs M, Dispenzieri A, Dingli D, Hayman SR, Gertz MA, Rajkumar SV, Kapoor P. Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. Am J Hematol. 2021 Sep 1; 96 (9):1131-1136 Epub 2021 July 05 PMID: 34115387 DOI: 10.1002/ajh.26269
 688. Ho M#, Zanwar S#, Kapoor P, Gertz M, Lacy M, Dispenzieri A, Hayman S, Dingli D, Baudi F, Muchtar E, Leung N, Kourelis T, Warsame R, Fonder A, Hwa L, Hobbs M, Kyle R, Rajkumar SV, **Kumar S**. The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple

- Myeloma (MM). Blood Cancer J. 2021 Sep 22; 11 (9):158 Epub 2021 Sept 22 PMID: 34552051 PMCID: PMC8458275 DOI: 10.1038/s41408-021-00548-7
689. Bansal R, Rakshit S, **Kumar S**. Extramedullary disease in multiple myeloma. Blood Cancer J. 2021 Sep 29; 11 (9):161 Epub 2021 Sept 29 PMID: 34588423 PMCID: PMC8481260 DOI: 10.1038/s41408-021-00527-y
 690. Kapoor P, **Kumar S**. Daratumumab for post-ASCT maintenance treatment of myeloma. Lancet Oncol. 2021 Oct; 22 (10):1345-1347 Epub 2021 Sept 13 PMID: 34529932 DOI: 10.1016/S1470-2045(21)00490-3
 691. Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Colby C, Larson D, Paludo J, He R, Warsame R, Greipp PT, King RL, Thompson CA, Witzig TE, Lacy MQ, Gonsalves W, Nowakowski GS, Dingli D, Go RS, Habermann TM, Vincent Rajkumar S, Kyle RA, **Kumar S**, Kapoor P. Disease outcomes and biomarkers of progression in smoldering Waldenstrom macroglobulinaemia. Br J Haematol. 2021 Oct; 195 (2):210-216 Epub 2021 Aug 02 PMID: 34340248 DOI: 10.1111/bjh.17691
 692. Dalland JC, Smadbeck JB, Sharma N, Meyer RG, Pearce KE, Greipp PT, Peterson JF, **Kumar S**, Ketterling RP, King RL, Baughn LB. Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. Genes Chromosomes Cancer. 2021 Oct; 60 (10):678-686 Epub 2021 June 22 PMID: 34124820 PMCID: PMC8453742 DOI: 10.1002/gcc.22977
 693. Anderson KC, Auclair D, Adam SJ, Agarwal A, Anderson M, Avet-Loiseau H, Bustoros M, Chapman J, Connors DE, Dash A, Di Bacco A, Du L, Facon T, Flores-Montero J, Gay F, Ghobrial IM, Gormley NJ, Gupta I, Higley H, Hillengass J, Kanapuru B, Kazandjian D, Kelloff GJ, Kirsch IR, Kremer B, Landgren O, Lightbody E, Lomas OC, Lonial S, Mateos MV, Montes de Oca R, Mukundan L, Munshi NC, O'Donnell EK, Orfao A, Paiva B, Patel R, Pugh TJ, Ramasamy K, Ray J, Roshal M, Ross JA, Sigman CC, Thoren KL, Trudel S, Ulaner G, Valente N, Weiss BM, Zamagni E, **Kumar SK**. Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clin Cancer Res. 2021 Oct 1; 27 (19):5195-5212 PMID: 34321279 PMCID: PMC9662886 DOI: 10.1158/1078-0432.CCR-21-1059
 694. Sharma N#, Smadbeck JB#, Abdallah N, Zepeda-Mendoza C, Binder M, Pearce KE, Asmann YW, Peterson JF, Ketterling RP, Greipp PT, Bergsagel PL, Rajkumar SV, **Kumar SK**, Baughn LB. The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma. Clin Cancer Res. 2021 Oct 1; 27 (19):5430-5439 PMID: 34233962 PMCID: PMC8738776 DOI: 10.1158/1078-0432.CCR-21-0005
 695. Costa LJ, Davies FE, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak A, Kaufman JL, Hong WJ, Dail M, Salem AH, Yang X, Masud AA, Munasinghe W, Ross JA, Bueno OF, **Kumar SK**, Stadtmauer EA. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv. 2021 Oct 12; 5 (19):3748-3759 PMID: 34470049 PMCID: PMC8679663 DOI: 10.1182/bloodadvances.2020004146
 696. Mellors PW, Kohlhagen MC, Dasari S, Willrich MAV, Gertz MA, **Kumar SK**, Lacy MQ, Murray DL, Dispenzieri A. Belantamab mafodotin detection by MASS-FIX and immunofixation. Clin Chem Lab Med 2021 Oct 26; 59 (11):e430-e433 Epub 2021 June 11 PMID: 34114387 DOI: 10.1515/cclm-2021-0326
 697. Facon T, **Kumar SK**, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Wang J, Van Rampelbergh R, Uhlar CM, Tromp B, Delioukina M, Vermeulen J, Usmani SZ. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAiA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Nov; 22 (11):1582-1596 Epub 2021 Oct 13 PMID: 34655533 DOI: 10.1016/S1470-2045(21)00466-6
 698. Ye L, Jin F, **Kumar SK**, Dai Y. The mechanisms and therapeutic targets of ferroptosis in cancer. Expert Opin Ther Targets. 2021 Nov; 25 (11):965-986 Epub 2021 Dec 30 PMID: 34821176 DOI: 10.1080/14728222.2021.2011206
 699. Munshi PN, Vesole DH, St Martin A, Davila O, **Kumar S**, Qazilbash M, Shah N, Hari PN, D'Souza A. Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. Cancer. 2021 Nov 15; 127 (22):4233-4239 Epub 2021 Aug 10 PMID: 34374445 PMCID: PMC8699178 DOI: 10.1002/cnrc.33831
 700. Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Baughn LB, Kyle RA, **Kumar S**. Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer J. 2021 Nov 26; 11 (11):186 PMID: 34836942 PMCID: PMC8626440 DOI: 10.1038/s41408-021-00569-2
 701. Chim CS, **Kumar S**, Wong VKC, Ngai C, Kwong YL. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma. Hematology. 2021 Dec; 26 (1):652-655 PMID: 34474661 DOI: 10.1080/16078454.2021.1965737
 702. Bisht K, Walker B, **Kumar SK**, Spicka I, Moreau P, Martin T, Costa LJ, Richter J, Fukao T, Mace S, van de Velde H. Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. Expert Rev Hematol. 2021 Dec; 14 (12):1099-1114 Epub 2021 Oct 08 PMID:

34551651 DOI: 10.1080/17474086.2021.1983427

703. Heybeli C, Bentall A, Wen J, Alexander MP, Buadi FK, Cosio FG, Dean PG, Dispenzieri A, Dingli D, El Ters M, Gertz MA, Amer H, Kapoor P, Khamash H, Kourelis T, **Kumar S**, Lorenz EC, Mai M, Muchtar E, Murray DL, Prieto M, Schinstock CA, Stegall MD, Warsame R, Leung N. Corrigendum to Heybeli C, Bentall A, Wen J, et al. A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. *Kidney Int.* 2021;99:707-715. *Kidney Int.* 2021 Dec; 100 (6):1348-1349 PMID: 34802563 DOI: 10.1016/j.kint.2021.10.001
704. Zanwar S, **Kumar S**. Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma. *Leuk Lymphoma.* 2021 Dec; 62 (13):3087-3097 Epub 2021 July 24 PMID: 34304677 DOI: 10.1080/10428194.2021.1957875
705. Vaxman I, **Kumar SK**, Buadi F, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Kourelis T, Warsame R, Muchtar E, Leung N, Kapoor P, Grogan M, Go R, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Gertz MA, Dispenzieri A. Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. *Leukemia* 2021 Dec; 35 (12):3604-3607 Epub 2021 May 21 PMID: 34021252 PMCID: PMC8632659 DOI: 10.1038/s41375-021-01297-z
706. Cummins NW, Baker J, Chakraborty R, Dean PG, Garcia-Rivera E, Krogman A, **Kumar S**, Kuzmichev YV, Laird GM, Landay A, Lichterfeld M, Mahmood M, Martinson J, Maynes M, Natesampillai S, Rajkumar V, Rassadkina Y, Ritter KD, Rivera CG, Rizza SA, Subramanian K, Tande AJ, Wonderlich ER, Whitaker JA, Zeuli J, Badley AD. Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo. *EClinicalMedicine.* 2021 Dec; 42:101225 Epub 2021 Nov 29 PMID: 34901797 PMCID: PMC8639424 DOI: 10.1016/j.eclinm.2021.101225
707. Al Saleh AS, Visram A, Parmar H, Muchtar E, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Leung N, Go RS, Gonsalves WI, Kourelis TV, Hayman SR, Kapoor P, Gertz MA, Kyle RA, Rajkumar SV, **Kumar SK**. Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. *Leuk Lymphoma.* 2021 Dec; 62 (12):3011-3018 Epub 2021 July 15 PMID: 34263694 DOI: 10.1080/10428194.2021.1950708
708. Vaxman I, Abeykoon J, Dispenzieri A, **Kumar SK**, Buadi F, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Reeder C, Sher T, Hayman S, Kourelis T, Warsame R, Muchtar E, Leung N, Go R, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Kristen M, Kapoor P, Gertz MA. "Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience. *Blood Cancer J.* 2021 Dec 7; 11 (12):196 Epub 2021 Dec 07 PMID: 34876555 PMCID: PMC8651684 DOI: 10.1038/s41408-021-00592-3
709. Miller ID, Kohlhagen MC, Ladwig PM, Dasari S, **Kumar S**, Dispenzieri A, Willrich MAV, Murray DL. Characterizing M-protein light chain glycosylation via mass spectrometry. *Clin Biochem.* 2022 Nov-Dec; 109-110:11-16. Epub 2022 Sep 13. PMID: 36113628 DOI: 10.1016/j.clinbiochem.2022.09.004
710. Lakshman A, **Kumar SK**. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update. *Am J Hematol.* 2022 Jan 01; 97(1):99-118. Epub 2021 Nov 10. PMID: 34661922 DOI: 10.1002/ajh.26379
711. Yang T, Liu X, **Kumar SK**, Jin F, Dai Y. Decoding DNA methylation in epigenetics of multiple myeloma. *Blood Rev.* 2022 Jan; 51:100872 Epub 2021 July 31 PMID: 34384602 DOI: 10.1016/j.blre.2021.100872
712. Macaudo A, Clay-Gilmour A, Hielscher T, Hildebrandt MAT, Kruszewski M, Orlowski RZ, **Kumar SK**, Ziv E, Orciuolo E, Brown EE, Forsti A, Waller RG, Machiela MJ, Chanock SJ, Camp NJ, Rymko M, Razny M, Cozen W, Varkonyi J, Piredda C, Pelosini M, Belachew AA, Subocz E, Hemminki K, Rybicka-Ramos M, Giles GG, Milne RL, Hofmann JN, Zaucha JM, Vangsted AJ, Goldschmidt H, Rajkumar SV, Tomczak W, Sainz J, Butrym A, Watek M, Iskierka-Jazdzewska E, Buda G, Robinson DP, Jurczyszyn A, Dudzinski M, Martinez-Lopez J, Sinnwell JP, Slager SL, Jamrozak K, Reis RMV, Weinhold N, Bhatti P, Carvajal-Carmona LG, Zawirska D, Norman AD, Mazur G, Berndt SI, Campa D, Vachon CM, Canzian F. Does a multiple myeloma polygenic risk score predict overall survival of patients with myeloma?. *Cancer Epidemiology, Biomarkers & Prevention.* 2022; 31 (9):1863-6
713. Wang W, Sun Y, Liu X, **Kumar SK**, Jin F, Dai Y. Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy. *Front Oncol.* 2022; 12:859455 Epub 2022 Apr 27 PMID: 35574302 PMCID: PMC9093074 DOI: 10.3389/fonc.2022.859455
714. Muchtar E, Drake MT, Leung N, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell S, Go RS, Binder M, Kyle RA, Rajkumar SV, **Kumar SK**, Gertz MA. Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome. *Front Endocrinol (Lausanne).* 2022; 13:891712 Epub 2022 June 21 PMID: 35800433 PMCID: PMC9253369 DOI: 10.3389/fendo.2022.891712
715. Motzer RJ, **Kumar SK**, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Elsedawy N, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P,

- Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Jan; 20 (1):71-90 PMID: 34991070 PMCID: PMC10191161 DOI: 10.6004/jnccn.2022.0001
716. Pasvolsky O#, Yeshurun M#, Fraser R, Estrada-Merly N, Rozovski U, Shargian-Alon L, Assal A, Banerjee R, Bumma N, Gale RP, Hagen P, Holmberg L, Hossain NM, Lazarus HM, Lee C, Mian H, Miller KC, Nathan S, Nagler A, Nishihori T, Parrondo RD, Patel S, Schroeder MA, Usmani SZ, Wang T, Wirk B, **Kumar S**, Shah N, Qazilbash MH, D'Souza A. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplant. 2022 Jan; 57 (1):31-37 Epub 2021 Oct 04 PMID: 34608275 PMCID: PMC8764606 DOI: 10.1038/s41409-021-01455-y
 717. Abeykoon JP, Tawfiq RK, **Kumar S**, Ansell SM. Monoclonal gammopathy of undetermined significance: evaluation, risk assessment, management, and beyond. Fac Rev. 2022; 11:34 Epub 2022 Nov 29 PMID: 36532706 PMCID: PMC9720897 DOI: 10.12703/r/11-34
 718. Bal S, **Kumar SK**, Fonseca R, Gay F, Hungria VT, Dogan A, Costa LJ. Multiple myeloma with t(11;14): unique biology and evolving landscape. Am J Cancer Res. 2022; 12 (7):2950-2965 Epub 2022 July 15 PMID: 35968339 PMCID: PMC9360221
 719. Callander NS, Baljevic M, Adekola K, Anderson LD Jr, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faïman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang YB, Larson S, Liedtke M, Martin T, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, **Kumar SK**. Multiple myeloma, version 3.2022: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network. 2022 Jan; 20 (1):8-19
 720. Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faïman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Liedtke M, Martin T, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, **Kumar SK**. NCCN Guidelines(R) Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022 Jan; 20 (1):8-19 PMID: 34991075 DOI: 10.6004/jnccn.2022.0002
 721. Baljevic M, Sborov DW, Lim MY, Hillengass J, Martin T, Castillo JJ, Streiff MB, **Kumar SK**, Callander NS. Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma. J Natl Compr Canc Netw. 2022 Jan; 20 (1):91-95 PMID: 34991076 DOI: 10.6004/jnccn.2021.7112
 722. Voorhees PM, Jakubowiak AJ, **Kumar SK**#, Kanapuru B, Baines AC, Bhatnagar V, Ershler R, Theoret MR, Gormley NJ, Pazdur R. Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025. Clin Cancer Res. 2022 Jan 1; 28 (1):23-26 Epub 2021 July 27 PMID: 34315721 DOI: 10.1158/1078-0432.CCR-21-1069
 723. Galanis E, Anderson SK, Twohy E, Butowski NA, Hormigo A, Schiff D, Omuro A, Jaeckle KA, **Kumar S**, Kaufmann TJ, Geyer S, Kumthekar PU, Campian J, Giannini C, Buckner JC, Wen PY. Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neurooncol Adv. 2022 Jan-Dec; 4 (1):vdac041 Epub 2022 Apr 04 PMID: 35664553 PMCID: PMC9154335 DOI: 10.1093/naojnl/vdac041
 724. Audil HY, Cook JM, Greipp PT, Kapoor P, Baughn LB, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Muchtar E, Siddiqui M, Gonsalves WL, Hwa YL, Leung N, Lin Y, Kourelis TV, Warsame R, Kyle RA, Ketterling RP, Rajkumar SV, **Kumar SK**. Prognostic significance of acquired 1q22 gain in multiple myeloma. Am J Hematol. 2022 Jan 1; 97 (1):52-59 Epub 2021 Nov 03 PMID: 34710241 DOI: 10.1002/ajh.26391
 725. Kumar H, Mazumder S, Sharma N, Chakravarti S, Long MD, Meurice N, Petit J, Liu S, Chesi M, Sanyal S, Stewart AK, **Kumar S**, Bergsagel L, Rajkumar SV, Baughn LB, Van Ness BG, Mitra AK. Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells. Front Oncol. 2022; 12:842200 Epub 2022 May 11 PMID: 35646666 PMCID: PMC9130773 DOI: 10.3389/fonc.2022.842200
 726. Tang HKK, Fung CY, Morgan GJ, **Kumar S**, Siu L, Ip HWA, Yip SF, Lau KNH, Lau CK, Lee H, Leung KH, Kho B, Wong H, Ngai C, Hwang YY, Sim J, Kwong YL, Chim CS. The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain. Ther Adv Hematol. 2022; 13:20406207221082043 Epub 2022 Apr 18 PMID: 35465644 PMCID: PMC9019371 DOI: 10.1177/20406207221082043
 727. Dimopoulos MA, Schjesvold F, Doronin V, Vinogradova O, Quach H, Leleu X, Montes YG, Ramasamy K, Pompa A, Levin MD, Lee C, Mellqvist UH, Fenk R, Demarquette H, Sati H, Vorog A, Labotka R, Du J, Darif M, **Kumar S**. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase I/II 2 trial. Blood Cancer J. 2022 Jan 24; 12 (1):9 PMID: 35075109 PMCID: PMC8786921 DOI: 10.1038/s41408-021-00593-2
 728. San-Miguel J, Avet-Loiseau H, Paiva B, **Kumar S**, Dimopoulos MA, Facon T, Mateos MV, Touzeau C,

- Jakubowiak A, Usmani SZ, Cook G, Cavo M, Quach H, Ukropec J, Ramaswami P, Pei H, Qi M, Sun S, Wang J, Krevvata M, DeAngelis N, Heuck C, Van Rampelbergh R, Kudva A, Kobos R, Qi M, Bahlis NJ. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. *Blood*. 2022 Jan 27; 139 (4):492-501 PMID: 34269818 PMCID: PMC8796656 DOI: 10.1182/blood.2020010439
729. Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder AL, Hobbs MA, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui MA, Kyle RA, Bergsagel PL, Fonseca R, Ketterling RP, **Kumar SK**. A simple additive staging system for newly diagnosed multiple myeloma. *Blood Cancer J*. 2022 Jan 31; 12 (1):21 PMID: 35102148 PMCID: PMC8803917 DOI: 10.1038/s41408-022-00611-x
 730. Mellors PW, Kourelis T, Go RS, Muchtar E, Gertz MA, **Kumar SK**, Buadi FK, Kapoor P, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Warsame R, Leung NR, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Dispenzieri A. Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. *Am J Hematol*. 2022 Feb 1; 97 (2):209-215 Epub 2021 Nov 30 PMID: 34822175 PMCID: PMC8738145 DOI: 10.1002/ajh.26422
 731. Raje NS, Anaissie E, **Kumar SK**, Lonial S, Martin T, Gertz MA, Krishnan A, Hari P, Ludwig H, O'Donnell E, Yee A, Kaufman JL, Cohen AD, Garderet L, Wechalekar AF, Terpos E, Khatry N, Niesvizky R, Yi Q, Joshua DE, Saikia T, Leung N, Engelhardt M, Mothy M, Branagan A, Chari A, Reiman AJ, Lipe B, Richter J, Rajkumar SV, Miguel JS, Anderson KC, Stadtmauer EA, Prabhala RH, McCarthy PL, Munshi NC. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. *Lancet Haematol*. 2022 Feb; 9 (2):e143-e161 PMID: 35114152 DOI: 10.1016/S2352-3026(21)00283-0
 732. Sidana S, **Kumar S**, Fraser R, Estrada-Merly N, Giralto S, Agrawal V, Anderson LD Jr, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. *Transplant Cell Ther*. 2022 Feb; 28 (2):83.e1-83.e9 Epub 2021 Nov 12 PMID: 34781066 PMCID: PMC8900987 DOI: 10.1016/j.jtct.2021.10.022
 733. Heybeli C, Alexander MP, Bentall AJ, Amer H, Buadi FK, Dean PG, Dingli D, Dispenzieri A, El Ters M, Gertz MA, Issa NS, Kapoor P, Kourelis T, Kukla A, **Kumar S**, Lacy MQ, Lorenz EC, Muchtar E, Murray DL, Nasr SH, Prieto M, Rajkumar SV, Schinstock CA, Stegall MD, Warsame R, Leung N. Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)-Associated Lesions: A Case Series. *Am J Kidney Dis*. 2022 Feb; 79 (2):202-216 Epub 2021 June 24 PMID: 34175375 PMCID: PMC8702583 DOI: 10.1053/j.ajkd.2021.04.015
 734. Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H, Paiva B, Bahlis NJ, Plesner T, Hungria V, Moreau P, Mateos MV, Perrot A, Iida S, Facon T, **Kumar S**, van de Donk NWCJ, Sonneveld P, Spencer A, Krevvata M, Heuck C, Wang J, Ukropec J, Kobos R, Sun S, Qi M, Munshi N. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. *Blood*. 2022 Feb 10; 139 (6):835-844 PMID: 34289038 PMCID: PMC8832474 DOI: 10.1182/blood.2021011101
 735. Gregory GP, **Kumar S**, Wang D, Mahadevan D, Walker P, Wagner-Johnston N, Escobar C, Bannerji R, Bhutani D, Chang J, Hernandez-Ilizaliturri FJ, Klein A, Pagel JM, Rybka W, Yee AJ, Mohrbacher A, Huang M, Farooqui M, Marinello P, Quach H. Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. *Blood Adv*. 2022 Feb 22; 6 (4):1232-1242 PMID: 34972202 PMCID: PMC8864641 DOI: 10.1182/bloodadvances.2021005872
 736. Kaddoura M, Binder M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Hwa L, Fonder A, Hobbs M, Hayman S, Leung N, Go RS, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Rajkumar V, **Kumar S**. Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. *Am J Hematol*. 2022 Mar 01; 97(3):267-273. Epub 2022 Jan 03. PMID: 34978743 DOI: 10.1002/ajh.26439
 737. Binder M#, Nandakumar B#, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, Lacy MQ, Gertz MA, Hayman SR, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Gonsalves WI, Russell S, Lin Y, Siddiqui M, Kyle RA, Dispenzieri A, **Kumar SK**. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. *Leukemia*. 2022 Mar; 36(3):801-808. Epub 2021 Oct 26. PMID: 34702976 DOI: 10.1038/s41375-021-01453-5
 738. Bal S, Malek E, Kansagra A, Usmani SZ, Vij R, Godby KN, Cornell RF, Kang Y, Umyarova E, Giri S, Chhabra S, Liedtke M, Callander NS, Hari P, **Kumar S**, Costa LJ. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. *Leukemia* 2022 Mar; 36 (3):877-880 Epub 2021 Nov 20 PMID: 34802043 DOI: 10.1038/s41375-021-01471-3

739. Kumar H#, Mazumder S#, Chakravarti S#, Sharma N, Mukherjee UK, **Kumar S**, Baughn LB, Van Ness BG, Mitra AK. secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics. *Blood Cancer J.* 2022 Mar 9; 12 (3):39 Epub 2022 Mar 09 PMID: 35264575 PMCID: PMC8907243 DOI: 10.1038/s41408-022-00636-2
740. Facon T, Cook G, Usmani SZ, Hulin C, **Kumar S**, Plesner T, Touzeau C, Bahlis NJ, Basu S, Nahi H, Goldschmidt H, Quach H, Mohty M, Venner CP, Weisel K, Raje N, Hebraud B, Belhadj-Merzoug K, Benboubker L, Decaux O, Manier S, Caillot D, Ukrepec J, Pei H, Van Rumpelbergh R, Uhlar CM, Kobos R, Zweegman S. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. *Leukemia.* 2022 Apr; 36 (4):1066-1077 Epub 2022 Jan 02 PMID: 34974527 PMCID: PMC8979809 DOI: 10.1038/s41375-021-01488-8
741. Obeng-Gyasi S, Graham N, **Kumar S**, Lee JW, Jacobus S, Weiss M, Cella D, Zhao F, Ip EH, O'Connell N, Hong F, Peipert DJ, Gareen IF, Timsina LR, Gray R, Wagner LI, Carlos RC. Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients. *Blood Cancer J.* 2022 Apr 1; 12 (4):53 Epub 2022 Apr 01 PMID: 35365604 PMCID: PMC8975964 DOI: 10.1038/s41408-022-00648-y
742. Visram A, Vachon C, Baughn LB, Larson D, Smadbeck J, Dispenzieri A, Kapoor P, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, Rajkumar SV, **Kumar S**. Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. *Leukemia.* 2022 Apr; 36 (4):1058-1065 Epub 2021 Nov 11 PMID: 34764424 DOI: 10.1038/s41375-021-01454-4
743. Heybeli C, Bentall AJ, Alexander MP, Amer H, Buadi FK, Dispenzieri A, Dingli D, Gertz MA, Issa N, Kapoor P, Kukla A, **Kumar S**, Lorenz EC, Rajkumar SV, Schinstock CA, Leung N. Kidney Transplant Outcomes of Patients With Multiple Myeloma. *Kidney Int Rep.* 2022 Apr; 7 (4):752-762 Epub 2022 Jan 10 PMID: 35497786 PMCID: PMC9039485 DOI: 10.1016/j.ekir.2022.01.003
744. Abdallah NH, Habermann T, Buadi FK, Gertz MA, Lacy MQ, Rajkumar SV, Dingli D, Go RS, Hayman SR, **Kumar SK**, Kourelis T, Warsame R, Kapoor P, Muchtar E, Hwa YL, Fonder AL, Hobbs MA, Lin Y, Leung N, Binder M, Siddiqui MA, Kyle RA, Witzig TE, Dispenzieri A. Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. *Am J Hematol.* 2022 Apr; 97 (4):401-410. Epub 2022 Jan 19. PMID: 35015310 DOI: 10.1002/ajh.26466
745. Claveau JS, Wetter DA, **Kumar S**. Cutaneous manifestations of monoclonal gammopathy. *Blood Cancer J.* 2022 Apr 11; 12 (4):58 PMID: 35411042 PMCID: PMC9001632 DOI: 10.1038/s41408-022-00661-1
746. Al Saleh AS#, Ebraheem MS#, Sidiqi MH, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Gonsalves W, Kourelis TV, Hogan WJ, Hayman SR, Kapoor P, **Kumar SK**, Gertz MA. Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. *Blood Cancer J.* 2022 Apr 11; 12 (4):59 PMID: 35410992 PMCID: PMC9001695 DOI: 10.1038/s41408-022-00655-z
747. Kleinstern G, Larson DR, Allmer C, Norman AD, Muntifering G, Sinnwell J, Visram A, Rajkumar V, Dispenzieri A, Kyle RA, Slager SL, **Kumar S**, Vachon CM. Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota. *Blood Cancer J.* 2022 Apr 19; 12 (4):67 PMID: 35440099 PMCID: PMC9018764 DOI: 10.1038/s41408-022-00659-9
748. Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, **Kumar S**, Mohyuddin GR. Financial toxicity in hematological malignancies: a systematic review. *Blood Cancer J.* 2022 Apr 22; 12 (4):74 PMID: 35459862 PMCID: PMC9033803 DOI: 10.1038/s41408-022-00671-z
749. Costa LJ, Lin Y, Cornell RF, Martin T, Chhabra S, Usmani SZ, Jagannath S, Callander NS, Berdeja JG, Kang Y, Vij R, Godby KN, Malek E, Neppalli A, Liedtke M, Fiala M, Tian H, Valluri S, Marino J, Jackson CC, Banerjee A, Kansagra A, Schechter JM, **Kumar S**, Hari P. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. *Clin Lymphoma Myeloma Leuk.* 2022 May; 22(5):326-335. Epub 2021 Oct 30. PMID: 34840088 DOI: 10.1016/j.clml.2021.10.013
750. Abdallah N, Murray D, Dispenzieri A, Kapoor P, Gertz MA, Lacy MQ, Hayman SR, Buadi FK, Gonsalves W, Muchtar E, Leung N, Dingli D, Kourelis T, Warsame R, Binder M, Kyle RA, Rajkumar SV, **Kumar S**. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. *Leukemia.* 2022 May; 36 (5):1449 PMID: 35414658 PMCID: PMC9061288 DOI: 10.1038/s41375-022-01567-4
751. Goel U, Usmani S, **Kumar S**. Current approaches to management of newly diagnosed multiple myeloma. *Am J Hematol.* 2022 May; 97 Suppl 1:S3-S25 Epub 2022 Mar 10 PMID: 35234302 DOI: 10.1002/ajh.26512
752. Karam D, Gertz M, Lacy M, Dispenzieri A, Hayman S, Dingli D, Buadi F, Kapoor P, Kourelis T, Warsame R,

- Hogan W, **Kumar S**. Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. *Bone Marrow Transplant*. 2022 May; 57 (5):803-809 Epub 2022 Mar 16 PMID: 35297404 DOI: 10.1038/s41409-022-01631-8
753. Keren DF, Bocsi G, Billman BL, Etzell J, Faix JD, **Kumar S**, Lipe B, McCudden C, Montgomery R, Murray DL, Rai AJ, Redondo TC, Souter L, Ventura CB, Ansari MQ. Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies. *Arch Pathol Lab Med*. 2022 May 1; 146 (5):575-590 PMID: 34347866 DOI: 10.5858/arpa.2020-0794-CP
 754. Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, **Kumar SK**. Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥ 100 . *Leukemia* 2022 May; 36 (5):1429-1431 Epub 2022 Feb 21 PMID: 35190659 PMCID: PMC9064933 DOI: 10.1038/s41375-022-01529-w
 755. Abdallah N, Murray D, Dispenzieri A, Kapoor P, Gertz MA, Lacy MQ, Hayman SR, Buadi FK, Gonsalves W, Muchtar E, Leung N, Dingli D, Kourelis T, Warsame R, Binder M, Kyle RA, Rajkumar SV, **Kumar S**. Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. *Leukemia* 2022 May; 36 (5):1426-1428 Epub 2022 Jan 29 PMID: 35091659 PMCID: PMC9061287 DOI: 10.1038/s41375-021-01501-0
 756. Facon T, San-Miguel J, Dimopoulos MA, Mateos MV, Cavo M, van Beekhuizen S, Yuan Z, Mendes J, Lam A, He J, Ammann E, **Kumar S**. Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. *Adv Ther*. 2022 May; 39 (5):1976-1992 Epub 2022 Mar 05 PMID: 35246820 PMCID: PMC9056460 DOI: 10.1007/s12325-022-02083-8
 757. Charalampous C, Goel U, Broski SM, Dingli D, Kapoor P, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi F, Hwa L, Leung N, Lin Y, Gonsalves W, Kourelis TV, Warsame R, Fonder A, Hobbs M, Binder M, Kyle RA, Rajkumar SV, **Kumar SK**. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. *Blood Adv*. 2022 May 10; 6 (9):2763-2772 PMID: 35235951 PMCID: PMC9092399 DOI: 10.1182/bloodadvances.2022007052
 758. Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, Poudyal BS, Costello C, Gay F, Cook G, Quach H, Einsele H, Schriber J, Hou J, Costa L, Aljurf M, Chaudhry M, Beksac M, Prince M, Mohty M, Janakiram M, Callander N, Biran N, Malhotra P, Otero PR, Moreau P, Abonour R, Iftikhar R, Silberman R, Mailankody S, Gregory T, Lin Y, Carpenter P, Hamadani M, Usmani S, **Kumar S**. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. *Transplant Cell Ther*. 2022 Jun; 28 (6):284-293 Epub 2022 Mar 17 PMID: 35306217 DOI: 10.1016/j.jct.2022.03.019
 759. Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, **Kumar SK**. Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥ 100 . *Leukemia*. 2022 Jun; 36 (6):1699 PMID: 35411097 DOI: 10.1038/s41375-022-01569-2
 760. Claveau JS, Buadi FK, **Kumar S**. Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma. *Oncol Ther*. 2022 Jun; 10 (1):105-122 Epub 2022 Apr 04 PMID: 35377068 PMCID: PMC9098709 DOI: 10.1007/s40487-022-00195-3
 761. Cook J#, Gonsalves Wl#, Gertz MA, Visram A, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Kapoor P, Kourelis TV, Hayman SR, Kyle RA, Muchtar E, **Kumar SK**, Hogan WJ, Jacob EK, Buadi FK. Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. *Bone Marrow Transplant* 2022 Jun; 57 (6):1007-1009 Epub 2022 Apr 02 PMID: 35368041 DOI: 10.1038/s41409-022-01659-w
 762. Cook J, Peng KW, Witzig TE, Broski SM, Villasboas JC, Paludo J, Patnaik M, Rajkumar V, Dispenzieri A, Leung N, Buadi F, Bennani N, Ansell SM, Zhang L, Packiriswamy N, Balakrishnan B, Brunton B, Giers M, Ginos B, Dueck AC, Geyer S, Gertz MA, Warsame R, Go RS, Hayman SR, Dingli D, **Kumar S**, Bergsagel L, Munoz JL, Gonsalves W, Kourelis T, Muchtar E, Kapoor P, Kyle RA, Lin Y, Siddiqui M, Fonder A, Hobbs M, Hwa L, Naik S, Russell SJ, Lacy MQ. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma. *Blood Adv*. 2022 Jun 14; 6 (11):3268-3279 PMID: 35175355 PMCID: PMC9198941 DOI: 10.1182/bloodadvances.2021006631
 763. Vachon CM, Murray J, Allmer C, Larson D, Norman AD, Sinnwell JP, Dispenzieri A, Kleinstern G, Visram A, Kyle RA, Rajkumar SV, Slager SL, **Kumar SK**, Murray DL. Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method. *Blood Adv*. 2022 Jun 28; 6 (12):3746-3750 PMID: 35316833 PMCID: PMC9631569 DOI: 10.1182/bloodadvances.2021006201
 764. **Kumar S**, Baizer L, Callander NS, Giralt SA, Hillengass J, Freidlin B, Hoering A, Richardson PG, Schwartz EI, Reiman A, Lentzsch S, McCarthy PL, Jagannath S, Yee AJ, Little RF, Raje NS. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. *Blood Cancer J*. 2022 Jun 29; 12 (6):98 Epub 2022 June 29 PMID: 35768410 PMCID:

PMC9243011 DOI: 10.1038/s41408-022-00695-5

765. Evans LA, Anderson EA, Jessen E, Nandakumar B, Atilgan E, Jevremovic D, Hitosugi T, Fonseca R, **Kumar SK**, Gonsalves WI. Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma. *Am J Hematol*. 2022 Jul; 97 (7):895-902 Epub 2022 May 06 PMID: 35481878 PMCID: PMC9197880 DOI: 10.1002/ajh.26577
766. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Grattinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, **Kumar S**, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. *Leukemia*. 2022 Jul; 36 (7):1720-1748 Epub 2022 June 22 PMID: 35732829 PMCID: PMC9214472 DOI: 10.1038/s41375-022-01620-2
767. Jakubowiak AJ, **Kumar S**, Medhekar R, Pei H, Lefebvre P, Kaila S, He J, Lefeuvre MH, Cortoos A, Londhe A, Mavros P, Lin TS, Usmani SZ. Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma. *Oncologist*. 2022 Jul 5; 27 (7):e589-e596 PMID: 35462406 PMCID: PMC9256027 DOI: 10.1093/oncolo/oyac067
768. Davies FE, Pawlyn C, Usmani SZ, San-Miguel JF, Einsele H, Boyle EM, Corre J, Auclair D, Cho HJ, Lonial S, Sonneveld P, Stewart AK, Bergsagel PL, Kaiser MF, Weisel K, Keats JJ, Mikhael JR, Morgan KE, Ghobrial IM, Orlowski RZ, Landgren CO, Gay F, Caers J, Chng WJ, Chari A, Walker BA, **Kumar SK**, Costa LJ, Anderson KC, Morgan GJ. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. *Blood Cancer Discov*. 2022 Jul 6; 3 (4):273-284 PMID: 35653112 PMCID: PMC9894570 DOI: 10.1158/2643-3230.BCD-21-0205
769. Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, Hansen DK, Anderson LD Jr, Banerjee R, Bumma N, Dhakal B, Khouri J, Landau H, Lee C, Mian H, Nathan S, Savani B, **Kumar S**, Qazilbash M, Shah N, D'Souza A. Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. *Blood Adv*. 2022 Jul 12; 6 (13):3991-3995 PMID: 35507742 PMCID: PMC9278304 DOI: 10.1182/bloodadvances.2022007218
770. Gagnon MF#, Tian S#, Geyer S, Sharma N, Vachon CM, Kusne Y, Bergsagel PL, Stewart AK, Rajkumar SV, **Kumar S**, Ailawadhi S, Baughn LB. Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms. *Blood Cancer J* 2022 Jul 26; 12 (7):112 Epub 2022 July 26 PMID: 35882836 PMCID: PMC9325693 DOI: 10.1038/s41408-022-00706-5
771. Weisel K, Nooka AK, Terpos E, Spencer A, Goldschmidt H, Dirnberger F, DeCosta L, Yusuf A, **Kumar S**. Carfilzomib 56 mg/m(2) twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DvD): a matching-adjusted indirect treatment comparison. *Leuk Lymphoma*. 2022 Aug; 63 (8):1887-1896 Epub 2022 Mar 15 PMID: 35289710 DOI: 10.1080/10428194.2022.2047962
772. Facon T, San-Miguel J, Dimopoulos MA, Mateos MV, Cavo M, van Beekhuizen S, Yuan Z, Mendes J, Lam A, He J, Ammann E, **Kumar S**. Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. *Adv Ther*. 2022 Aug; 39 (8):3868-3869 PMID: 35764866 PMCID: PMC9309122 DOI: 10.1007/s12325-022-02211-4
773. Sidana S, Dueck AC, Thanarajasingam G, Griffin JM, Thompson C, Griffin JM, Thompson C, Durani U, Burtis M, Warsame R, Paludo J, Gertz MA, Dispenzieri A, Ansell SM, Rajkumar SV, Yost K, Bannani N, Lin Y, **Kumar S**. Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant. *Transplant Cell Ther*. 2022 Aug; 28 (8):473-482 Epub 2022 May 09 PMID: 35550440 PMCID: PMC9357185 DOI: 10.1016/j.jct.2022.05.004
774. Sidana S, Allmer C, Larson MC, Dueck A, Yost K, Warsame R, Thanarajasingam G, Cerhan JR, Paludo J, Rajkumar SV, Habermann TM, Nowakowski GS, Lin Y, Gertz MA, Witzig T, Dispenzieri A, Gonsalves WI, Ansell SM, Thompson CA, **Kumar SK**. Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. *JCO Oncol Pract*. 2022 Aug; 18 (8):e1320-e1333 Epub 2022 May 17 PMID: 35580285 PMCID: PMC9377715 DOI: 10.1200/OP.21.00789
775. Goel U, **Kumar S**. An update on the safety of ixazomib for the treatment of multiple myeloma. *Expert Opin Drug Saf*. 2022 Sep; 21 (9):1143-1160 Epub 2022 Oct 05 PMID: 36178708 DOI: 10.1080/14740338.2022.2130892
776. Macaudo A#, Clay-Gilmour A#, Hielscher T, Hildebrandt MAT, Kruszewski M, Orlowski RZ, **Kumar SK**, Ziv E, Orciuolo E, Brown EE, Forsti A, Waller RG, Machiela MJ, Chanock SJ, Camp NJ, Rymko M, Razny M, Cozen

- W, Varkonyi J, Piredda C, Pelosini M, Belachew AA, Subocz E, Hemminki K, Rybicka-Ramos M, Giles GG, Milne RL, Hofmann JN, Zaucha JM, Vangsted AJ, Goldschmidt H, Rajkumar SV, Tomczak W, Sainz J, Butrym A, Watek M, Iskierka-Jazdzewska E, Buda G, Robinson DP, Jurczyszyn A, Dudzinski M, Martinez-Lopez J, Sinnwell JP, Slager SL, Jamroziak K, Reis RMV, Weinhold N, Bhatti P, Carvajal-Carmona LG, Zawirska D, Norman AD, Mazur G, Berndt SI, Campa D#, Vachon CM#, Canzian F#. Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma? *Cancer Epidemiol Biomarkers Prev.* 2022 Sep 2; 31 (9):1863-1866 PMID: 35700034 PMCID: PMC11375313 DOI: 10.1158/1055-9965.EPI-22-0043
777. Rajkumar SV, **Kumar S**, Lonial S, Mateos MV. Smoldering multiple myeloma current treatment algorithms. *Blood Cancer J.* 2022 Sep 5; 12 (9):129 Epub 2022 Sept 05 PMID: 36064707 PMCID: PMC9445066 DOI: 10.1038/s41408-022-00719-0
778. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G, San-Miguel J, Seymour JF, Treon SP, Vose JM, Zucca E, Advani R, Ansell S, Au WY, Barrionuevo C, Bergsagel L, Chan WC, Cohen JI, d'Amore F, Davies A, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, **Kumar S**, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, Lopez-Guillermo A, Mateos MV, Macintyre E, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris M, Pro B, Rajkumar V, Rosen ST, Sander B, Sehn L, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. *Blood.* 2022 Sep 15; 140 (11):1229-1253 PMID: 35653592 PMCID: PMC9479027 DOI: 10.1182/blood.2022015851
779. Muchtar E, Gertz MA, LaPlant BR, Buadi FK, Leung N, O'Brien P, Bergsagel PL, Fonder A, Hwa YL, Hobbs M, Helgeson DK, Bradt EE, Gonsalves W, Lacy MQ, Kapoor P, Siddiqui M, Larsen JT, Warsame R, Hayman SR, Go RS, Dingli D, Kourelis TV, Dispenzieri A, Rajkumar SV, **Kumar SK**. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. *Blood Adv.* 2022 Sep 27; 6 (18):5429-5435 PMID: 35737873 PMCID: PMC9631712 DOI: 10.1182/bloodadvances.2022007781
780. Warsame R, Cook J, Fruth B, Hubbard J, Croghan K, Price KAR, Jatoti A, **Kumar S**, Thompson C, Buckner J, Dispenzieri A, Sloan J, Dueck AC. A prospective, randomized trial of patient-reported outcome measures to drive management decisions in hematology and oncology. *Contemp Clin Trials Commun.* 2022 Oct; 29:100964 Epub 2022 July 13 PMID: 35928285 PMCID: PMC9344350 DOI: 10.1016/j.conctc.2022.100964
781. Yao L, Jayasinghe RG, Lee BH, Bhasin SS, Pilcher W, Doxie DB, Gonzalez-Kozlova E, Dasari S, Fiala MA, Pita-Juarez Y, Strausbauch M, Kelly G, Thomas BE, **Kumar SK**, Cho HJ, Anderson E, Wendl MC, Dawson T, D'souza D, Oh ST, Cheloni G, Li Y, DiPersio JF, Rahman AH, Dhodapkar KM, Kim-Schulze S, Vij R, Vlachos IS, Mehr S, Hamilton M, Auclair D, Kourelis T, Avigan D, Dhodapkar MV, Gnjjatic S, Bhasin MK, Ding L. Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis. *Cancer Res Commun.* 2022 Oct; 2 (10):1255-1265 Epub 2022 Oct 25 PMID: 36969740 PMCID: PMC10035369 DOI: 10.1158/2767-9764.CRC-22-0022
782. Gong H, Baffour FI, Glazebrook KN, Rhodes NG, Tiegs-Heiden CA, Thorne JE, Cook JM, **Kumar S**, Fletcher JG, McCollough CH, Leng S. Deep learning-based virtual noncalcium imaging in multiple myeloma using dual-energy CT. *Med Phys.* 2022 Oct; 49 (10):6346-6358 Epub 2022 Aug 28 PMID: 35983992 PMCID: PMC9588661 DOI: 10.1002/mp.15934
783. Abeykoon JP, Vaxman J, Patel SV, **Kumar S**, Malave GC, Young KS, Ailawadhi S, Larsen JT, Dispenzieri A, Muchtar E, Gonsalves W, Kourelis T, Leung N, Warsame R, Go RS, Bergsagel L, Lacy MQ, Rajkumar SV, Gertz MA, Kapoor P. Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma. *Br J Haematol.* 2022 Oct; 199(1):95-99. Epub 2022 Jun 13. PMID: 35694818 DOI: 10.1111/bjh.18298
784. Gertz MA, Warsame R, Muchtar E, Buadi F, Dispenzieri A, Gonsalves W, Dingli D, Hayman S, Kapoor P, Kourelis T, **Kumar SK**, Lacy MQ, Hogan W. Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. *Leuk Lymphoma.* 2022 Oct; 63 (10):2422-2427 Epub 2022 May 12 PMID: 35549799 PMCID: PMC9679915 DOI: 10.1080/10428194.2022.2074993
785. Costa LJ, Hari P, Berdeja JG, De Stefano V, Gay F, Hooper B, Bartlett M, Haltner A, Rosta E, **Kumar S**, Martin T, Mateos MV, Moreau P, Usmani SZ, Olyslager Y, Schechter JM, Rocchia T, Garrett A, Lee S, Nesheiwat T, Pacaud L, Zhou C, Samjoo IA, Lin Y, Diels J, Valluri S, Weisel K. Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. *Curr Med Res Opin.* 2022 Oct; 38 (10):1759-1767 Epub 2022 Aug 10 PMID: 35815818 DOI: 10.1080/03007995.2022.2100651
786. Alsomali D, Mohty D, Grogan M, Dispenzieri A, Aljurf M, **Kumar S**, Gertz MA, Hanbali A, Hashmi SK. Treatment of amyloid light chain cardiac amyloidosis: systematic review and future directions. *Clin Adv Hematol Oncol.* 2022 Oct; 20 (10):609-618 PMID: 36206073

787. D'Souza A, Shah N, Rodriguez C, Voorhees PM, Weisel K, Bueno OF, Pothacamury RK, Freise KJ, Yue S, Ross JA, Polepally AR, Talati C, Lee S, Jin Z, Buelow B, Vij R, **Kumar S**. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen x CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. *J Clin Oncol*. 2022 Nov 1; 40 (31):3576-3586 Epub 2022 Aug 27 PMID: 36029527 PMCID: PMC9622641 DOI: 10.1200/JCO.22.01504
788. Ebraheem M, **Kumar SK**, Dispenzieri A, Jevremovic D, Buadi FK, Dingli D, Cook J, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Binder M, Lin Y, Go RS, Siddiqui MA, Kyle RA, Rajkumar SV, Gonsalves WI, Gertz MA. Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy. *Transplant Cell Ther*. 2022 Nov; 28 (11):760.e1-760.e5 Epub 2022 Aug 05 PMID: 35940527 PMCID: PMC9674950 DOI: 10.1016/j.jct.2022.07.030
789. Ebraheem M, **Kumar SK**, Dispenzieri A, Jevremovic D, Buadi FK, Dingli D, Cook J, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Binder M, Lin Y, Go RS, Siddiqui MA, Kyle RA, Rajkumar SV, Gonsalves WI, Gertz MA. Deepening responses after upfront autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in the era of novel agent induction therapy. *Transplantation and Cellular Therapy*. 2022 Nov; 28 (11):Pages 760.e1-5
790. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan AA, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, **Kumar S**. Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance. *Blood*. 2022 Nov 3; 140 (18):1997-2000 PMID: 36096078 PMCID: PMC9474409 DOI: 10.1182/blood.2022017616
791. Goldman-Mazur S, Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, **Kumar SK**. Second- and third-line treatment strategies in multiple myeloma: a referral-center experience. *Blood Cancer J*. 2022 Dec 6; 12 (12):164 Epub 2022 Dec 06 PMID: 36473843 PMCID: PMC9723783 DOI: 10.1038/s41408-022-00757-8
792. Koleilat A, Tang H#, Sharma N, Yan H, Tian S, Smadbeck J, Shivaram S, Meyer R, Pearce K, Baird M, Zepeda-Mendoza CJ, Xu X, Greipp PT, Peterson JF, Ketterling RP, Bergsagel PL, Vachon C, Rajkumar SV, **Kumar S**, Asmann YW, Elhaik E, Baughn LB. Disparity in the detection of chromosome 15 centromere in patients of African ancestry with a plasma cell neoplasm. *Genet Med Open*. 2023; 1 (1):100816 Epub 2023 May 09 PMID: 39669246 PMCID: PMC11613710 DOI: 10.1016/j.gimo.2023.100816
793. Charalampous C, Goel U, Gertz M, Lacy M, Dispenzieri A, Hayman S, Dingli D, Buadi F, Kapoor P, Kourelis T, Warsame R, Hogan WJ, **Kumar S**. Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma. *Bone Marrow Transplant*. 2023 Jan; 58 (1):46-53 Epub 2022 Oct 06 PMID: 36203088 PMCID: PMC9812760 DOI: 10.1038/s41409-022-01835-y
794. **Kumar SK**. Incorporating immunotherapeutic strategies in the management of relapsed/refractory multiple myeloma. *Journal of the National Comprehensive Cancer Network: JNCCN*. 2023; 21:20-2
795. Cook J, Rajendran K, Ferrero A, Dhillon P, **Kumar S**, Baffour F. Photon Counting Detector Computed Tomography: A New Frontier of Myeloma Bone Disease Evaluation. *Acta Haematol*. 2023; 146 (5):419-423 Epub 2023 June 20 PMID: 37339614 PMCID: PMC10568597 DOI: 10.1159/000531461
796. Baffour FI, Huber NR, Ferrero A, Rajendran K, Glazebrook KN, Larson NB, **Kumar S**, Cook JM, Leng S, Shanblatt ER, McCollough CH, Fletcher JG. Photon-counting Detector CT with Deep Learning Noise Reduction to Detect Multiple Myeloma. *Radiology*. 2023 Jan; 306(1):229-236. Epub 2022 Sep 06. PMID: 36066364 PMCID: PMC9771909 DOI: 10.1148/radiol.220311
797. Ho M#, Zanwar S#, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan A, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, **Kumar S**. Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. *Am J Hematol*. 2023 Jan; 98 (1):49-55 Epub 2022 Oct 24 PMID: 36226510 PMCID: PMC9874728 DOI: 10.1002/ajh.26762
798. Xu T, Roose J, Williamson M, Sawas A, Hong WJ, Jin H, Maignan K, Rocci A, Yousefi K, **Kumar S**, Tyanova S. RWD-derived response in multiple myeloma. *PLoS One*. 2023; 18 (5):e0285125 Epub 2023 May 11 PMID: 37167221 PMCID: PMC10174483 DOI: 10.1371/journal.pone.0285125
799. **Kumar SK**, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Rosenberg A, Shorov D, Valent J, Berardi R, Kumar R. Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2023 Jan; 21 (1):67-81 PMID: 36652935 DOI: 10.6004/jnccn.2023.0001

800. Chng WJ, Lonial S, Morgan GJ, Iida S, Moreau P, **Kumar SK**, Twumasi-Ankrah P, Villarreal M, Dash AB, Vorog A, Zhang X, Suryanarayan K, Labotka R, Dimopoulos MA, Rajkumar SV. A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma. *Blood Cancer J*. 2023 Jan 12; 13 (1):14 PMID: 36631458 PMCID: PMC9834310 DOI: 10.1038/s41408-022-00768-5
801. Dicanio M, Giaccherini M, Clay-Gilmour A, Macaudo A, Sainz J, Machiela MJ, Rybicka-Ramos M, Norman AD, Tyczynska A, Chanock SJ, Barington T, **Kumar SK**, Bhatti P, Cozen W, Brown EE, Suska A, Hastrup EK, Orlowski RZ, Dudzinski M, Garcia-Sanz R, Kruszezski M, Martinez-Lopez J, Beider K, Iskierka-Jazdzewska E, Pelosini M, Berndt SI, Razny M, Jamrozak K, Rajkumar SV, Jurczynszyn A, Vangsted AJ, Collado PG, Vogel U, Hofmann JN, Petrini M, Butrym A, Slager SL, Ziv E, Subocz E, Giles GG, Andersen NF, Mazur G, Watek M, Lesueur F, Hildebrandt MAT, Zawirska D, Ebbesen LH, Marques H, Gemignani F, Dumontet C, Varkonyi J, Buda G, Nagler A, Druzd-Sitek A, Wu X, Kadar K, Camp NJ, Grzasko N, Waller RG, Vachon C, Canzian F, Campa D. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk. *Int J Cancer*. 2023 Jan 15; 152 (2):239-248 Epub 2022 Oct 01 PMID: 36082445 PMCID: PMC9828677 DOI: 10.1002/ijc.34278
802. Pilcher W, Thomas BE, Bhasin SS, Jayasinghe RG, Yao L, Gonzalez-Kozlova E, Dasari S, Kim-Schulze S, Rahman A, Patton J, Fiala M, Cheloni G, Kourelis T, Dhodapkar MV, Vij R, Mehr S, Hamilton M, Cho HJ, Auclair D, Avigan DE#, **Kumar SK**#, Gnjjatic S#, Ding L#, Bhasin M#. Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma. *NPJ Genom Med*. 2023 Jan 26; 8 (1):3 PMID: 36702834 PMCID: PMC9879959 DOI: 10.1038/s41525-022-00340-x
803. Mailankody S, Matous JV, Chhabra S, Liedtke M, Sidana S, Oluwole OO, Malik S, Nath R, Anwer F, Cruz JC, Htut M, Karski EE, Lovelace W, Dillon M, Butz E, Ying W, Balakumaran A, **Kumar SK**. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. *Nat Med*. 2023 Feb; 29 (2):422-429 Epub 2023 Jan 23 PMID: 36690811 DOI: 10.1038/s41591-022-02182-7
804. Yang P, Chen H#, Liang X, Xu W, Yu S, Huang W, Yi X, Guo Q, Tian M, Yue T, Li M, Zhang Y, Zhang M, Yan Y, Hu Z, **Kumar SK**, Zhou F, Dai Y, Jin F. Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma. *Am J Hematol*. 2023 Feb; 98 (2):251-263 Epub 2022 Nov 08 PMID: 36309982 DOI: 10.1002/ajh.26774
805. Nandakumar B, Baffour F, Abdallah NH, **Kumar SK**, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Go RS, Kyle RA, Gertz MA, Rajkumar SV, Klug J, Korfiatis P, Gonsalves WL. Sarcopenia identified by computed tomography imaging using a deep learning-based segmentation approach impacts survival in patients with newly diagnosed multiple myeloma. *Cancer*. 2023 Feb 1; 129 (3):385-392 Epub 2022 Nov 22 PMID: 36413412 PMCID: PMC9822865 DOI: 10.1002/cncr.34545
806. Ryu AJ, **Kumar S**, Dispenzieri A, Kyle RA, Rajkumar SV, Kingsley TC. Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance. *Blood Cancer J*. 2023 Feb 17; 13 (1):28 PMID: 36797276 PMCID: PMC9935510 DOI: 10.1038/s41408-023-00798-7
807. Muchtar E, Dispenzieri A, Wisniewski B, Palladini G, Milani P, Merlini G, Schonland S, Veelken K, Hegenbart U, Geyer SM, **Kumar SK**, Kastritis E, Dimopoulos MA, Liedtke M, Witteles R, Sanchowawala V, Szalat R, Landau H, Petrlik E, Lentzsch S, Coltoff A, Blade J, Cibeira MT, Cohen O, Foard D, Wechalekar A, Gertz MA. Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis. *J Clin Oncol*. 2023 Mar 1; 41 (7):1393-1403 Epub 2022 Oct 10 PMID: 36215675 PMCID: PMC10489422 DOI: 10.1200/JCO.22.00643
808. Wechalekar AD, Cibeira MT, Gibbs SD, Jaccard A, **Kumar S**, Merlini G, Palladini G, Sanchowawala V, Schonland S, Venner C, Boccadoro M, Kastritis E. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. *Amyloid*. 2023 Mar; 30 (1):3-17 Epub 2022 July 15 PMID: 35838162 DOI: 10.1080/13506129.2022.2093635
809. Ludwig H, **Kumar S**. Prevention of infections including vaccination strategies in multiple myeloma. *Am J Hematol*. 2023 Mar; 98 Suppl 2:S46-S62 Epub 2022 Nov 24 PMID: 36251367 DOI: 10.1002/ajh.26766
810. Chohan KL, Paludo J, Vallumsetla N, Larson D, King RL, He R, Gonsalves W, Inwards D, Witzig TE, Swaika A, Jain T, Leung N, Ailawadhi S, Reeder CB, Lacy MQ, Rajkumar SV, **Kumar S**, Kyle RA, Gertz MA, Ansell SM, Kapoor P. Survival trends in young patients with Waldenstrom macroglobulinemia: Over five decades of experience. *Am J Hematol*. 2023 Mar; 98 (3):432-439 Epub 2023 Jan 01 PMID: 36588384 DOI: 10.1002/ajh.26807
811. Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, **Kumar S**. Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival. *Am J Hematol*. 2023 Mar; 98 (3):413-420 Epub 2023 Jan 01 PMID: 36588396 DOI: 10.1002/ajh.26806
812. Goldman-Mazur S, Visram A, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Binder M, Fonder A, Hobbs M, Hwa YL, Kyle RA,

- Rajkumar SV, **Kumar SK**. Outcomes after biochemical or clinical progression in patients with multiple myeloma. *Blood Adv*. 2023 Mar 28; 7 (6):909-917 PMID: 35413102 PMCID: PMC10025108 DOI: 10.1182/bloodadvances.2022007082
813. Soefje SA, Carpenter C, Carlson K, Awasthi S, Lin TS, Kaila S, Tarjan D, Kayal N, Kirkup C, Wagner TE, Gray KS, **Kumar S**. Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers. *JCO Oncol Pract*. 2023 Apr; 19 (4):e542-e549 Epub 2023 Feb 09 PMID: 36758192 PMCID: PMC10101255 DOI: 10.1200/OP.22.00421
 814. Hillengass J, Martin T, Puig N, Paiva B, Usmani S, **Kumar S**, San-Miguel J. Disease Monitoring In Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2023 Apr; 23 (4):244-248 Epub 2023 Jan 14 PMID: 36774297 DOI: 10.1016/j.clml.2023.01.005
 815. Facon T, **Kumar SK**, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, Perrot A, Weisel K, Raje N, Macro M, Frenzel L, Leleu X, Wang J, Rampelbergh RV, Uhlar CM, Vermeulen J, Duran J, Borgsten F, Usmani SZ. Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma. *Future Oncol* 2023 Apr; 19 (13):887-895 Epub 2023 May 22 PMID: 37212642 DOI: 10.2217/fon-2023-0082
 816. D'Souza A, **Kumar S**. Reply to E.R.S. Cliff et al. *J Clin Oncol* 2023 Apr 1; 41 (10):1951-1952 Epub 2023 Jan 30 PMID: 36716406 DOI: 10.1200/JCO.22.02691
 817. Bansal R#, Baksh M#, Larsen JT#, Hathcock MA, Dingli D, Stewart AK, Kapoor P, Kourelis T, Hayman SR, Warsame RM, Fonseca R, Bergsagel PL, Ailawadhi S, **Kumar SK**#, Lin Y#. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. *Blood Cancer J*. 2023 Apr 5; 13 (1):47 Epub 2023 Apr 05 PMID: 37019896 PMCID: PMC10076306 DOI: 10.1038/s41408-023-00820-y
 818. Kanack AJ, Schaefer JK, Sridharan M, Splinter NP, Kohlhausen MC, Singh B, De Lorenzo SB, Mauch EE, Hussein MA, Shaikh M, **Kumar S**, Wen R, Wang D, Murray DL, Padmanabhan A. Monoclonal gammopathy of thrombotic/thrombocytopenic significance. *Blood*. 2023 Apr 6; 141 (14):1772-1776 PMID: 36626584 PMCID: PMC10113173 DOI: 10.1182/blood.2022018797
 819. Panakkal V, Lakshman A, Shi M, Olteanu H, Horna P, Timm MM, Otteson GE, Baughn LB, Greipp PT, Gonsalves WI, Kapoor P, Gertz MA, Binder M, Buadi FK, Dispenzieri A, Rajkumar SV, **Kumar SK**, Jevremovic D. Utility of flow cytometry screening before MRD testing in multiple myeloma. *Blood Cancer J* 2023 Apr 20; 13 (1):55 PMID: 37080968 PMCID: PMC10119092 DOI: 10.1038/s41408-023-00832-8
 820. **Kumar S**. One disease, many faces. *Haematologica* 2023 May 1; 108 (5):1213-1215 Epub 2023 May 01 PMID: 36172815 PMCID: PMC10153510 DOI: 10.3324/haematol.2022.281417
 821. Fonseca R, Facon T, Hashim M, Nair S, He J, Ammann E, Lam A, Wildgust M, **Kumar S**. Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma. *Oncologist*. 2023 May 8; 28 (5):e263-e269 PMID: 37002943 PMCID: PMC10166176 DOI: 10.1093/oncolo/oyad053
 822. Clavero E, Sanchez-Maldonado JM, Macaudo A, Ter Horst R, Sampaio-Marques B, Jurczynszyn A, Clay-Gilmour A, Stein A, Hildebrandt MAT, Weinhold N, Buda G, Garcia-Sanz R, Tomczak W, Vogel U, Jerez A, Zawirska D, Watek M, Hofmann JN, Landi S, Spinelli JJ, Butrym A, Kumar A, Martinez-Lopez J, Galimberti S, Sarasquete ME, Subocz E, Iskierka-Jazdzewska E, Giles GG, Rybicka-Ramos M, Kruszewski M, Abildgaard N, Verdejo FG, Sanchez Rovira P, da Silva Filho MI, Kadar K, Razny M, Cozen W, Pelosini M, Jurado M, Bhatti P, Dudzinski M, Druzd-Sitek A, Orciuolo E, Li Y, Norman AD, Zaucha JM, Reis RM, Markiewicz M, Rodriguez Sevilla JJ, Andersen V, Jamrozziak K, Hemminki K, Berndt SI, Rajkumar V, Mazur G, **Kumar SK**, Ludovico P, Nagler A, Chanock SJ, Dumontet C, Machiela MJ, Varkonyi J, Camp NJ, Ziv E, Vangsted AJ, Brown EE, Campa D, Vachon CM, Netea MG, Canzian F, Forsti A, Sainz J. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization. *Int J Mol Sci*. 2023 May 9; 24 (10) Epub 2023 May 09 PMID: 37239846 PMCID: PMC10218542 DOI: 10.3390/ijms24108500
 823. Abdallah NH, Smith AN, Geyer S, Binder M, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Hwa YL, Lin Y, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, **Kumar SK**. Conditional survival in multiple myeloma and impact of prognostic factors over time. *Blood Cancer J*. 2023 May 15; 13 (1):78 PMID: 37188699 PMCID: PMC10185675 DOI: 10.1038/s41408-023-00852-4
 824. Baughn LB, Jessen E, Sharma N, Tang H, Smadbeck JB, Long MD, Pearce K, Smith M, Dasari S, Sachs Z, Linden MA, Cook J, Keith Stewart A, Chesi M, Mitra A, Leif Bergsagel P, Van Ness B, **Kumar SK**. Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma. *Blood Cancer J*. 2023 May 22; 13 (1):84 PMID: 37217482 PMCID: PMC10203138 DOI: 10.1038/s41408-023-00851-5
 825. Wiedmeier-Nutor JE, Iqbal M, Rosenthal AC, Bezerra ED, Garcia-Robledo JE, Bansal R, Johnston PB, Hathcock M, Larsen JT, Bergsagel PL, Wang Y, Reeder CB, Leis JF, Fonseca R, Palmer JM, Gysbers BJ,

- Mwangi R, Warsame RM, Kourelis T, Hayman SR, Dingli D, Kapoor P, **Kumar SK**, Durani U, Villasboas JC, Paludo J, Bennani NN, Nowakowski G, Ansell SM, Castro JE, Kharfan-Dabaja MA, Lin Y, Vergidis P, Murthy HS, Munoz J. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2023 Jun; 23 (6):456-462 Epub 2023 Mar 07 PMID: 37003846 PMCID: PMC9990888 DOI: 10.1016/j.clml.2023.03.002
826. Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD Jr, Wirk B, Kaur G, Qazilbash MH, Shah N, **Kumar SK**, Usmani SZ. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. *Blood Adv*. 2023 Jun 27; 7 (12):2746-2757 PMID: 36827681 PMCID: PMC10275699 DOI: 10.1182/bloodadvances.2022009138
 827. Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Mauermann M, Witzig TE, Johnston P, Kyle RA, King RL, Habermann TM, **Kumar S**, Kapoor P. Central nervous system involvement (Bing-Neel Syndrome) in patients with Waldenstrom macroglobulinemia. *Leuk Lymphoma* 2023 Jul-Aug; 64 (8):1490-1493 Epub 2023 June 10 PMID: 37300306 DOI: 10.1080/10428194.2023.2214026
 828. Rozenova K, Willrich M, Snyder M, Dasari S, Kourelis T, Rajkumar SV, **Kumar S**, Dispenzieri A, Murray DL. Kappa Free Light Chain Drift Prompts the Need for a New Upper Limit of Normal Free Light Chain Ratio to Avoid an Epidemic of Kappa Light Chain Monoclonal Gammopathy of Undermined Significance. *J Appl Lab Med*. 2023 Jul 5; 8 (4):742-750 PMID: 37232112 DOI: 10.1093/jalm/jfad027
 829. Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, **Kumar S**, Qazilbash MH, Shah N, D'Souza A, Sidana S. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. *Cancer*. 2023 Jul 15; 129 (14):2179-2191 Epub 2023 Apr 06 PMID: 37021929 PMCID: PMC10516285 DOI: 10.1002/cncr.34778
 830. Visram A, Hayman SR, Dispenzieri A, Kapoor P, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Warsame R, Kourelis T, Cook J, Binder M, Gonsalves W, Muchtar E, Leung N, Roy V, Rajkumar SV, **Kumar S**. A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CAMEL). *Am J Hematol*. 2023 Aug; 98 (8):1277-1285 Epub 2023 June 19 PMID: 37334773 DOI: 10.1002/ajh.26990
 831. Seth A, Murray D, Buadi FK, Gertz MA, Yadav U, **Kumar SK**, Gonsalves WI. Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti-CD38 monoclonal antibody. *Eur J Haematol*. 2023 Aug; 111 (2):318-321 Epub 2023 May 20 PMID: 37209032 PMCID: PMC10524502 DOI: 10.1111/ejh.14008
 832. Schmit GD, Kurup AN, Morris JM, **Kumar SK**, Schmitz JJ, Welch BT, Kassmeyer BA, Callstrom MR. Percutaneous Cryoablation of Plasmacytomas: Oncologic Effectiveness and Adverse Events. *J Vasc Interv Radiol*. 2023 Aug; 34(8):1303-1310. Epub 2023 Apr 25. PMID: 37100197 DOI: 10.1016/j.jvir.2023.04.013
 833. Boddicker NJ, Parikh SA, Norman AD, Rabe KG, Griffin R, Call TG, Robinson DP, Olson JE, Dispenzieri A, Rajkumar V, **Kumar S**, Kay NE, Hanson CA, Cerhan JR, Murray D, Braggio E, Shanafelt TD, Vachon CM#, Slager SL#. Relationship among three common hematological premalignant conditions. *Leukemia* 2023 Aug; 37 (8):1719-1722 Epub 2023 May 05 PMID: 37147423 PMCID: PMC10400408 DOI: 10.1038/s41375-023-01914-z
 834. Wood WA, Anderson KC, **Kumar SK**, Semmel EA, Hewitt K, Plovnick RM, Pappas G. A pandemic preparedness network for individuals living with compromised immune systems. *Blood Adv*. 2023 Aug 8; 7 (15):3925-3927 PMID: 37023227 PMCID: PMC10405186 DOI: 10.1182/bloodadvances.2023010035
 835. Schmidt WM, Perera ND, Buadi FK, Hayman SR, **Kumar SK**, Dispenzieri A, Dingli D, Cook J, Lacy MQ, Kapoor P, Leung N, Muchtar E, Warsame RM, Kourelis T, Binder M, Gonsalves WI, Hogan WJ, Gertz MA. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma. *Blood Cancer J*. 2023 Aug 18; 13 (1):126 PMID: 37591876 PMCID: PMC10435482 DOI: 10.1038/s41408-023-00900-z
 836. Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, **Kumar SK**. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy. *Blood Adv*. 2023 Aug 22; 7 (16):4371-4380 PMID: 37276429 PMCID: PMC10432608 DOI: 10.1182/bloodadvances.2023009681
 837. Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, **Kumar SK**. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy. *Blood Adv*. 2023 Aug 22; 7 (16):4371-4380 PMID: 37603349 PMCID: PMC10432608 DOI: 10.1182/bloodadvances.2023009681

838. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, de Oliveira Araujo IB, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Di Napoli A, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, **Kumar S**, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Suzuki R, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W, International Agency for Research on Cancer/World Health Organization. Correction: "The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" Leukemia. 2022 Jul;36(7):1720-1748. Leukemia. 2023 Sep; 37 (9):1944-1951 PMID: 37468552 PMCID: PMC10457187 DOI: 10.1038/s41375-023-01962-5
839. **Kumar S**, Dispenzieri A, Bhutani D, Gertz M, Wechalekar A, Palladini G, Comenzo R, Fonseca R, Jaccard A, Kastritis E, Schonland S, la Porte C, Pei H, Tran N, Merlini G. Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study. Amyloid. 2023 Sep; 30 (3):268-278 Epub 2023 Feb 13 PMID: 36779691 DOI: 10.1080/13506129.2022.2164488
840. Abdallah N, Dispenzieri A, Muchtar E, Buadi FK, Kapoor P, Lacy MQ, Hwa YL, Fonder A, Hobbs MA, Hayman SR, Leung N, Dingli D, Go RS, Lin Y, Gonsalves WI, Binder M, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Gertz MA, **Kumar SK**. The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow up. Amyloid. 2023 Sep; 30 (3):261-267 Epub 2022 Dec 19 PMID: 36533960 DOI: 10.1080/13506129.2022.2155809
841. Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, Dispenzieri A, Dingli D, Fonder A, Gertz MA, Gonsalves W, Hayman SR, Hwa Y, Hobbs M, Kourelis T, Lacy MQ, Leung N, Muchtar E, Warsame R, Jevremovic D, Kyle RA, Rajkumar SV, **Kumar S**. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol. 2023 Oct; 98 (10):1540-1549 Epub 2023 July 08 PMID: 37421603 DOI: 10.1002/ajh.27023
842. Streck JM, Lee JW, Walter AW, Rosen RL, Gareen IF, Kircher SM, Herman BA, Carlos RC, **Kumar S**, Mayer IA, Saba NF, Fenske TS, Neal JW, Atkins MB, Hodi FS, Kyriakopoulos CE, Tempny C, Shanafelt TD, Wagner LI, Land SR, Park ER, Ostroff JS. Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials. Cancer Epidemiol Biomarkers Prev. 2023 Nov 1; 32 (11):1552-1557 PMID: 37410096 PMCID: PMC10773003 DOI: 10.1158/1055-9965.EPI-23-0420
843. Richardson PG, Durie BG, Rosinol L, Mateos MV, Dispenzieri A, Moreau P, **Kumar S**, Raje N, Munshi N, Laubach JP, O'Gorman P, O'Donnell E, Voorhees P, Facon T, Blade J, Lonial S, Perrot A, Anderson KC. Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma. Haematologica. 2023 Nov 1; 108 (11):2894-2912 Epub 2023 Nov 01 PMID: 37608773 PMCID: PMC10620581 DOI: 10.3324/haematol.2022.282624
844. Richardson PG, Facon T, Venner CP, Bahlis NJ, Offner F, White D, Karlin L, Benboubker L, Voog E, Yoon SS, Suzuki K, Shibayama H, Zhang X, Villarreal M, Twumasi-Ankrah P, Labotka R, Rifkin RM, Lonial S, **Kumar SK**, Rajkumar SV, Moreau P. Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial. EJHaem. 2023 Nov; 4 (4):995-1005 Epub 2023 Aug 03 PMID: 38024593 PMCID: PMC10660432 DOI: 10.1002/jha2.759
845. Yadav U, **Kumar SK**, Baughn LB, Dispenzieri A, Greipp P, Ketterling R, Jevremovic D, Buadi FK, Dingli D, Lacy MQ, Fonseca R, Bergsagel PL, Ailawadhi S, Roy V, Parrondo R, Sher T, Hayman SR, Kapoor P, Leung N, Cook J, Binder M, Muchtar E, Warsame R, Kourelis TV, Go RS, Lin Y, Seth A, Lester SC, Breen WG, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas. Blood. 2023 Nov 30; 142 (22):1871-1878 PMID: 37494698 PMCID: PMC10731916 DOI: 10.1182/blood.2023021187
846. **Kumar SK**, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Kumar R, Snedeker J. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Dec; 21 (12):1281-1301 PMID: 38081133 DOI: 10.6004/jnccn.2023.0061
847. Mailankody S, Matous JV, Chhabra S, Liedtke M, Sidana S, Oluwole OO, Malik S, Nath R, Anwer F, Cruz JC, Htut M, Karski EE, Lovelace W, Dillon M, Butz E, Ying W, Balakumaran A, **Kumar SK**. Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023 Dec; 29 (12):3271 PMID: 36932247 DOI: 10.1038/s41591-023-02306-7

848. Mitra AK, Mukherjee UK, Mazumder S, Madhira V, Bergquist T, Shao YR, Liu F, Song Q, Su J, **Kumar S**, Bates BA, Sharafeldin N, Topaloglu U, National COVID Cohort Collaborative Consortium. Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma. *Blood Cancer J*. 2023 Dec 7; 13 (1):180 Epub 2023 Dec 07 PMID: 38057320 PMCID: PMC10700604 DOI: 10.1038/s41408-023-00901-y
849. Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, **Kumar SK**. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma. *Blood Cancer J* 2023 Dec 11; 13 (1):183 PMID: 38072941 PMCID: PMC10711005 DOI: 10.1038/s41408-023-00957-w
850. Abdallah NH, Nagayama H, Takahashi N, Gonsalves W, Fonder A, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Hobbs M, Gertz MA, Binder M, Kapoor P, Warsame R, Hayman SR, Kourelis T, Hwa YL, Lin Y, Kyle RA, Rajkumar SV, Broski SM, **Kumar SK**. Muscle and fat composition in patients with newly diagnosed multiple myeloma. *Blood Cancer J*. 2023 Dec 12; 13 (1):185 PMID: 38086801 PMCID: PMC10716405 DOI: 10.1038/s41408-023-00934-3
851. Badawi M, Coppola S, Eckert D, Gopalakrishnan S, Engelhardt B, Doelger E, Huang W, Dobkowska E, **Kumar S**, Menon RM, Salem AH. Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety. *Hematol Oncol*. 2024 Jan; 42 (1):e3222 Epub 2023 Sept 23 PMID: 37740931 DOI: 10.1002/hon.3222
852. **Kumar SK**, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Derman B, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee H, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Snedeker J, Kumar R. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2024 Jan; 22 (1D):e240001 PMID: 38244272 DOI: 10.6004/jnccn.2024.0001
853. Croghan IT, **Kumar S**, Dugani SB, Hurt RT, Raffals LE, Schletty AA, Schroeder DR, Gathje SR, Shah V. Writing Groups for Healthcare Professionals in Academic Medicine. *J Prim Care Community Health*. 2024 Jan-Dec; 15:21501319241266102 PMID: 39051662 PMCID: PMC11273704 DOI: 10.1177/21501319241266102
854. Gagnon MF, Midthun SM, Fangel JA, Schuh CM, Luoma IM, Pearce KE, Meyer RG, Ailawadhi S, Arribas MJ, Braggio E, Fonseca R, Rajkumar SV, Zepeda-Mendoza C, Xu X, Greipp PT, Timm MM, Otteson GE, Shi M, Jevremovic D, Olteanu H, Peterson JF, Ketterling RP, **Kumar S**, Baughn LB. Superior detection rate of plasma cell FISH using FACS-FISH. *Am J Clin Pathol*. 2024 Jan 4; 161 (1):60-70 PMID: 37658775 DOI: 10.1093/ajcp/qaad108
855. Abdallah NH, Lakshman A, **Kumar SK**, Cook J, Binder M, Kapoor P, Dispenzieri A, Gertz MA, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Lin Y, Kourelis T, Warsame R, Bergsagel L, Rajkumar SV. Mode of progression in smoldering multiple myeloma: a study of 406 patients. *Blood Cancer J*. 2024 Jan 17; 14 (1):9 PMID: 38228628 PMCID: PMC10791688 DOI: 10.1038/s41408-024-00980-5
856. Walter AW, Lee JW, Streck JM, Gareen IF, Herman BA, Kircher SM, Carlos RC, **Kumar SK**, Mayer IA, Saba NF, Fenske TS, Neal JW, Atkins MB, Hodi FS, Kyriakopoulos CE, Tempany-Afdhal CM, Shanafelt TD, Wagner LI, Land SR, Ostroff JS, Park ER. The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG-ACRIN Cancer Research Group trials. *Cancer*. 2024 Feb 1; 130 (3):439-452 Epub 2023 Oct 05 PMID: 37795845 PMCID: PMC10841845 DOI: 10.1002/cncr.35039
857. Rees MJ, **Kumar S**. BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them. *Leuk Lymphoma*. 2024 Mar; 65 (3):287-300 Epub 2023 Nov 21 PMID: 38354090 DOI: 10.1080/10428194.2023.2284088
858. Gupta R, Jevremovic D, Mathew SJ, **Kumar S**. Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice. *Clin Lymphoma Myeloma Leuk*. 2024 Mar; 24 (3):e88-e95 Epub 2023 Nov 27 PMID: 38142203 DOI: 10.1016/j.clml.2023.11.006
859. Goldman-Mazur S, Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, **Kumar SK**. Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2024 Mar; 24 (3):e104-e111.e1 Epub 2023 Nov 27 PMID: 38135634 DOI: 10.1016/j.clml.2023.11.008
860. Peipert JD, Zhao F, Lee JW, Shen SE, Ip E, O'Connell N, Carlos RC, Graham N, Smith ML, Gareen IF, Raper PJ, Weiss M, **Kumar SK**, Rajkumar SV, Cella D, Gray R, Wagner LI. Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma. *JAMA Netw Open*. 2024 Mar 4; 7

(3):e243854 Epub 2024 Mar 04 PMID: 38536173 PMCID: PMC10973895 DOI: 10.1001/jamanetworkopen.2024.3854

861. Goel U, Charalampous C, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder A, Gertz MA, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame RM, Kyle RA, Rajkumar SV, **Kumar SK**. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide. *Blood Cancer J*. 2024 Mar 26; 14 (1):55 PMID: 38531841 PMCID: PMC10966094 DOI: 10.1038/s41408-024-01039-1
862. Abdallah N, **Kumar SK**. New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma. *Hematol Oncol Clin North Am*. 2024 Apr; 38 (2):511-532 Epub 2024 Jan 11 PMID: 38216384 DOI: 10.1016/j.hoc.2023.12.013
863. Rajkumar SV, Bergsagel PL, **Kumar S**. Smoldering Multiple Myeloma: Observation Versus Control Versus Cure. *Hematol Oncol Clin North Am*. 2024 Apr; 38 (2):293-303 Epub 2023 Dec 28 PMID: 38158241 PMCID: PMC11404782 DOI: 10.1016/j.hoc.2023.12.001
864. Dimopoulos M, Sonneveld P, Manier S, Lam A, Rocca T, Schechter JM, Cost P, Pacaud L, Poirier A, Tremblay G, Lan T, Valluri S, **Kumar S**. Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma. *BMC Cancer*. 2024 Apr 29; 24 (1):541 PMID: 38684948 PMCID: PMC11057089 DOI: 10.1186/s12885-024-12263-0
865. Durie BGM, **Kumar SK**, Ammann EM, Fu AZ, Kaila S, Lam A, Usmani SZ, Facon T. Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data. *Adv Ther*. 2024 May; 41 (5):1923-1937 Epub 2024 Mar 18 PMID: 38494542 PMCID: PMC11052858 DOI: 10.1007/s12325-024-02807-y
866. Alodhaibi I, Ailawadhi S, Burbano GP, O'Brien PJ, Buadi FK, Hayman S, **Kumar SK**, Gonsalves WI. An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2024 May; 24 (5):298-304 Epub 2024 Jan 06 PMID: 38220589 PMCID: PMC11045312 DOI: 10.1016/j.clml.2024.01.002
867. Abdallah N, Witzig TE, **Kumar SK**, Lacy MQ, Hayman SR, Dispenzieri A, Roy V, Gertz MA, Bergsagel PL, Rajkumar SV. Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up. *Leukemia*. 2024 May; 38 (5):1169-1171 Epub 2024 Feb 28 PMID: 38418610 DOI: 10.1038/s41375-024-02192-z
868. Ghobrial IM, Gormley N, **Kumar SK**, Mateos MV, Bergsagel PL, Chesi M, Dhodapkar MV, Dispenzieri A, Fonseca R, Getz G, Kastritis E, Kristinsson SY, Martinez-Climent JA, Manier S, Marinac CR, Maura F, Morgan GJ, Davies FE, Nadeem O, Nuvolone M, Paiva B, O'Donnell E, Prosper F, Shah UA, Sklaventis-Pistofidis R, Sperling AS, Vassiliou GS, Munshi NC, Castle PE, Anderson KC, San Miguel JF. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma. *Blood Cancer Discov*. 2024 May 1; 5 (3):146-152 PMID: 38441243 PMCID: PMC11061588 DOI: 10.1158/2643-3230.BCD-24-0022
869. Pilcher WC, Yao L, Gonzalez-Kozlova E, Pita-Juarez Y, Karagkouni D, Acharya CR, Michaud ME, Hamilton M, Nanda S, Song Y, Sato K, Wang JT, Satpathy S, Ma Y, Schulman J, D'Souza D, Jayasinghe RG, Cheloni G, Bakhtiari M, Pabustan N, Nie K, Foltz JA, Saldarriaga I, Alaaeldin R, Lepisto E, Chen R, Fiala MA, Thomas BE, Cook A, Dos Santos JV, Chiang IL, Figueiredo I, Fortier J, Slade M, Oh ST, Rettig MP, Anderson E, Li Y, Dasari S, Strausbauch MA, Simon VA, Rahman AH, Chen Z, Lagana A, DiPersio JF, Rosenblatt J, Kim-Schulze S, Dhodapkar MV, Lonial S, **Kumar S**, Bhasin SS, Kourelis T, Vij R, Avigan D, Cho HJ, Mulligan G, Ding L, Gnajatic S, Vlachos IS, Bhasin M, Immune Atlas Consortium. A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma. *bioRxiv* 2024 May 17 PMID: 38798338 PMCID: PMC11118283 DOI: 10.1101/2024.05.15.593193
870. Rees MJ, D'Agostino M, Leyboldt LB, **Kumar S**, Weisel KC, Gay F. Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies. *Am Soc Clin Oncol Educ Book*. 2024 Jun; 44 (3):e433520 PMID: 38772002 DOI: 10.1200/EDBK_433520
871. Zanwar S, Gertz MA, Muchtar E, Buadi FK, Kourelis T, Gonsalves W, Go RS, Hayman S, Kapoor P, Binder M, Cook J, Dingli D, Leung N, Lin Y, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, **Kumar S**, Dispenzieri A. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. *Leukemia* 2024 Jun; 38 (6):1423-1426 Epub 2024 Apr 09 PMID: 38594348 PMCID: PMC11147750 DOI: 10.1038/s41375-024-02243-5
872. Zanwar S#, Sidana S#, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD Jr, McGuirk JP, Wagner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK#, **Kumar SK**#, Hansen DK. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. *J Hematol Oncol* 2024 Jun 6; 17 (1):42 Epub 2024 June 06 PMID: 38845015 PMCID: PMC11157748 DOI: 10.1186/s13045-024-01555-4
873. Zanwar S, Le-Rademacher J, Durot E, D'Sa S, Abeykoon JP, Mondello P, **Kumar S**, Sarosiek S, Paludo J, Chhabra S, Cook JM, Parrondo R, Dispenzieri A, Gonsalves WI, Muchtar E, Ailawadhi S, Kyle RA, Rajkumar SV, Delmer A, Fonseca R, Gertz MA, Treon SP, Ansell SM, Castillo JJ, Kapoor P. Simplified Risk

Stratification Model for Patients With Waldenstrom Macroglobulinemia. *J Clin Oncol*. 2024 Jul 20; 42(21):2527-2536 Epub 2024 May 24 PMID: 38788183 PMCID: PMC11268554 DOI: 10.1200/JCO.23.02066

874. Rees MJ, Mammadzadeh A, Bolarinwa A, Elhaj ME, Bohra A, Bansal R, Ailawadhi S, Parrondo R, Chhabra S, Khot A, Hayman S, Dispenzieri A, Buadi F, Dingli D, Warsame R, Kapoor P, Gertz MA, Muchtar E, Kourelis T, Gonsalves W, Rajkumar SV, Lin Y, **Kumar S**. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma. *Blood Cancer J*. 2024 Jul 23; 14(1):122. PMID: 39043638 PMCID: PMC11266661 DOI: 10.1038/s41408-024-01081-z
875. Jevremovic D, Shi M, Horna P, Otteson GE, Timm MM, Baughn LB, Greipp PT, Gonsalves WI, Kapoor P, Gertz MA, Binder M, Buadi FK, Zhou J, Dispenzieri A, Kourelis T, Muchtar E, Rajkumar SV, **Kumar SK**, Olteanu H. Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms. *Blood Cancer J* 2024 Jul 31; 14 (1):126 Epub 2024 July 31 PMID: 39085227 PMCID: PMC11291477 DOI: 10.1038/s41408-024-01113-8
876. Ramasamy K, Bahlis NJ, **Kumar SK**, Kumar A, Cranmer H, Wang B, Dabora J, Labotka R, Richardson PG, Moreau P. Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone. *Haematologica*. 2024 Aug 1; 109 (8):2585-2593 Epub 2024 Aug 01 PMID: 38426294 PMCID: PMC11290535 DOI: 10.3324/haematol.2023.283713
877. Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O'Dwyer M, Schjesvold F, Sidana S, van de Donk NW, Weisel K, Zweegman S, Raje N, Otero PR, Anderson LD Jr, **Kumar S**, Martin T, International Myeloma Working Group. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. *Lancet Oncol*. 2024 Aug; 25(8):e374-e387. Epub 2024 May 28. PMID: 38821074 DOI: 10.1016/S1470-2045(24)00094-9
878. Visram A, Vachon C, Baughn LB, Larson D, Smadbeck J, Dispenzieri A, Kapoor P, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, Rajkumar SV, **Kumar S**. Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. *Leukemia*. 2024 Aug; 38 (8):1865 PMID: 38886492 DOI: 10.1038/s41375-024-02309-4
879. Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, **Kumar SK**. Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥ 100 . *Leukemia*. 2024 Aug; 38 (8):1862 PMID: 38956316 DOI: 10.1038/s41375-024-02306-7
880. Vaxman I, **Kumar SK**, Buadi F, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Kourelis T, Warsame R, Muchtar E, Leung N, Kapoor P, Grogan M, Go R, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Gertz MA, Dispenzieri A. Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. *Leukemia*. 2024 Aug; 38 (8):1866 PMID: 38886493 PMCID: PMC11286503 DOI: 10.1038/s41375-024-02311-w
881. Abdallah N, Murray D, Dispenzieri A, Kapoor P, Gertz MA, Lacy MQ, Hayman SR, Buadi FK, Gonsalves W, Muchtar E, Leung N, Dingli D, Kourelis T, Warsame R, Binder M, Kyle RA, Rajkumar SV, **Kumar S**. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. *Leukemia*. 2024 Aug; 38 (8):1864 PMID: 38886491 PMCID: PMC11286504 DOI: 10.1038/s41375-024-02308-5
882. Claveau JS, Murray DL, Dispenzieri A, Kapoor P, Binder M, Buadi F, Dingli D, Fonder A, Gertz M, Gonsalves W, Hayman S, Hobbs M, Hwa YL, Kourelis T, Lacy M, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar V, **Kumar SK**. Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment. *Leukemia*. 2024 Aug; 38 (8):1863 PMID: 38886490 DOI: 10.1038/s41375-024-02307-6
883. Rees MJ, **Kumar S**. High-risk multiple myeloma: Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy. *Am J Hematol*. 2024 Aug; 99 (8):1560-1575 Epub 2024 Apr 13 PMID: 38613829 DOI: 10.1002/ajh.27327
884. **Kumar S**, Rajkumar SV, Jevremovic D, Kyle RA, Shifrin Y, Nguyen M, Husain Z, Alikhah A, Jafari A, Mai S, Anderson K, Louis S. Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma. *Am J Hematol*. 2024 Aug; 99 (8):1532-1539 Epub 2024 May 15 PMID: 38747543 DOI: 10.1002/ajh.27364
885. Vanderboom PM, Chawla Y, Dasari S, Kapoor I, **Kumar SK**, Nair KS, Gonsalves WI. Differences in the proteome within extracellular vesicles between premalignant and malignant plasma cell disorders. *Eur J Haematol*. 2024 Sep; 113 (3):351-356 Epub 2024 May 28 PMID: 38804098 PMCID: PMC11296916 DOI:

10.1111/ejh.14246

886. Charalampous C, Goel U, Kapoor P, Binder M, Buadi F, Dingli D, Dispenzieri A, Fonder A, Gertz M, Gonsalves W, Hayman S, Hobbs M, Hwa YL, Kourelis T, Lacy M, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar V, **Kumar SK**. Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies. *Clin Lymphoma Myeloma Leuk*. 2024 Oct; 24(10):e329-e335. Epub 2024 Jun 01. PMID: 38955580 DOI: 10.1016/j.clml.2024.05.020
887. Muchtar E, Wisniewski B, Geyer S, Palladini G, Milani P, Merlini G, Schonland S, Veelken K, Hegenbart U, Leung N, Dispenzieri A, **Kumar SK**, Kastritis E, Dimopoulos MA, Liedtke M, Ulloa P, Sanchowala V, Szalat R, Dooley K, Landau H, Petrlik E, Lentzsch S, Coltoff A, Blade J, Cibeira MT, Cohen O, Foard D, Gillmore J, Lachmann H, Wechalekar A, Gertz MA. Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis. *JAMA Oncol*. 2024 Oct 1; 10 (10):1362-1369 PMID: 39088206 PMCID: PMC11295065 DOI: 10.1001/jamaoncol.2024.2629
888. Charalampous C, Shah D, **Kumar S**, Chakraborty R. Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines. *Ann Hematol*. 2024 Oct; 103 (10):3881-3888 Epub 2024 Apr 17 PMID: 38630132 DOI: 10.1007/s00277-024-05733-9
889. Sidana S, Bankova AK, Hosoya H, **Kumar SK**, Holmes TH, Tamaresis J, Le A, Muffly LS, Maysel-Auslender S, Johnston L, Arai S, Lowsky R, Meyer E, Rezvani A, Weng WK, Frank MJ, Shiraz P, Maecker HT, Lu Y, Miklos DB, Shizuru JA. Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma. *Blood Cancer J*. 2024 Oct 9; 14 (1):173 Epub 2024 Oct 09 PMID: 39384609 PMCID: PMC11464886 DOI: 10.1038/s41408-024-01152-1
890. Chohan KL, Pruthi RK, Zanwar S, Paludo J, Go R, Pardani A, Ashrani A, Cook JM, Thompson CA, Chanan-Khan A, Ailawadhi S, Habermann TM, Witzig TE, Gertz MA, Dingli D, Buadi FK, Dispenzieri A, Leung N, **Kumar SK**, Rajkumar V, Nichols WL, Kyle RA, Ansell SM, Kapoor P, Sridharan M, Abeykoon JP. The clinical impact of acquired von Willebrand syndrome secondary to Waldenstrom macroglobulinemia: an underrecognized source of major bleeding events. *Leukemia*. 2024 Nov; 38 (11):2497-2500 Epub 2024 Aug 28 PMID: 39198620 DOI: 10.1038/s41375-024-02393-6
891. Abdallah N, **Kumar SK**. Up-Front Treatment of Elderly (Age $\geq$ 75 Years) and Frail Patients With Multiple Myeloma. *J Natl Compr Canc Netw*. 2024 Nov; 22 (9) PMID: 39536451 DOI: 10.6004/jnccn.2024.7039
892. Essiaw LA, Bolarinwa A, Tang H, Kudowor G, Shivaram S, Sharma N, Linden MA, Buadi FK, Rajkumar SV, **Kumar S**, Dei-Adomakoh Y, Cook JM, Baughn LB, Paemka L. Comparison of Laboratory Data at Initial Diagnosis of Multiple Myeloma Between Black Africans, African Americans and White patients. *Clin Lymphoma Myeloma Leuk* 2024 Dec; 24 (12):863-868 Epub 2024 July 17 PMID: 39117531 PMCID: PMC11602365 DOI: 10.1016/j.clml.2024.07.010
893. Jevremovic D, Shi M, Horna P, Otteson GE, Timm MM, Bennett SA, Baughn LB, Greipp PT, Gonsalves WI, Kapoor P, Gertz MA, Binder M, Buadi FK, Dispenzieri A, Kourelis T, Muchtar E, Zhou J, Rajkumar SV, **Kumar SK**, Olteanu H. FDA IDE validation of multiple myeloma MRD test by flow cytometry. *Am J Hematol* 2024 Dec; 99 (12):2399-2401 Epub 2024 Sept 18 PMID: 39291868 DOI: 10.1002/ajh.27484
894. Dimopoulos MA, Migkou M, Bhutani M, Ailawadhi S, Kalff A, Walcott FL, Pore N, Brown M, Wang F, Cheng LI, Kagiampakis I, Williams M, Kinneer K, Wu Y, Jiang Y, Kubiak RJ, Zonder JA, Larsen J, Sirdesai S, Yee AJ, **Kumar S**. Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma. *Leuk Lymphoma*. 2024 Dec; 65 (12):1789-1800 Epub 2024 Oct 15 PMID: 39404476 DOI: 10.1080/10428194.2024.2373331
895. **Kumar SK**. What is the ideal approach-doublet, triplet, or quadruplet(s)? *Hematology Am Soc Hematol Educ Program*. 2024 Dec 6; 2024 (1):551-560 PMID: 39644003 PMCID: PMC11665711 DOI: 10.1182/hematology.2024000581
896. Chakraborty R, Zanwar S, Hegenbart U, Bhutani D, Gertz MA, Dispenzieri A, **Kumar S**, D'Souza A, Patwari A, Cowan A, Chen G, Milani P, Palladini G, Sanchowala V, Bodanapu G, Schonland SO, Lentzsch S, Muchtar E. Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy. *Blood*. 2024 Dec 19; 144 (25):2613-2624 PMID: 39197073 DOI: 10.1182/blood.2024025899
897. Goel U, Charalampous C, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder A, Gertz MA, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame RM, Kyle RA, Rajkumar SV, **Kumar SK**. Retreatment of multiple myeloma with previously refractory drugs. *Blood Adv*. 2024 Dec 24; 8(24):6321-6328. PMID: 39536293 PMCID: PMC11700264 DOI: 10.1182/bloodadvances.2024014723
898. Morgan HT, Derman BA, Ma H, **Kumar SK**. Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias. *Front Immunol*. 2025; 16:1558275 Epub 2025 Apr 08 PMID: 40264764 PMCID: PMC12011880 DOI: 10.3389/fimmu.2025.1558275
899. Visram A, Chan KK, Seow H, Pond G, Gayowsky A, Mohyuddin GR, McCurdy A, Sandhu I, Venner C, Lancman G, Balitsky A, Kouroukis T, Bruins R, **Kumar S**, Fonseca R, Mian H. Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study.

Haematologica. 2025 Jan 1; 110 (1):228-233 Epub 2025 Jan 01 PMID: 39219457 PMCID: PMC11694101 DOI: 10.3324/haematol.2024.285768

900. Liang X, Xu W, Zhou F, Huang W, Yi X, Zhang Y, Yan Y, Zhang N, Wang J, Sun X, Hu R, Zhu Y, Ma X, Sun Y, Lan M, Long M, **Kumar SK**, Dai Y, Jin F. Dissecting the high-risk property of 1q gain/amplification in patients with newly diagnosed multiple myeloma. Am J Cancer Res. 2025; 15 (2):501-516 Epub 2025 Feb 15 PMID: 40084363 PMCID: PMC11897644 DOI: 10.62347/FXVH4425
901. Tang H#, Yan H#, Shivaram S#, Lehman S, Sharma N, Smadbeck J, Zepeda-Mendoza C, Tian S, Asmann Y, Vachon C, Gaspar Maia A, Keats J, Bergsagel PL, Fonseca R, Stewart AK, Hsu JS, Kandasamy RK, Pandey A, Kaddoura MA, Maura F, Mitra A, Rajkumar SV, **Kumar SK**, Elhaik E, Braggio E, Baughn LB. Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14). Leukemia. 2025 Jan; 39 (1):42-50 Epub 2024 Oct 14 PMID: 39402215 PMCID: PMC11717701 DOI: 10.1038/s41375-024-02363-y
902. Banerjee R, Sexton R, Cowan AJ, Rosenberg AS, Ailawadhi S, Rajkumar SV, **Kumar S**, Dispenzieri A, Lonial S, Durie BGM, Richardson PG, Usmani SZ, Hoering A, Orlowski RZ. Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. Blood. 2025 Jan 2; 145 (1):75-84 PMID: 39321347 DOI: 10.1182/blood.2024025939
903. Visram A, Larson D, Norman A, Dispenzieri A, Murray DL, Kyle R, Rajkumar SV, Slager S, **Kumar S**, Vachon C. Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection. Blood. 2025 Jan 16; 145 (3):325-333 PMID: 39437710 PMCID: PMC12060158 DOI: 10.1182/blood.2024025415
904. Vaxman I, **Kumar S**, Cohen I, Shimony S, Dispenzieri A, Buadi F, Dingli D, Muchtar E, Kapoor P, Hogan W, Hayman S, Leung N, Gonsalves W, Kourelis T, Warsame R, Gertz M. Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiM. Br J Haematol. 2025 Feb; 206 (2):607-614 Epub 2024 Nov 29 PMID: 39613336 PMCID: PMC11829144 DOI: 10.1111/bjh.19936
905. Faghani S, Moassefi M, Yadav U, Buadi FK, **Kumar SK**, Erickson BJ, Gonsalves WI, Baffour FI. Whole-body low-dose computed tomography in patients with newly diagnosed multiple myeloma predicts cytogenetic risk: a deep learning radiogenomics study. Skeletal Radiol. 2025 Feb; 54 (2):267-273 Epub 2024 June 27 PMID: 38937291 PMCID: PMC11652250 DOI: 10.1007/s00256-024-04733-0
906. Chawla Y#, Anderson EI, Smith M, Jain S, Evans LA, Neff J, Jang JS, Vazquez Rosario IK, Jevremovic D, Petterson XM, Sebastian S, Fonseca R, **Kumar SK**, Hitosugi T, Gonsalves WI. Lactate metabolism in clonal plasma cells and its therapeutic implications in multiple myeloma patients with elevated serum LDH levels. Cancer Metab. 2025 Feb 13; 13 (1):9 PMID: 39948621 PMCID: PMC11827136 DOI: 10.1186/s40170-025-00379-1
907. Zanwar S, Jevremovic D, Kapoor P, Olteanu H, Buadi F, Horna P, Gonsalves W, Otteson G, Bolarinwa AB, Hayman S, Abdallah N, Binder M, Cook J, Dispenzieri A, Dingli D, Gertz MA, Kourelis T, Leung N, Lin Y, Muchtar E, Warsame R, Fonder A, Hobbs M, Hwa YL, Rogers M, Kyle RA, Rajkumar SV, **Kumar S**. Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma. Blood Cancer J. 2025 Feb 18; 15 (1):20 PMID: 39966346 PMCID: PMC11836398 DOI: 10.1038/s41408-025-01232-w
908. Abdallah N, Bohra A, Mammadzadeh A, Buadi F, Kapoor P, Dispenzieri A, Gertz M, Hayman S, ElHaj M, Dingli D, Cook J, Binder M, Lin Y, Kourelis T, Warsame R, Thompson C, Menser T, Rajkumar SV, **Kumar S**. Prognostic impact of patient-reported symptoms in multiple myeloma. Blood Adv. 2025 Feb 25; 9(4):884-892. PMID: 39637309 PMCID: PMC11875160 DOI: 10.1182/bloodadvances.2024014232
909. Lee K, Kourelis T, Tschautscher M, Warsame R, Buadi F, Gertz M, Muchtar E, Dingli D, Hayman S, Go R, Hwa L, Fonder A, Gonsalves W, Hobbs M, Kyle R, Kapoor P, Leung N, Binder M, Cook J, Lin Y, Rogers M, Rajkumar SV, **Kumar S**, Dispenzieri A. Capillary leak phenotype as a major cause of death in patients with POEMS syndrome. Leukemia. 2025 Mar; 39 (3):703-709 Epub 2024 Dec 16 PMID: 39681639 PMCID: PMC11879873 DOI: 10.1038/s41375-024-02489-z
910. Moreau P, Facon T, Usmani SZ, Bahlis N, Raje N, Plesner T, Orlowski RZ, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Tiab M, Macro M, Frenzel L, Leleu X, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, **Kumar SK**. Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study. Leukemia. 2025 Mar; 39 (3):710-719 Epub 2025 Jan 15 PMID: 39815052 DOI: 10.1038/s41375-024-02506-1
911. Adams D, Wixner J, Polydefkis M, Berk JL, Conceicao IM, Dispenzieri A, Peltier A, Ueda M, Bender S, Capocelli K, Jay PY, Yureneva E, Obici L, **patisiran Global OLE study group**. Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension. JAMA Neurol. 2025 Mar 1; 82 (3):228-236 PMID: 39804640 PMCID: PMC11894486 DOI: 10.1001/jamaneurol.2024.4631
912. Netzel BC, Charlesworth MC, Johnson KL, French AJ, Dispenzieri A, Maleszewski JJ, McPhail ED, Grogan M, Redfield MM, Weivoda M, Muchtar E, Gertz MA, **Kumar SK**, Misra P, Vrana J, Theis J, Hayman SR, Ramirez-Alvarado M, Dasari S, Kourelis T. Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage. Amyloid. 2025 Mar; 32 (1):72-80 Epub 2025 Jan 08 PMID: 39773246 PMCID:

PMC11825277 DOI: 10.1080/13506129.2024.2448440

913. Abdallah N, Dizona P, Kumar A, LaPlant B, Menser T, Schaeferle G, Aug S, Weivoda M, Dispenzieri A, Buadi FK, Warsame R, Cook J, Lacy MQ, Hayman S, Gertz MA, Rajkumar SV, **Kumar SK**. Cumulative deficits frailty index and relationship status predict survival in multiple myeloma. *Blood Adv*. 2025 Mar 11; 9 (5):1137-1146 PMID: 39693516 PMCID: PMC11914168 DOI: 10.1182/bloodadvances.2024014624
914. Li SS, D'Souza A, Lentzsch S, Zafar F, Pivneva I, Watson T, Guerin A, **Kumar S**. Treatment Patterns and Clinical Outcomes of Patients With Systemic Light Chain Amyloidosis in the United States: Evidence From Real-World Clinical Practice. *Clin Lymphoma Myeloma Leuk*. 2025 Mar 28 [Epub ahead of print] PMID: 40287350 DOI: 10.1016/j.clml.2025.03.012
915. Price SN, Lee JW, Gareen IF, Kircher SM, **Kumar SK**, Mayer IA, Saba NF, Fenske TS, Atkins MB, Hodi FS, Kyriakopoulos CE, Tempany-Afdhal CM, Shanafelt TD, Park ER, Wagner LI. Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials. *J Pain Symptom Manage*. 2025 Apr; 69 (4):370-384 Epub 2024 Dec 31 PMID: 39746495 PMCID: PMC11867858 DOI: 10.1016/j.jpainsymman.2024.12.021
916. Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani SZ, Chari A, Plesner T, Orlowski RZ, Bahlis N, Basu S, Hulin C, Quach H, O'Dwyer M, Perrot A, Jacquet C, Venner CP, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Cook G, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, **Kumar SK**. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. *Leukemia*. 2025 Apr; 39 (4):942-950 Epub 2025 Feb 27 PMID: 40016302 PMCID: PMC11976258 DOI: 10.1038/s41375-024-02505-2
917. Dingli S, Rothweiler P, Binder M, Cook J, Gertz MA, Hayman S, Kapoor P, Kourelis T, **Kumar SK**, Siddiqui M, Warsame R, Lin Y, Erdman AG, Dingli D. Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma. *Leukemia*. 2025 Apr; 39(4):1005-1008. Epub 2025 Mar 05. PMID: 40044958 PMCID: PMC11976287 DOI: 10.1038/s41375-025-02547-0
918. Ravi G#, Richard S#, **Kumar S**, Atrash S, Liedtke M, Kaur G, Derman B, Bergsagel PL, Mailankody S, McCarthy P, Shrestha A, Kelly LM, Ly T, Das S, Thorpe J, Maier A, Varun D, Navarro G, Burgess MR, Hege K, Koegel AK, Costa LJ. Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T(R) Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma. *Leukemia*. 2025 Apr; 39 (4):816-826 Epub 2025 Feb 05 PMID: 39910285 PMCID: PMC11976278 DOI: 10.1038/s41375-025-02518-5
919. Zanwar S, **Kumar S**. Risk-adapted treatment for multiple myeloma: assessing the current potential and a roadmap for the future. *Leuk Lymphoma*. 2025 Apr; 66 (4):573-583 Epub 2024 Dec 22 PMID: 39709634 DOI: 10.1080/10428194.2024.2443550
920. Banerjee R, Fritz AR, Akhtar OS, Freeman CL, Cowan AJ, Shah N, Landau HJ, **Kumar SK**, Vogl DT, Efebera YA, McCarthy PL, Vesole DH, Mendizabal A, Krishnan AY, Somlo G, Stadtmauer EA, Pasquini MC. Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702. *Leukemia*. 2025 Apr; 39 (4):1001-1004 Epub 2025 Feb 24 PMID: 39994463 PMCID: PMC11978488 DOI: 10.1038/s41375-025-02534-5
921. **Kumar S**, Leleu X, Weisel KC, Popat R, Suero B, Craigie S, Spin P, Patel L, Ramirez AO, Hampp C, Ge W, Ma Q, Jagannath S. Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review. *Clin Lymphoma Myeloma Leuk*. 2025 Apr 3 Epub 2025 Apr 03 PMID: 40410023 DOI: 10.1016/j.clml.2025.03.013
922. Bolarinwa A, Nagaraj M, Zanwar S, Abdallah N, Bergsagel PL, Binder M, Buadi F, Chhabra S, Cook J, Dingli D, Dispenzieri A, Gertz MA, Gonsalves W, Hayman S, Kapoor P, Kourelis T, Leung N, Lin Y, Muchtar E, Parrondo R, Roy V, Sher T, Siddiqui M, Warsame R, Fonder A, Hobbs M, Hwa YL, Rogers M, Yadav U, Wiedmeier-Nutor JE, Baughn LB, Vincent Rajkumar S, Fonseca R, Ailawadhi S, **Kumar S**. Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes. *Blood Cancer J*. 2025 Apr 4; 15 (1):57 Epub 2025 Apr 04 PMID: 40185701 PMCID: PMC11971353 DOI: 10.1038/s41408-025-01264-2
923. Charalampous C, Claveau JS, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Christenson LH, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, **Kumar SK**. Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomes. *Blood Adv*. 2025 Apr 8; 9 (7):1559-1570 PMID: 39883947 PMCID: PMC11986228 DOI: 10.1182/bloodadvances.2024013355
924. Shi Q, Paiva B, Pederson LD, Dimier N, Talpes E, Prior TJ, Orfao A, Moreau P, Sonneveld P, **Kumar SK**, Dixon JG, Patel R, Bartlett BJ, Schechter J, McCarthy P, Hose D, Seckinger A, Mattia D, Goldschmidt H, Oliva S, Owen RG, Anderson KC, San-Miguel J, Durie BGM, Munshi N, International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM) Group. Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of

Individual Patient Data From Multiple Randomized Trials. J Clin Oncol. 2025 Apr 10; 43 (11):1289-1301 Epub 2025 Feb 12 PMID: 39938021 DOI: 10.1200/JCO-24-02020

925. Puttkammer JR, Barreto JN, Jensen CJ, Nedved AN, Wilson-Miller JL, Cole KC, Holmes LM, Kosobud AR, Kapoor P, Gertz MA, Dingli D, Gonsalves WI, **Kumar SK**, Hayman SR, Kourelis TV, Warsame R, Binder M, Cook J, Lin Y, Sandahl TB. Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization. JCO Oncol Pract. 2025 Apr 15; OP2400930 [Epub ahead of print] PMID: 40233295 DOI: 10.1200/OP-24-00930
926. Boddicker NJ, Mwangi R, Robinson DP, Allmer C, Rosenthal AC, Habermann TM, Feldman AL, Rimsza LM, King RL, Larson MC, Negaard BJ, Norman AD, Rajkumar N, Ansell SM, Dispenzieri A, Murray DL, Rajkumar V, **Kumar S**, Abeykoon JP, Nowakowski GS, Witzig TE, Novak AJ, Slager SL#, Vachon CM#, Cerhan JR#, Regeneron Genetics Center. Risk of lymphoid malignancy associated with cancer predisposition genes. Blood Cancer J. 2025 Apr 19; 15 (1):71 PMID: 40253392 PMCID: PMC12009404 DOI: 10.1038/s41408-025-01283-z
927. Yohannan B, Rees M, Gertz MA, Dispenzieri A, Kapoor P, Buadi FK, Dingli D, Leung N, Lacy MQ, Hayman SR, Gonsalves W, Kourelis T, Cook J, Binder M, Siddiqui M, Lin Y, Hwa L, Rogers MG, Hobbs M, Fonder A, Warsame R, Rajkumar SV, **Kumar SK**, Muchtar E. Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis. Blood Neoplasia. 2025 May; 2 (2):100092 Epub 2025 Mar 10 PMID: 40453144 PMCID: PMC12067897 DOI: 10.1016/j.bneo.2025.100092
928. **Kumar SK**, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Costello C, D'Angelo C, Derman B, Devarakonda S, Elsedawy N, Godara A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Vogl D, Kovach E, Kumar R. NCCN Guidelines(R) Insights: Multiple Myeloma, Version 1.2025. J Natl Compr Canc Netw. 2025 May; 23 (5):132-140 PMID: 40340857 DOI: 10.6004/jnccn.2025.0023
929. Sandahl TB, Soefje SA, Fonseca R, Ailawadhi S, Parrondo R, Lin D, Wu B, Calay ES, Silvert E, Kim N, Carpenter C, Wagner TE, Fowler J, Hester L, Rangarajan N, Murugadoss K, Marshall A, Stoy P, Gifkins D, Lin Y, **Kumar S**. Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration. JCO Oncol Pract. 2025 May; 21 (5):702-709 Epub 2024 Dec 20 PMID: 39705632 PMCID: PMC12165516 DOI: 10.1200/OP-24-00489
930. Perrot A, Facon T, Plesner T, Usmani SZ, **Kumar S**, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, Wang G, Gupta-Werner N, Kaila S, Pei H, Matt K, Gries KS, Carson R, Borgsten F, Weisel K. Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes. Eur J Haematol. 2025 May; 114 (5):883-889 Epub 2025 Feb 14 PMID: 39952901 PMCID: PMC11976685 DOI: 10.1111/ejh.14392
931. Katodritou E, Terpos E, Lentzsch S, **Kumar S**. Optimizing Outcomes in Relapsed and Refractory Multiple Myeloma: Personalized Approaches and Adverse Event Management. Am J Hematol. 2025 May 5 Epub 2025 May 05 PMID: 40322955 DOI: 10.1002/ajh.27646
932. Dingli S, Rothweiler P, Binder M, Cook J, Gertz MA, Hayman S, Kapoor P, Kourelis T, **Kumar SK**, Siddiqui M, Warsame R, Lin Y, Erdman AG, Dingli D. The ratio of brain to liver glucose activity and disease activity in multiple myeloma. Blood Cancer J. 2025 May 7; 15 (1):90 Epub 2025 May 07 PMID: 40335455 PMCID: PMC12059036 DOI: 10.1038/s41408-025-01280-2
933. Zanwar S, Novak J, Gonsalves WI, Howe M, Braggio E, Rajkumar SV, Binder M, Jevremovic D, Dasari S, **Kumar SK**. Extramedullary Myeloma is Genomically Complex and Characterized by Near-Universal MAPK Pathway Alterations. Blood Adv. 2025 May 14 [Epub ahead of print] PMID: 40367415 DOI: 10.1182/bloodadvances.2025016619
934. Crespo-Diaz RJ, daSilva-deAbreu AJ, Rosenbaum AN, Bernard SA, Gandhi MJ, **Kumar S**, Kourelis T, Behfar A, Clavell AL, Dunlay SM, Frantz RP, Kushwaha SS, Pereira NL, Wong YW, Daly RC, Spencer PJ, Theodulov MAV, Boilson BA. Daratumumab monotherapy as a desensitization strategy prior to cardiac transplantation. J Heart Lung Transplant. 2025 May 16 [Epub ahead of print] PMID: 40407767 DOI: 10.1016/j.healun.2025.01.021
935. Rees MJ, Geyer S, Yohannan B, Toumeh N, Atallah-Yunes SA, Gertz MA, Dispenzieri A, Hayman SR, Buadi F, Dingli D, Warsame R, Kapoor P, Grogan M, Cook J, Binder M, Leung N, Kourelis T, Gonsalves W, Rajkumar VS, **Kumar S**, Muchtar E. Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response. Haematologica. 2025 May 22 [Epub ahead of print] PMID: 40400470 DOI: 10.3324/haematol.2025.287848
936. Bohra A, Hassan R, Zanwar S, Jevremovic D, Olteanu H, Gonsalves WI, Otteson G, Horna P, Rajkumar SV, **Kumar S**. Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia. Leukemia. 2025 May 26 [Epub ahead of print] PMID: 40419655 DOI: 10.1038/s41375-025-02653-z
937. Naiki H, Johnson M, Walters K, Carpinteiro A, Cibeira MT, D'Souza A, Kastritis E, Maurer MS, Mendelson L,

- Merlini G, Muchtar E, Palladini G, Riva E, Sekijima Y, Westermarck P, **Kumar S**, Schonland SO. Global patterns of amyloid typing: results of a survey by the International Society of Amyloidosis (ISA). *Amyloid*. 2025 Jun; 32 (2):139-144 Epub 2025 Feb 10 PMID: 39928315 DOI: 10.1080/13506129.2025.2462992
938. Chawla Y, Anderson EI, Jevremovic D, **Kumar SK**, Hitosugi T, Gonsalves WI. Mass spectrometry-based lipidomics identifies select triacylglycerol species as differentially abundant in the bone marrow microenvironment of patients with multiple myeloma compared to monoclonal gammopathy of unknown significance. *Metabolomics*. 2025 Jun 1; 21 (3):73 Epub 2025 June 01 PMID: 40451988 DOI: 10.1007/s11306-025-02271-x
 939. Rees MJ, Muchtar E, Atallah-Yunes SA, Dasari S, Leung N, Gertz M, Dispenzieri A, McPhail E, **Kumar S**, Anderson E, Dick C, Kourelis T. Proteomic determinants of renal organ response in light-chain amyloidosis. *Amyloid*. 2025 Jun; 32 (2):200-202 Epub 2025 Feb 19 PMID: 39972595 DOI: 10.1080/13506129.2025.2467282
 940. Claveau JS, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves WI, Hayman SR, Hobbs MA, Christenson LH, Kourelis TV, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, **Kumar SK**. Eliminating The Need for Sequential Confirmation of Response in Multiple Myeloma. *Blood*. 2025 Jun 9 Epub 2025 June 09 PMID: 40489635 DOI: 10.1182/blood.2024027949
 941. Avet-Loiseau H, Davies FE, Samur MK, Corre J, D'Agostino M, Kaiser MF, Raab MS, Weinhold N, Gutierrez NC, Paiva SB, Neri P, Weisel K, Maura F, Walker BA, Bustoros M, Stewart AK, Usmani SZ, Hillengass J, Chng WJ, Keats JJ, Martinez-Lopez J, Sperling AS, Touzeau C, Zhan F, Raje NS, Cavo M, Bolli N, Ghobrial IM, Dhodapkar MV, Jagannath S, Spencer A, Parekh S, Bahlis NJ, Lonial S, Sonneveld P, Bergsagel L, Orlowski RZ, Morgan G, Mateos MV, Rajkumar SV, San Miguel JF, Anderson KC, Moreau P, **Kumar S**, Prosper F, Munshi NC. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. *J Clin Oncol*. 2025 Jun 9; JCO2401893 Epub 2025 June 09 PMID: 40489728 DOI: 10.1200/JCO-24-01893
 942. Diamond BT, Baughn LB, Poorebrahim M, Poos AM, Lee H, Kaddoura M, Wiedmeier-Nutor JE, Durante MA, Otteson GE, Jevremovic D, Tang H, Frohling S, Baertsch MA, Papadimitriou M, Ziccheddu B, Jelinek T, Lemoine C, Rak A, Green DJ, Landgren CO, Neri P, Bergsagel PL, Braggio E, **Kumar SK**, Raab MS, Fonseca R, Bahlis N, Weinhold N, Maura F. Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma. *Blood*. 2025 Jun 10 Epub 2025 June 10 PMID: 40493883 DOI: 10.1182/blood.2024028107
 943. Rees MJ, Toumeh N, Dispenzieri A, Gertz M, Yohannan B, Atallah-Yunes SA, Kapoor P, Kourelis T, Leung N, Hayman S, Buadi F, Dingli D, Cook J, Warsame R, Binder M, Gonsalves W, Rajkumar SV, **Kumar S**, Muchtar E. Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survival. *Amyloid*. 2025 Jun 12; 1-9 Epub 2025 June 12 PMID: 40509545 DOI: 10.1080/13506129.2025.2516790

Conference Reports

1. Sharma Neeraj, Tang Hongwei, Yan Huihuang, Tian Shulan, Shivaram Suganti, Kourelis Taxiarchis, **Kumar Shaji**, Baughn Linda. Variation in the Immune Tumor Microenvironment in Relation to Self-Reported Race in Individuals with Multiple Myeloma *Blood*.2022

Books

1. **Kumar S**. Multiple Myeloma Kumar S. Vol. 1. New York (NY): Demos Medical; 2010. (Emerging Cancer Therapeutics)
2. Zimmerman TM, **Kumar SK**. Biology and management of unusual plasma cell dyscrasias. 2017. 202 p..

Book Chapters

1. **Kumar S**, Greipp PR. Monoclonal gammopathy of undetermined significance. In: Sekeres MA, Kalaycio ME, Bolwell BJ. *Clinical malignant hematology*. New York: McGraw-Hill Medical; 2007. p. 943-54.
2. **Kumar S**. Lenalidomide for initial therapy of newly diagnosed multiple myeloma. In: Lonial S, editor. *Myeloma therapy: pursuing the plasma cell*. Totowa: Humana; 2008. (Contemporary Hematology.). p. 279-88.
3. Podar K, **Kumar S**, Chauhan D, Anderson KC. Pathophysiologic role of VEGF in hematologic malignancies. In: Davis DW, Herbst RS, Abbruzzese JL, editors. *Antiangiogenic cancer therapy*. Boca Raton: CRC Press; 2008. p. 91-129.
4. Dispenzieri A, **Kumar S**. Current therapies for light-chain amyloidosis. In: Ramirez-Alvarado M; Kelly JW; Dobson CM editor. *Protein misfolding diseases: current and emerging principles and therapies*. Hoboken: Wiley; 2010. (Wiley Series in Protein and Peptide Science.). p. 775-93.
5. **Kumar S**, Rajkumar SV. Multiple myeloma: molecular biology, diagnosis and treatment. In: *Advances in malignant hematology*. 2011. p. 315-41.

6. **Kumar S.** Promising clinical trials in multiple myeloma. In: Multiple myeloma - a new era of treatment strategies. 2012. p. 120-7.
7. Singla A, **Kumar S.** Newer IMiDs. In: Advances in biology and therapy of multiple myeloma. Volume 2. 2013. p. 181-213.
8. Mikhael J, **Kumar S,** Rajkumar SV. Approach to relapsed refractory myeloma. In: Gertz MA; Rajkumar SV editor. Multiple myeloma: diagnosed and treatment. New York: Springer; 2014. p. 95-100.
9. Dispenzieri A, Lacy MQ, **Kumar S.** Multiple myeloma. In: Greer JP; et al editor. Wintrobe's clinical hematology. Thirteenth Edition. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014. p. 2046-97.
10. Singh PP, **Kumar SK.** Multiple myeloma. In: The Bethesda handbook of clinical oncology. Fourth Edition. 2014. p. 343-60.
11. **Kumar S,** McCurdy A. New agents for multiple myeloma. In: Gertz MA; Rajkumar SV editor. Multiple myeloma: diagnosed and treatment. New York: Springer; 2014. p. 131-40.
12. **Kumar S,** Russell SJ. Treatment of newly diagnosed multiple myeloma. In: Gertz MA; Rajkumar SV editor. Multiple myeloma: diagnosis and treatment. New York: Springer; 2014. p. 81-94.
13. Gonsalves WI, **Kumar SK.** Plasma cell leukemia. In: Zimmerman TM; Kumar SK editors., Biology and Management of Unusual Plasma Cell Dyscrasias. 2017. p. 1-16.
14. Tandon N, **Kumar SK.** Plasmacytoma – current approach to diagnosis and management. In: Zimmerman TM; Kumar SK editors., Biology and management of unusual plasma cell dyscrasias. 2017. p. 17-39.
15. Lakshman A, **Kumar SK.** Multiple myeloma. In: Abraham J; Gulley JL editors., The Bethesda review of clinical oncology. First Edition. Philadelphia: Wolters Kluwer; 2019. (Review of clinical oncology). p. 247-9.
16. * Lakshman A, **Kumar SK.** Multiple myeloma. In: Abraham J, Gulley JL, editor(s). The Bethesda Handbook of Clinical Oncology. 6 ed. Chapter 27. Philadelphia: Lippincott Williams & Wilkins; 2022. p. 415-446.

Editorials

1. **Kumar S,** Gertz MA. Cutaneous and systemic amyloidoses. Int J Dermatol. 2002 Mar; 41(3):133-4.
2. **Kumar S,** Kyle RA. A new era in the management of multiple myeloma - The Ghobrial/Ghobrial/Mitsiades et al article reviewed. Oncology (Williston Park) 2007 Jun; 21(7):800.
3. **Kumar SK,** Anderson KC. Immune Therapies in Multiple Myeloma. Clin Cancer Res 2016 Nov 15; 22(22):5453-5460
4. Sidana S, **Kumar SK,** Gonsalves WI. Should we measure clonal circulating plasma cells in light chain amyloidosis? Oncotarget 2018 Nov 2; 9 (86):35607-35608 Epub 2018 Nov 02
5. Muller AMS, **Kumar SK,** Bruno B. The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all? Haematologica 2019 Feb; 104 (2):222-225
6. Auclair D, Lonial S, Anderson KC, **Kumar SK.** Precision medicine in multiple myeloma: are we there yet? Expert Review Of Precision Medicine And Drug Development 2019 Mar 4; 4 (2):51-3
7. **Kumar SK.** Recycling therapies for myeloma: The need for prospective trials. Cancer 2019 Sep 1; 125(17):2920-2922 Epub 2019 May 15
8. Palladini G, Schonland SO, Sanchirawala V, **Kumar S,** Wechalekar A, Hegenbart U, Milani P, Ando Y, Westermarck P, Dispenzieri A, Merlini G. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid 2021 Mar; 28 (1):1-2 Epub 2021 Jan 07
9. Inam S, Ross JA, Touzeau C, Moreau P, **Kumar SK,** Harrison SJ. Paving the way to precision medicine in multiple myeloma. Expert Rev Hematol 2021 Apr; 14 (4):323-327 Epub 2021 Apr 12
10. Claveau JS, Murray DL, Dispenzieri A, Kapoor P, Binder M, Buadi F, Dingli D, Fonder A, Gertz M, Gonsalves W, Hayman S, Hobbs M, Hwa YL, Kourelis T, Lacy M, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar V, **Kumar SK.** Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment. Leukemia 2023 Jan; 37 (1):1-4 Epub 2022 Dec 08
11. Baljevic M#, Sborov DW#, **Kumar SK#.** Long term responders in frontline multiple myeloma-exception vs expectation of the modern era. Blood Cancer J 2024 Jul 17; 14 (1):115 Epub 2024 July 17

Commentaries

1. **Kumar S.** Progress in the treatment of multiple myeloma. *Lancet* 2006 Mar 11; 367 (9513):791-2
PMID:16530557 DOI:10.1016/S0140-6736(06)68311-6
2. **Kumar S.** Combination therapy with melphalan, prednisone, and thalidomide (MPT) for multiple myeloma. *American Journal of Hematology/Oncology*. 2006 Aug; 5(8):491-4. PMID:0 DOI:
3. **Kumar S.** Solitary plasmacytoma: is radiation therapy sufficient? *Am J Hematol*. 2008 Sep; 83(9):695-6.
PMID:18645990 DOI:10.1002/ajh.21248
4. **Kumar S, Rajkumar SV.** Many facets of bortezomib resistance/susceptibility. *Blood* 2008 Sep 15; 112 (6):2177-8 PMID:18779399 DOI:10.1182/blood-2008-07-167767
5. **Kumar S, Rajkumar SV.** Commentary on myeloma presentations. *Clinical Advances in Hematology and Oncology*. 2009; 7(2 Suppl. 6):11-2.
6. Madan S, **Kumar S.** Review: extramedullary disease in multiple myeloma. *Clin Adv Hematol Oncol*. 2009 Dec; 7(12):802-4. PMID:20332751 DOI:
7. Kyle RA, **Kumar S.** The significance of monoclonal gammopathy of undetermined significance. *Haematologica*. 2009 Dec; 94(12):1641-4. PMID:19996115 DOI:10.3324/haematol.2009.013961
8. Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, **Kumar S**, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. *Mayo Clin Proc*. 2010 Feb; 85(2):197-9; author reply 201-4. PMID:20118399 DOI:10.4065/mcp.2009.0559
9. Palladini G, Dispenzieri A, Gertz M, **Kumar S**, Wechalekar A, Hawkins PN, Schonland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. Reply to S. Girnius et al. *J Clin Oncol*. 2013 Jul 20; 31(21):2750-1. PMID:24040662 DOI:
10. Dispenzieri A, **Kumar S.** Treatment for high-risk smoldering myeloma. *N Engl J Med*. 2013 Oct 31; 369 (18):1764. PMID:24171529 DOI:10.1056/NEJMc1310911#SA3
11. **Kumar SK, Rajkumar SV.** The current status of minimal residual disease assessment in myeloma. *Leukemia* 2014 Feb; 28 (2):239-40 PMID:24496282 DOI:10.1038/leu.2013.306
12. **Kumar SK, Gertz MA.** Risk adapted therapy for multiple myeloma: back to basics. *Leuk Lymphoma* 2014 Oct; 55 (10):2219-20 Epub 2014 Apr 22 PMID:24684226 DOI:10.3109/10428194.2014.905775
13. **Kumar S.** Blind men and an elephant. *Blood* 2015 Jan 29; 125 (5):745-7 PMID:25634613 DOI:10.1182/blood-2014-12-615328
14. **Kumar S.** Don't let the genie out of the bottle! *Blood* 2024 Feb 15; 143 (7):564-566 PMID:38358852 DOI:10.1182/blood.2023023293

Abstracts

1. Mow B, **Kumar S**, Monahan KH, Severson CJ, Schroeder G, Fonseca R, McGoon MD, Philyly RL. Thrombocytopenia during epoprostenol infusion for primary pulmonary hypertension: is there a relation to dose? *Blood*. 1998; 92(10 Suppl 1 Part 1-2):87b.
2. **Kumar S**, Litzow M, Chen M, Gastineau D, Gertz M, Inwards D, Lacy M, Tefferi A. Prophylaxis of GVHD with cyclosporine-prednisone is associated with an increased risk of chronic GVHD. (Poster). *American Society of Bone Marrow Transplantation Annual Conference*. 1999 Feb.
3. **Kumar S**, Pruthi RK, Nichols WL. Estimation of prevalence and natural history of acquired von Willebrand disease. (Abstract #4). *Haemophilia*. 2000;6:212-31.
4. **Kumar S**, Mow BF, Gertz MA, Tefferi A. Splenectomy in chronic immune thrombocytopenia and salvage therapies for post-splenectomy relapses. *International Journal of Hematology*. 2000; 72(1S):183.
5. **Kumar S**, Kamath PS. Natural history of acute portal and acute mesenteric venous thrombosis. *Gastroenterology*. 2000 Apr; 118(4 Suppl 2 Part 1):AASLD A972.
6. **Kumar S**, Nichols WL, Pruthi RK. A 25-year single institutional experience with autoimmune factor VIII inhibitors (acquired hemophilia). *Blood*. 2000 Nov 16; 96(11 Part 1):268a.
7. **Kumar S**, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar

SV. Bone marrow (BM) angiogenesis in multiple myeloma (MM): effect of therapy and prognostic value. Blood. 2000 Nov 16; 96(11 Part 1):363a.

8. **Kumar S**, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR. Early prediction of relapse after allogeneic transplant for acute myelogenous leukemia. Blood. 2000 Nov 16; 96(11 Part 1):197a.
9. **Kumar S**, Dispenzieri A, Gertz MA, Lacy MQ. High incidence of gastrointestinal bleeding following high dose chemotherapy and stem cell rescue for primary systemic amyloidosis. Blood. 2000 Nov 16; 96(11 Part 1):389a.
10. **Kumar S**, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR. Omission of day +11 methotrexate for graft-versus-host disease prophylaxis after allogeneic BMT increases the risk of severe acute graft- versus- host disease. Blood. 2000 Nov 16; 96(11 Part 1):398a.
11. **Kumar S**, Diehn F, Gertz MA, Tefferi A. Splenectomy for adult immune thrombocytopenic purpura and treatment of post-splenectomy relapses. Blood. 2000 Nov 16; 96(11 Part 1):252a.
12. **Kumar S**, Porrata LF, Okuno SH, Edmonson J, Buckner JC, Moynihan TJ. Primary cardiac sarcomas-A single institution experience. J Clin Oncol. 2001; 20:365a.
13. **Kumar S**, Porrata LF, Buckner JC, Okuno SH, Edmonson J, Moynihan TJ. Primary cardiac sarcomas-Mayo Clinic experience. (Abstract 1455). Program/Proc Am Soc Clin Oncol. 2001; 20(1 of 2):365a.
14. **Kumar S**, Lacy M, Inwards D, Litzow M, Tefferi A. Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Blood. 2001 Nov 16; 98(11 Part 1):192a.
15. Porrata LF, Litzow MR, Tefferi A, Letendre L, **Kumar S**, Geyer SM, Markovic SN. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Blood. 2001 Nov 16; 98(11 Part 2):397b.
16. **Kumar S**, Timm M, Haug J, Wellik L, Witzig TE, Greipp PR, Rajkumar SV. Expression of VEGF and its receptors by myeloma cells. Blood. 2001 Nov 16; 98(11 Part 1):373a.
17. **Kumar S**, Dispenzieri A, Lacy MQ, Lust J, Gertz MA. Myelomatous meningitis at relapse following high dose therapy: Report of three cases. Blood. 2001 Nov 16; 98(11 Part 2):299b.
18. **Kumar S**, Lacy MQ, Inwards DJ, Tefferi A, Gastineau DA, Gertz MA, Litzow MR. Slow lymphocyte recovery predicts increased risk for relapse after allogeneic bone marrow transplantation for acute lymphocytic leukemia. Blood. 2001 Nov 16; 98(11 Part 2):368b.
19. **Kumar S**, Witzig TE, Thompson MA, Haug J, Wellik L, Timm MM, Greipp PR, Rajkumar SV. Expression of angiogenic cytokines by plasma cells: a comparison of MGUS, smoldering myeloma and newly diagnosed symptomatic myeloma (Abstract 3186). Blood. 2002; 100(11).
20. **Kumar S**, Lacy MQ, Dispenzieri A, Grogan M, Gertz MA. Peripheral blood stem cell transplantation for primary systemic amyloidosis with cardiac involvement (Abstract 674). Blood. 2002; 100(11).
21. Fielding A, Bucheit A, **Kumar S**, Lin Y, von Messling V. Replicating attenuated measles virus can be engineered to enter cells through the CD20 antigen (Abstract 756). Blood. 2002; 100(11).
22. **Kumar S**, Ahmann G, Witzig TE, Kyle RA, Greipp PR. Serum syndecan (CD138) levels are increased in patients with symptomatic multiple myeloma compared to normal controls, MGUS, and smoldering myeloma (Abstract 3185). Blood. 2002; 100(11).
23. **Kumar S**, Lacy MQ, Inwards DJ, Tefferi A, Gastineau DA, Gertz MA, Litzow MR. Slow lymphocyte recovery predicts increased risk for relapse after allogeneic bone marrow (i.e. marrow) transplantation for acute lymphocytic leukemia. (Abstract 114). Biol Blood Marrow Transplant. 2002; 8(2):93.
24. Greipp PR, **Kumar S**, Blood EA, Rue M, Jacobson J, Therneau TM, Larson DR, Anderson KC, Oken MM, Kyle RA. A simple classification to identify poor-risk untreated myeloma (Abstract 2351). Blood. 2002 Nov 16; 100(11).
25. Thompson MA, Witzig TE, Timm MM, Haug J, **Kumar S**, Fonseca R, Greipp PR, Rajkumar SV. Angiogenesis and angiogenic cytokines in patients receiving thalidomide for multiple myeloma (MM) (Abstract 3205). Blood. 2002 Nov 16; 100(11):811a.
26. **Kumar S**, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Iturria N, Allmer C, Lust JA, Witzig TE, Greipp PR, Kyle RA, Litzow MR, Gertz MA. Autologous peripheral blood stem cell transplantation for primary refractory multiple myeloma (Abstract 1674). Blood. 2002 Nov 16; 100(11):432a-433a.
27. **Kumar S**, Chandra J, Grote D, Cattaneo R, Kaufmann S, Fielding A. Bcl-2 over-expression results in decreased measles virus mediated cytotoxicity in lymphoma cell lines (Abstract 2268). Blood. 2002 Nov 16; 100(11).
28. **Kumar S**, Larson DR, Therneau TM, Kyle RA, Greipp PR. Natural history of relapsed multiple myeloma

(Abstract 2352). Blood. 2002 Nov 16; 100(11).

29. **Kumar S**, Rajkumar SV, Greipp PR, Witzig TE. Plasma cell labeling index: comparison of peripheral blood vs bone marrow myeloma plasma cells (Abstract 1525). Blood. 2002 Nov 16; 100(11).
30. **Kumar S**, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Wellik L, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Prognostic value of angiogenesis in solitary plasmacytoma (Abstract 2355). Blood. 2002 Nov 16; 100(11):599a.
31. **Kumar S**, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Iturria N, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. Single agent dexamethasone for induction in patients with multiple myeloma undergoing autologous stem cell transplants (Abstract 1673). Blood. 2002 Nov 16; 100(11):432a.
32. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer S, Iturria N, **Kumar S**, Lust JA, Kyle RA, Greipp PR, Witzig TE. Single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma (Abstract 1567). Blood. 2002 Nov 16; 100(11):403a-404a.
33. Ghobrial IM, **Kumar S**, Porrata LF, Gertz MA, Gastineau DA, Ansell SM, Lacy MQ, Rajkumar VS, Micallef IN, Tefferi A, Dispenzieri A, Inwards D, Litzow MR, Markovic SN. Thalidomide does not affect immune reconstitution post-autologous bone marrow transplantation in multiple myeloma (Abstract 1679). Blood. 2002 Nov 16; 100(11).
34. **Kumar S**, Litzow MR, Rajkumar S. Effect of allogeneic stem cell transplantation on bone marrow (BM) angiogenesis in chronic myelogenous leukemia (Abstract 80). Biol Blood Marrow Transplant. 2003 Feb; 9(2):88.
35. **Kumar S**, Micallef IN, Porrata LF, Elliot MA, Ansell SM, Dispenzieri A, Lacy MQ, Inwards DJ, Tefferi A, Gastineau DA, Gertz MA, Litzow MR. Lymphocyte recovery after allogeneic stem cell transplantation: comparison of bone marrow and peripheral blood stem cell transplantation (Abstract 138). Biol Blood Marrow Transplant. 2003 Feb; 9(2):106.
36. Elliott MA, Plumhoff EA, Nichols WL, Heit JA, Fass DN, **Kumar SK**, Tefferi A. Acquired von Willebrand syndrome (AVWS) in chronic myeloproliferative disorders (MPD): Clinical and laboratory features, and response to therapy. Blood. 2003 Nov 16; 102(11):311a.
37. **Kumar S**, Witzig TE, Wellik L, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Kyle RA, Gertz MA, Greipp PR, Rajkumar SV. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Blood. 2003 Nov 16; 102(11):387b.
38. Lacy MQ, Dispenzieri A, Gertz MA, Witzig TE, Greipp PR, Fonseca R, Lust JA, **Kumar S**, Zeldenrust S, Kyle RA, Snow D, Hayman SR, Sidor CF, Treston AM, Zeldis JB, Rajkumar SV. ENMD-0995 (S 3-APG), a novel thalidomide analogue, has promising clinical activity for patients with relapsed refractory multiple myeloma. Preliminary results of a Phase I clinical trial. Blood. 2003 Nov 16; 102(11):453a.
39. **Kumar S**, Gertz MA, Dispenzieri A, Lacy MQ, Wellik L, Fonseca R, Lust JA, Witzig TE, Kyle RA, Greipp PR, Rajkumar SV. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high dose therapy. Blood. 2003 Nov 16; 102(11):983a-4a.
40. **Kumar S**, Rajkumar SV, Dispenzieri A, Lacy MQ, Fonseca R, Lust JA, Kyle RA, Witzig TE, Greipp PR, Gertz MA. Prognostic value of bone marrow plasma cell labeling index in primary systemic amyloidosis. Blood. 2003 Nov 16; 102(11):377b.
41. **Kumar S**, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, Lust JA, Gertz MA, Greipp PR, Witzig TE. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. Blood. 2003 Nov 16; 102(11):938a.
42. **Kumar S**, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. Clinical and biological correlates of CD45 expression on bone marrow plasma cells from patients with multiple myeloma. Blood. 2004 Nov 16; 104(11 Part 1):918A.
43. **Kumar S**, Lacy MQ, Dispenzieri A, Hayman SR, Rajkumar SV, Witzig TE, Lust JA, Greipp PR, Kyle R, Litzow MR, Gertz MA. Comparison of early and late autologous stem cell transplants for multiple myeloma: A single institution experience. Blood. 2004 Nov 16; 104(11 Part 1):266A.
44. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, **Kumar SK**, Clark R, Kyle RA, Litzow MR, Inwards DJ, Elliott MA, Micallef IV, Ansell SM, Porrata LF, Johnston P, Zeldenrust SR, Witzig TE, Greipp PR, Lust JA, Russell SR, Gertz MA. Absolute values of serum immunoglobulin free light chains predict for survival in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplant (Abstract 422). Blood. 2005 Nov; 106(11):127a.
45. Kline M, Kimlinger T, Timm M, Haug J, Lust JA, Rajkumar SV, **Kumar S**. ABT-737, an inhibitor of Bcl-2/Bcl-X (L) proteins, is cytotoxic in multiple myeloma cells (Abstract 1589). Blood. 2005 Nov; 106(11):455a.

46. **Kumar S**, Kline M, Kimlinger T, Timm M, Haug J, Greipp PR, Yang D, Rajkumar SV. AT-101, a small molecule inhibitor of Bcl-2 family proteins, has significant in vitro activity in multiple myeloma (Abstract 1581). *Blood*. 2005 Nov; 106(11):453a-454a.
47. **Kumar S**, Lacy M, Dispenzieri A, Hayman S, Hogan W, Porrata L, Elliott M, Ansell S, Johnston P, Micallef I, Inwards D, Gastineau D, Litzow M, Gertz M. Autologous stem cell transplantation for multiple myeloma in patients over 70 years: a matched comparison with patients under 65 years (Abstract 1173). *Blood*. 2005 Nov; 106(11):342a-343a.
48. Leung N, Dispenzieri A, Lacy MQ, **Kumar SK**, Hayman SR, Gertz MA. Baseline serum albumin and proteinuria predict renal response after autologous stem cell transplantation in AL amyloidosis (Abstract 1165). *Blood*. 2005 Nov; 106(11):340a-341a.
49. Chng WJ, Gonzalez-Paz N, **Kumar S**, Van Wier S, Ahmann G, Price-Troska T, Henderson K, Chesi M, Gertz M, Rajkumar SV, Lacy M, Dispenzieri A, Kyle R, Greipp P, Fonseca R, Bergsagel PL. Cancer/testis antigen profiling in multiple myeloma define a cohort of patients with poor prognosis regardless of genetic subtypes (Abstract 3381). *Blood*. 2005 Nov; 106(11):945a.
50. Gertz MA, Dispenzieri A, Hayman SR, **Kumar SK**, Ansell SM, Elliott MA, Gastineau DA, Inwards DJ, Johnston PB, Micallef IN, Porrata LF, Litzow MR. Clinical outcome of IgM amyloidosis (AL) following stem cell transplantation (Abstract 5470). *Blood*. 2005 Nov; 106(11):455b.
51. Gonzalez-Paz NC, Chng WJ, **Kumar S**, Price-Troska T, Van Wier S, Ahmann G, Henderson K, Gertz M, Kyle R, Greipp P, Fonseca R. Clinical significance of the tumor suppression p53 codon 72 polymorphic variants in multiple myeloma (Abstract 5102). *Blood*. 2005 Nov; 106(11):358b.
52. Rajkumar SV, Hayman S, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, **Kumar S**, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma (Abstract 781). *Blood*. 2005 Nov; 106(11):230a-231a.
53. **Kumar S**, Timm M, Lacy MQ, Dispenzieri A, Hayman SR, Gertz MA, Rajkumar SV, Greipp PR, Witzig TE. Combining measurements of plasma cell apoptosis and proliferation in multiple myeloma identifies patients with poor survival (Abstract 3410). *Blood*. 2005 Nov; 106(11):952a.
54. **Kumar S**, Greipp PR, Haug J, Kline M, Blood E, Chng WJ, Lust JA, Bergsagel L, Gertz MA, Fonseca R, Rajkumar SV. Comparison of myeloma cell gene expression profiles pre and post thalidomide - dexamethasone therapy provides insight into potential mechanisms (Abstract 3480). *Blood*. 2005 Nov; 106(11):971a-972a.
55. **Kumar S**, Greipp PR, Haug JL, Kline M, Chng WJ, Blood E, Lust JA, Bergsagel L, Gertz MA, Fonseca R, Rajkumar SV. Comparison of newly diagnosed and relapsed refractory multiple myeloma using transcriptional profiling of myeloma cells (Abstract 1555). *Blood*. 2005 Nov; 106(11):446a.
56. Raje N, **Kumar S**, Hideshima T, Ishitsuka K, Yasui H, Shiraishi N, Kiziltepe T, Chhetri S, Munshi NC, Anderson KC. Didox induced apoptosis occurs by inhibiting DNA synthesis and repair via down-regulation of ribonucleotide reductase M1 in multiple myeloma (MM) (Abstract 5153). *Blood*. 2005 Nov; 106(11):371b.
57. Holtan SG, Porrata LF, Inwards DJ, Ansell SA, Padley DJ, Micallef IN, Litzow MR, Johnston PB, Hayman SR, **Kumar SK**, Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Teferi A, Elliot M, Hogan WJ, Markovic SN. Effect of AMD3100 on T lymphocyte subpopulations in apheresis products of patients undergoing autologous hematopoietic stem cell transplantation for non Hodgkin lymphoma (Abstract 2918). *Blood*. 2005 Nov; 106(11):819a.
58. Chng WJ, Gonzalez-Paz N, **Kumar S**, Van Wier S, Ahmann G, Price-Troska T, Henderson K, Chesi M, Gertz M, Rajkumar SV, Kyle R, Lacy M, Dispenzieri A, Greipp P, Bergsagel PL, Fonseca R. Gene expression profiling identifies 4 sub-classes with distinct clinical associations in hyperdiploid myeloma (Abstract 1537). *Blood*. 2005 Nov; 106(11):441a.
59. **Kumar S**, Greipp PR, Haug J, Kline M, Chng WJ, Blood E, Bergsagel L, Lust JA, Gertz MA, Fonseca R, Rajkumar SV. Gene expression profiling of myeloma cells at diagnosis can predict response to therapy with thalidomide and dexamethasone combination (Abstract 508). *Blood*. 2005 Nov; 106(11):152a.
60. Kline M, Rajkumar SV, Haug J, Wellik L, Lust JA, Fonseca R, Greipp PR, **Kumar S**. Identification of genes associated with increased bone marrow angiogenesis in multiple myeloma (Abstract 5109). *Blood*. 2005 Nov; 106(11):359b-360b.
61. Naina HVK, Lacy MQ, Dispenzieri A, **Kumar S**, Greipp PR, Witzig TE, Gertz MA, Rajkumar SV. Incidence and clinical course of peripheral neuropathy in patients receiving thalidomide for the treatment of multiple myeloma (Abstract 3475). *Blood*. 2005 Nov; 106(11):970a.
62. Dispenzieri A, Lacy MQ, Zeldenrust SR, Geyer SM, Lust JA, Hayman SR, **Kumar SK**, Allred JB, Rajkumar

- SV, Kabat B, Witzig TE, Greipp PR, Russell SR, Ghobrial I, Gertz MA. Lenalidomide has activity in a phase II trial in patients with primary systemic amyloidosis (Abstract 252). *Blood*. 2005 Nov; 106(11):77a.
63. Fonseca R, Van Wier S, Chng WJ, Ketterling R, Lacy M, Dispenzieri A, Bergsagel PL, Rajkumar SV, Greipp P, Litzow M, **Kumar S**, Gonzalez-Paz N, Henderson K, Ahmann G, Gertz M. Low level amplification (duplication) of 1q21 in myeloma and prognosis; the role of CKS1B (Abstract 624). *Blood*. 2005 Nov; 106(11):185a.
 64. Dispenzieri A, Lacy MQ, Hayman SR, Kyle RA, **Kumar SK**, Litzow MR, Gastineau DA, Inwards DJ, Micallef IN, Elliott MA, Porrata LF, Hogan WJ, Johnston PB, Gertz MA. Powerful risk stratification in patients with AL using serum cardiac biomarkers (Abstract 1162). *Blood*. 2005 Nov; 106(11):339a.
 65. **Kumar S**, Haug JL, Wellik L, Witzig TE, Lust JA, Kline M, Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Rajkumar SV. Prognostic value of bone marrow angiogenesis in newly diagnosed multiple myeloma: a comparison with conventional prognostic factors (Abstract 5111). *Blood*. 2005 Nov; 106(11):360b.
 66. Bryce AH, Dispenzieri A, Kyle RA, Lacy M, Rajkumar SV, Inwards DJ, Yasenchak C, **Kumar S**, Gertz MA. Reponse to rituximab in type II cryoglobulinemia (Abstract 3499). *Blood*. 2005 Nov; 106(11):977a.
 67. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**, Ansell SM, Elliott MA, Gastineau DA, Inwards DJ, Johnston PB, Micallef IN, Porrata LF, Litzow MR. Role of second stem cell transplant in patients with amyloidosis who are refractory or relapsing (Abstract 5469). *Blood*. 2005 Nov; 106(11):455b.
 68. Kline M, Donovan K, Wellik L, Lust C, Jin W, Moon-Tasson L, **Kumar S**, Witzig TE, Rajkumar SV, Lust JA. Stromal cell IL-8 production is increased in MM and may impact both tumor cells and microenvironment (Abstract 2508). *Blood*. 2005 Nov; 106(11):704a-705a.
 69. Raje N, **Kumar S**, Hideshima T, Ishitsuka K, Yasui H, Tai YT, Shiraishi N, Kizeltepe T, Chhetri S, Vallet S, Schlossman RL, Richardson PG, Munshi NC, Anderson KC. The role of B cell-activating factor (BAFF) in the biology of multiple myeloma (MM) (Abstract 3380). *Blood*. 2005 Nov; 106(11):944a-945a.
 70. Porrata LF, Hayman SR, Gertz MA, Lacy MQ, Dispenzieri A, **Kumar SK**, Litzow MR, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, Tefferi A, Elliot M, Hogan WJ, Markovic SN. The role of stem cell mobilization regimen on lymphocyte collection yield and survival after autologous hematopoietic stem cell transplantation in multiple myeloma (Abstract 1174). *Blood*. 2005 Nov; 106(11):343a.
 71. **Kumar S**, Timm M, Kimlinger T, Kline M, Haug JL, Rajkumar SV, Greipp PR. Thymoglobulin (polyclonal rabbit anti thymocyte globulin) has in vitro activity in multiple myeloma (Abstract 5190). *Blood*. 2005 Nov; 106(11):381b.
 72. **Kumar S**, Gertz MA, Hayman SR, Lacy MQ, Dispenzieri A, Zeldenrust SR, Lust JA, Greipp PR, Kyle RA, Fonseca R, Rajkumar SV. Use of the serum free light chain assay in assessment of response to therapy in multiple myeloma: validation of recently proposed response criteria in a prospective clinical trial of lenalidomide plus dexamethasone for newly diagnosed multiple myeloma (Abstract 3479). *Blood*. 2005 Nov; 106(11):971a.
 73. **Kumar S**, Lacy M, Dispenzieri A, Hayman S, Hogan W, Poratta L, Elliot M, Ansell S, Johnston P, Micallef I, Inwards D, Gastineau D, Litzow M, Gertz M. Autologous stem cell transplantation for multiple myeloma in patients over 70 years: a matched comparison with patients under 65 years (Abstract 326). *Biol Blood Marrow Transplant*. 2006 Feb; 12(2 Suppl 1):114.
 74. Zirakzadeh A, Montori V, Imran H, Litzow M, **Kumar S**. Ursodiol prophylaxis against hepatic veno-occlusive disease in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis (Abstract 395). *Biol Blood Marrow Transplant*. 2006 Feb; 12(2 Suppl 1):137-8.
 75. Simpson L, **Kumar S**, Allred J, Lacy M, Dispenzieri A, Hayman S, Zeldenrust S, Rajkumar SV, Lust JA, Greipp PR. A phase II study of alemtuzumab in the treatment of plasma cell disorders (Abstract 5126). *Blood*. 2006 Nov; 108(11 part 2):372b.
 76. **Kumar S**, Lacy MQ, Dispenzieri A, Hayman SR, Rajkumar SV, Zeldenrust S, Lust JA, Greipp PR, Kyle RA, Gastineau DA, Gertz MA. Analysis of outcome after autologous stem transplantation in patients with newly diagnosed myeloma: comparison of different induction regimens (Abstract 3079). *Blood*. 2006 Nov; 108(11 part 1):877a.
 77. Kimlinger TKL, Rajkumar SV, Kline M, Timm MM, Haug JL, Witzig TE, **Kumar S**. Apoptosis rates in myeloma cells can be significantly affected by CD138 sorting and by the specific method used to detect apoptotic cells (Abstract 3442). *Blood*. 2006 Nov; 108(11 part 1):982a.
 78. **Kumar S**, Lacy M, Dispenzieri A, Leung N, Rajkumar V, Zeldenrust S, Lust J, Greipp P, Gastineau D, Gertz M. Autologous stem cell transplantation for multiple myeloma in patients with reduced renal function: a matched set comparison (Abstract 3091). *Blood*. 2006 Nov; 108(11 part 1):881a.
 79. **Kumar S**, Lacy M, Dispenzieri A, Hayman S, Rajkumar SV, Zeldenrust S, Lust JA, Greipp PR, Kyle R, Gertz

- M. Autologous stem cell transplantation provides additional cytoreduction following induction therapy in multiple myeloma (Abstract 3099). *Blood*. 2006 Nov; 108(11 part 1):883a.
80. Dispenzieri A, Lacy M, Zeldenrust S, Hayman SR, **Kumar S**, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA. Cardiac biomarkers predict for ability to tolerate and complete therapy with lenalidomide +/- dexamethasone in AL amyloidosis (Abstract 130). *Blood*. 2006 Nov; 108(11 part 1):43a.
 81. Kimlinger TK, Rajkumar SV, Kline MP, Haug JL, Timm MM, Witzig TE, **Kumar S**. Changes in bone marrow plasma cell surface markers following CD138-magnetic bead based positive selection (Abstract 3516). *Blood*. 2006 Nov; 108(11 part 1):1003a.
 82. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Greipp PR, Witzig TE, **Kumar S**, Geyer SM, Moon Tasson LL, Rajkumar SV, Donovan KA. Clinical and biologic studies in smoldering/indolent multiple myeloma (SMM/IMM) suggest that therapies that specifically inhibit IL-6 production are more effective at targeting the proliferative myeloma component than apoptosis inducing agents (Abstract 3500). *Blood*. 2006 Nov; 108(11 part 1):998a.
 83. **Kumar S**, Rajkumar SV, Plevak M, Kyle RA, Katzmman JA, Dispenzieri A. Comparison of serum free light chain levels and 24 hour urinary monoclonal protein secretion in patients with myeloma: concordant changes with response to therapy (Abstract 5064). *Blood*. 2006 Nov; 108(11 part 2):355b.
 84. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, **Kumar SK**, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Gertz MA. Efficacy of lenalidomide +/- dexamethasone in primary systemic amyloidosis (AL) - cardiac biomarkers predict for outcome. *Amyloid*. 2006 Nov; 13(Suppl 1):26-7.
 85. **Kumar S**, Timm MM, Haug JL, Kimlinger TK, Wellik L, Kline MP, Rajkumar SV. Epigallocatechin-3-gallate (EGCG), a polyphenol extracted from green tea, has significant in vitro activity against myeloma cells (Abstract 3465). *Blood*. 2006 Nov; 108(11 part 1):988a-9a.
 86. Chen C, Reece DE, Siegel D, Niesvizky R, Boccia RV, Stadtmauer EA, Abonour R, Irwin D, Polikoff J, **Kumar S**, Gams RA, Kenvin L, McElveen D, Hu A, Peitronigro D, Knight RD. Expanded access program (EAP) for lenalidomide (Revlimid(R))plus dexamethasone in over 1400 subjects with relapsed or refractory multiple myeloma (Abstract 3556). *Blood*. 2006 Nov; 108(11 part 1):1015a-6a.
 87. Mahmood ST, **Kumar S**, Kimlinger TK, Haug JL, Timm M, Wellik L, Kline M, Rajkumar SV. Expression of CD126 (IL-R alpha) on plasma cells in monoclonal gammopathies (Abstract 5066). *Blood*. 2006 Nov; 108(11 part 2):356b.
 88. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**, Gastineau DA. Extent of hematologic response is important in determining outcome in transplanted patients with primary amyloidosis AL. Importance of achieving CR (Abstract 611). *Blood*. 2006 Nov; 108(11 part 1):184a-5a.
 89. Hayman SR, Lacy MQ, Dispenzieri A, **Kumar SK**, Gastineau DA, Gertz MA. Extent of hematologic response is important in determining outcome in transplanted patients with primary amyloidosis AL. Importance of achieving CR. *Amyloid*. 2006 Nov; 13(Suppl 1):31.
 90. **Kumar S**, Fonseca R, Dispenzieri A, Katzmman JA, Kyle RA, Clark R, Rajkumar SV. High incidence of IgH translocations in monoclonal gammopathies with abnormal free light chain levels (Abstract 3514). *Blood*. 2006 Nov; 108(11 part 1):1002a.
 91. Simpson L, Wolfe RC, Gastineau DA, Hogan WJ, **Kumar S**. Implications of body weight calculations for autologous peripheral blood stem cell transplantation (Abstract 5445). *Blood*. 2006 Nov; 108(11 part 2):456b.
 92. Haug JL, Rajkumar SV, Lust JA, Witzig TE, Kimlinger TK, Timm MM, Kline MP, Wellik L, **Kumar S**. Induction of vascular endothelial growth factor (VEGF) and interleukin 6 (IL-6) in stromal cells by plasma cells from different stages of myeloma (Abstract 5065). *Blood*. 2006 Nov; 108(11 part 2):356b.
 93. Lacy M, Gertz M, Dispenzieri A, Hayman S, Geyer S, Zeldenrust S, **Kumar S**, Greipp P, Fonseca R, Lust J, Russell S, Kyle R, Witzig T, Gergsagel L, Rajkumar SV. Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival (Abstract 798). *Blood*. 2006 Nov; 108(11 part 1):239a.
 94. Hayman S, Gertz M, Lacy M, Dispenzieri A, Fonseca R, Geyer S, **Kumar S**, Zeldenrust S, Russell S, Lust J, Kyle R, Greipp P, Witzig T, Rajkumar SV. Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma (Abstract 3568). *Blood*. 2006 Nov; 108(11 part 1):1019a.
 95. **Kumar S**, Timm M, Kline MP, Haug JL, Kimlinger TK, Yang D, Rajkumar SV. Mi-63, a small molecule inhibitor of MDM2-p53 interaction, has significant in vitro activity in multiple myeloma (Abstract 3464). *Blood*. 2006 Nov; 108(11 part 1):988a.
 96. Kimlinger TK, Timm MM, Rajkumar SV, Haug JL, Kline MP, Witzig TE, **Kumar S**. Phenotypic characterization of the CD45+ and CD45-plasma cell compartments on monoclonal gammopathies (Abstract 3505). *Blood*.

2006 Nov; 108(11 part 1):999a-1000a.

97. Leung N, Dispenzieri A, Lacy MQ, Hayman SR, **Kumar S**, Gertz MA. Risk factors of treatment related mortality during autologous stem cell transplant in patients with light chain associated amyloidosis (AL) (Abstract 3082). Blood. 2006 Nov; 108(11 part 1):878a.
98. Lacy M, Dispenzieri A, Hayman SR, **Kumar S**, Kyle R, Rajkumar SV, Edwards BS, Rodeheffer RJ, Robert FP, Kushwaha SS, Clavell AL, Dearani JA, Sundt TM, Daly RC, McGregor CGA, Gastineau DA, Gertz MA. Sequential heart and autologous stem cell transplantation for AL amyloidosis (Abstract 3092). Blood. 2006 Nov; 108(11 part 1):881a-2a.
99. Lacy MQ, Dispenzieri A, Hayman SR, **Kumar S**, Edwards BS, Rodeheffer RJ, Frantz RP, Kushwaha SS, Clavell AL, Dearani JA, Sundt TM, Daly RC, McGregor CGA, Gastineau DA, Gertz MA. Sequential heart and autologous stem cell transplantation for AL. Amyloid. 2006 Nov; 13(Suppl 1):39-40.
100. Morice WG, Frederick LA, **Kumar S**, Witzig TE, Greipp PR. Single tube 6-color flow cytometry for high speed, sensitive detection of monocytic plasma cells in plasma cell proliferative disorders (Abstract 3504). Blood. 2006 Nov; 108(11 part 1):999a.
101. Neri P, **Kumar S**, Fulciniti M, Vallet S, Chhetri S, Yasui H, Tai YT, Chauhan D, Hideshima T, Tassone P, Venuta S, Munshi NC, Anderson KC, Raje N. The in vivo activity of neutralizing B cell-activating factor (BAFF) antibody in the treatment of multiple myeloma (MM) (Abstract 843). Blood. 2006 Nov; 108(11 part 1):253a.
102. Dingli D, Pacheco JM, Dispenzieri A, Hayman SR, **Kumar S**, Lacy M, Gastineau DA, Gertz MA. The serum M-spike and transplant outcome in patients with multiple myeloma (Abstract 5441). Blood. 2006 Nov; 108(11 part 2):455b.
103. Timm M, Wellik L, Kimlinger T, Haug J, Kline M, Rajkumar SV, Greipp P, **Kumar S**. Thymoglobulin (polyclonal rabbit anti thymocyte globulin) has in vivo activity in a mouse model of myeloma (Abstract 3487). Blood. 2006 Nov; 108(11 part 1):994a.
104. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**, Gastineau DA. Transplantation without growth factor. Engraftment kinetics following stem cell transplantation for primary amyloidosis. Amyloid. 2006 Nov; 13(Suppl 1):30.
105. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**, Gastineau DA. Transplantation without growth factor. Engraftment kinetics following stem cell transplantation for primary systemic amyloidosis (Abstract 2956). Blood. 2006 Nov; 108(11 part 1):837a-8a.
106. Simpson L, Wolfe RC, Gastineau DA, Hogan WJ, **Kumar S**. Implications of body weight calculations for autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2007 Feb; 13(2 Suppl 2):40.
107. **Kumar S**, Lacy M, Dispenzieri A, Hayman S, Rajkumar S, Gertz M. Impact of novel therapies on patient outcome in multiple myeloma. Haematologica. 2007 Jun; 92(6 Suppl 2):209.
108. Podar K, Tonon G, Sattler M, Tai YT, Le Gouill S, Yasui H, Ishitsuka K, **Kumar S**, Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC. In vitro and in vivo activity of the VEGF inhibitor pazopanib in multiple myeloma. Haematologica. 2007 Jun; 92(Suppl 1):98.
109. Podar K, Tonon G, Sattler M, Tai YT, LeGouill S, Yasui H, Ishitsuka K, **Kumar S**, Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC. In vitro and in vivo activity of the VEGF inhibitor pazopanib. Haematologica. 2007 Jun; 92(6 Suppl 2):150.
110. Nowakowski GS, Lacy MQ, Gertz MA, Dispenzieri A, Dingli D, Greipp PR, **Kumar S**, Geyer S, Fonseca R, Vivek R, Hayman S, Lust JA, Kyle RA, Witzig TE, Rajkumar SV. Initial therapy with thalidomide/dexamethasone versus lenalidomide/dexamethasone in newly diagnosed multiple myeloma: A retrospective analysis of two phase II trials. Haematologica. 2007 Jun; 92(6 Suppl 2):179.
111. **Kumar S**. Microarray analysis to predict response to thalidomide and the imids. Haematologica. 2007 Jun; 92(6 Suppl 2):9-10.
112. Verma R, **Kumar S**, Lacy M, Dispenzieri A, Hayman S, Greipp P, Rajkumar S, Gertz M. Myeloma international staging system retains its prognostic value at disease relapse. Haematologica. 2007 Jun; 92(6 Suppl 2):208.
113. Simpson L, Verma R, **Kumar S**, Lacy MQ, Dispenzieri A, Hayman SR, Rajkumar SV, Litzow MR, Gertz MA. Outcome after second stem cell transplantation for relapsed multiple myeloma. Haematologica. 2007 Jun; 92(6 Suppl 2):188-9.
114. Leung N, Zeldenrust SR, **Kumar S**, Dispenzieri A, Lacy MO, Gertz MA, Kyle RA, Rajkumar SV, Winters JL. Plasma exchange is an important and useful adjuvant therapy in cast nephropathy. Haematologica. 2007 Jun; 92(6 Suppl 2):211-2.

115. Haug JL, Rajkumar SM, Lust J, **Kumar S**. VEGF and IL6 secretion by stromal cells and myeloma cells. *Haematologica*. 2007 Jun; 92(6 Suppl 2):114.
116. Bryce AH, Ketterling R, Gertz M, Zeldenrust S, Lacy M, **Kumar S**, Hayman S, Buadi F, Greipp P, Lust J, Rajkumar V, Fonseca R, Dingli D, Russell S, Kyle R, Dispenzieri A. 14q32 abnormalities and 13q deletions are common in primary systemic amyloidosis using cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg-FISH). *Blood*. 2007 Nov; 110(11):730A-1A.
117. Costa LJ, **Kumar S**, Dispenzieri A, Hayman SE, Buadi FK, Litzow MR, Gertz MA, Lacy MQ. Allogeneic HSC transplantation for multiple myeloma: A single institution experience. *Blood*. 2007 Nov; 110(11):892A.
118. **Kumar S**, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Litzow MR, Rajkumar SV, Gertz MA. Delayed platelet engraftment and outcome of stem cell transplant for multiple myeloma: Possible microenvironment effect (Abstract 939)? *Blood*. 2007 Nov; 110(11):285A-6A.
119. **Kumar S**, Zhang L, Greipp PR, Rajkumar SV. Effect of thrombotic events on overall survival in patients with newly diagnosed myeloma: Analysis from a randomized phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00). *Blood*. 2007 Nov; 110(11):803A.
120. Dispenzieri A, Lacy MQ, Hayman SR, **Kumar SK**, Buadi F, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Elliott MA, Micallef IN, Ansell SM, Hogan WJ, Porrata LF, Afessa B, Bryce A, Kyle RA, Gertz MA. Engraftment syndrome is common in patients with POEMS syndrome undergoing PBSCT. *Blood*. 2007 Nov; 110(11):879A.
121. Dispenzieri A, Kyle RA, Katzmann JA, Larson D, Benson J, Clark R, Melton LJ, Gertz MA, **Kumar SK**, Fonseca R, Jelinek DF, Rajkumar SV. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering multiple myeloma. *Blood*. 2007 Nov; 110(11):445A.
122. **Kumar S**, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell S, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improving survival in multiple myeloma: Impact of novel therapies (Abstract 3594). *Blood*. 2007 Nov; 110(11):1051A.
123. Nowakowski GS, Li CY, Dingli D, **Kumar S**, Gertz MA, Lacy MQ, Lust JA, Dispenzieri A, Greipp PR, Zeldenrust S, Buadi F, Hayman S, Kyle RA, Rajkumar VS. Increased cytotoxic T-cell infiltrates in the bone marrow is an independent adverse prognostic factor in patients with newly diagnosed multiple myeloma. *Blood*. 2007 Nov; 110(11):446A-7A.
124. Verma R, **Kumar S**, Lacy MQ, Dispenzieri A, Hayman S, Greipp PR, Rajkumar SV, Gertz MA. Myeloma international staging system retains its prognostic value at disease relapse. *Blood*. 2007 Nov; 110(11):441A.
125. **Kumar S**, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders (Abstract 945). *Blood*. 2007 Nov; 110(11):287A.
126. **Kumar S**, Blade J, San Miguel J, Hajek R, Nagler A, Sonneveld P, Spencer A, Sutherland HJ, Robak T, Mundle SD, Zhuang SH, Harousseau JL, Orlowski RZ. Pegylated liposomal doxorubicin (PLD) in combination with bortezomib (B) may provide therapeutic advantage for high-risk multiple myeloma patients relapsing within 12 months of stem cell transplant. *Blood*. 2007 Nov; 110(11):802A.
127. **Kumar S**, Hayman SR, Buadi FK, Lacy MQ, Stewart K, Greipp PR, Russell S, Zeldenrust S, Gertz MA, Bergsagel L, Fonseca R, Allred J, Campbell M, Lust JA, Witzig TE, Kyle RA, Rajkumar SV, Dispenzieri A. Phase II trial of lenalidomide, cyclophosphamide, and dexamethasone (CRd) for newly diagnosed myeloma. *Blood*. 2007 Nov; 110(11):64A.
128. **Kumar S**, Lacy MQ, Dispenzieri A, Hayman S, Buadi FK, Dingli D, Litzow MR, Gertz MA. Prognostic value of serum lactate dehydrogenase (LDH) in patients with primary, systemic amyloidosis undergoing stem cell transplantation (Abstract 2871). *Blood*. 2007 Nov; 110(11):844A-5A.
129. **Kumar SK**, Dispenzieri A, Lacy MQ, Hayman SR, Leung N, Zeldenrust SR, Buadi FK, Kyle RA, Rajkumar V, Gertz MA. Serum uric acid is a novel prognostic factor in patients with primary systemic amyloidosis. *Blood*. 2007 Nov; 110(11):202A-3A.
130. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, **Kumar SK**, Buadi F, Leung N, Litzow MR. Should troponin level be an exclusion criterion for stem cell primary amyloidosis? *Blood*. 2007 Nov; 110(11):882A.
131. Simpson L, Gertz M, Lacy MQ, Dispenzieri A, Hayman S, Buadi F, Rajkumar VS, **Kumar S**. Thalidomide based induction chemotherapy prior to stem cell transplantation in myeloma is associated with decreased response to retreatment with thalidomide at first relapse post transplant. *Blood*. 2007 Nov; 110(11):1055A.
132. **Kumar S**, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Litzow MR, Gertz MA. Delayed platelet engraftment and outcome of stem cell transplant for multiple myeloma: possible microenvironment effect? *Biol Blood Marrow Transplant*. 2008 Feb; 14(2 Suppl 2):94.
133. Perreault SK, Burzynski JA, Hoskin TL, Leung N, Buadi FK, Dispenzieri A, Hayman SR, **Kumar SK**, Lacy MQ,

- Gertz MA, Wolf RC. Fluid related complications with filgrastim (G-Csf) 10 Mcg/Kg once daily versus 5 Mcg/Kg twice daily in amyloidosis patients undergoing peripheral blood stem cell mobilization. *Biol Blood Marrow Transplant*. 2008 Feb; 14(2 Suppl 2):100.
134. **Kumar S**, Dingli D, Dispenzieri A, Lacy M, Hayman S, Buadi F, Rajkumar SV, Litzow MR, Gertz MA. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceeding plasma cell disorders. *Biol Blood Marrow Transplant*. 2008 Feb; 14(2 Suppl 2):88.
 135. Dispenzieri A, Lacy MQ, Hayman SR, **Kumar SK**, Buadi F, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Elliott MA, Micallef IN, Ansell SM, Hogan WJ, Porrata LF, Johnston PB, Afessa B, Bryce A, Kyle RA, Gertz MA. Peripheral blood stem cell transplant for Poems syndrome is associated with high rates of engraftment syndrome. *Biol Blood Marrow Transplant*. 2008 Feb; 14(2 Suppl 2):87.
 136. Micallef INM, Ansell SM, Buadi F, Dispenzieri A, Elliott MA, Gertz MA, Hayman SR, Hogan WJ, Inwards DJ, Gastineau DA, Johnston PB, **Kumar S**, Lacy MQ, Porrata LF, Marzolf M, Shaw T, Winters JL, Calandra G, Litzow MR. Rescue mobilization of hematopoietic progenitor cells with Amd3100+G-Csf is successful in patients who previously failed mobilization. *Biol Blood Marrow Transplant*. 2008 Feb; 14(2 Suppl 2):255.
 137. Charatcharoenwithaya N, **Kumar S**, Rajkumar SV, Kyle RA, Achenbach SJ, Holets MF, McCready LK, Amin S, Drake MT. Microstructural changes at the ultradistal radius in monoclonal gammopathy of undetermined significance. *J Bone Miner Res*. 2008 Sep; 23(Suppl S):S300.
 138. Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, Elliott MA, Gastineau DA, Hayman SR, Hogan WJ, Inwards DJ, Johnston PB, **Kumar S**, Lacy MQ, Leung N, Micallef IN, Porrata LF, Schafer BA, Wolf RC, Litzow MR. A Multidisciplinary Quality Initiative for Stem Cell Transplantation in Multiple Myeloma: Outpatient Transplant with Low Therapy Related Mortality. *Blood*. 2008 Nov; 112:4440.
 139. **Kumar S**, Zhang L, Dispenzieri A, Van Wier S, Katzmann J, Snyder M, Blood E, DeGoey R, Henderson K, Bradwell A, Kyle R, Greipp P, Rajkumar SV, Fonseca R. Association of high levels of free light chain and the presence of Igh translocations in multiple myeloma and prognostic implications. *Blood*. 2008 Nov; 112(11):592-3.
 140. Dingli D, **Kumar SK**, Buadi FK, Dispenzieri A, Hayman SR, Lacy MQ, Gastineau DA, Litzow MR, Gertz MA. Autologous stem cell transplantation in patients with autonomic neuropathy due to AL amyloidosis. *Blood*. 2008 Nov; 112(11):1139-40.
 141. Gertz MA, **Kumar S**, Lacy M, Dispenzieri A, Hayman S, Buadi F, Dingli D, Gastineau D, Winters J, Litzow M. Comparison of high-dose cyclophosphamide and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. *Blood*. 2008 Nov; 112(11):802-3.
 142. Jacobus S, **Kumar S**, Callander NS, Abonour R, Fonseca R, Siegel D, Greipp P, Rajkumar SV. Effect of venous thrombotic events on overall survival in multiple myeloma: analysis of thrombotic events occurring in E4A03A randomized trial of Lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma, a trial coordinated by the Eastern Cooperative Oncology Group (ECOG). *Blood*. 2008 Nov; 112(11):613-4.
 143. Aravamudan B, Tong C, Lacy MQ, Hayman SR, Buadi F, Gertz MA, **Kumar S**, Dispenzieri A. Immunoglobulin variable light chain restriction, cytokine expression and plasma cell-stromal cell interactions in POEMS syndrome patients. *Blood*. 2008 Nov; 112(11):947-8.
 144. Vachon CM, Kyle R, Therneau T, Larson DR, Colby C, Foreman BJ, Dispenzieri A, **Kumar S**, Katzmann J, Rajkumar SV. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. *Blood*. 2008 Nov; 112(11):591.
 145. Dispenzieri A, Lacy M, Zeldenrust SR, Hayman SR, **Kumar SK**, Lust JA, Allred J, Rajkumar SV, Greipp PR, Laumann K, Russell S, Buadi F, Witzig TE, Gertz MA. Long term follow-up of patients with immunoglobulin light chain amyloidosis treated with lenalidomide and dexamethasone. *Blood*. 2008 Nov; 112(11):612-3.
 146. Leung N, Gunderson HD, Tan TS, Dispenzieri A, Gertz MA, Zeldenrust SR, Lacy MQ, Buadi FK, Hayman SR, **Kumar S**. Melphalan and Dexamethasone is less effective for patients with immunoglobulin light chain amyloidosis (AL) with high bone marrow plasmacytosis. *Blood*. 2008 Nov; 112(11):612.
 147. **Kumar S**, Dispenzieri A, Larson D, Colby C, Kyle R, Gertz M, Rajkumar SV. Normalization of the serum free light chain (FLC) ratio is associated with superior overall survival among myeloma patients achieving immunofixation negative state: results support incorporation of serum FLC ratio in stringent CR definition. *Blood*. 2008 Nov; 112(11):598.
 148. Roy V, Stewart AK, Bergsagel PL, Dispenzieri A, Laumann K, Allred J, Lacy MQ, Fonseca R, Reeder CB, **Kumar S**, Rivera CE, Gertz MA, Greipp PR, Buadi FK, Hayman SR, Rajkumar SV. Phase II study of melphalan, prednisone and lenalidomide combination for newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation. *Blood*. 2008 Nov; 112(11):955.

149. **Kumar S**, Hayman S, Buadi F, Lacy M, Stewart K, Allred J, Laumann K, McCarty T, Bergsagel L, Dingli D, Fonseca R, Gertz M, Greipp P, Lust J, Russell S, Reeder C, Witzig T, Zeldenrust S, Kyle R, Rajkumar SV, Dispenzieri A. Phase II trial of lenalidomide (Revlimid (TM)) with cyclophosphamide and dexamethasone (RCd) for newly diagnosed myeloma. *Blood*. 2008 Nov; 112(11):40.
150. Lacy MQ, Hayman SR, Gertz MA, Allred JB, Mandrekar SJ, Dispenzieri A, Zeldenrust SR, **Kumar S**, Greipp PR, Lust JA, Russell SJ, Buadi F, Kyle RA, Bergsagel PL, Fonseca R, Roy V, Mikhael J, Stewart AK, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone (Pom/dex) is highly effective therapy in relapsed multiple myeloma. *Blood*. 2008 Nov; 112(11):320.
151. Lacy MQ, Mandrekar S, Kabat B, Dispenzieri A, Hayman S, **Kumar S**, Buadi F, Dingli D, Litzow M, Wettstein P, Rajkumar SV, Gastineau D, Gertz MA. Post autologous transplantation consolidation of multiple myeloma with idiotype-pulsed antigen presenting (Dendritic) cells (APC8020) is associated with prolonged survival. *Blood*. 2008 Nov; 112(11):613.
152. Kapoor PN, **Kumar S**, Greipp PR, Laumann KM, Mandrekar S, Rajkumar SV, Witzig TE. Prognostic impact of the plasma cell labeling index (LI) in newly diagnosed myeloma patients treated with thalidomide-dexamethasone (Thal/Dex) or lenalidomide-dexamethasone (Len/Dex). *Blood*. 2008 Nov; 112(11):609.
153. **Kumar S**, Flinn IW, Noga SJ, Hari P, Rifkin RM, Callander NS, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman DD, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson P, Rajkumar SV. Safety and efficacy of novel combination therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in newly diagnosed multiple myeloma: initial results from the phase I/II multicenter EVOLUTION study. *Blood*. 2008 Nov; 112(11):41-2.
154. **Kumar S**, Dispenzieri A, Clark R, Larson D, Colby C, Zeldenrust S, Lacy M, Hayman S, Buadi F, Leung N, Ramirez-Alvarado M, Kyle R, Katzmann J, Rajkumar SV, Gertz M. Serum immunoglobulin free light chain in primary amyloidosis: prognostic value and correlations with clinical features. *Blood*. 2008 Nov; 112(11):944-5.
155. **Kumar S**, Lacy M, Dispenzieri A, Hayman S, Buadi F, Dingli D, Miceli T, Litzow M, Rajkumar SV, Gertz M. Stem cell mobilization following initial therapy with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. *Blood*. 2008 Nov; 112(11):1189.
156. Kapoor P, **Kumar S**, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz M, Dalton R, Mikhael J, Dingli D, Reeder CB, Lust JA, Russell S, Roy V, Zeldenrust SR, Stewart K, Kyle RA, Greipp PR, Rajkumar SV. Survival in patients with newly diagnosed myeloma undergoing therapy with lenalidomide and dexamethasone: impact of high-risk cytogenetic risk status on outcome. *Blood*. 2008 Nov; 112(11):42-3.
157. Chee CE, **Kumar S**, Larson DR, Kyle RA, Dispenzieri A, Gertz MA, Colby CL, Rajkumar SV. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. *Blood*. 2008 Nov; 112(11):610.
158. **Kumar S**. Antiangiogenic agents in multiple myeloma. *Clin Lymphoma Myeloma*. 2009 Feb; 9(Suppl 2):S44-5.
159. Howle EL, Wolf RC, Burzynski JA, Gastineau DA, Lacy MQ, Gertz MA, Dispenzieri A, **Kumar S**, Dingli D, Buadi F, Inwards DJ, Ansell SM, Micallef INM, Johnston PB, Porrata LF, Elliott MA, Hogan WJ, Litzow MR. Clinical outcomes with and without sargramostim (Gm-Csf) post autologous peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant*. 2009 Feb; 15(2 Suppl 2):109.
160. **Kumar S**, Dispenzieri A, Lacy MQ, Hayman S, Buadi FK, Dingli D, Rajkumar SV, Litzow MR, Gertz MA. Continued M protein responses beyond day 100 after autologous transplantation for myeloma: implications for post transplant strategies. *Biol Blood Marrow Transplant*. 2009 Feb; 15(2 Suppl 2):191.
161. Micallef IN, Maurer M, Ansell SM, Buadi F, Dispenzieri A, Gastineau DA, Gertz MA, Hayman SR, Hogan WJ, Inwards DJ, Johnston PB, **Kumar S**, Lacy MQ, Litzow MR, Porrata LF, Winters JL, Marzolf M, Shaw T, Calandra G. Peripheral blood Cd34 count can predict successful progenitor cell mobilization in poor mobilizers treated with plerixafor and G-Csf. *Biol Blood Marrow Transplant*. 2009 Feb; 15(2 Suppl 2):188.
162. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Zeldenrust SR, **Kumar S**, Greipp PR, Lust JA, Russell SJ, Buadi F, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Allred JB, Laumann K, Thompson M, Mandrekar SJ, Rajkumar SV, Dingli D, Reeder C. Pomalidomide (CC4047) plus low-dose dexamethasone (pom/dex) as therapy for relapsed multiple myeloma. *Clin Lymphoma Myeloma*. 2009 Feb; 9(Suppl 2):S46-7.
163. Kapoor P, Kyle RA, **Kumar SK**, Rajkumar SV, Greipp PR, Witzig TE, Dispenzieri A, Lacy MQ, Lust JA, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Gertz MA. Relevance of conventional prognostic factors in multiple myeloma (MM) in the era of novel therapies. *Clin Lymphoma Myeloma*. 2009 Feb; 9(Suppl 1):S60.
164. **Kumar S**, Lacy MQ, Dispenzieri A, Hayman SR, Dingli D, Miceli T, Litzow MR, Rajkumar SV, Gertz MA. Stem

cell mobilization in patients with newly diagnosed multiple myeloma following therapy with lenalidomide and dexamethasone. *Biol Blood Marrow Transplant*. 2009 Feb; 15(2 Suppl 2):177.

165. Kapoor P, **Kumar S**, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Greipp PR, Rajkumar SV, Gertz MA. Prognostic value of stringent complete response (sCR) post-autologous stem cell transplant (SCT) in multiple myeloma (MM). *J Clin Oncol*. 2009 May 20; 27(Suppl S):8587.
166. Kimlinger TK, Halling TM, Rajkumar SV, **Kumar SK**. A method for absolute quantification of plasma cells by flow cytometry using a lyse no wash procedure. *Cytometry Part B-clinical Cytometry*. 2009 Nov; 76B(6):401.
167. **Kumar S**, Dispenzieri A, Lacy MQ, Hayman S, Buadi F, Zeldenrust SR, Leung N, Ramirez-Alvarado M, Kyle RA, Rajkumar SV, Gertz MA. A novel prognostic staging system for light chain amyloidosis (AL) incorporating markers of plasma cell burden and organ involvement. *Blood*. 2009 Nov 20; 114(22):1094.
168. **Kumar S**, Hayman SR, Buadi F, Allred J, Laumann K, Roy V, Lacy MQ, Gertz MA, Detweiler K, Birgin A, Bergsagel L, Dingli D, Mikhael JR, Reeder CB, Stewart K, Zeldenrust SR, Rajkumar V, Dispenzieri A. A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with light chain amyloidosis. *Blood*. 2009 Nov 20; 114(22):1482.
169. Micallef I, Ansell SM, Buadi F, Dingli D, Dispenzieri A, Gastineau D, Gertz M, Hayman SR, Hogan W, Inwards DJ, Johnston PL, **Kumar S**, Lacy MQ, Litzow MR, Porrata L, Wolf R, Miceli T, Winters J. A risk adapted approach utilizing plerixafor in autologous peripheral blood stem cell mobilization. *Blood*. 2009 Nov 20; 114(22):1244.
170. **Kumar S**, Shrestha S, Zhang MJ, Dispenzieri A, Milone GA, Lonial S, Hari PN. Allogeneic stem cell transplantation (SCT) for multiple myeloma (MM) - what has changed? a CIBMTR analysis from 1989-2005. *Blood*. 2009 Nov 20; 114(22):28-9.
171. Siragusa S, Morice W, Gertz MA, Kyle R, Greipp PR, Lust JA, Witzig TE, Lacy MQ, Zeldenrust SR, Rajkumar SV, Hayman SR, Buadi F, Russell SJ, **Kumar S**, Dingli D, Dispenzieri A. Asymptomatic amyloidosis at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering multiple myeloma. *Blood*. 2009 Nov 20; 114(22):1096.
172. Naina HV, **Kumar S**, Bitla S, Winters J, Hogan W, Greiner C, Gastineau D. Comparable outcomes with or without routine granulocyte growth factor support following autologous peripheral blood stem cell transplantation (PBSCT): a single center experience. *Blood*. 2009 Nov 20; 114(22):484.
173. Dingli D, Gay F, Buadi F, Dispenzieri A, Hayman SR, **Kumar S**, Lacy MQ, Russell SJ, Rajkumar V, Gertz M. Depth of response with stem cell transplantation and outcome for multiple myeloma in the era of novel agents. *Blood*. 2009 Nov 20; 114(22):506.
174. Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, Bergsagel PL, Lacy MQ, Dingli D, Ketterling RP, Kyle R, Greipp PR, Dispenzieri A, **Kumar S**. Evidence for cytogenetic and fluorescence in situ hybridization (FISH) risk stratification of newly diagnosed multiple myeloma in the era of novel therapies. *Blood*. 2009 Nov 20; 114(22):716.
175. Gay F, Rajkumar SV, Falco P, **Kumar S**, Dispenzieri A, Gertz M, Di Raimondo F, Lacy MQ, Crippa C, Buadi F, Falcone A, Hayman SR, Giuliani N, Short KED, Musto P, Roy V, Corradini P, Fonseca R, Petrucci MT, Greipp PR, Boccadoro M, Stewart AK, Palumbo A. Lenalidomide plus dexamethasone versus lenalidomide plus melphalan and prednisone: a case-control study in newly diagnosed elderly myeloma patients. *Blood*. 2009 Nov 20; 114(22):1123.
176. Kapoor P, Rajkumar SV, Dispenzieri A, Lacy MQ, Dingli D, Kyle R, Gertz MA, Greipp PR, **Kumar S**, Mandrekar SJ. Melphalan and prednisone (MP) versus melphalan, prednisone and thalidomide (MPT) as initial therapy for previously untreated elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis of randomized controlled trials. *Blood*. 2009 Nov 20; 114(22):254-5.
177. **Kumar S**, Blade J, Crowley J, Goldschmidt H, Hoering A, Jagannath S, Lahuerta JJ, Laubach J, Moreau P, Morgan G, Orlowski RZ, Palumbo A, Richardson P, San Miguel JF, Sezer O, Siegel D, Sonneveld P, Szymonifka J, Rajkumar SV, Durie BGM. Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. *Blood*. 2009 Nov 20; 114(22):1123-4.
178. **Kumar S**, Lacy MQ, Dispenzieri A, Buadi F, Hayman SR, Dingli D, Gay F, Hogan W, Rajkumar SV, Gertz MA. Novel agents for initial therapy of multiple myeloma: comparable results with continued initial therapy and delayed transplantation at relapse versus early transplantation. *Blood*. 2009 Nov 20; 114(22):395.
179. **Kumar S**, Flinn IW, Hari PN, Callander N, Noga SJ, Stewart AK, Glass J, Raje N, Rifkin RM, Shi HL, Webb IJ, Richardson PG, Rajkumar SV. Novel three- and four-drug combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for newly diagnosed multiple myeloma: encouraging results from the multi-center, randomized, phase 2 evolution study. *Blood*. 2009 Nov 20; 114(22):57-8.

180. Madan S, **Kumar S**, Dispenzieri A, Lacy MQ, Hayman S, Buadi F, Dingli D, Gertz MA. Outcomes with high dose therapy and peripheral blood stem cell transplantation for light chain (AL) amyloidosis with cardiac involvement. *Blood*. 2009 Nov 20; 114(22):223.
181. Lacy MQ, Gertz MA, Hayman SR, Short KD, Dispenzieri A, **Kumar S**, Zeldenrust SR, Greipp PR, Lust JA, Russell SJ, Buadi F, Kyle R, Fonseca R, Bergsagel L, Roy V, Mikhael JR, Stewart AK, Reeder CB, Dingli D, Allred J, Laumann K, Mandrekar S, Rajkumar SV. Pomalidomide (CC4047) plus low dose dexamethasone (pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). *Blood*. 2009 Nov 20; 114(22):178.
182. Sinha S, Gastineau DA, Hogan WJ, Micallef IN, Buadi FK, Dingli D, Dispenzieri A, Gertz MA, Greiner C, Hayman S, Inwards DJ, Johnston PB, Lacy MQ, Litzow MR, Porrata LF, Winters J, **Kumar S**. Predicting poor peripheral blood stem cell mobilization in multiple myeloma (MM) using initial peripheral CD34 counts: developing target-based cut-points for early intervention. *Blood*. 2009 Nov 20; 114(22):1252-3.
183. Ramakrishnan V, Haug J, Kimlinger T, Halling T, Wellik L, Pardhanani AD, Tefferi A, Rajkumar SV, **Kumar S**. Significant in-vitro activity of a novel JAK2 inhibitor in multiple myeloma associated with preferential cytotoxicity for CD45+myeloma cells. *Blood*. 2009 Nov 20; 114(22):1112.
184. Gertz MA, **Kumar S**, Lacy MQ, Dispenzieri A, Dingli D, Hayman SR, Buadi F, Hogan W. Stem cell transplant in multiple myeloma: impact of response failure in the era of novel therapies. *Blood*. 2009 Nov 20; 114(22):745-6.
185. Leung N, **Kumar S**, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Dingli D, Hogan WJ, Gertz MA. A model using cardiac troponin T, albumin and uric acid accurately predicts treatment-related mortality in patients with amyloidosis undergoing autologous stem cell transplantation. *Amyloid*. 2010 Apr; 17(Suppl 1):63.
186. **Kumar S**, Dispenzieri A, Lacy M, Hayman S, Buadi F, Zeldenrust S, Leung N, Ramirez-Alvarado M, Kyle RA, Rajkumar SV, Gertz M. A novel prognostic staging system for light chain amyloidosis (AL). *Amyloid*. 2010 Apr; 17(Suppl 1):182.
187. Buadi F, Dispenzieri A, Hayman S, Allred J, Laumann K, Roy V, Lacy M, Gertz M, Detweiler-Short K, Birgin A, Bergsagel L, Dingli D, Mikhael J, Reeder C, Stewart K, Zeldenrust S, Rajkumar SV, **Kumar S**. A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with primary amyloidosis. *Amyloid*. 2010 Apr; 17(Suppl 1):170-1.
188. **Kumar S**, Gertz M, Lacy M, Hayman S, Buadi F, Zeldenrust S, Ramirez-Alvarado M, Leung N, Dispenzieri A. Changes in serum free light chain rather than intact monoclonal immunoglobulin levels predict outcome with therapy in patients with light chain amyloidosis. *Amyloid*. 2010 Apr; 17(Suppl 1):181.
189. Madan S, Dispenzieri A, Lacy M, Buadi F, Hayman S, Detweiler-Short K, Zeldenrust S, Dingli D, Greipp P, Russell S, Lust J, Kyle R, Rajkumar SV, Gertz M, **Kumar S**. Clinical features and treatment response of AL amyloidosis diagnosed in patients with myeloma. *Amyloid*. 2010 Apr; 17(Suppl 1):175-6.
190. Leung N, Irazabal MV, Eirin A, Lacy MQ, Dispenzieri A, Buadi FK, Zeldenrust SR, Hayman SR, **Kumar S**, Russell SJ, Kyle RA, Ramirez-Alvarado M, Sethi S, Erickson SB, Fervenza FC, Gertz MA. Differences in clinical presentation and outcomes of patients with vascular limited light chain amyloidosis (AL) versus diffuse. *Amyloid*. 2010 Apr; 17(Suppl 1):173.
191. Dispenzieri A, **Kumar SK**, Lacy MQ, Kyle RA, Leung N, Zeldenrust SR, Hayman SR, Buadi F, Greipp PR, Russell SR, Detweiler-Short K, Dingli D, Lust JA, Rajkumar SV, Gertz MA. Do the immune modulatory drugs (IMiDs (R)) affect levels of troponin T (TnT) and N-terminal brain natriuretic peptide (NTproBNP) in patients with immunoglobulin light chain amyloidosis (AL)? *Amyloid*. 2010 Apr; 17(Suppl 1):178-9.
192. Leung N, Gertz MA, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Dingli D, Hogan WJ, Irazabal MV, Eirin A, **Kumar S**. Engraftment syndrome presenting as acute renal failure in light chain amyloidosis patients after autologous stem cell transplantation. *Amyloid*. 2010 Apr; 17(Suppl 1):172.
193. Dispenzieri A, Gertz MA, Saenger AK, **Kumar SK**, Lacy MQ, Kyle RA, Leung N, Zeldenrust SR, Hayman SR, Buadi F, Greipp PR, Rajkumar SV, Russell SR, Detweiler-Short K, Dingli D, Lust JA, Jaffe AS. High sensitivity troponin assay (hsTnT): utility in patients with AL. *Amyloid*. 2010 Apr; 17(Suppl 1):154-5.
194. **Kumar S**, Dispenzieri A, Lacy M, Hayman S, Buadi F, Detweiler-Short K, Zeldenrust S, Leung N, Dingli D, Greipp P, Lust J, Russell S, Kyle R, Rajkumar V, Gertz M. Improved survival in light chain amyloidosis. *Amyloid*. 2010 Apr; 17(Suppl 1):89-90.
195. Leung N, Herrmann SMS, Dispenzieri A, **Kumar S**, Lacy MQ, Russell SJ, Buadi FK, Hayman SR, Zeldenrust SR, Dingli D, Dean PG, Prieto M, Nyberg S, Stegall M, Fervenza FC, Gertz MA. Long-term outcome after kidney transplantation with or without stem cell transplantation in immunoglobulin light chain (AL) amyloidosis. *Amyloid*. 2010 Apr; 17(Suppl 1):168.
196. Dingli D, Buadi FK, Dispenzieri A, Hayman SR, Lacy MQ, **Kumar S**, Gastineau DA, Hogan WJ, Gertz MA.

Outcome of stem cell transplantation in patients with AL amyloidosis and autonomic neuropathy. *Amyloid*. 2010 Apr; 17(Suppl 1):169-70.

197. Madan S, **Kumar S**, Dispenzieri A, Lacy MQ, Hayman S, Buadi F, Dingli D, Gertz MA. Outcomes with high-dose therapy (HDT) and peripheral blood (PB) stem cell transplantation for AL amyloidosis with cardiac involvement. *Amyloid*. 2010 Apr; 17(Suppl 1):182-3.
198. Dispenzieri A, Gertz MA, Hayman SR, Buadi F, **Kumar SK**, Reeder C, Zeldenrust SR, Rajkumar SV, Detweiler-Short K, Lust JA, Witzig TE, Kyle RA, Greipp PR, Russell SJ, Dingli D, Allred JB, Laumann K, Thompson M, Fonseca R, Bergsagel L, Stewart K, Mikhael J, Roy V, Lacy MQ. Pomalidomide and dexamethasone for previously treated AL: a phase 2 study. *Amyloid*. 2010 Apr; 17(Suppl 1):87.
199. Gertz MA, Lacy MQ, Dispenzieri A, **Kumar S**, Hayman SR, Buadi F, Dingli D, Leung N, Hogan WJ. Trend towards improved day 100 and 2 year survival following stem cell transplantation for AL. A comparison before and after 2006. *Amyloid*. 2010 Apr; 17(Suppl 1):89.
200. Galanis E, Jaeckle K, Anderson S, Kaufmann T, Uhm J, Giannini C, **Kumar S**, Northfelt D, Flynn P, Buckner J. NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM. *J Clin Oncol*. 2010 May; 28(15s):2018.
201. Aguirre RL, **Kumar S**, Coenen MJ, Demaray SA, Bahn RS. Effect of insulin like growth factor-1 on adipocyte differentiation in preadipocytes derived from lean and obese adults. *Endocr Rev*. 2010 Jun; 31(Suppl 1).
202. Gay F, Hayman S, Buadi F, Detweiler-Short K, Lacy M, **Kumar S**, Dispenzieri A, Gertz M, Rajkumar V. Safety and efficacy of lenalidomide plus dexamethasone in elderly newly diagnosed multiple myeloma patients 70 years of age and older. *Haematologica*. 2010 Jun; 95(Suppl 2):0379.
203. Irazabal MV, Eirin A, Gertz MAA, Dispenzieri A, **Kumar S**, Buadi F, Lacy M, Hayman SR, Dingli D, Hogan WJ, Leung N. Acute renal failure is a common presentation of engraftment syndrome in light chain amyloidosis (AL) patients after autologous stem cell transplantation. *Blood*. 2010 Nov 19; 116(21):1424-5.
204. **Kumar S**, Dispenzieri A, Lacy M, Buadi F, Dingli D, Hogan WJ, Gastineau D, Gertz M. Comparison of troponin T and N terminal pro brain natriuretic peptides in two models of treatment related mortality in al amyloidosis patients following autologous stem cell transplantation. *Blood*. 2010 Nov 19; 116(21):1470-1.
205. Madan S, Lacy M, Dispenzieri A, Gertz M, Buadi F, Hayman SR, Detweiler-Short K, Dingli D, Zeldenrust S, Lust J, Greipp PR, Rajkumar SV, **Kumar S**. Efficacy of retreatment with immunomodulatory compounds in patients receiving initial therapy for newly diagnosed multiple myeloma. *Blood*. 2010 Nov 19; 116(21):820.
206. Lin Y, Gertz M, Mandrekar S, Laumann K, Dispenzieri A, Hayman SR, Buadi F, Dingli D, Padley D, Gastineau D, **Kumar S**, Rajkumar V, Lacy M. Five-year follow-up of randomized, phase II trial of idiotype-pulsed dendritic cell vaccine with adjuvant cytokines in plateau phase and post-transplant multiple myeloma. *Blood*. 2010 Nov 19; 116(21):816-7.
207. Chee CE, Rajkumar SV, Gertz MAA, Lacy M, Zeldenrust S, **Kumar S**, Hayman SR, Buadi F, Russell S, Kyle R, Greipp PR, Dispenzieri A. Higher plasma cell burden predicts for early death in patients with AL amyloidosis. *Blood*. 2010 Nov 19; 116(21):790.
208. **Kumar S**, Dispenzieri A, Lacy M, Hayman SR, Buadi F, Dingli D, Short KD, Lust J, Zeldenrust S, Russell S, Greipp PR, Kyle R, Gertz M, Rajkumar V. Improvement in renal function in newly diagnosed myeloma improves survival, but still remains inferior to those with normal renal function. *Blood*. 2010 Nov 19; 116(21):1224-5.
209. Short KD, Rajkumar SV, Buadi F, Larson D, Hayman SR, Dispenzieri A, Gertz MAA, **Kumar S**, Mikhael JR, Roy V, Kyle R, Lacy M. Increased incidence of extramedullary plasmacytomas in patients with multiple myeloma in the era of novel therapy and effect of pomalidomide on extramedullary disease. *Blood*. 2010 Nov 19; 116(21):1256.
210. Bianchi G, Ramakrishnan VG, Kimlinger T, Haug J, Rajkumar SV, **Kumar S**. Investigational agent MLN2238/MLN9708, a specific, orally available, small molecule proteasome inhibitor, shows promising in vitro activity against multiple myeloma cell lines. *Blood*. 2010 Nov 19; 116(21):1242.
211. Ramakrishnan VG, Kimlinger T, Haug J, Halling T, Wellik L, Rajkumar SV, **Kumar S**. Mechanism of action of a novel c met inhibitor MK2461 in multiple myeloma. *Blood*. 2010 Nov 19; 116(21):1660.
212. Dispenzieri A, Kyle R, Katzmann JA, Larson D, **Kumar S**, Mead GP, Bradwell A, Rajkumar SV. Non clonal serum immunoglobulin free light chains (FLC) as markers of overall survival. *Blood*. 2010 Nov 19; 116(21):1590.
213. **Kumar S**, Flinn IW, Richardson PG, Hari P, Callander NS, Noga SJ, Stewart AK, Glass J, Rifkin RM, Wolf JL, Estevam J, Mulligan G, Shi HL, Webb IJ, Rajkumar SV. Novel three and four drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma results from the multi center, randomized, phase 2 evolution study. *Blood*. 2010 Nov 19; 116(21):273.

214. Sinha S, Gertz M, Lacy M, Dispenzieri A, Hayman S, Buadi F, Dingli D, Micallef I, Hogan W, Gastineau D, Rajkumar V, **Kumar S**. Peripheral blood stem cell collection in patients undergoing induction therapy with lenalidomide based regimens: failure rates and salvage approaches. *Blood*. 2010 Nov 19; 116(21):926-7.
215. **Kumar S**, Porrata LF, Ansell SM, Colgan JP, LaPlant B, Gertz MA, Inwards DJ, Johnston PB, Haberman T, Micallef IN, Nowakowski GS, Witzig TE. Phase 1 trial of sorafenib and everolimus in patients with lymphoma or multiple myeloma. *Blood*. 2010 Nov 19; 116(21):1155-6.
216. Lacy M, Mandrekar S, Gertz MAA, Hayman SR, Short KD, Buadi F, Dispenzieri A, **Kumar S**, Zeldenrust S, Dingli D, Greipp PR, Lust J, Russell S, Kyle R, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Allred J, Laumann K, Reeder CB, Rajkumar SV, Mikhael JR. Pomalidomide plus low dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide comparison of two dosing strategies in dual refractory disease. *Blood*. 2010 Nov 19; 116(21):377. Abstract no. 863.
217. Madan S, **Kumar S**, Lacy M, Dispenzieri A, Buadi F, Hayman SR, Dingli D, Rajkumar SV, Gertz M. Pre stem cell transplant induction therapy does not affect post-transplant survival in light chain (AL) amyloidosis. *Blood*. 2010 Nov 19; 116(21):167-8.
218. **Kumar S**, Gertz M, Lacy M, Dingli D, Hayman SR, Buadi F, Detweiler-Short K, Zeldenrust S, Leung N, Greipp PR, Lust J, Russell S, Kyle R, Rajkumar V, Dispenzieri A. Recent improvements in survival in light chain amyloidosis and the importance of an early mortality risk score. *Blood*. 2010 Nov 19; 116(21):789.
219. Sinha S, **Kumar S**, Hayman S, Buadi F, Short KD, Mikhael J, Dispenzieri A, Gertz M, Dingli D, Rajkumar SV, Lacy M. Response to salvage therapies and outcome of patients with multiple myeloma relapsing after pomalidomide therapy. *Blood*. 2010 Nov 19; 116(21):820-1.
220. Haug J, Ramakrishnan VG, Kimlinger T, Halling T, Wellik L, Rajkumar SV, **Kumar S**. Significant in vitro activity of a novel inhibitor of apoptosis (LAP) inhibitor LC161 in multiple myeloma. *Blood*. 2010 Nov 19; 116(21):1236.
221. Wear S, Richardson PG, Revta C, Vij R, Fiala M, Lonial S, Francis D, Siegel DSD, Schramm A, Jakubowiak AJ, Harvey CK, Reece DE, Hon EG, Jagannath S, La L, Hofmeister CC, Jansak H, Stewart K, Hagerty R, Wolf JL, Davis B, Krishnan A, Duarte L, Zimmerman TM, Cisneros A, **Kumar S**, Birgin A, Ott R, Tasca L, Kelley SL, Anderson KC, Giusti K. The Multiple Myeloma Research Consortium (MMRC) model reduced time to trial activation and improved accrual metrics. *Blood*. 2010 Nov 19; 116(21):1555-6.
222. Gertz MAA, Lacy M, Dispenzieri A, **Kumar S**, Buadi F, Dingli D, Ansell SM, Gastineau D, Inwards DJ, Johnston PB, Litzow MR, Micallef I, Porrata L, Leung N, Wolf R, Hogan WJ, Hayman SR. Transplantation for immunoglobulin light chain amyloidosis a statistical analysis of factors predicting outcome in over 400 patients. *Blood*. 2010 Nov 19; 116(21):1463-4.
223. Gertz MA, Lacy M, Dispenzieri A, **Kumar S**, Buadi F, Dingli D, Leung N, Hogan WJ, Hayman SR. Trend towards improved day 100 and 2 year survival after SCT for AL amyloidosis outcomes before and after 2006. *Blood*. 2010 Nov 19; 116(21):1461-2.
224. Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, Hayman SR, Hogan WJ, Johnston PB, Lacy MQ, Ansell SM, Buadi F, Dingli D, Dispenzieri A, Litzow MR, Porrata LF, Winters JL, **Kumar S**. A cost effective analysis of a risk-adapted algorithm for plerixafor use in autologous peripheral blood stem cell mobilization. *Biol Blood Marrow Transplant*. 2011 Feb; 17(Suppl 2):S159-60.
225. Bleeker JS, Gertz MA, Pellikka PA, Buadi F, Dingli D, Dispenzieri A, Hayman SR, Hogan W, **Kumar S**, Lacy MQ. Cardiomyopathy following high dose melphalan conditioning prior to autologous peripheral blood stem cell transplantation for multiple myeloma and primary amyloidosis. *Biol Blood Marrow Transplant*. 2011 Feb; 17(Suppl 2):S203.
226. Ozsan GH, Micallef INM, Dispenzieri A, **Kumar S**, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Wolf RC, Gastineau DA, Hogan WJ, Gertz MA. Predictors for "poor mobilizers" after cyclophosphamide mobilization in multiple myeloma. *Biol Blood Marrow Transplant*. 2011 Feb; 17(Suppl 2):S202-3.
227. Glavey SV, Gertz MA, Dispenzieri A, **Kumar S**, Buadi F, Lacy M, Hayman SR, Dingli D, Hogan WJ, Gastineau DA, Leung N. Long term outcome of renal failure in multiple myeloma following autologous stem cell transplant. *Am J Kidney Dis*. 2011 Apr; 57(4):A41.
228. Johnston PB, **Kumar S**, Porrata L, Micallef IN, Habermann T, Colgan J, Laplant B, Witzig T. Everolimus plus sorafenib for the treatment of Hodgkin lymphoma. *Ann Oncol*. 2011 Jun; 22(Suppl 4):181.
229. Gertz MA, Lacy MQ, Dispenzieri A, **Kumar S**, Hayman SR, Buadi F, Dingli D, Leung N, Hogan WJ. Trend toward improved day 100 and two-year survival following stem cell transplantation for AL: a comparison before and after 2006. *Amyloid*. 2011 Jun; 18(1):137-8.
230. Galanis E, Anderson SK, Lafky JM, Kaufmann TJ, Uhm JH, Giannini C, **Kumar SK**, Northfelt DW, Flynn PJ, Jaeckle KA, Buckner JC. NCCTG phase II trial of bevacizumab in combination with sorafenib (BEV/SOR) in

recurrent glioblastoma (RGM). *Neuro-oncol.* 2011 Nov; 13(3):62.

231. Dispenzieri A, Gertz MA, Lacy MQ, Laumann K, LaPlant BR, **Kumar S**, Buadi FK, Hayman SR, Dingli D, Hogan WJ, Ansell SM, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Johnston PB, Litzow MR, Witzig TE. A phase I trial of zevalin radioimmunotherapy with high-dose melphalan (HDM) and autologous stem cell transplant (ASCT) for multiple myeloma (mm). *Blood.* 2011 Nov 18; 118(21):1337-8.
232. Leung N, Bridoux F, **Kumar S**, Cook M, Rajkumar SV, Ecotiere L, Ludwig H, Hutchison CA. Both hematologic and renal response affect overall survival of myeloma patients with acute kidney injury. *Blood.* 2011 Nov 18; 118(21):1688-9.
233. **Kumar S**, Lee JH, Lahuerta JJ, Morgan GJ, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hullin C, Klein SK, Sonneveld P, Siegel DS, Blade J, Goldschmidt H, Jagannath S, San Miguel JF, Orlowski RZ, Palumbo A, Sezer O, Rajkumar SV, Durie BGM. Differences in patterns of treatment and outcome among patients with relapsed refractory myeloma from United States, Europe and Asia. *Blood.* 2011 Nov 18; 118(21):1707-8.
234. Rana V, Srivastava G, Hayman SR, Buadi FK, Gertz MA, Lacy MQ, Greipp PR, Zeldenrust SR, Dispenzieri A, Kyle RA, Lust JA, Short KD, Dingli D, Russell SJ, Rajkumar SV, **Kumar S**. Factors predicting early mortality in patients with newly diagnosed multiple myeloma. *Blood.* 2011 Nov 18; 118(21):1704.
235. Braggio E, Keats JJ, **Kumar S**, Ahmann G, Mantei J, Stewart K, Bergsagel PL, Fonseca R. Generation of an automated tool for the identification of genetics markers and signatures in multiple myeloma risk-stratification. *Blood.* 2011 Nov 18; 118(21):1243.
236. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Greipp PR, Witzig TE, **Kumar S**, Moon-Tasson LL, Rajkumar SV, Donovan KA. Long term follow-up of il-1 receptor antagonist and dexamethasone phase II clinical trial in patients with smoldering/indolent myeloma shows improved survival in responsive patients: implications for targeting interleukin-1 induced il-6 production and the myeloma proliferative component. *Blood.* 2011 Nov 18; 118(21):1271.
237. Mikhael JR, Hayman SR, Laumann K, Roy V, LaPlant BR, **Kumar S**, Buadi FK, Reeder CB, Gertz MA, Dispenzieri A, Lust JA, Stewart AK, Russell S, Bergsagel PL, Dingli D, Zeldenrust S, Fonseca R, Greipp PR, Hall RL, Rajkumar SV, Lacy MQ. Long term outcomes of pomalidomide and dexamethasone in patients with relapsed multiple myeloma: analysis 4 years after the original cohort. *Blood.* 2011 Nov 18; 118(21):1269-70. Abstract no. 2942.
238. Lin Y, Gertz MA, Sims RB, Mandrekar S, Laumann K, LaPlant B, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Padley D, Gastineau DA, **Kumar S**, Rajkumar V, Lacy MQ. Matched case control analysis comparing long term survival of multiple myeloma patients who received stem cell transplant with and without idiotype-pulsed dendritic cell vaccine. *Blood.* 2011 Nov 18; 118(21):291-2.
239. Berdeja JG, Richardson PG, Lonial S, Niesvizky R, Hui AM, Berg D, Gupta N, Liu GH, Di Bacco A, **Kumar S**. Phase 1/2 study of oral MLN9708, a novel, investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (mm). *Blood.* 2011 Nov 18; 118(21):223.
240. **Kumar S**, Mikhael JR, Lacy MQ, LaPlant BR, Buadi FK, Dingli D, Gertz MA, Miceli T, Mahlman M, Bergsagel PL, Hayman SR, Reeder CB, Dispenzieri A, Gastineau DA, Winters J. Phase II trial of intravenously administered AMD3100 (plerixafor) for stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplantation following a lenalidomide-based initial therapy. *Blood.* 2011 Nov 18; 118(21):1289. Abstract no. 2292.
241. Knorr DA, Ni ZY, Bock A, Ramakrishnan VG, **Kumar S**, Kaufman DS. Pluripotent stem cell-derived human natural killer cells with potent anti-multiple myeloma activity. *Blood.* 2011 Nov 18; 118(21):1723.
242. Lacy MQ, LaPlant BR, Laumann K, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, **Kumar S**, Lust JA, Russell S, Dingli D, Zeldenrust SR, Greipp PR, Fonseca R, Bergsagel PL, Roy V, Stewart K, Reeder CB, Hall RL, Rajkumar SV, Mikhael JR. Pomalidomide and dexamethasone in relapsed myeloma: results of 225 patients treated in five cohorts over three years. *Blood.* 2011 Nov 18; 118(21):1695. Abstract no. 3963.
243. D'Souza A, Buadi FK, Lacy MQ, Gertz MA, Hayman SR, **Kumar S**, Dingli D, Zeldenrust SR, Dispenzieri A. Relapse of poems following autologous stem cell transplantation: a single center experience. *Blood.* 2011 Nov 18; 118(21):1340.
244. Larsen JT, **Kumar S**, Rajkumar SV. Serum free light chain ratio in distinguishing smoldering multiple myeloma from active multiple myeloma. *Blood.* 2011 Nov 18; 118(21):1688.
245. Kapoor P, Gertz MA, Rajkumar SV, Lacy MQ, Dingli D, Hayman SR, Russell SJ, Lust JA, Buadi FK, Zeldenrust SR, Greipp PR, Dispenzieri A, Kyle RA, **Kumar S**. Survival outcome of young multiple myeloma (MM) patients in the era of novel therapies. *Blood.* 2011 Nov 18; 118(21):1273.

246. Glavey SV, Dispenzieri A, Gertz MA, **Kumar S**, Lacy MQ, Buadi FK, Rajkumar SV, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Dingli D, Hall RL, Leung N. The depth of renal response strongly predicts overall survival in patients with al amyloidosis. *Blood*. 2011 Nov 18; 118(21):1237-8.
247. Wear SM, Richardson PG, Revta C, Vij R, Fiala M, Lonial S, Mitchell AR, Siegel DS, Aleman A, Jakubowiak AJ, Durecki DE, Reece DE, Gul E, Chari A, Jagannath S, La L, Hofmeister CC, Bowers MA, Stewart AK, Hagerty R, Wolf JL, Pelle-Day G, Krishnan A, Duarte L, Zimmerman TM, Larsen D, **Kumar S**, Birgin A, Raje NS, Roy V, Maharaj M, Fay JW, Messing T, Ott RF, Tasca L, Anderson KC, Giusti K. The multiple myeloma research consortium (mmrc): accelerated start up and accrual metrics speeds drug development. *Blood*. 2011 Nov 18; 118(21):470-1.
248. Leung N, **Kumar S**, Dispenzieri A, Lacy MQ, Buadi FK, Hayman SR, Dingli D, Hogan WJ, Gastineau DA, Glavey SV, Gertz MA. The timing of acute renal failure strongly affects survival of immunoglobulin light chain (AL) amyloidosis patients undergoing autologous stem cell transplantation. *Blood*. 2011 Nov 18; 118(21):1761.
249. Dispenzieri A, Gertz MA, Saenger AK, Grogan M, **Kumar S**, Lacy MQ, Kyle RA, Leung N, Zeldenrust S, Hayman SR, Buadi FK, Greipp PR, Rajkumar SV, Russell S, Dingli D, Lust JA, Jaffe A. The utility of high sensitivity cardiac troponin among patients with immunoglobulin light chain amyloidosis. *Blood*. 2011 Nov 18; 118(21):1245-6.
250. Bang SM, Kyle RA, Lee JH, Dispenzieri A, Larson D, Colby CL, Rajkumar SV, **Kumar S**. Treatment patterns and outcomes in elderly patients with multiple myeloma. *Blood*. 2011 Nov 18; 118(21):1703.
251. **Kumar S**, Bensinger WL, Reeder CB, Zimmerman TM, Berenson JR, Berg D, Liu GH, Gupta N, Di Bacco A, Hui AM, Niesvizky R. Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma: results from a phase 1 dose-escalation study. *Blood*. 2011 Nov 18; 118(21):371-2.
252. Singla A, Hogan WH, Ansell SM, Buadi FK, Dingli D, Dispenzieri A, Gastineau DA, Gertz MA, Hayman SR, Inwards DJ, Johnston PB, Lacy MQ, Litzow MR, Micallef IN, Porrata LF, **Kumar SK**. Incidence of cardiac arrhythmias during autologous peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant*. 2012 Feb; 18(2):S207.
253. **Kumar S**, Mikhael J, Lacy M, LaPlant B, Buadi F, Dingli D, Gertz M, Miceli T, Bergsagel L, Hayman S, Reeder C, Stewart K, Dispenzieri A, Gastineau D, Winters J. Phase ii trial of intravenously administered amd3100 (plerixafor) for stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplantation following a lenalidomide based initial therapy. *Biol Blood Marrow Transplant*. 2012 Feb; 18(2):S247.
254. **Kumar SK**, Berdeja JG, Niesvizky R, Lonial S, Hamadani M, Stewart AK, Roy V, Hari P, Vescio R, Berg D, Lin JC, Di Bacco A, Gupta N, Hui AM, Richardson PG. A phase 1/2 study of weekly mln9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (mm). *Blood*. 2012 Nov 16; 120(21).
255. Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins L, Schmidt J, Ahmann G, **Kumar SK**, Rajkumar SV, Mikhael JR, Roy V, LaPlant BR, Laumann K, Barlogie B, Shaughnessy JD Jr, Fonseca R, Bergsagel L, Lacy MQ, Stewart K. Cereblon expression predicts response, progression free and overall survival after pomalidomide and dexamethasone therapy in multiple myeloma. *Blood*. 2012 Nov 16; 120(21).
256. Roeker LE, Larson D, Kyle RA, **Kumar SK**, Dispenzieri A, Rajkumar SV. Development of myelodysplastic syndrome and acute leukemias in patients with monoclonal gammopathy of undetermined significance (mgus): a population-based study of 17,315 patients. *Blood*. 2012 Nov 16; 120(21).
257. Kapoor P, Gertz MA, Dispenzieri A, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Russell S, Lin Y, Witzig TE, Lust JA, Zeldenrust SR, Greipp PR, Kyle RA, Rajkumar V, **Kumar SK**. Importance of achieving sustained stringent complete response (scr) following autologous stem cell transplantation in multiple myeloma. *Blood*. 2012 Nov 16; 120(21).
258. Parikh SA, Kapoor P, **Kumar SK**, Letendre L, Wolanskyj A. Outcome of adult patients with hemophagocytic syndrome: a tertiary care center experience. *Blood*. 2012 Nov 16; 120(21).
259. Humeniuk M, Gertz MA, Lacy MQ, Kyle RA, Hayman SR, **Kumar SK**, Lust JA, Witzig TE, Buadi FK, Rajkumar SV, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Kapoor P, Leung N, Dispenzieri A. Outcomes of patients with pooms syndrome treated initially with radiation. *Blood*. 2012 Nov 16; 120(21).
260. **Kumar SK**, LaPlant BR, Chng WJ, Zonder JA, Callander N, Roy V, Furth B, Erlichman C, Stewart K. Phase 1/2 trial of a novel cdk inhibitor dinaciclib (sch727965) in patients with relapsed multiple myeloma demonstrates encouraging single agent activity. *Blood*. 2012 Nov 16; 120(21).
261. Lust JA, Usmani SZ, Hamadani M, Barranco C, Lacy MQ, Dispenzieri A, Gertz MA, Dingli D, Russell S, Buadi FK, Zeldenrust SR, Hayman SR, Rajkumar SV, **Kumar SK**, Thompson J, Taylor CA, Dondero R. Phase 1b/2a

- open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of snc01-t administered by intravenous infusion in patients with relapsed or refractory multiple myeloma. *Blood*. 2012 Nov 16; 120(21).
262. **Kumar SK**, Krishnan A, Roy V, Zimmerman TM, Gertz MAA, Stockerl-Goldstein KE, Buadi FK, Rosenbaum C, Birgin A, Fiala M, Jimenez V, Maharaj M, Needle MN, Vij R. Phase i/ii, multicenter, open-label, dose-escalation study of bendamustine in combination with lenalidomide and dexamethasone (brd) in patients with relapsed multiple myeloma: a multiple myeloma research consortium study. *Blood*. 2012 Nov 16; 120(21).
 263. Lacy MQ, **Kumar SK**, LaPlant BR, Laumann K, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Russell S, Dingli D, Zeldenrust SR, Fonseca R, Bergsagel PL, Stewart K, Roy V, Sher T, Chanan-Khan A, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone (POM/DX) in relapsed myeloma: long term follow up and factors predicting outcome in 345 patients. *Blood*. 2012 Nov 16; 120(21).
 264. Ramakrishnan VG, Kimlinger TK, Halling T, Haug J, Painuly U, Rajkumar SV, **Kumar SK**. Preclinical evaluation of at219, a small molecule inhibitor of mdm2 as an anti-myeloma agent. *Blood*. 2012 Nov 16; 120(21).
 265. Ramakrishnan VG, Kimlinger TK, Painuly U, Haug J, Rajkumar SV, **Kumar SK**. Simultaneous inhibition of ciap1, ciap2 and xiap is required for inducing apoptosis in multiple myeloma cells. *Blood*. 2012 Nov 16; 120(21).
 266. Raval GG, Gertz MA, Lacy MQ, Hayman SR, **Kumar SK**, Buadi FK, Lust JA, Zeldenrust S, Dingli D, Hall RL, Hwa L, Lin Y, Kapoor P, Witzig TE, Kyle RA, Russell S, Leung N, Rajkumar SV, Dispenzieri A. Survival after second, third, and fourth line therapy better than expected in patients with previously treated al amyloidosis who were not transplant candidates at diagnosis. *Blood*. 2012 Nov 16; 120(21).
 267. Burnette BL, Dispenzieri A, **Kumar S**, Sloan J, Tilburt J, Kyle RA, Rajkumar SV. Treatment trade-offs in myeloma: a survey of consecutive patients. *Blood*. 2012 Nov 16; 120(21).
 268. Hashmi S, Pandya C, Khera N, Gertz M, Dispenzieri A, Hogan W, Siddiqui M, Noyes K, **Kumar S**. Cost effectiveness decision tree analysis of early versus late autologous stem cell transplantation (asct) in multiple myeloma (mm) in the United States (us). *Biol Blood Marrow Transplant*. 2013 Feb; 19(2):S130-1.
 269. Morice WG, Timm MM, Jevremovic D, Ketterling RP, **Kumar S**, Reichard KK. Plasma cell phenotyping and dna content analysis by 8-color flow cytometry: a highly sensitive assay that simultaneously measures clonality, ploidy, and proliferation. *Mod Pathol*. 2013 Feb; 26:349A-50A.
 270. Morice WG, Timm MM, Jevremovic D, Ketterling RP, **Kumar S**, Reichard KK. Plasma cell phenotyping and dna content analysis by 8-color flow cytometry: a highly sensitive assay that simultaneously measures clonality, ploidy, and proliferation. *Lab Invest*. 2013 Feb; 93:349A-50A.
 271. Burnette BL, Gertz M, **Kumar S**, Lacy M, Buadi F, Hayman S, Dingli D, Inwards DJ, Johnston PB, Micallef IN, Porrata LE, Hogan W, Litzow MR, Patnaik M, Hashmi S, Leung N, Afessa B, Gastineau D, Ansell SM, Holtan S, Dispenzieri A. Redefining engraftment syndrome: the new Mayo Clinic criteria. *Biol Blood Marrow Transplant*. 2013 Feb; 19(2):S180-1.
 272. Smeltzer J, Gertz M, Rajkumar SV, Dispenzieri A, Lacy M, Buadi F, Hayman S, Dingli D, Kapoor P, **Kumar S**. Suppression of involved immunoglobulin free light chain post therapy and survival outcomes following autologous stem cell transplantation for myeloma. *Biol Blood Marrow Transplant*. 2013 Feb; 19(2):S156.
 273. Costa LJ, Nista EJ, Buadi FK, Lacy MQ, Dispenzieri A, Kramer CP, Kang Y, Gertz MA, Stuart RK, **Kumar SK**. Prediction of poor mobilization of autologous cd34+cells in multiple myeloma (mm): implications for risk-stratification. *Transfusion*. 2013 Sep; 53:21A.
 274. Dispenzieri A, Lacy MQ, Laumann KM, LaPlant B, Dingli D, Gertz MA, Buadi F, Lowe V, O'Connor M, Leung N, Rajkumar SV, **Kumar SK**, Tong C, Birgin A, Peng KW, Federspiel MJ, Russell SJ. Activity of mv-nis in a phase i trial for patients with relapsed, refractory multiple myeloma (mm). *Haematologica*. 2014 Jun 1; 99:111.
 275. Kaufman GP, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, **Kumar SK**. Kinetics of organ response and survival following normalization of the serum free light chain ratio in al amyloidosis. *Haematologica*. 2014 Jun 1; 99:794-5.
 276. Gonsalves WI, Gertz MA, Gupta V, Rajkumar SV, Morice WG, Timm MM, Singh PP, Dispenzieri A, Buadi FK, Lacy MQ, Kapoor P, **Kumar SK**. Prognostic significance of quantifying circulating plasma cells in multiple myeloma. *Clin Lymphoma Myeloma Leuk*. 2014 Sep; 14:S147.
 277. Greenberg AJ, Philip S, Paner A, Velinova S, Badros A, Catchatourian R, Larson D, Ketterling R, Kyle RA, **Kumar S**, Vachon CM, Rajkumar SV. Evidence of decreased prevalence of the t(11;14) translocation in black patients with multiple myeloma: a multi-center study. *Cancer Res*. 2014 Oct 1; 74(19).
 278. Ziv E, Dean E, Hu DL, Martino A, Serie D, Campa D, Aftab B, Bracci P, Buda G, Caswell J, Dumontet C, Dudzinski M, Fejerman L, Greenberg A, Hunstman S, Jurczyszyn A, Jamrozik K, **Kumar S**, Marques H,

- Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Vangsted AJ, Watek M, Wolf J, Slager S, Canzian F, Vachon C. Genome wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. *Cancer Res.* 2014 Oct 1; 74(19).
279. Kaufman GP, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Rajkumar SV, **Kumar S**. Adverse Cytogenetics, with or without Trisomies, in Patients Undergoing High Dose Therapy for Multiple Myeloma and Impact of Post-Transplant Maintenance Therapy. *Blood.* December 5, 2014; *Blood* 2014 124:3456.
 280. Kortuem KM, Stewart AK, Bruins LA, Ahmann G, Vasmatzis G, Rajkumar SV, **Kumar S**, Dispenzieri A, Lacy MQ, Gertz MA, Fonseca R, Champion M, Bergsagel PL, Braggio E. Development and results of a multiple myeloma specific custom 77-gene mutation panel for clinical targeted sequencing. *Blood.* 2014 Dec 6; 124(21).
 281. Costa LJ, Gonsalves WI, **Kumar S**. Early mortality in multiple myeloma: risk factors and impact on population outcomes. *Blood.* 2014 Dec 6; 124(21):1320.
 282. Beiggi S, O'Brien DR, Achenbach SJ, Rabe KG, Call TG, Kay NE, Shanafelt TD, Norman AD, Cunningham JM, Rajkumar V, **Kumar S**, Cerhan JR, Vachon CM, Slager SL. Exome sequencing in chronic lymphocytic leukemia (cll) and multiple myeloma (mm) families identifies cosegregating functional variants. *Blood.* 2014 Dec 6; 124(21).
 283. Hwa YL, Lacy MQ, Gertz MA, Buadi F, Rajkumar SV, **Kumar S**, Kapoor P, Go RS, Hayman SR, Lin Y, Lust JA, Dingli D, Russell SJ, Gonsalves WI, Dispenzieri A. Impact of beta blocker on clinical outcomes of multiple myeloma (mm) patients. *Blood.* 2014 Dec 6; 124(21):4751.
 284. Paludo J, Vallumsetla N, **Kumar S**, Ketterling R, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Painuly U, Leung N, Kyle R, Rajkumar SV, Kapoor P. Impact of novel agents on young patients with t(11;14) multiple myeloma. *Blood.* 2014 Dec 6; 124(21).
 285. Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Buadi F, Lacy MQ, Dingli D, Kapoor P, Go RS, Lust JA, Hayman SR, Lin Y, Zeldenrust SR, Kyle RA, Gertz MA, **Kumar S**. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. *Blood.* 2014 Dec 6; 124(21).
 286. **Kumar S**, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart K, Hari PN, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Hui AM, Rajkumar SV, Richardson PG. Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomib-lenalidomide-dexamethasone induction in patients (pts) with previously untreated multiple myeloma (mm): phase 2 study results. *Blood.* 2014 Dec 6; 124(21):82.
 287. Kochuparambil ST, Morice WG, Rajkumar SV, Dispenzieri A, Timm MM, Lacy MQ, Gertz MA, **Kumar S**. Measurement of the proliferation of clonal plasma cells by multiparametric flow cytometry is a clinically useful tool in multiple myeloma. *Blood.* 2014 Dec 6; 124(21):2053.
 288. Gomez M, Ramakrishnan VG, Prasad V, Kimlinger TK, Painuly U, Bi LT, Rajkumar V, **Kumar S**. Overcoming resistance to apoptosis in multiple myeloma by simultaneous inhibition of bcl2 and iap families of anti-apoptotic proteins. *Blood.* 2014 Dec 6; 124(21):2088.
 289. Dykstra BL, **Kumar S**, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, Kapoor P, Gonsalves WI, Gertz MA, Rajkumar SV. Pet-ct has major diagnostic value in the evaluation of smoldering multiple myeloma. *Blood.* 2014 Dec 6; 124(21).
 290. Raab MS, Ocio EM, Thomas SK, Gunther A, Goh YT, Lebovic D, Jakubowiak A, Song DW, Xiang F, Patel A, Vanasse KG, **Kumar S**. Phase 1 study update of the novel pan-pim kinase inhibitor lgh447 in patients with relapsed/ refractory multiple myeloma. *Blood.* 2014 Dec 6; 124(21).
 291. Lacy MQ, LaPlant BR, Laumann KM, **Kumar S**, Gertz MA, Hayman SR, Buadi F, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell S, Dingli D, Go RS, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Ailawadhi S, Chanan-Khan A, Stewart AK, Reeder CB, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone (pom/dex) in relapsed lenalidomide refractory myeloma: long term follow up and comparison of 2 mg vs 4 mg doses. *Blood.* 2014 Dec 6; 124(21).
 292. Lacy MQ, LaPlant BR, Laumann KM, **Kumar S**, Gertz MA, Hayman SR, Buadi F, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Ailawadhi S, Chanan-Khan A, Stewart AK, Reeder CB, Rajkumar SV, Mikhael JR. Pomalidomide, bortezomib and dexamethasone (pvd) for patients with relapsed lenalidomide refractory multiple myeloma (mm). *Blood.* 2014 Dec 6; 124(21):304.
 293. Mullikin TC, Rajkumar V, Dispenzieri A, Gertz MA, Lacy MQ, Buadi F, Kapoor P, Katzmman JA, Larson D, Kyle R, **Kumar S**. Progression and outcome in patients with biclonal gammopathies. *Blood.* 2014 Dec 6; 124(21).

294. Paul S, Kochuparambil ST, Thompson CA, Shanafelt TD, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Dingli D, Kapoor P, Hayman SR, Hwa L, Case JK, Rajkumar V, **Kumar S**. Quality of life and outcomes in multiple myeloma patients. *Blood*. 2014 Dec 6; 124(21):2605.
295. Moustafa MA, Rajkumar SV, Dispenzieri A, Buadi FK, Gertz MA, Lacy MQ, Kapoor P, Hayman SR, Dingli D, Kyle R, **Kumar S**. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response. *Blood*. 2014 Dec 6; 124(21).
296. Gonsalves WI, Gertz M, Dispenzieri A, Lacy M, Buadi F, Dingli D, Hayman S, Kapoor P, Rajkumar SV, **Kumar S**. Predictors of survival in multiple myeloma patients after relapse from a delayed autologous stem cell transplant. *Biol Blood Marrow Transplant*. 2015 Feb; 21(2):S137.
297. Ferzoco RM, Micallef IN, Winters J, Ansell S, Buadi F, Dingli D, Dispenzieri A, Gastineau DA, Gertz M, Hashmi S, Hayman S, Hogan W, Inwards DJ, Johnston PB, Kapoor P, Lacy M, Litzow MR, Patnaik M, Porrata LF, **Kumar S**. Updated results of the mayo clinic risk adapted algorithm for peripheral blood stem cell mobilization utilizing g-csf and plerixafor. *Biol Blood Marrow Transplant*. 2015 Feb; 21(2):S50-1.
298. Moustafa MA, Rajkumar SV, Dispenzieri A, Lacy M, Gertz MA, Buadi F, Dingli D, Hayman SR, Kapoor P, Hwa YL, Lust JA, Go RS, Kyle RA, **Kumar S**. Clinical outcomes in t(11;14) multiple myeloma. *J Clin Oncol*. 2015 May 20; 33(15).
299. Kim S, Gertz M, Dispenzieri A, Lacy M, Buadi F, Hayman SR, Dingli D, Kapoor P, Winters J, Gastineau DA, Hogan WJ, Porrata LF, **Kumar S**. Higher cd3 cell counts in apheresis collection in relation to superior survival in patients with multiple myeloma. *J Clin Oncol*. 2015 May 20; 33(15).
300. Kourelis T, Kyle RA, **Kumar S**, Gertz MA, Lacy M, Kapoor P, Buadi F, Go RS, Lust JA, Hayman SR, Rajkumar V, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Leung N, Dispenzieri A. Outcomes and treatment of patients with poeys syndrome experiencing progression or relapse after first line treatment. *J Clin Oncol*. 2015 May 20; 33(15).
301. Kaufman GP, Gertz MA, Dispenzieri A, Lacy M, Buadi F, Dingli D, Hayman SR, Kapoor P, Rajkumar SV, **Kumar S**. Outcomes of high, t(11;14), and standard cytogenetic risk multiple myeloma following early high dose therapy and autologous hematopoietic cell transplantation (sct). *J Clin Oncol*. 2015 May 20; 33(15).
302. Larsen JT, Ramakrishnan V, Wellik L, Kimlinger TK, Rajkumar SV, **Kumar S**. Patterns of akt, mtor, erk, and stat3 pathway activation in mgus, smoldering multiple myeloma, and multiple myeloma. *J Clin Oncol*. 2015 May 20; 33(15).
303. **Kumar S**, Vij R, Kaufman JL, Mikhael J, Facon T, Moreau P, Amiot M, Alzate S, Morris LJ, Ross JA, Dunbar M, Zhu M, Agarwal SK, Leverson J, Enschede SH, Humerickhouse R, Touzeau C. Phase i interim safety and efficacy of venetoclax (abt-199/gdc-0199) monotherapy for relapsed/refractory (r/r) multiple myeloma (mm). *J Clin Oncol*. 2015 May 20; 33(15).
304. Gertz MA, Lacy M, Dispenzieri A, Buadi F, Dingli D, Hayman SR, **Kumar S**, Leung N, Lust JA, Rajkumar SV, Russell SJ, Suman V, Hogan WJ. Phase iii trial of stem cell transplantation compared to melphalan and dexamethasone in the treatment of immunoglobulin light chain amyloidosis (al). *J Clin Oncol*. 2015 May 20; 33(15).
305. Vallumsetla N, Paludo J, Gertz M, Ansell SM, Go RS, Rajkumar V, Kyle RA, Buadi F, Dispenzieri A, Lacy M, Dingli D, Hayman SR, Leung N, **Kumar S**, Kapoor P. Survival trends in young patients with waldenstrom macroglobulinemia (wm). *J Clin Oncol*. 2015 May 20; 33(15).
306. Gonsalves WI, Rajkumar V, Morice W, Timm M, Dispenzieri A, Buadi F, Lacy M, Lin Y, Dingli D, Hayman SR, Zeldenrust SR, Russell SJ, Leung N, Kapoor P, Gertz MA, **Kumar S**. The prognostic significance of cd45 expression by clonal bone marrow plasma cells in multiple myeloma. *J Clin Oncol*. 2015 May 20; 33(15).
307. Warsame R, **Kumar S**, Carrie T, Morie G, Lacy M, Francis B, Suzanne H, Nelson L, David D, John L, Yi L, Kapoor P, Go R, Zeldenrust S, Kyle R, Rajkumar SV, Dispenzieri A. Al amyloidosis and quality of life outcomes. *Haematologica*. 2015 Jun; 100:511-2.
308. Abou Hussein AK, Rajkumar SV, Dispenzieri A, Gertz M, Lacy M, Buadi F, Hayman S, Dingli D, Hwa YL, Lust J, Russell S, Kapoor P, Go R, Kyle R, **Kumar S**. Assessing treatment response in multiple myeloma: implications of using bone marrow plasma cell content as a marker of disease burden. *Haematologica*. 2015 Jun; 100:506-7.
309. Paul S, Kochuparambil S, Rajkumar SV, Dispenzieri A, Gertz M, Lacy M, Buadi F, Hayman S, Dingli D, Hwa YL, Lust J, Russell S, Kapoor P, Go R, Kyle R, **Kumar S**. Impact of fish abnormalities on risk of progression in patients with monoclonal gammopathy of undetermined significance. *Haematologica*. 2015 Jun; 100:257.
310. Hussain S, Aitchison R, Regensburger J, Engebretson A, Dispenzieri A, Rajkumar SV, Tunquist B, **Kumar S**. Impact of serum alpha 1-acid glycoprotein (aag), a potential patient selection marker for filanesib, on survival and response to conventional therapies in patients with relapsed multiple myeloma (rmm). *Haematologica*.

2015 Jun; 100:516.

311. Majithia N, Rajkumar SV, Dispenzieri A, Gertz M, Lacy M, Francis B, Hayman S, Dingli D, Hwa L, Lust J, Russell S, Kapoor P, Go R, Kyle R, **Kumar S**. Outcomes of patients with primary refractory multiple myeloma in the era of novel therapies. *Haematologica*. 2015 Jun; 100:84-5.
312. Vallumsetla N, **Kumar S**, Gertz M, Painuly U, Dispenzieri A, Lacy M, Buadi F, Go R, Dingli D, Leung N, Kyle R, Rajkumar V, Kapoor P. Post relapse outcomes in young patients with multiple myeloma in the era of novel agents. *Haematologica*. 2015 Jun; 100:257-8.
313. Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Dingli D, Kapoor P, Lust JA, Go RS, Hayman SR, Lin Y, Zeldenrust S, Kyle RA, Gertz MA, **Kumar SK**. The reversal of renal impairment and its impact on survival in newly diagnosed multiple myeloma patients *Clinical Lymphoma Myeloma & Leukemia*. 2015 Jun; 15:S239.
314. Ferzoco R, Micallef I, Winters J, Ansell S, Buadi F, Dingli D, Dispenzieri A, Gastineau D, Gertz M, Hashmi S, Hayman S, Hogan W, Inwards D, Johnston P, Kapoor P, Lacy M, Litzow M, Patnaik M, Porrata L, **Kumar S**. Updated results of the Mayo Clinic risk adapted algorithm for peripheral blood stem cell mobilization utilizing g-csf and plerixafor. *Haematologica*. 2015 Jun; 100:116-7.
315. **Kumar S**, Vij R, Kaufman JL, Mikhael J, Facon T, Moreau P, Amiot M, Alzate S, Morris L, Ross J, Dunbar M, Zhu M, Agarwal S, Levenson J, Enschede S, Humerickhouse R, Touzeau C. Venetoclax (abt-199/gdc-0199) monotherapy for relapsed/refractory multiple myeloma: phase i safety and efficacy. *Haematologica*. 2015 Jun; 100:256-7.
316. Larsen JT, Ramakrishnan V, Haug J, Kimlinger T, Sen S, Mahajan D, Dugar S, Rajkumar SV, **Kumar SK**. Preclinical activity of dual pi3k/mtor inhibitor spr965 in multiple myeloma *Cancer Research*. 2015 Aug 1; 75 (Suppl 15). Epub 1900 Jan 01.
317. Bergsagel PL, Lacy MQ, Dingli D, **Kumar SK**, Ailawadhi S, Dispenzieri A, Buadi F, Gertz MA, Stewart AK, Reeder CB, Kosiorek HE, Dueck AC, Lin Y, Chanan-Khan AA, Chesi M. Anti-tumor phagocytic cell activation in multiple myeloma by the iap antagonist Icl161: results of a phase ii clinical trial *Blood*. 2015 Dec 3; 126: (23)3039.
318. Quill TA, **Kumar SK**, Lentzsch S, Lonial S, Roodman GD, Brady ED, Mortimer J, Obholz KL, Anderson KC. Changes in expert recommendations and global practice patterns from 2012-2015: results from an annually updated online decision aid for multiple myeloma (mm) *Blood*. 2015 Dec 3; 126: (23)2105.
319. Hwa YL, **Kumar SK**, Lacy MQ, Gertz MA, Buadi F, Rajkumar SV, Go RS, Leung N, Kapoor P, Dingli D, Russell SJ, Lust JA, Hayman SR, Kourelis T, Dispenzieri A. Impact of bone marrow plasmacytosis on outcome in patients with al amyloidosis following autologous stem cell transplant *Blood*. 2015 Dec 3; 126: (23)3177.
320. Milani P, Dispenzieri A, Gertz MA, Lacy MQ, Baudi FK, **Kumar SK**, Maurer MS, Klarich K, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Hwa YL, Zeldenrust SR, Kyle RA, Rajkumar SV, Grogan M. In patients with light-chain (al) amyloidosis myocardial contraction fraction (mcf) is a simple, but powerful prognostic measure that can be calculated from a standard echocardiogram (echo) *Blood*. 2015 Dec 3; 126: (23)1774.
321. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson S, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, **Kumar SK**, Touzeau C, Buadi F, Laubach JP, Lin JC, Berg D, DiBacco A, Hui AM, Richardson PG. Ixazomib, an investigational oral proteasome inhibitor (pi), in combination with lenalidomide and dexamethasone (ird), significantly extends progression-free survival (pfs) for patients (pts) with relapsed and/or refractory multiple myeloma (rrmm): the phase 3 tourmaline-mm1 study (nct01564537) *Blood*. 2015 Dec 3; 126: (23)727.
322. van Beers E, van Vliet M, de Best L, Anderson KC, Chari A, Jagganath S, Jakubowiak A, **Kumar SK**, Lebovic D, Levy J, Auclair D, Lonial S, Reece D, Richardson PG, Siegel D, Stewart AK, Trudel S, Vij R, Zimmerman T, Fonseca R. Low-risk multiple myeloma by sky92+iss validated in the multiple myeloma genomics initiative study *Blood*. 2015 Dec 3; 126: (23)5322.
323. Milani P, Gertz MA, Merlini G, Palladini G, Lacy MQ, Baudi FK, **Kumar SK**, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Zeldenrust SR, Hwa YL, Kyle RA, Rajkumar SV, Dispenzieri A. N-terminal fragment of the type-b natriuretic peptide (nt-probnp) is a prognostic factor for overall survival in newly diagnosed patients with multiple myeloma (mm) *Blood*. 2015 Dec 3; 126: (23)3292.
324. Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi F, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, **Kumar SK**. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma *Blood*. 2015 Dec 3; 126: (23)4176.
325. **Kumar SK**, Lee JH, Dimopoulos MA, Terpos E, Kastritis E, Chng WJ, Jurczyszyn AJ, Handa H, Ozaki S,

- Leleu X, Moreau P, Lahuerta JJ, Shustik C, Waller DD, Beksac M, Vij R, Kim K, Kim JS, Badros AZ, Alsina M, Durie BGM. Outcomes after initial relapse of multiple myeloma: an international myeloma working group study Blood. 2015 Dec 3; 126: (23)4204.
326. **Kumar SK**, Laplant BR, Reeder CB, Roy V, Buadi F, Gertz MA, Laumann K, Bergsagel PL, Dispenzieri A, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Witzig TE, Ailawadhi S, Dingli D, Go RS, Lin Y, Rivera CE, Rajkumar SV, Lacy MQ. Randomized phase 2 trial of two different doses of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib Blood. 2015 Dec 3; 126: (23)3050.
 327. **Kumar SK**, Vij R, Kaufman JL, Mikhael JR, Facon T, Pegourie B, Benboubker L, Moreau P, Amiot M, Alzate S, Morris L, Ross J, Dunbar M, Zhu M, Maciag P, Agarwal S, Leverson J, Enschede SH, Humerickhouse RA, Touzeau C. Safety and efficacy of venetoclax (abt-199/gdc-0199) monotherapy for relapsed/refractory multiple myeloma: phase 1 preliminary results Blood. 2015 Dec 3; 126: (23)4219.
 328. Mitra AK, Mukherjee U, Harding T, Stessman H, Li Y, Jin J, **Kumar SK**, Rajkumar SV, Van Ness BG. Scattome: a single-cell analysis of targeted transcriptome program to predict drug sensitivity of single cells within human myeloma tumors Blood. 2015 Dec 3; 126: (23)4249.
 329. Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, **Kumar SK**. Prognostic factors in patients with multiple myeloma and standard-risk cytogenetics Haematologica. 2016 Jun; 101: (Suppl 1)263-4.
 330. **Kumar SK**, Durie BG, Diels J, Bacon T, Soltoft F, Lam A. An updated adjusted comparison suggests daratumumab is associated with prolonged survival compared with standard of care therapies in heavily pre-treated and high refractory multiple myeloma patients Haematologica. 2017 Jun 26; 102:273-4.
 331. Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, **Kumar SK**. Prognostic implications of multiple cytogenetic high-risk abnormalities in patients with newly diagnosed multiple myeloma Haematologica. 2017 Jun 26; 102:107.
 332. Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Rajkumar SV, **Kumar SK**, Gonsalves WI. Prognostic significance of clonal circulating plasma cells by multi-parametric flow cytometry in patients with light chain amyloidosis undergoing autologous stem cell transplantation Haematologica. 2017 Jun 26; 102:267-8.
 333. Sidana S, Tandon N, Jevremovic D, Ketterling RP, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Morice W, Hanson CA, Timm M, Greipp P, Baughn LB, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Rajkumar SV, **Kumar SK**. Hyperdiploidy in plasma cell disorders using multi-parametric flow cytometry (mfc) vs. fish Cancer Research. 2018 Jul; 78(13):655
 334. Dasari S., Dispenzieri A., **Kumar S.**, Barnidge D.R., Madden B. J., Kourelis T., Arendt B.K., Kohlhagen M.C., Milani P., Merlini G., Ramirez-Alvarado M., Murray D.L.. Screening for Light Chain Glycosylation: A Potential Route to Earlier Diagnosis of AL Amyloidosis 2018 Annual AACC Meeting. 07/31/2018.
 335. Sidiqi MH, Aljama MA, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis T, Hogan WJ, Rajkumar SV, **Kumar SK**, Gertz MA. Bortezomib, lenalidomide and dexamethasone (vrd) followed by autologous stem cell transplant for newly diagnosed multiple myeloma; the Mayo Clinic experience Blood. 2018 Nov 29; 132(Suppl 1):2147. Epub 1900 Jan 01.
 336. Aljama MA, Sidiqi MH, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder A, Hayman SR, Hobbs M, Gonsalves WI, Warsame R, Kourelis T, Hwa L, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, **Kumar SK**. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain amyloidosis Blood. 2018 Nov 29; 132(Suppl 1):3182
 337. Paludo J, Abeykoon JP, Gertz MA, Kapoor P, Paulus A, Ailawadhi S, Reeder CB, Witzig TE, Habermann TM, Novak AJ, Buadi FK, Dispenzieri A, Lin Y, Go RS, Lacy MQ, **Kumar SK**, Rajkumar SV, Kyle RA, Ansell SM. Depth of response in Waldenstrom macroglobulinemia Blood. 2018 Nov 29; 132(Suppl 1):4141
 338. Mellors P, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa Y, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust S, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, **Kumar SK**. Development of thrombocytopenia and survival outcomes in newly diagnosed multiple myeloma Blood. 2018 Nov 29; 132(Suppl 1):1902
 339. Binder M, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust S, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, **Kumar SK**. Early prediction of treatment response in new diagnosed multiple myeloma Blood. 2018 Nov 29; 132(Suppl 1):3159
 340. Rosenthal KM, Ghobrial IM, Huff CA, Lonial S, Raje N, Obholz KL, **Kumar SK**. Evolving areas of consensus

and disagreement among experts in treatment of patients with multiple myeloma (mm) Blood. 2018 Nov 29; 132(Suppl 1):5664

341. Binder M, Rajkumar SV, Lakshman A, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust S, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, **Kumar SK**. Expected survival in patients with smoldering multiple myeloma and multiple myeloma Blood. 2018 Nov 29; 132(Suppl 1):4497
342. Baughn LB, Larson D, Polley MY, Pearce KE, Elhaik E, Baird ML, Colby C, Benson J, Li Z, Asmann Y, Therneau T, Cerhan JR, Vachon CM, Stewart AK, Bergsagel PL, Dispenzieri A, **Kumar SK**, Rajkumar SV. Genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry Blood. 2018 Nov 29; 132(Suppl 1):4458
343. Abeykoon JP, Zanwar S, Ailawadhi S, Larsen J, Gertz MA, Gonsalves WI, Buadi FK, **Kumar SK**, Rajkumar SV, King RL, Inwards DJ, Lacy MQ, Habermann TM, Dispenzieri A, Witzig TE, Leung N, Hobbs M, Dingli D, Kyle RA, Ansell SM, Kapoor P. Ibrutinib therapy in patients with Waldenstrom macroglobulinemia: outcomes outside of clinical trial setting Blood. 2018 Nov 29; 132(Suppl 1):1606
344. Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp P, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder A, Hayman SR, Hobbs M, Gonsalves WI, Hwa Y, Leung N, Go RS, Lin Y, Kourelis T, Warsame R, Lust JA, Russell SJ, Zeldenrust S, Kyle RA, **Kumar SK**. Impact of acquired del(17p) in patients with multiple myeloma Blood. 2018 Nov 29; 132(Suppl 1):4449
345. Zanwar S, Abeykoon JP, Ansell SM, King RL, He R, Gertz MA, Greipp PT, Kyle RA, Habermann TM, Dingli D, Novak A, Inwards DJ, Buadi FK, Nowakowski GS, Thompson CA, Johnston PB, Thanarajasingam G, Bennani NN, Witzig TE, Micallef IN, Porrata LF, Villasboas JC, Dispenzieri A, Lacy MQ, Go RS, Muchtar E, Kourelis T, Gonsalves WI, Lin Y, Rajkumar S, **Kumar SK**, Kapoor P. Impact of MYD88(L265P) mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia Blood. 2018; 132(Suppl 1):2884.
346. Demmer I, Huschens S, Potthoff D, Tomeczkowski J, Englisch C, Thilakarathne P, Diels J, **Kumar SK**, Durie BGM, Eisele L. Indirect comparison using individual patient level data comparing efficacy and safety of a daratumumab monotherapy vs. EU approved comparator therapies in patients with multiple myeloma Blood. 2018 Nov 29; 132(Suppl 1):3541
347. Clay-Gilmour AI, Camp NJ, Wei X, Norman AD, Sinnwell JP, Demangel D, Waller RG, Dumontet C, McKay J, Offit K, Chen S, O'Brien DR, Rajkumar SV, Klein R, **Kumar SK**, Lipkin S, Slager SL, Vachon CM. Large-scale linkage analysis of multiple myeloma (mm) and monoclonal gammopathy of undetermined significance (mgus) families Blood. 2018 Nov 29; 132(Suppl 1):4501
348. Dispenzieri A, Dasari S, Arendt BK, Kohlhagen MK, Kourelis T, Gertz MA, **Kumar SK**, Rajkumar SV, Buadi FK, Dingli D, Leung N, Kapoor P, Go RS, Kyle RA, Muchtar E, Hwa Y, Warsame R, Gonsalves WI, Zeldenrust S, Fonder A, Hobbs M, Lust JA, Russell SJ, Murray DL. Mass spectrometry to measure response in immunoglobulin light chain amyloidosis (al) Blood. 2018 Nov 29; 132(Suppl 1):4502
349. Gandhi UH, Lakshman A, Gahvari Z, McGehee E, Jagosky MH, Gupta R, Varnado W, Chhabra S, Fiala MA, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli AK, Liedtke M, Godby KN, Kang YB, Kansagra A, Scott EC, Umyarova E, Hari P, Vij R, Usmani SZ, Callander NS, Cornell RF, **Kumar SK**, Costa LJ. Natural history of patients with multiple myeloma refractory to cd38-targeted monoclonal antibody-based treatment Blood. 2018 Nov 29; 132(Suppl 1):3233
350. Varnado W, Jagosky MH, Gahvari Z, Chhabra S, Gandhi UH, Lakshman A, McGehee E, Gupta R, Malek E, Fiala MA, Mansour J, Paul B, Barnstead A, Kodali S, Amarendra N, Liedtke M, Godby KN, Kang YB, Kansagra A, Scott EC, Umyarova E, Hari P, Vij R, Usmani SZ, Cornell RF, **Kumar SK**, Callander NS, Costa LJ. Natural history of patients with multiple myeloma refractory to elotuzumab and outcomes of subsequent therapy with anti-cd38 monoclonal antibodies Blood. 2018 Nov 29; 132(Suppl 1):3303
351. Muchtar E, Dispenzieri A, Leung N, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves WI, Kourelis T, Warsame R, Russell SJ, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, **Kumar SK**, Gertz MA. Optimizing deep response assessment for al amyloidosis using involved free light chain level at end of therapy Blood. 2018 Nov 29; 132(Suppl 1):3227
352. Warsame R, Fruth B, Croghan K, Engebretson A, Kourelis T, Aug S, Ellingson S, Irlbeck C, Gertz MA, Buadi FK, Go RS, Gonsalves WI, Muchtar E, **Kumar SK**, Rajkumar SV, Lust JA, Leung N, Dingli D, Lin Y, Hayman SR, Lacy MQ, Fonder A, Hobbs M, Hwa YL, Thompson CA, Kyle RA, Buckner J, Dispenzieri A, Sloan JA. Patient-reported outcome driven case management system for hematology - a prospective study Blood. 2018 Nov 29; 132:719
353. Costa LJ, Stadtmayer EA, Morgan G, Monohan G, Kovacsovic T, Burwick N, Jakubowiak A, Kaufman JL, Mobasher M, Freise KJ, Ross JA, Pesko J, Munasinghe W, Gudipati S, Mudd S, Bueno O, **Kumar SK**. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma Blood. 2018 Nov 29; 132(Suppl 1):303

354. **Kumar SK**, Kapoor P, Laplant B, Muchtar E, Buadi FK, Gonsalves WI, Dingli D, Go RS, Warsame R, Kourelis T, Lust JA, Lacy MQ, Dispenzieri A, Hayman SR, Hwa Y, Fonder A, Hobbs M, Leung N, Rajkumar SV, Gertz MA, Wolfe E. Phase 2 trial of ixazomib, lenalidomide, dexamethasone and daratumumab in patients with newly diagnosed multiple myeloma Blood. 2018 Nov 29; 132(Suppl 1):304
355. Facon T, **Kumar SK**, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Ahmadi T, Chiu C, Wang JP, Van Rumpelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ. Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (d-rd) versus lenalidomide and dexamethasone (rd) in patients with newly diagnosed multiple myeloma (ndmm) ineligible for transplant (maia) Blood. 2018 Nov 29; 132(Suppl 1):LBA-2
356. Lacy MQ, Peng KW, Russell SJ, Dueck AC, Patnaik MM, Witzig TE, Ginos BF, Buadi FK, Dispenzieri A, Gertz MA, Go RS, Hayman SR, Lust JA, Dingli D, Rajkumar SV, Leung N, Warsame R, Gonsalves WI, Kourelis T, Muchtar E, Broski S, Murphy RC, Kapoor P, Kyle RA, Zeldenrust S, Al-Kali A, Litzow MR, Naik S, Federspiel MJ, **Kumar SK**. Phase i trial of systemic administration of vesicular stomatitis virus genetically engineered to express nis and human interferon, in patients with relapsed or refractory multiple myeloma (mm), acute myeloid leukemia (aml), and t-cell neoplasms (tcl) Blood. 2018 Nov 29; 132(Suppl 1):3268
357. Zanwar S, Abeykoon JP, Ansell SM, Dispenzieri A, Gertz MA, Inwards DJ, Witzig TE, Lacy MQ, Habermann TM, Dingli D, Buadi FK, Go RS, Gonsalves WI, Muchtar E, Kyle RA, Rajkumar SV, **Kumar SK**, Kapoor P. Prognosis of patients with Waldenstrom macroglobulinemia: a simplified model Blood. 2018 Nov 29; 132 (Suppl 1):4152
358. Binder M, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust S, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, **Kumar SK**. Prognostic significance of early immune reconstitution in newly diagnosed multiple myeloma Blood. 2018 Nov 29; 132(Suppl 1):3158
359. **Kumar SK**, Fu A, Mezzi K, Braunlin M, Kim C, Iskander K, Niesvizky R, Jagannath S, Boccia R, Raje N. Renal response in carfilzomib (k)- versus bortezomib (v)-treated patients (pts) with relapsed or refractory multiple myeloma (rrmm) in the real-world practice setting Blood. 2018 Nov 29; 132(Suppl 1):3253
360. Cornell RF, Gandhi UH, Lakshman A, Gahvari Z, Jagosky MH, McGehee E, Varnado W, Gupta R, Chhabra S, Fiala MA, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli AK, Liedtke M, Godby KN, Kang YB, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Costa LJ, **Kumar SK**. Subsequent treatment outcomes of multiple myeloma refractory to cd38-monoclonal antibody therapy Blood. 2018 Nov 29; 132(Suppl 1):2015
361. Jin FY, **Kumar SK**, Dai Y. The lysine-specific demethylase kdm4a/jmjd2a acts as a tumor suppressor in multiple myeloma Blood. 2018 Nov 29; 132(Suppl 1):191
362. Clay-Gilmour AI, Hildebrandt MA, Camp NJ, Ziv E, Brown EE, Hofmann JN, Spinelli JJ, Giles GG, Bhatti P, Cozen W, Wu XF, Robinson DP, Norman AD, Sinnwell JP, **Kumar SK**, Rajkumar SV, Slager SL, Vachon CM. Associations between a polygenic risk score and risk of multiple myeloma and its precursor Cancer Research. 2019 Jul; 79(13 Suppl):2686
363. Binder M, Nandakumar B, Gertz MA, Dispenzieri A, Lacy MQ, Maurer MJ, Hayman SR, Buadi FK, Dingli D, Kapoor P, Go RS, Hwa YL, Fonder A, Hobbs MA, Lin Y, Leung N, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, **Kumar SK**. Mortality of patients with multiple myeloma after the introduction of novel therapies in the United States. Blood. 2019; 134(Suppl 1):72.
364. Buadi FK, Lacy MQ, Dispenzieri A, Perez G, Gertz MA, Kapoor P, Hayman SR, Dingli D, Go RS, Fonder A, Hwa YL, Hobbs MA, Gonsalves WI, Helgeson DK, Kourelis T, Laplant B, Russell SJ, Muchtar E, Warsame RM, Rajkumar SV, Kyle RA, **Kumar SK**. Phase 2 Trial of LDE225 and Lenalidomide maintenance post autologous stem cell transplant for multiple myeloma. Blood. 2019; 134(Suppl 1):1905.
365. Henderson , KJ, Kimlinger TK. The Transcriptions of Immunomodulator-Resistant Multiple Myeloma Blood. 2019.
366. Costa LJ, Lin Y, Martin TG, Chhabra S, Usmani SZ, Jagannath S, Callander NS, Berdeja JG, Kang Y, Vij R, Tian H, Valluri S, Marino J, Jackson CC, Banerjee A, Kansagra A, Schechter JM, **Kumar SK**, Hari P. Cilta-cel versus conventional treatments in patients with relapse/refractory multiple myeloma. Journal of Clinical Oncology. 2021; 39(Supplement 15):8030. Abstract no. 8030. Epub 2021 May 28.
367. Evans LJ, **Kumar SK**, Dingli D, Dispenzieri A, Lacy MQ, Go RS, Buadi F, Leung N, Lin Y, Hayman SR, Russell SJ, Muchtar E, Kapoor P, Siddiqui MA, Warsame R, Kourelis T, Kyle RA, Gertz MA, Rajkumar S, Gonsalves WI. Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM). Journal of Clinical Oncology. 2021; 39 (Supplement 15). Abstract no. e20016. Epub 2021 May 28.
368. Evans LA, **Kumar SK**, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Kourelis TV,

- Muchtar E, Go RS, Warsame R, Leung N, Hobbs M, Hwa YL, Fonder A, Kyle RA, Gertz M, Rajkumar SV, Gonsalves WI. Impact of stratification of levels of serum lactate dehydrogenase (ldh) at diagnosis on overall survival (os) in newly diagnosed multiple myeloma (ndmm) Clinical Lymphoma Myeloma & Leukemia. 2021 Sep; 21:S435
369. Cook J, Peng K, Witzig TE, Broski SM, Villasboas Bisneto J, Paludo J, Patnaik M, Rajkumar S, Dispenzieri A, Leung N, Buadi F, Bennani NN, Ansell SM, Zhang L, Packiriswamy N, Balakrishnan B, Brunton BA, Giers MJ, Ginos BF, Dueck AC, Geyer S, Gertz MA, Warsame R, Go RS, Hayman SR, Dingli D, **Kumar SK**, Bergsagel P, Gonsalves WI, Kourelis T, Muchtar E, Kapoor P, Kyle RA, Lin Y, Siddiqui MA, Fonder AL, Hobbs MA, Hwa YL, Russell SJ, Lacy MQ. An Analysis of Virtus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFN β -NIS) Blood. 2021; 138(Supplement 1):1333.
 370. Kaddoura M, Binder M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Hwa YL, Fonder A, Hobbs MA, Hayman SR, Leung N, Go R, Lin Y, Gonsalves WI, Kourelis T, Warsame RM, Kyle RA, Rajkumar SV, **Kumar SK**. Impact of achieving an early complete response in multiple myeloma and predictors of subsequent outcome. Blood. 2021; 138(Suppl 1):3773.
 371. Binder M, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, Lacy MQ, Gertz MA, Hayman SR, Leung N, Fonder A, Hobbs MA, Hwa YL, Muchtar E, Warsame RM, Kourelis T, Gonsalves WI, Russell SJ, Lin Y, Siddiqui MA, Kyle RA, Dispenzieri A, **Kumar SK**. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Blood. 2021; 138(Suppl 1):119.
 372. Paludo J, Bansal R, Holland AT, Haugen KL, Spychalla MT, McClanahan AL, Truong TA, Hathcock MA, Khurana A, Alkhateeb H, Dingli D, Hayman SR, Kapoor P, Gertz MA, Wang Y, Kenderian S, Kourelis T, **Kumar SK**, Shah M, Siddiqui MA, Warsame R, Villasboas J, Bennani NN, Johnston PB, Ansell SM, Haddad TC, Lin Y. Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy Blood. 2021; 138(Supplement 1):568. Epub 2021 Nov 05.
 373. Warsame RM, Gertz MA, Buadi FK, Go R, **Kumar SK**, Dingli D, Kyle RA, Leung N, Kourelis T, Hayman SR, Lin Y, Lacy MQ, Lust JA, Hwa YL, Fonder A, Kapoor P, Hobbs MA, Gonsalves WI, Rajkumar SV, Muchtar E, Visram A, Russell SJ, Dispenzieri A. Prognostic role of IL-6 in POEMS syndrome. Blood. 2021; 138(Suppl 1):2700.
 374. Wiedmeier-Nutor JE, Iqbal M, Munoz J, Bezerra E, Garcia Robledo JE, Bansal R, Johnston PB, Hathcock MA, Larsen JT, Bergsagel P, Wang Y, Reeder CB, Leis JF, Fonseca R, Palmer JM, Warsame R, Kourelis T, Hayman SR, Dingli D, Kapoor P, **Kumar SK**, Durani U, Villasboas Bisneto J, Paludo J, Bennani NN, Ansell SM, Castro JE, Kharfan Dabaja M, Lin Y, Vergidis P, Murthy H, Rosenthal AC. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Blood. 2021; 138(Supplement 1):1750. Epub 2021 Nov 05.
 375. **Kumar SK**, Jessen E, Dispenzieri A, Kapoor P, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Leung N, Muchtar E, Warsame RM, Kourelis T, Russell SJ, Lin Y, Siddiqui MA, Jang JS, Kyle RA, Rajkumar SV, Gertz MA, Fonseca R, Gonsalves WI. The impact of the central carbon energy metabolism transcriptome in the pathogenesis and outcomes of multiple myeloma. Blood. 2021; 138(Suppl 1):2650.
 376. Abeykoon JP, Tawfiq RK, **Kumar S**, Ansell SM. Monoclonal gammopathy of undetermined significance: evaluation, risk assessment, management, and beyond. Fac Rev. 2022; 11:34. Epub 2022 Nov 29.
 377. Abeykoon J, **Kumar S**, Castillo JJ, D'Sa S, Kastiris E, Durot E, Uppal E, Pierre M, Paludo J, Tawfiq RK, Sarosiek S, Ogunbiyi O, Cornillet-Lefebvre P, Kyle RA, Delmer A, Gertz M, Dimopoulos M, Treon S, Ansell S, Kapoor P. Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study Journal of Clinical Oncology. 2022; 40(16_suppl):7566.
 378. Ragon BK, D'Souza A, Estrada-Merly N, Fraser R, George G, Gowda L, Shah N, Qazilbash MH, **Kumar SK**, Horowitz MM, Usmani SZ, Shah M. Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis Journal of Clinical Oncology. 2022; 8057. Abstract no. 382311. Epub 2022 Jun 02.
 379. Goldschmidt H, Facon T, **Kumar SK**, Plesner T, Moreau P, Bahlis N, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Pei H, Borgsten F, Usmani SZ. Speed and duration of response and patient reports endpoints (pros) of daratumumab plus lenalidomide and dexamethasone therapy vs lenalidomide and dexamethasone in non-transplantable patients with newly diagnosed multiple myeloma: phase 3 maia study. Oncology Research and Treatment. 2022 Sep; 45(Suppl 2):90-1
 380. Barreto JN, Barreto EF, Mara KC, Rule AD, Powell MZ, Bansal R, Hathcock MA, Herrmann SM, Nedved AN, Ansell SM, Bennani NN, Paludo J, Johnston PB, Durani U, Sandahl TB, Wang Y, Khurana A, Alkhateeb HB, Shah MV, Kapoor P, Gertz MA, **Kumar SK**, Dingli D, Kourelis T, Warsame RM, Hayman SR, Leung N, Lin Y. Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric

Antigen Receptor T-Cell Therapy. Blood. 2022; 140(1):10942-10944.

381. Gonsalves WI, Nepariidze N, Allred JB, **Kumar SK**, Reid JM, Shapiro G, Costello BA, Piekarz R, Baz RC, Devarakonda S. A multicenter phase i dose-escalation trial of a novel glutaminase inhibitor telaglenastat in combination with carfilzomib and dexamethasone in relapsed and refractory multiple myeloma. Blood. 2022 Nov 15; 140(Suppl 1):7315-6
382. Voorhees PM, D'Souza A, Weisel K, Hurd DD, Teipel R, Chung A, Rodriguez C, Tuchman SA, Korde N, Safah H, Bueno OF, Pumford N, Rosenberg TS, Pothacamury RK, Ross JA, Polepally AR, Lee S, Jin ZY, Talati C, Vij R, **Kumar SK**. A phase 1 first-in-human study of abbv-383, a bcma x cd3 bispecific t-cell-redirecting antibody, as monotherapy in patients with relapsed/refractory multiple myeloma. Blood. 2022 Nov 15; 140:4401-4
383. Bonolo De Campos C, Smadbeck JB, Arribas M, Sharma N, Ahmann GJ, **Kumar SK**, Stewart AK, Fonseca R, Bergsagel PL, Asmann Y, Baughn LB, Braggio E. A single next generation sequencing assay for detection of driver mutations, translocations and copy number alterations in patients with multiple myeloma. Blood. 2022 Nov 15; 140:7180-1
384. Muchtar E, Dasari S, Grogan M, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Kourelis T, Attia IZ, Lopez-Jimenez F, Murphree D, Friedman PA, **Kumar SK**, Dispenzieri A. Artificial intelligence-enhanced models to predict light chain amyloidosis from patients with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood. 2022 Nov 15; 140(Suppl 1):7230-2
385. Sharon D, Dunbar F, Jung P, Wang XF, Li XT, Mantis C, Bueno OF, Touzeau C, Moreau P, Harrison SJ, Costa LJ, Kaufman JL, Bahlis NJ, **Kumar SK**, Ross JA, Epling-Burnette PK. Clinical genomic analyses demonstrate t(11;14) multiple myeloma retains b-cell biology and distinct mitochondrial metabolism that convey increased sensitivity to bcl-2 inhibition by venetoclax. Blood. 2022 Nov 15; 140:4242-4
386. Baughn LB, Mearns ES, Nixon M, Chopra VS, Girvan A, Cornell RF, Saxena J, Slifko BM, Clark J, **Kumar SK**. Current testing practices for t(11;14) rearrangements in patients with newly diagnosed multiple myeloma in the United States. Blood. 2022 Nov 15; 140:10114-5
387. Moreau P, Facon T, Usmani S, Bahlis NJ, Raje N, Plesner T, Orlowski RZ, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Tiab M, Macro M, Frenzel L, Leleu X, Pei H, Krevvata M, Carson R, Borgsten F, **Kumar SK**. Daratumumab plus lenalidomide and dexamethasone (d-rd) versus lenalidomide and dexamethasone (rd) in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (ndmm): clinical assessment of key subgroups of the phase 3 maia study. Blood. 2022 Nov 15; 140(Suppl 1):7297-300
388. Facon T, **Kumar SK**, Weisel K, Usmani S, Moreau P, Plesner T, Orlowski RZ, Bahlis NJ, Basu S, Nahi H, Hulin C, Quach H, O'Dwyer M, Perrot A, Venner CP, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Pei HL, Carson R, Borgsten F, Goldschmidt H. Daratumumab plus lenalidomide and dexamethasone in patients with transplant-ineligible newly diagnosed multiple myeloma: maia age subgroup analysis. Blood. 2022 Nov 15; 140:10133-6
389. **Kumar SK**, Alsina M, Laplant B, Badros AZ, Abdallah AO, Abonour R, Asmus EJ, Dhakal B, Rosenbaum CA, Egan D, Bhutani M, Jakubowiak A, Durie BGM. Fixed duration therapy with daratumumab, carfilzomib, lenalidomide and dexamethasone for high risk smoldering multiple myeloma-results of the ascent trial. Blood. 2022 Nov 15; 140(Suppl 1):1830-2
390. Perrot A, Facon T, Plesner T, Usmani S, **Kumar SK**, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, Pei H, Gupta N, Kaila S, Matt K, Gries KS, Carson R, Borgsten F, Weisel K. Health-related quality of life for frail transplant-ineligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone: subgroup analysis of maia trial. Blood. 2022 Nov 15; 140:1142-5
391. Badawi MA, Coppola S, Eckert D, Gopalakrishnan S, Doelger E, Dobkowska E, **Kumar SK**, Huang WZ, Menon R, Salem AH. Impact of venetoclax exposure on clinical efficacy and safety in biomarker-selected patients with relapsed or refractory multiple myeloma: implication for dose selection. Blood. 2022 Nov 15; 140(Suppl 1):4281-2
392. **Kumar SK**, Garfall AL, Trudel S, Ocio EM, Scott E, Huang L, Ma X, Olyslager Y, Thakkar P, Pei L, Heuck C, Terpos E. Monumental-5: a phase 3 study of talquetamab versus belantamab mafodotin in patients with relapsed/refractory multiple myeloma who received >= 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-cd38 monoclonal antibody. Blood. 2022 Nov 15; 140(Suppl 1):7292-3
393. Jayasinghe RG, Mulligan G, Cook A, Hamilton M, Gnjatich S, Kim-Schulze S, Cho HJ, **Kumar SK**. Myeloma developing regimens using genomics (mydrug): longitudinal single-cell transcriptional landscape of the myeloma and immune microenvironment in relapsed/refractory multiple myeloma patients treated with mek-inhibitor, cobimetinib. Blood. 2022 Nov 15; 140(Suppl 1):7090-1

394. Schmidt WM, Buadi FK, Hayman SR, **Kumar SK**, Dispenzieri A, Dingli D, Cook J, Lacy MQ, Kapoor P, Leung N, Muchtar E, Warsame RM, Kourelis T, Binder M, Gonsalves WI, Gertz MA. Outcomes of allogeneic stem cell transplant for multiple myeloma. *Blood*. 2022 Nov 15; 140:7182-4
395. Bansal R, Paludo J, Hathcock MA, Spychalla MT, Khurana A, Hampel PJ, Durani U, Alkhateeb HB, Dingli D, Hayman SR, Kapoor P, Wang Y, Kenderian SS, Binder M, Kourelis T, **Kumar SK**, Shah MV, Warsame RM, Bennani NN, Gertz MA, Johnston PB, Ansell SM, Siddiqui MA, Lin Y. Outpatient practice pattern for recently approved car-t in patients with lymphoma and multiple myeloma. *Blood*. 2022 Nov 15; 140(Suppl 1):2399-401
396. Bansal R, Ailawadhi S, Larsen JT, Gertz MA, Hathcock MA, Dingli D, Kapoor P, Kourelis T, Hayman SR, Warsame RM, Binder M, Parrondo RD, Fonseca R, Bergsagel PL, **Kumar SK**, Lin Y. Prognostic value of month 1 bone marrow and pet mrd status in car-t therapy for myeloma. *Blood*. 2022 Nov 15; 140(Suppl 1):1862-4
397. Costa LJ, **Kumar SK**, Atrash S, Liedtke M, Kaur G, Derman BA, Bergsagel PL, Mailankody S, McCarthy PL, Limones J, Chen Y, Das S, Thorpe J, Cacciatore J, Navarro G, Koegel AK, Burgess MR, Hege K, Richard S. Results from the first phase 1 clinical study of the b-cell maturation antigen (bcma) nex t chimeric antigen receptor (car) t cell therapy cc-98633/bms-986354 in patients (pts) with relapsed/refractory multiple myeloma (rrmm). *Blood*. 2022 Nov 15; 140(Suppl 1):1360-2
398. Dai Y, Liu X, Yang T, **Kumar SK**, Jin F. Tet2 down-regulation confers bortezomib resistance in multiple myeloma. *Blood*. 2022 Nov 15; 140(Suppl 1):4185-6
399. **Kumar SK**, Hofmeister CC, Biran N, Kaur G, Ye JC, Zonder JA, Syed U, Yesil J, Woolley K, Mulligan G, Cho HJ. The mydrug platform trial: efficacy and safety of daratumumab, ixazomib, pomalidomide, and dexamethasone in patients with functionally high-risk multiple myeloma. *Blood*. 2022 Nov 15; 140(Suppl 1):4434-5
400. Otero PR, Joseph NS, **Kumar SK**, Lee HC, Leleu X, Manier S, Dimopoulos MA, Mateos MV, Oriol A, Bumma N, Gong W, Roy P, Lorenc KR, Kroog GS, Sarkaria SM. Trial in progress: regn5458, a bcmaxcd3 bispecific antibody, in a phase ib multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma. *Blood*. 2022 Nov 15; 140(Suppl 1):4444-6
401. Mailankody S, Matous JV, Liedtke M, Sidana S, Oluwole OO, Mohan M, Cruz JC, Nath R, Anwer F, Rossi A, Htut M, Malik SA, Ghatta S, Dillon M, Ying W, Navale L, Karski EE, Balakumaran A, **Kumar SK**. Universal updated phase 1 data highlights role of allogeneic anti-bcma allo-715 therapy for relapsed/refractory multiple myeloma. *Blood*. 2022 Nov 15; 140(Suppl 1):4620-2
402. Ahmed S, Mazumder S, Wiesen L, Sharma N, Mukherjee UK, **Kumar SK**, Baughn LB, Van Ness BG, Mitra AK. Validation of a novel rac1 inhibitor as potent secdrug against activating ras mutant and drug-resistant multiple myeloma. *Blood*. 2022 Nov 15; 140(Suppl 1):4249-50
403. Sharma N, Tang H, Yan H, Tian S, Shivaram S, Kourelis T, **Kumar SK**, Baughn LB. Variation in the immune tumor microenvironment in relation to self-reported race in individuals with multiple myeloma. *Blood*. 2022 Nov 15; 140:4209-10
404. Chohan K, Zanwar S, Go R, Paludo J, Thompson CA, Chanan-Khan A, Ailawadhi S, Habermann TM, Witzig TE, Gertz MA, Ansell SM, **Kumar SK**, Pruthi RK, Nichols WL, Kapoor P, Sridharan M, Abeykoon JP. Waldenstrom macroglobulinemia and the clinical implications of acquired von Willebrand syndrome. *Blood*. 2022 Nov 15; 140:9363-5
405. **Kumar SK**, Moreau P, Bahlis N, Facon T, Plesner T, Orlowski RZ, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Wang G, Krevvata M, Carson R, Borgsten F, Usmani SZ. Daratumumab plus lenalidomide and dexamethasone (d-rd) versus lenalidomide and dexamethasone (rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (ndmm): updated analysis of the phase 3 maia study. *Oncology Research and Treatment*. 2023 Oct 3; 46(Suppl 5):183-4
406. Moreau P, Facon T, Usmani SZ, Bahlis N, Raje N, Plesner T, Orlowski RZ, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Tiab M, Macro M, Frenzel L, Leleu X, Wang G, Krevvata M, Carson R, Borgsten F, **Kumar SK**. Daratumumab plus lenalidomide and dexamethasone (d-rd) versus lenalidomide and dexamethasone (rd) in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (ndmm): clinical assessment of key subgroups of the phase 3 maia study. *Oncology Research and Treatment*. 2023 Oct 3; 46(Suppl 2):238
407. Moreau P, Facon T, Usmani SZ, Bahlis N, Raje N, Plesner T, Orlowski RZ, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Tiab M, Macro M, Frenzel L, Leleu X, Pei H, Krevvata M, Carson R, Borgsten F, **Kumar SK**. Daratumumab plus lenalidomide and dexamethasone (d-rd) versus lenalidomide and dexamethasone (rd) in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (ndmm): clinical assessment of key subgroups of the phase 3 maia study. *Oncology*

Research and Treatment. 2023 Oct 3; 46(Suppl 5):316-7

408. Abdallah N, Rees M, Gupta S, Elhaj M, Bansal R, Schaeferle G, Cook J, Kourelis T, Warsame R, Gonsalves W, Kapoor P, Buadi F, Hayman S, Dingli D, Gertz M, Menser T, Lin Y, **Kumar S**. Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma Blood. 2023; 142(Supplement 1).
409. Visram A, Chan KKW, Seow H, Pond G, Gayowsky A, McCurdy A, Sandhu I, Venner CP, Lancman G, Balitsky A, Bruins R, **Kumar SK**, Fonseca R, Mian H. Comparison of the efficacy in clinical trials versus effectiveness in the real-world of treatments for multiple myeloma: a population-based cohort study. Blood. 2023 Nov 2; 142(Suppl 1):541
410. Brandt KG, Rosenthal K, **Kumar SK**, Lentzsch S, Lonial S, Usmani SZ, Quill TA, Mikhael JR. Contemporary multiple myeloma treatment patterns among hcps and concordance with expert recommendations: analysis of an interactive online decision support tool. Blood. 2023 Nov 2; 142(Suppl 1):7284
411. Paludo J, Bansal R, Hathcock M, Pritchett JC, De Menezes Silva Corraes A, Oyarzabal BA, Harmsen WS, Lunde JJ, Coffey JD, Haugen KL, Spychalla M, Khurana A, Alkhateeb H, Dingli D, Hayman SR, Kapoor P, Gertz MA, Wang Y, Binder M, Hampel PJ, Kenderian SS, Kourelis T, **Kumar SK**, Shah MV, Siddiqui MA, Warsame RM, Villasboas JC, Bennani NN, Johnston PB, Ansell SM, Haddad TC, Lin Y. Healthcare utilization outcomes of outpatient car-t cell therapy with remote patient monitoring program. Blood. 2023 Nov 2; 142(Suppl 1):5075
412. Muchtar E, Palladini G, Schonland S, Dispenzieri A, Wisniewski B, Merlini G, Milani P, Hegenbart U, Ditttrich T, Kastiris E, Dimopoulos MA, Sanchowawala V, Szalat RE, Liedtke M, Gupta M, Landau H, Lentzsch S, Hughes MS, Blade J, **Kumar SK**, Wechalekar AD, Gertz MA. Hepatic response and progression criteria in light chain amyloidosis: a multicenter validation study. Blood. 2023 Nov 2; 142(Suppl 1):3411
413. Hassan H, Samur MK, Cohen AD, Moreau P, Otero PR, **Kumar SK**, Mateos MV, Avigan D, Sperling AS, Nadeem O, Hudecek M, de Larrea CF, Martinez-Lopez J, Themeli M, Yong K, Berdeja JG, Chari A, Sonneveld P, Gay F, Krishnan A, Usmani SZ, Anderson KC, Jagannath S, Einsele H, Munshi NC, Midha S. Heterogeneity in access and toxicity management of commercially available bcma-directed car-t and bispecific t-cell engager therapy among the international myeloma community. Blood. 2023 Nov 2; 142(Suppl 1):7248
414. Pita-Juarez Y, Karagkouni D, Gonzalez-Kozlova E, Ma YL, Yao LJ, Pilcher W, Thomas B, Lagana A, Satpathy S, Bhasin S, Song YZ, Vij R, D'Souza D, Dawson T, Kelly G, Schulman JW, **Kumar SK**, Avigan D, Kim-Schulze S, Ding L, Cho HJ, Kourelis T, Lepisto E, Bhasin M, Cook A, Hamilton M, Mulligan G, Network I, Vlachos I, Gnajatic S. In-depth characterization of the high risk-associated tumor immune landscape in multiple myeloma. Blood. 2023 Nov 2; 142(Suppl 1):648
415. Chawla Y, Anderson E, Vasquez IR, Simon RA, Hitosugi T, **Kumar SK**, Gonsalves WI. Levels of individual mid and long chain polyunsaturated triacylglycerols (tags) are different between the bone marrow microenvironment of patients with multiple myeloma (mm) and monoclonal gammopathy of unknown significance (mgus). Blood. 2023 Nov 2; 142(Suppl 1):4708
416. Van Ness B, Mitra AK, Wiesen L, Baughn LB, **Kumar SK**, Petit J, Pfizer J, Gytoku K. Mutant n- and k- ras show distinct effects on growth, signaling and drug response in crispr-cas edited alleles of a myeloma cell line. Blood. 2023 Nov 2; 142(Suppl 1):3320
417. Bansal R, Paludo J, Corraes A, Spychalla M, Haugen K, Khurana A, Hampel PJ, Durani U, Dingli D, Hayman SR, Kapoor P, Wang Y, Binder M, Kenderian SS, Kourelis T, **Kumar SK**, Warsame RM, Bennani NN, Gertz MA, Johnston PB, Ansell SM, Lin Y. Outpatient management of car-t and teclistamab for patients with lymphoma and multiple myeloma. Blood. 2023 Nov 2; 142(Suppl 1):253-55
418. Polepally AR, Biesdorf C, Uddin ME, Boehm N, Ross JA, **Kumar SK**, Voorhees PM, D'Souza A, Weisel K, Bueno O, Talati C, Menon RM. Pharmacokinetics and immunogenicity of abbv-383, a b-cell maturation antigen (bcma) x cd3 bispecific t-cell-redirecting antibody, in patients with relapsed/refractory multiple myeloma (rrmm). Blood. 2023 Nov 2; 142(Suppl 1):6722
419. Alodhaibi I, Ailawadhi S, Perez Burbano GE, O'Brien P, Buadi F, Hayman SR, **Kumar SK**, Gonsalves WI. Results of an open-label phase 1 study repurposing oral metformin and nelfinavir in combination with subcutaneous bortezomib in patients with relapsed and/or refractory multiple myeloma. Blood. 2023 Nov 2; 142(Suppl 1):6733
420. Richter J, Zonder JA, Nathwani N, Bianchi G, Hofmeister CC, Vij R, Pianko M, Kaur G, Hultcrantz M, Wozniak K, Martillo M, Cho HJ, **Kumar SK**. Selinexor, ixazomib, pomalidomide and dexamethasone in functionally high-risk multiple myeloma: results from the myeloma developing regimens using genomics (mydrug) sub-protocol y3. Blood. 2023 Nov 2; 142(Suppl 1):3387
421. Vij R, **Kumar SK**, D'Souza A, McKay JT, Voorhees PM, Chung A, Tuchman SA, Korde N, Weisel K, Teipel R, Bueno O, Feng Z, Rosenberg TS, Pothacamury RK, Polepally AR, Lee S, Jin Z, Ross JA, Ahsan A, Talati C,

Rodriguez C. Updated safety and efficacy results of abbv-383, a bcma x cd3 bispecific t-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed/refractory multiple myeloma. *Blood*. 2023 Nov 2; 142(Suppl 1):3378

422. Sandahl T, Abajue U, Bubik R, Cole K, **Kumar S**. Impact of Bone Modifying Agent Initiation Time, Frequency, and Duration on Skeletal-Related Events in Patients with Multiple Myeloma *Blood*. 2023; Abstract no. 6631.
423. Rees MJ, Yohannan B, Toumeh N, Atallah-Yunes, Gertz M, Dispenzieri A, Gonsalves WI, Geyer S, Buadi F, Dingli D, Hayman SR, **Kumar SK**, Rajkumar S, Leung N, Kourelis T, Kapoor P, Warsame R, Grogan M, Cook J, Binder M, Muchtar E. Predictors of timely and deep renal responses in AL amyloidosis *Amyloid: The Journal of Protein Folding Disorders*. 2024.
424. Abdallah N, ElHaj M, Gupta S, Rees M, Atallah S, Menser T, Bansal R, Schaeferle G, Knepper C, Warsame R, Gonsalves W, Kapoor P, Buadi F, Hayman S, Lin Y, **Kumar S**. Impact of Age and Frailty on Outcomes of Patients with Multiple Myeloma Receiving CAR T-Cell Therapies – A single center experience *HemaSphere*. 2024.
425. Tyler 1, Jenna 1, Chelsea 1, Adrienne 1, Justine 1, Kristin 1, Lucy 2, Allison 2, Prashant 3, Morie 2, David 3, Wilson 2, **Shaji 3**, Suzanne 2, Taxiarchis 3, Rahma 3, Moritz 3, Joselle 2, Yi 3, Jason 1. Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization *Blood*. 2024; 144.

Letters

1. Jatoi A, Nguyen P, **Kumar S**, Sloan J, Loprinzi C. Hazards of quality-of-life data for clinical decision making - reply. *J Clin Oncol*. 2001; 19(2):595. PMID:0 DOI:
2. Riegert-Johnson DL, **Kumar S**, Volcheck GW. A patient with anaphylactoid hypersensitivity to intravenous cyclosporine and subcutaneous phytonadione (vitamin K(1)). *Bone Marrow Transplant*. 2001 Dec; 28 (12):1176-7. PMID:11803365 DOI:10.1038/sj.bmt.1703305
3. **Kumar S**, Sarr MG, Kamath PS. Mesenteric venous thrombosis - Reply. *N Engl J Med*. 2002 Apr 18; 346 (16):1253. PMID:11961161 DOI:
4. **Kumar S**, Dispenzieri A, Gertz MA. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. *N Engl J Med*. 2008 Jan 3; 358(1):91; author reply 92-3. PMID:18172183 DOI:10.1056/NEJMc072918
5. **Kumar S**, Gertz MA. Reply to 'Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients'. *Leukemia*. 2008 Jun; 22(6):1281-2.
6. Ng AC, **Kumar SK**, Russell SJ, Rajkumar SV, Drake MT. Dexamethasone and the risk for adrenal suppression in multiple myeloma. *Leukemia*. 2009 May; 23(5):1009-11. Epub 2009 Jan 08. PMID:19151775 DOI:10.1038/leu.2008.373
7. Kapoor P, **Kumar S**, Mandrekar SJ, Laumann KM, Dispenzieri A, Lacy MQ, Dingli D, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV, Witzig TE. Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma. *Leukemia*. 2011 Jul; 25(7):1195-7. Epub 2011 Apr 5 PMID:21468037 DOI:10.1038/leu.2011.54
8. Sinha S, Lacy M, Mikhael J, Hayman S, Buadi F, Detweiler-Short K, Dispenzieri A, Gertz M, Dingli D, Rajkumar SV, **Kumar SK**. Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. *Leukemia*. 2012 Apr; 26(4):839-41. Epub 2011 Oct 11. PMID:21986842 DOI:10.1038/leu.2011.279
9. Sinha S, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Micallef IN, Hogan WJ, Gastineau DA, Rajkumar SV, **Kumar SK**. Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies. *Leukemia*. 2012 May; 26 (5):1119-22. Epub 2011 Oct 28. PMID:22033494 DOI:10.1038/leu.2011.308
10. Bang SM, Kyle RA, Rajkumar SV, **Kumar S**. Treatment patterns and outcomes in elderly patients with multiple myeloma. *Leukemia*. 2013 Apr; 27(4):971-4. Epub 2012 Sep 05. PMID:22948538 DOI:10.1038/leu.2012.259
11. Ding W, Shanafelt TD, Lesnick CE, Erlichman C, Leis JF, Secreto C, Sasso TR, Call TG, Bowen DA, Conte M, **Kumar S**, Kay NE. Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis. *Br J Haematol* 2014 Jan; 164 (1):146-50 Epub 2013 Sept 20 PMID:24111951 DOI:10.1111/bjh.12564
12. Kourelis TV, **Kumar SK**, Srivastava G, Gertz MA, Lacy MQ, Buadi FK, Kyle RA, Dispenzieri A. Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma. *Leukemia* 2014 Feb; 28 (2):455-7 Epub 2013 Oct 22 PMID:24150218 DOI:10.1038/leu.2013.300
13. Roy V, Stewart AK, Bergsagel PL, Dispenzieri A, Laumann K, Allred J, Lacy MQ, Fonseca R, Reeder CB, **Kumar S**, Rivera CE, Gertz MA, Buadi FK, Hayman SR, Rajkumar SV. Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not

candidates for stem cell transplantation. Blood Cancer J 2015 Mar 20; 5:e294 PMID:25794130
DOI:10.1038/bcj.2015.23

14. Costa LJ, Gonsalves WI, **Kumar SK**. Early mortality in multiple myeloma. Leukemia 2015 Jul; 29 (7):1616-8 Epub 2015 Feb 12 PMID:25673239 DOI:10.1038/leu.2015.33
15. **Kumar SK**. Call for submissions European Oncology and Haematology 2017; 13 (2):75
16. Chakraborty R, Gertz MA, Dispenzieri A, Gonsalves WI, Zeldenrust SR, Russell SJ, Go RS, Kapoor P, Rajkumar VS, Hayman SR, Hwa YL, Lacy MQ, Kyle RA, Leung N, **Kumar SK**. Natural history of amyloidosis isolated to fat and bone marrow aspirate. Br J Haematol 2017 Oct; 179 (1):170-172 Epub 2016 June 22 PMID:27328653 DOI:10.1111/bjh.14205
17. Abeykoon JP, King R, Ansell SM, Rajkumar SV, Paludo J, Kyle RA, **Kumar S**, Gertz MA, Kapoor P. Reply to Castillo et al. Am J Hematol 2018 Mar; 93 (3):E71-E73 Epub 2018 Feb 05 PMID:29314230 DOI:10.1002/ajh.25029
18. Lakshman A, Ravi P, Rajkumar SV, **Kumar SK**. Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'. Leukemia 2018 Sep; 32 (9):2083-2085 Epub 2018 May 25 PMID:29802327 DOI:10.1038/s41375-018-0155-4
19. Muchtar E, **Kumar SK**, Gertz MA, Grogan M, AbouEzzeddine OF, Jaffe AS, Dispenzieri A. Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. Blood 2019 Feb 14; 133 (7):763-766 Epub 2018 Dec 13 PMID:30545829 DOI:10.1182/blood-2018-10-875252
20. Majer IM, **Kumar SK**, Palmer S. Time Horizons in Cost Analyses. JAMA 2019 Aug 13; 322 (6):582-583 PMID:31408128 DOI:10.1001/jama.2019.7853
21. Al Saleh AS, Sidiqi MH, Gertz MA, Muchtar E, Lacy MQ, Warsame RM, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Kapoor P, Buadi FK, Dispenzieri A, Dingli D, **Kumar SK**. Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. Am J Hematol 2020 Jan; 95 (1):E8-E10 Epub 2019 Oct 21 PMID:31591735 DOI:10.1002/ajh.25654
22. Sidana S, Dispenzieri A, Murray DL, Go RS, Buadi FK, Lacy MQ, Gonsalves WI, Dingli D, Warsame R, Kourelis T, Muchtar E, Hayman SR, Kapoor P, Kyle RA, Leung N, Rajkumar SV, Gertz MA, **Kumar SK**. Revisiting complete response in light chain amyloidosis. Leukemia 2020 May; 34 (5):1472-1475 Epub 2019 Nov 26 PMID:31772296 DOI:10.1038/s41375-019-0664-9
23. Deshpande S, Gertz MA, Dispenzieri A, **Kumar SS**, Parikh SA, Muchtar E. Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement. Leuk Lymphoma 2020 Jul; 61 (7):1752-1755 Epub 2020 Mar 11 PMID:32159403 DOI:10.1080/10428194.2020.1737688
24. Anagnostou T, Sakemura R, Forsman CL, Patnaik MS, Paludo J, Gastineau DA, Buadi FK, Porrata LF, **Kumar SK**, Gertz MA, Lacy MQ, Dispenzieri A, Gonsalves WI, Lehman JS, Hogan WJ, Hashmi SK, Alkhateeb H, Shah MV, Litzow MR, Kenderian SS. Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a 'graft versus host'-like syndrome and poor outcomes. Bone Marrow Transplant 2020 Sep; 55 (9):1879-1881 Epub 2020 Mar 11 PMID:32161319 DOI:10.1038/s41409-020-0851-3
25. Ruan G, Zanwar S, Abeykoon JP, Ansell SM, Gertz M, Go RS, Muchtar E, Gonsalves WI, Paludo J, Thanarajasingam G, Inwards DJ, Thompson CA, Habermann TM, Lin Y, Nowakowski GS, Bisneto JCV, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Kourelis T, Warsame R, Rajkumar SV, **Kumar S**, Kapoor P. Predictors of short-term survival in Waldenström Macroglobulinemia. Leuk Lymphoma. 2020 Dec; 61 (12):2975-2979. Epub 2020 Jul 14. PMID:32662697 DOI:10.1080/10428194.2020.1789625
26. **Kumar SK**, Jacobus SJ, Rajkumar SV. Treatments for newly diagnosed multiple myeloma: when endurance is interrupted - Authors' reply. Lancet Oncol 2020 Dec; 21 (12):e541 PMID:33271098 DOI:10.1016/S1470-2045 (20)30695-1
27. Vaxman I, Visram A, Kapoor P, **Kumar S**, Dispenzieri A, Buadi F, Dingli D, Muchtar E, Gonsalves W, Rajkumar V, Kourelis T, Warsame R, Lacy M, Gertz MA. Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation. Am J Hematol 2021 Jan; 96 (1):E35-E38 Epub 2020 Nov 02 PMID:33068019 DOI:10.1002/ajh.26023
28. Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, Chhabra S, Fiala MA, Gahvari Z, Gandhi U, Godby K, Gupta R, Jagannath S, Jagosky M, Kang Y, Kansagra A, Kauffman M, Kodali S, **Kumar SK**, Lakshman A, Liedtke M, Lonial S, Ma X, Malek E, Mansour J, McGehee EF, Neppalli A, Paul B, Richardson P, Scott EC, Shacham S, Shah J, Siegel DS, Umyarova E, Usmani SZ, Varnado W, Vij R, Costa L. Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol. 2021 Jan; 96(1):E5-E8. Epub 2020 Oct 21. PMID:32974944 DOI:10.1002/ajh.26010
29. Al Saleh AS, Parmar HV#, Vaxman I, Visram A, Hasib Sidiqi M, Muchtar E, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Gonsalves WI, Wolf RC, Kourelis TV, Hogan WJ, Hayman SR, Kapoor P,

- Kumar SK**, Gertz MA. Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. *Bone Marrow Transplant* 2021 Jan; 56 (1):274-277 Epub 2020 July 04 PMID:32623446 DOI:10.1038/s41409-020-0990-6
30. Hwa YL, Lacy MQ, Gertz MA, **Kumar SK**, Muchtar E, Buadi FK, Dingli D, Leung N, Kapoor P, Go RS, Hobbs MA, Fonder AL, Gonsalves WI, Warsame R, Kourelis TV, Hayman SR, Siddiqui MA, Rajkumar SV, Dispenzieri A. Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. *Eur J Haematol* 2021 Mar; 106 (3):433-436 Epub 2021 Jan 05 PMID:33259093 DOI:10.1111/ejh.13559
 31. Wudhikarn K, Padrnos L, Lasho T, LaPlant B, **Kumar S**, Dispenzieri A, Lacy M, Rajkumar SV, Gertz M, Mangaonkar AA, Gonsalves W, Ketterling R, Shi CX, Fonseca R, Stewart AK, Patnaik MM. Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. *Am J Hematol* 2021 May 1; 96 (5):E157-E162 Epub 2021 Feb 23 PMID:33580975 DOI:10.1002/ajh.26125
 32. Liu J#, Hu X#, Jia Y#, Lu J, Lee JH, Kim K, Chen W, Liu A, Liu Y, Chen Q, Zhang C, Suh C, Kim MK, Zhou F, Chng WJ, **Kumar SK**, Durie B, Hou J#, Fu W#, Du J#. Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN). *Leukemia* 2021 Jun; 35 (6):1797-1802 Epub 2020 Oct 20 PMID:33082513 DOI:10.1038/s41375-020-01060-w
 33. Tan CR, Estrada-Merly N, Landau H, Lekakis L, Banerjee R, Mian H, Usmani SZ, Hanbali A, Lazarus HM, Kyle RA, Dholaria B, Bal S, Strouse C, Murthy HS, Wirk B, Nishihori T, **Kumar S**, Shah N, Qazilbash M, D'Souza A. A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. *Bone Marrow Transplant* 2022 Feb; 57 (2):295-298 Epub 2021 Nov 20 PMID:34802047 DOI:10.1038/s41409-021-01527-z
 34. Zanwar S, Ho M, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Fonder A, Hobbs M, Hwa Y, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, Rajkumar SV, **Kumar S**. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. *Leukemia* 2022 Mar; 36 (3):873-876 Epub 2021 Oct 11 PMID:34635783 DOI:10.1038/s41375-021-01433-9
 35. Saw JL, Sidiqi MH, Ruff M, Hocker S, Alkhateeb H, Ansell SM, Bennani NN, Dingli D, Hayman SR, Johnston PB, Kapoor P, Kenderian SJ, Kourelis TV, **Kumar SK**, Paludo J, Shah MV, Siddiqui MA, Warsame R, Rosenthal A, Grill M, Castro JE, Siegel J, Abdel Rahman ZH, Kharfan-Dabaja MA, So E, Lin Y. Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). *Blood Cancer J*. 2022 Apr 13; 12(4):62. PMID:35418113 DOI:10.1038/s41408-022-00657-x
 36. Clay-Gilmour A#, Chattopadhyay S#, Hildebrandt MAT, Thomsen H, Weinhold N, Vodicka P, Vodickova L, Hoffmann P, Nothen MM, Jockel KH, Schmidt B, Langer C, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Spath F, Houlston R, Goldschmidt H, Manasanch EE, Norman A, **Kumar S**, Rajkumar SV, Slager S, Forsti A, Vachon CM, Hemminki K#. Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6. *Blood Cancer J* 2022 Apr 13; 12 (4):60 PMID:35418122 DOI:10.1038/s41408-022-00658-w
 37. Zanwar S#, Ho M#, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan A, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Vincent Rajkumar S, **Kumar S**. Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy. *Blood Cancer J* 2022 Nov 24; 12 (11):160 PMID:36424376 DOI:10.1038/s41408-022-00752-z
 38. Goel U, Charalampous C, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder A, Gertz MA, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame RM, Kyle RA, Rajkumar SV, **Kumar SK**. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma. *Blood Cancer J* 2023 Jan 11; 13 (1):11 PMID:36631454 DOI:10.1038/s41408-023-00785-y
 39. Yang P, Xu W, Liang X, Yu S, Yi X, Liu M, Tian M, Yue T, Zhang Y, Yan Y, Hu Z, Guo Q, Zhang N, Wang J, Sun X, Hu R, **Kumar SK**, Dai Y, Jin F. Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma. *Am J Hematol* 2023 Mar; 98 (3):E61-E64 Epub 2022 Dec 21 PMID:36540935 DOI:10.1002/ajh.26810
 40. Vaxman I, **Kumar SK**, Buadi F, Lacy MQ, Dingli D, Hayman S, Kourelis T, Warsame R, Hwa Y, Fonder A, Hobbs M, Muchtar E, Leung N, Kapoor P, Go R, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Gertz MA, Dispenzieri A. Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience. *Blood Cancer J* 2023 May 31; 13 (1):91 PMID:37253713 DOI:10.1038/s41408-023-00859-x
 41. Macaуда A, Briem K, Clay-Gilmour A, Cozen W, Forsti A, Giaccherini M, Corradi C, Sainz J, Niazi Y, Ter Horst R, Li Y, Netea MG, Vogel U, Hemminki K, Slager SL, Varkonyi J, Andersen V, Iskierka-Jazdzewska E,

Martinez-Lopez J, Zaucha J, Camp NJ, Rajkumar SV, Druzdz-Sitek A, Bhatti P, Chanock SJ, **Kumar SK**, Subocz E, Mazur G, Landi S, Machiela MJ, Jerez A, Norman AD, Hildebrandt MAT, Kadar K, Berndt SI, Ziv E, Buda G, Nagler A, Dumontet C, Razny M, Watek M, Butrym A, Grzasko N, Dudzinski M, Rybicka-Ramos M, Matera EL, Garcia-Sanz R, Goldschmidt H, Jamrozak K, Jurczyszyn A, Clavero E, Giles GG, Pelosini M, Zawirska D, Kruszewski M, Marques H, Haastrup E, Sanchez-Maldonado JM, Bertsch U, Rymko M, Raab MS, Brown EE, Hofmann JN, Vachon C#, Campa D#, Canzian F#. Identification of novel genetic loci for risk of multiple myeloma by functional annotation. *Leukemia* 2023 Nov; 37 (11):2326-2329 Epub 2023 Sept 18 PMID:37723249 DOI:10.1038/s41375-023-02022-8

42. Bal S, Estrada-Merly N, Costa LJ, Qazilbash MH, **Kumar S**, D'Souza A. Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies. *Blood Cancer J* 2023 Nov 15; 13 (1):170 PMID:37968258 DOI:10.1038/s41408-023-00945-0
43. Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD Jr, McGuirk JP, Wagner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK, **Kumar SK**, Hansen DK. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. *J Hematol Oncol* 2024 Jun 6; 17 (1):42 Epub 2024 June 06 PMID:38845015 DOI:10.1186/s13045-024-01555-4
44. Mohyuddin GR, Rubinstein SM, **Kumar S**, Rajkumar SV, Fonseca R, Abdallah NH, Calip GS, Wang X, Parrinello CM, Sborov D. Performance of newer myeloma staging systems in a contemporary, large patient cohort. *Blood Cancer J* 2024 Jun 11; 14 (1):95 Epub 2024 June 11 PMID:38862493 DOI:10.1038/s41408-024-01076-w
45. Giaccherini M, Clay-Gilmour AI#, Liotti R, Macaudo A, Gentiluomo M, Brown EE, Machiela MJ, Chanock SJ, Hildebrandt MAT, Norman AD, Manasanch E, Rajkumar SV, Hofmann JN, Berndt SI, Bhatti P, Giles GG, Ziv E, **Kumar SK**, Camp NJ, Cozen W, Slager SL, Canzian F, Gemignani F, Vachon CM#, Campa D. Genetically determined telomere length in monoclonal gammopathy of undetermined significance, multiple myeloma risk and outcome. *Blood Cancer J*. 2024 Nov 11; 14(1):200. PMID:39528488 DOI:10.1038/s41408-024-01181-w
46. Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, Atrash S, Bachanova V, Beitinjaneh AM, Bhurtel E, Castaneda Puglianini O, Chhabra S, Cicero KI, Davis JA, Dhakal B, Dima D, Ferreri CJ, Forsberg PA, Freeman CL, Herr MM, Jain T, Janakiram M, Khouri J, Kocoglu MH, Kumar A, Liu Y, Locke F, McGuirk JP, Mikkilineni L, Nadeem O, Parrondo RD, Pasvolsky O, Peres LC, Purvey S, Raza S, Reshef R, Richard S, Rossi AC, Sborov DW, Shune L, Wagner CB, Zanwar SS, Sidana S, Patel KK, Hansen DK, **Kumar SK**, Lin Y, Martin TG, Voorhees PM, Anderson LD Jr, Cowan AJ, Kaur G. Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma. *Blood Adv*. 2025 May 13; 9 (9):2336-2340 PMID:40088469 DOI:10.1182/bloodadvances.2025016131

Ask Mayo Expert Model

1. Reeder CB , Kapoor P , Ansell SM , Fonseca R , Gertz M , **Kumar SK** , Kyle RA , Rajkumar S . Waldenstrom macroglobulinemia (adult) In: AskMayoExpert.2023. Available from: <http://askmayoexpert.mayoclinic.org>

Ask Mayo Expert Topic

1. Muchtar E, **Kumar SK**, Rajkumar S, Gertz MA, Dispenzieri A, Jain S, Roy V, Sher T. Immunoglobulin light chain amyloidosis (adult) <https://askmayoexpert.mayoclinic.org/topic/clinical-answers.2019>;

Miscellaneous

1. **Kumar S**. A study of red cell survival and prevalence of PNH and hepatitis viral markers in patients with aplastic anemia. Thesis presented in fulfillment of requirements for post graduation in (MD) in Internal Medicine, All India Institute of Medical Sciences, New Delhi, India. 1995.
2. Zimmerman TM, **Kumar SK**. Preface. In: Zimmerman TM; Kumar SK editors., *Biology and management of unusual plasma cell dyscrasias*. 2017. p. v-vi.
3. **Kumar SK**. mSMART (Mayo Stratification of Myeloma and Risk-Adapted Therapies) Guidelines not applicable. 2023.
4. Lin Y, Lugui Qiu Qiu L, Saad Usmani Usmani S, Chng Wee Joo Wee Joo C, Luciano Costa Costa L, Benjamin Derman Derman B, Juan Du Du J, Herman Einsele Einsele H, Carlos Fernandez de Larrea Fernandez C, Roman Hajek Hajek R, P Joy Ho Ho PJ, Efstathios Kastiris Kastiris E, Joaquin Martinez-Lopez Martinez J, Maria-Victoria Mateos Mateos MV, Joseph Mikhael Mikhael J, Philippe Moreau Moreau P, Chandramouli Nagarajan Nagarajan C, Ajay Nooka Nooka A, Michael O'Dwyer O'Dwyer M, Frederick Schjesvold Schjesvold F, Surbhi Sidana Sidana S, Niels WCJ van de Donk van de Donk NCWJ, Katja Weisel Weisel K, Sonja Zweegman Zweegman S, Noopur Raje Raje N, Paula Rodriguez Otero Rodriguez P, Larry D Anderson Jr. Anderson LD, **Kumar SK**. Consensus Guidelines and Recommendations for the Management and Response Assessment of Chimeric Antigen Receptor T-Cell Therapy in Clinical Practice for Relapsed and

Refractory Multiple Myeloma: A Report from the International Myeloma Working Group Immunotherapy Committee The Lancet Oncology. 2024; 25(8):E374-387.

Forthcoming

1. Rajkumar S, Abdallah N, Lakshman A, **Kumar S**, Cook J, Binder M, Kapoor P, Dispenzieri A, Gertz M, Lacy M, Hayman S, Buadi F, Dingli D, Lin Y, Kourelis T, Warsame R, Bergsagel PL. Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients. Res Sq 2023 Oct 23

* Indicates the primary author was a mentee of this author.

Indicates the authors contributed equally.